Functional analysis of the chemokine receptor, CCX-CKR by Comerford, Iain
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
FUNCTIONAL ANALYSIS OF THE 
CHEMOKINE RECEPTOR, CCX-CKR
Iain Comerford 
August 2005
This thesis is submitted to the University of Glasgow 
in accordance with the requirements for the degree of 
Doctor of Philosophy in the Faculty of Medicine
Cancer Research UK Beatson Laboratories 
Switchback Road 
Glasgow 
G61 1BD
Department of Immunology, Infection and Inflammation 
University of Glasgow 
University Avenue 
Glasgow 
G12 8QQ
© Iain Comerford
ProQuest Number: 10800573
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10800573
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
(GLASCOW 1
UNIVERSITY
LIBRARY:V —  _ /
ACKNOWLEDGEMENTS
First of all, I would like to thank my supervisor, Rob Nibbs, for all of his hard work, 
patience, encouragement, and support during the past three and a bit years (although the 
less said about his ‘banter’, the better...). Thanks also to Gerry Graham for his support, 
time, and useful advice and my advisor, Dave Gillespie, for all of his time and interest 
during my studentship. Thanks to all past and present members of R6  and R2 (now the 
Chemokine Research Group). I’d have been at a loss on many occasions if I hadn’t been 
able to steal your reagents, pens, protocols etc. over the last 3 years. Some of you were also 
fun to work with (at times!). They were, in no particular order, and hopefully not missing 
anyone out, Tam, Val, Jane, Tim, Derek, Clare Simpson, Emma, Jan, Jemma, Rhona, 
Pauline, Maureen, Paul, Kenny, Clare Shepherd, Chris, Paz, Wendy, Michele Weber, and 
Michelle Bryson. Thanks to various members of the Immunology department for their help, 
especially Yvonne Bordon for her time, advice, and smiles. I ’d also like to thank Dr. Gracie 
at Glasgow Royal Infirmary and Colin Nixon at Glasgow Vet school for their assistance. 
Huge thanks also to Steve Forrow and his transgenic team for all their hard work and 
persistence with my project. I would also like to thank all the members of the Beatson 
animal facility, especially Steven Bell, Maria Hendry, Tom Hamilton, Tom Byars, and 
Derek Millar, and all the support staff at the Beatson for the sequencing, IT support etc. 
Billy Clark, Shaeron Wylie, Peter McHardy and Iain White to name but a few. Finally, I 
would like to thank my Mum and Dad and the rest of my family for all o f their 
encouragement and support. Lastly, I would like to give a special thank you to the beautiful, 
and long suffering, Yvonne.
TABLE OF CONTENTS
Acknowledgements.......................................................................................................................... ii
List of Tables...................................................................................................................................ix
List of Figures...................................................................................................................................x
Publications Arising From This W ork....................................................................................... xiii
Abbreviations................................................................................................................................ xiv
Abstract........................................................................................................................................... xx
Chapter I: In troduction ................................................................................................................ 1
1.1 The Imm une System................................................................................................................ 1
1.1.1 The Systemic Organisation of the Immune System....................................................5
1.1.2 The Multi-step Paradigm of Leukocyte Extravasation............................................. 11
1.2 The Chemokines..................................................................................................................... 13
1.2.1 Historical Perspectives................................................................................................. 13
1.2.2 Nomenclature................................................................................................................. 16
1.2.3 Chemokine Stucture and Subclassifications.............................................................. 18
1.2.4 Genetic Organisation and Phylogenic Origin............................................................22
1.2.5 Redundancy and Promiscuity...................................................................................... 24
1.3 Chemokine R eceptors.......................................................................................................... 26
1.3.1 The Structure of Chemokine Receptors..................................................................... 26
1.3.2 Chemokine Receptor Expression................................................................................27
1.3.3 The Chemokine/Chemokine Receptor Interaction................................................... 29
1.3.4 Signal Transduction...................................................................................................... 31
1.3.5 Desensitisation, Endocytosis, and Recycling of Chemokine Receptors................ 37
1.4 Post-Translational Control of Chem okines..................................................................... 42
1.4.1 Chemokine Storage and Release.................................................................................42
1.4.2 Chemokine Presentation...............................................................................................44
1.4.3 Proteolytic Control of Chemokines.............................................................................45
1.4.4 Microbial Regulation of Chemokines........................................................................ 50
1.4.5 Chemokine Decoy and Transport Receptors.............................................................52
1.4.5.1 Duffy Antigen/Receptor for Chemokines (D ARC)........................................54
1.4.5.2 D6 : A Pro-inflammatory Chemokine Scavenger............................................56
iii
1.4.6 CCX-CKR, a Chemokine Receptor o f Unknown Function.....................................60
1.5 Immunological Function of CCX-CKR Ligands............................................................62
1.5.1 The Primary Lymphoid Organs.................................................................................. 62
1.5.1.1 The Bone Marrow................................................................................................62
1.5.1.2 The Thymus......................................................................................................... 63
1.5.2 The Secondary Lymphoid Organs..............................................................................6 6
1.5.2.1 Chemokines and the Organogenesis of Secondary Lymphoid Organs 67
1.5.2.2 Ectopic Secondary Lymphoid Formation.........................................................69
1.5.2.3 Lymphocyte Entry via High Endothelial Venules...........................................70
1.5.2.4 ‘Remote Control’ and Chemokine Transcytosis............................................. 73
1.5.2.5 Chemokines and Lymphocyte Compartmentalisation.....................................74
1.5.2.6 Lymphocyte Egress.............................................................................................76
1.5.2.7 Dendritic Cell Traffic to Secondary Lymphoid Organs................................. 77
1.5.2.8 Lymphocyte Activation...................................................................................... 80
1.5.3 Tissue Specific Homing of Antigen Activated Cells................................................ 81
1.5.4 Immune Responses in Null M ice................................................................................83
1.6 Aims of S tudy ......................................................................................................................... 85
C hapter II: M aterials and M ethods........................................................................................ 86
2.1 M ateria ls............................................................................................................................... 86
2.1.1 Antibodies and Secondary Detection Reagents.........................................................86
2.1.2 Bacteriology...................................................................................................................86
2.1.3 Cell Culture....................................................................................................................87
2.1.4 Chemicals....................................................................................................................... 88
2.1.5 Chemokines...................................................................................................................89
2.1.6 Enzymes and K its......................................................................................................... 89
2.1.7 Miscellaneous............................................................................................................... 90
2.1.8 Oligonucleotides........................................................................................................... 91
2.1.8.1 Tagged Expression Construct Oligos................................................................91
2.1.8.2 Sequencing Oligos...............................................................................................91
2.1.8.3 Genotyping Oligos...............................................................................................92
2.1.8.4 Screening Oligos..................................................................................................92
2.1.8.5 cDNA Amplification Oligos..............................................................................92
2.1.9 Plasmids......................................................................................................................... 93
2.2 M ethods................................................................................................................................. 94
2.2.1 Molecular Biology........................................................................................................ 94
2.2.1.1 Oligonucleotide Synthesis.................................................................................. 94
2.2.1.2 Nucleic Acid Preparation................................................................................... 94
2.2.1.2.1 Genomic DNA extraction with Phenol................................................... 94
2.2.1.2.2 Genomic DNA extraction on 96 well plates........................................... 95
2.2.1.2.3 Preparation of Genomic DNA from Tailtips for Genotyping............. 95
2.2.1.2.4 Preparation of Genomic DNA from Tailtips for Southern blots......... 96
2.2.1.2.5 Plasmid DNA preparation (Minipreps/Maxipreps)............................... 96
2.2.1.2.6 Plasmid DNA Precipitations.................................................................... 96
2.2.1.2.7 RNA extraction with Trizol™ ................................................................. 97
2.2.1.2.8 cDNA synthesis from R N A ..................................................................... 98
2.2.1.3 Polymerase Chain Reaction (P C R ).................................................................. 98
2.2.1.4 Agarose Gel Electrophoresis..............................................................................99
2.2.1.5 Restriction Enzyme Digests............................................................................. 100
2.2.1.6 Gel purification of DNA fragments................................................................ 100
2.2.1.7 DNA Ligation.................................................................................................... 100
2.2.1.8 Transformation of DH5a Competent Bacterial Cells...................................101
2.2.1.9 Cloning of DNA Fragments into TOPO® Plasmids....................................... 101
2.2.1.10 Southern Blotting.............................................................................................102
2.2.1.11 DNA Sequencing.............................................................................................104
2.2.1.12 Plasmid Construction......................................................................................105
2.2.1.12.1 FLAG-hCCR7........................................................................................105
2.2.1.12.2.HA-hCCR7-GFP................................................................................... 105
2.2.1.12.3 HA-hCCX-CKR-GFP...........................................................................106
2.2.1.12.4 CCX-CKR GFP KIKO..........................................................................106
2.2.1.13 SDS-PAGE and Western blotting................................................................. 107
2.2.2 Cell Culture.................................................................................................................. 107
2.2.2.1 Harvesting Cells................................................................................................. 108
2.2.2.2 Freezing Cells.................................................................................................... 108
2.2.2.3 Defrosting Cells................................................................................................. 108
2.2.2.4 Cell Counts........................................................................................................ 109
2.2.2.5 Transfection of HEK293 Cells.........................................................................109
2.2.2.5.1 Transient Transfections...........................................................................109
2.2.2.5.2 Stable Transfections..............................................................................110
2.2.3 Analysis of Cell Fluorescence................................................................................... 110
2.2.3.1 Confocal M icroscopy........................................................................................110
2.2.3.2 Flow Cytometry................................................................................................. 111
2.2.4 In Vitro Assays.............................................................................................................115
2.2.4.1 Radioligand Internalisation Assays................................................................. 115
2.2.4.2 Radioligand Degradation Assays.....................................................................115
2.2.4.3 Radioligand Uptake Assay............................................................................... 116
2.2.4.4 Radioligand Binding Assays............................................................................116
2.2.4.5 Radioligand Dissociation A ssay......................................................................117
2.2.4.6 Chemotaxis A ssay.............................................................................................117
2.2.4.7 Biotinylated Chemokine Uptake Assays........................................................117
2.2.4.8 Antibody Staining for Surface CCX-CKR or C C R 7....................................118
2.2.5 Gene Targeting............................................................................................................119
2.2.6 Animals and In vivo A ssays.......................................................................................119
2.2.6.1 Maintenance of M ice.........................................................................................119
2.2.6.2 Genotyping of Mice...........................................................................................119
2.2.6.3 Sacrifice of M ice............................................................................................... 120
2.2.6.4 Dissection of Mice............................................................................................. 120
2.2.6.5 Weighing Inguinal Lymph Nodes................................................................... 120
22.6.6 Harvesting of Leukocytes...............................................................................120
2.2.6.1 Immunostaining of Mouse Leukocytes for Flow Cytometry.................... 120
2.2.6 .8  Histology of Mouse T issue..............................................................................121
2.2.6 .9 Cutaneous PMA Paint.......................................................................................121
2.2.6.10 Subcutaneous Immunisation with OVA/CFA............................................. 121
2.2.6.11 Measuring OVA-Specific Total Serum IgG Antibody by ELISA............ 122
2.2.6.12 Measuring Antigen Specific Cell Proliferation........................................... 122
2.2.6.13 Measuring Antigen Specific Cytokine Production......................................123
2.2.6.14 Induction of Contact Sensitivity with the Hapten D N FB .......................... 124
2.2.7 Statistical Analysis...................................................................................................... 124
C hapter HI: Results................................................................................................................... 125
3.1 Biochemical Analysis of human CCX-CKR and C C R 7...........................................125
3.1.1 Constructs and Cell Lines.........................................................................................125
vi
3.1.1.1 FLAG tagged hCCR7........................................................................................ 127
3.1.1.2 GFP fusion HA tagged receptors..................................................................... 128
3.1.2 Internalisation and Degradation o f CCL19 by its Receptors................................130
3.1.2.1 CCL19 Internalisation....................................................................................... 130
3.1.2.1.1 Optimisation of Radioligand Internalisation A ssay .............................130
3.1.2.1.2 CCX-CKR and CCR7 Internalise Bound 125I-CCL19........................ 131
3.1.2.1.3 Internalisation of Biotinylated CCL19/ Streptavidin-Cy3.................. 133
3.1.2.2 Fate of Internalised CCL 19...............................................................................134
3.1.2.2.1 Degradation of Preloaded 125I-CCL19 by CCX-CKR and CCR7 135
3.1.2.2.2 Dissociation of CCL19 from CCX-CKR and CCR7.......................... 137
3.1.2.2.3 Effect of Cold Competitor and Endosomal Neutralisation.................139
3.1.2.2.4 CCL19 Degradation in Continuous Culture......................................... 142
3.1.2.2.5 Inhibition of Splenocyte Chemotactic Responses................................146
3.1.3 Receptor Behaviour after Chemokine Exposure..................................................... 148
3.1.3.1 Biotinylated CCL 19 Uptake............................................................................. 148
3.1.3.2 Radiolabelled CCL 19 Uptake..........................................................................155
3.1.3.3 Surface Receptor Levels following Ligand Exposure...................................156
3.1.4 Molecular Mechanisms of CCL 19 Uptake.............................................................. 161
3.1.4.1 Dynamin..............................................................................................................161
3.1.4.2 p-arrestins...........................................................................................................163
3.1.4.3 EPS 15.................................................................................................................. 166
3.1.4.4 RabGTPases....................................................................................................... 168
3.1.4.5 Caveolae and Lipid Rafts................................................................................. 172
3.2 Generation of CCX-CKR Knock-out mice.................................................................... 179
3.2.1 Strategy........................................................................................................................ 179
3.2.2 Construction of CCX-CKR Targeting Vectors........................................................181
3.2.3 Targeting of CCX-CKR.............................................................................................183
3.2.4 In Vitro Cre-Mediated Excision o f Neomycin Resistance Cassette.....................186
3.2.5 Blastocyst Injections, Chimeras, and Test Breeds.................................................. 189
3.2.6 In vivo Cre-Mediated Excision o f Neomycin Resistance Cassette.......................190
3.2.7 Other CCX-CKR KIKO Strains................................................................................192
3.2.8 Targeting of D6 ........................................................................................................... 194
3.3 Analysis of CCX-CKR Knock-out mice......................................................................... 195
3.3.1 Fertility and Viability...............................................................................................195
3.3.2 Histological Analysis...................................................................................................195
3.3.3 Secondary Lymphoid Organs.....................................................................................196
3.3.3.1 The Spleen.......................................................................................................... 196
3.3.3.2 Inguinal Lymph Nodes......................................................................................199
3.3.4 Inguinal Lymph Node and Skin Responses to Topical Application of the Phorbol 
Ester Irritant PMA........................................................................................................................ 205
3.3.5 Primary Immune Responses to Subcutaneous Antigen.......................................... 211
3.3.6 Contact Hypersensitivity Responses to the Hapten DNFB....................................219
3.4 R eporter Expression in CCX-CKR K IKO A nim als.................................................223
C hapter IV: Discussion.............................................................................................................226
4.1 Comparative Biochemistry of CCX-CKR and C C R 7 ................................................ 226
4.2 The In  Vivo Expression of C C X -C K R ............................................................................237
4.3 The In  Vivo Function of CCX -CK R................................................................................ 239
4.3.1 Steady-State Analysis................................................................................................. 241
4.3.2 Function of CCX-CKR in Immunity and Inflammation........................................245
4.4 Overall Conclusions and Future Perspectives.............................................................. 248
C hapter V: References..............................................................................................................250
Chapter VI: Appendices...........................................................................................................279
6.1 The Genetic Code.................................................................................................................. 279
6.2 The Amino Acids................................................................................................................... 280
6.3 The Greek Alphabet...............................................................................................................281
6.4 Primary Sequence Line-up of CCX-CKR Across Species............................................... 282
SV40 simian virus 40
TCA trichloroacetic acid
TCR T cell receptor
Thl T helper cell type 1
Th2 T helper cell type 2
T r e g regulatory T cell
TM transmembrane
TNFa tumour necrosis factor-a
Tween-20 polyoxyethylene-sorbitanmonolaurate
VCAM-1 vascular cellular adhesion molecule- 1
vCKBP viral chemokine binding protein
WT wild-type
w/v weight per unit volume
LIST OF FIGURES
Number Page
1.1.1 Cells of The Immune System................................................................................................2
1.1.2 Structure of a Lymph N ode................................................................................................... 9
1.1.3 Structure of the Spleen.........................................................................................................11
1.1.4 The Multistep Paradigm of Leukocyte Extravasation......................................................12
1.2.1 The Chemokine Subfamilies............................................................................................... 19
1.2.2 Chemokines: Primary, Secondary and Tertiary Structure............................................... 20
1.2.3 Genetic Organisation of Chemokines................................................................................24
1.3.1 General Structural Features of a Chemokine Receptor................................................... 27
1.3.2 Chemokine Receptor Ligation............................................................................................30
1.3.3 G-protein Activation.............................................................................................................32
1.3.4 Signaling Pathways Downstream of Chemokine Receptor Ligation............................. 33
1.3.5 Signal Transduction Leading to Rapid Integrin Activation............................................ 36
1.3.6 Molecular Control of Endocytosis and Vesicular Traffic............................................... 39
1.4.1 Proteolytic Control of Chemokines.................................................................................... 46
1.4.2 Regulation of Chemokine Function by Chemokine Decoy or Transport Receptors....54
1.4.3 D6 and Cutaneous Inflammation........................................................................................59
1.4.4 CCX-CKR Ligands...............................................................................................................61
1.5.1 The Role of CCR7 in Thymocyte Development.............................................................. 66
1.5.2 Organogenesis of Secondary Lymphoid Organs..............................................................68
1.5.3 The Multi-step Adhesion Cascade for Naive T cell Entry into LN from the Blood ....72
1.5.4 The Splenic Architecture in CXCR5-/-, C C R 7-/- and C X C R5-/-CCR7-/- Mice 75
2.2.1 A Southern Blot by Capillary Transfer............................................................................ 102
2.2.2 Setting up the Flow Cytometer for Single Colour Analysis.......................................... 112
2.2.3 Setting up the Flow Cytometer for 2 Colour Analysis...................................................113
2.2.4 FACS Analysis of Mouse Leukocytes............................................................................. 114
3.1.1 125I-CCL19 Binding and CCX-CKR Surface Expression by HEK-hCCX-CKR 
C ells....................................................................................................................................126
3.1.2 Plasmids and Tagged Receptors used in Study.............................................................. 127
3.1.3 125I-CCL19 Binding and CCR7 Surface Expression by HEK-hCCR7 C ells..............129
x
3.1.4 Optimisation of Acid W ash............................................................................................... 131
3.1.5 Internalisation of 125I-CCL19 by HEK-hCCX-CKR and HEK-hCCR7...................... 132
3.1.6 Kinetics of 125I-CCL19 Internalisation by HEK-hCCX-CKR and HEK-hCCR7...... 133
3.1.7 Internalisation of BioCCL19/Cy3 by HEK-hCCX-CKR and HEK-hCCR7...............134
3.1.8 Degradation of 125I-CCL19 by HEK-hCCX-CKR and HEK-hCCR7 Cells................136
3.1.9 Effect of Alterations in pH on 125I-CCL19 Binding to CCX-CKR and CCR7.......... 138
3.1.10 Effect of Cold Competitor and Endosomal Neutralisation................................... 140-41
3.1.11 Degradation of CCL 19 by HEK-hCCX-CKR Cells in Continuous Culture 143
3.1.12 SDS-PAGE Analysis of Supernatants from Continuous Culture with CCL 19........ 144
3.1.13 Activity of HEK-hCCX-CKR Supernatants on 125I-CCL19 Degradation.................145
3.1.14 Inhibition of Splenocyte Chemotaxis by Pre-incubation of CCL 19 with CCX- 
CKR................................................................................................................................................146
3.1.15 Uptake of BioCCL 19/PE is Dependent on the Expression o f a CCL 19 Receptor... 149
3.1.16 Continued Chemokine Accumulation by HEK-hCCX-CKR Cells...........................150
3.1.17 BioCCL 19/PE Uptake Assay Measures Total Chemokine Accumulation................151
3.1.18 Priming and Desensitisation of HEK-hCCX-CKR and HEK-hCCR7 Cells 152
3.1.19 Dose and Time Dependent Priming of CCX-CKR by CCL 19, CCL21 and 
CCL25............................................................................................................................................153
3.1.20 Chemokine Priming of CCX-CKR Increases the Rate of BioCCL19/PE Uptake ...154
3.1.21 Radioligand Uptake by CCX-CKR and CCR7 Following Chemokine 
Stimulation.................................................................................................................................... 156
3.1.22 CCL 19 Causes CCX-CKR Internalisation in a Dose Dependent M anner................157
3.1.23 CCL21 and CCL25 Induce Similar CCX-CKR Internalisation as CCL 19...............158
3.1.24 Internalisation of CCR7 Following Ligand Stimulation............................................. 158
3.1.25 Effect of Dynamin (K44A) on BioCCL 19/PE Uptake by CCX-CKR...................... 162
3.1.26 Effect of P-arrestin-1 (V53D) on BioCCL 19/PE Uptake by CCX-CKR 163-64
3.1.27 Uptake of BioCCL19/Cy3 by MEFs (-/- or +/+ for P-arrestins)................................165
3.1.28 Mutants o f EPS 15.............................................................................................................167
3.1.29 Effect of Genetic Inhibition of EPS 15 on BioCCL 19/PE Uptake............................. 169
3.1.30 Effect of Genetic Inhibition of RabGTPases on BioCCL 19/PE Uptake 170-71
3.1.31 Effect of Cholesterol Depletion on BioCCL19/PE Uptake......................................... 173
3.1.32 Effect of Genetic Inhibition and Overexpression of Caveolin-1 CCL19 Uptake 175
3.1.33 Effect of Over-expression of Caveolin-1 on CCX-CKR Surface Receptor 
Levels.............................................................................................................................................176
xi
3.2.1 Targeting constructs for CCX-CKR containing lacZ or GFP....................................... 181
3.2.2 Restriction Maps of the Mouse CCX-CKR Genomic Clone and Targeting 
Constructs...................................................................................................................................... 182
3.2.3 PCR Screen for Targeted Integration of CCX-CKR KIKO Constucts........................ 184
3.2.4 Southern Blot Analysis of Targeted CCX-CKR KIKO ES Cell Clones..................... 185
3.2.5 PCR and Southern Blot Screen for in vitro Cre Recombination...................................187
3.2.6 Genotyping of Pups at CCX-CKR Locus........................................................................ 190
3.2.7 Southern Blots of CCX-CKR GFP KIKO neo Recombination After ZP3/Cre 
Cross...............................................................................................................................................191
3.2.8 Screening of Genomic DNA from CCX-CKR GFP KIKO Founder M ouse..............192
3.2.9 Overall Strategy for Generation of CCX-CKR KIKO Mice......................................... 193
3.3.1 Effect of CCX-CKR Ablation on Mouse Fertility.......................................................... 195
3.3.2 Analysis of Leukocyte Populations in Spleens of CCX-CKR +/+ and -/-. P a rti....... 197
Analysis of Leukocyte Populations in Spleens of CCX-CKR +/+ and -/-. Part2....... 198
3.3.3 Analysis of H+E Sections of ILNs from CCX-CKR +/+ and -/-................................. 200
3.3.4 Weight and Cell Number from ILNs of CCX-CKR +/+ and -/- ...................................201
3.3.5 Analysis of Leukocytes in ILNs from CCX-CKR +/+ and -/- ................................202-03
3.3.6 Expression of CCX-CKR in Normal Mouse Skin..........................................................206
3.3.7 Histolgical Analysis of Mouse Skin Following 3xPMA P ain t.....................................207
3.3.8 Analysis of Inguinal Lymph Node Weight Following 3xPMA Paint..........................207
3.3.9 Analysis of Cellularity of ILNs 3 Days After 3xPMA Paint........................................208
3.3.10 Analysis of Leukocytes in ILNs 3 Days After 3xPMA Paint.....................................209
3.3.11 Analysis of ILN Weight and Cellularity 3 Days After OVA/CFA............................212
3.3.12 Analysis of Leukocytes in ILNs on Day 3 After OVA/CFA......................................213
3.3.13 Cellularity of ILNs Following OVA/CFA Immunisation...........................................214
3.3.14 Analysis of OVA-Specific IgG in Mouse Serum After OVA/CFA..........................214
3.3.15 Analysis of OVA-Specific Proliferation in ILN Cell Culture.....................................215
3.3.16 Analysis of Cytokine Levels in Supernatants from ILN Cell Culture.......................217
3.3.17 Analysis of ILN Weight and Cellularity on Day 3 After DNFB Paint......................220
3.3.18 Measurements of Ear Thickness in Mice Following DNFB Challenge....................221
3.3.19 Analysis of H+E Sections of Ears Either Painted or Unpainted with DNFB........... 222
3.4.1 Analysis of CCX-CKR and GFP Expression in +/+ and +/- CCX-CKR GFP KIKO Mice ..224
4.1.1 Proposed Model of CCL19 Uptake by CCX-CKR and CCR7.................................... 234
PUBLICATIONS ARISING FROM THIS WORK
Comerford, I., and Nibbs, R. J. (2005). Post-translational control of chemokines: a role 
for decoy receptors? Immunol Lett 96, 163-174.
Comerford, I., Milasta, S., Morrow, V., Milligan, G., Nibbs, R.J (2005) Non-desen sitised, 
caveolin-regulated, sequestration of the chemokine CCL19 by its receptor, CCX- 
CKR. (J Biol Chem, submitted)
Morrow, V., Simpson, C.V., Milasta, S., Comerford, I., Battle, J., Milligan, G., Nibbs, R.J 
(2005) The D6 chemokine receptor is localised to lipid rafts and requires beta- 
arrestins for continuous but not transient chemokine uptake. Manuscript in 
preparation.
ABBREVIATIONS
°C degrees celcius
fig microgram
fil microlitre
-/- knock-out
+/- heterozygote
+/+ wild type
-RT without reverse transcriptase
Ab antibody
ADAM a disintegrin and metalloproteinase
Ag antigen
AIDS acquired immunodeficiency syndrome
APC antigen presenting cell
BAL bronchoalveolar lavage
bioCCL 19 biotinylated CCL 19
bioCCL19/cy3 biotinylated CCL 19 conjugated to streptavidin-cy3
bioCCL 19/PE biotinylated CCL 19 conjugated to streptavidin-PE
BITS Beatson Institute Technology Services
BITU Beaston Institute Transgenics Unit
BM bone marrow
bp base pair
Ca2+ calcium ion
CCL CC chemokine ligand
CCPs clathrin-coated pits
CCR CC chemokine receptor
CCVs clathrin-coated vesicles
CD cluster of differentiation
CFA complete Freund’s adjuvant
CLA cutaneous lymphocyte antigen
CMV cytomegalovirus
CNS central nervous system
CO2 carbon dioxide
ConA Concanavalin-A
cpm counts per minute
CX3CL CX3C chemokine ligand
CX3CR CX3C chemokine receptor
CXCL CXC chemokine ligand
CXCR CXC chemokine receptor
DAG diacyl-glycerol
DARC Duffy antigen/receptor for chemokines
DC dendritic cell
ddH2 0  distilled water
DEPC diethylpyrocarbonate
DMEM Dulbecco’s modified Eagle’s medium
DMSO dimethyl sulphoxide
DNA deoxyribonucleuic acid
DNFB di-Nitro-Fluoro-Benzene
dsRNA double stranded RNA
DTH delayed-type hypersensitivity
EC endothelial cell
ECM extracellular matrix
E.coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
EH EPS 15 homology
ELISA enzyme linked immunosorbent assay
EPS 15 epidermal growth factor receptor substrate 15
ER endoplasmic reticulem
ES cell embryonic stem cell
EST expressed sequence tag
EtOH ethanol
FACS fluorescence activated cell sort
FAK focal adhesion kinase
FITC fluorescein isothiocyanate
FCS foetal calf serum
FDC follicular DC
fMLP formyl-methionyl-leucyl-phenylalanine
g gram
xv
G418 geneticin
GAG glycosaminoglycan
GAP GTPase activating protein
GC germinal centre
G-CSF granulocyte colony stimulating factor
GDP guanine biphosphate
GEF GDP exchange factors
GFP green fluorescent protein
GPCR G protein coupled receptor
GRK G protein coupled receptor kinase
GTP guanine triphosphate
h hour(s)
H+E haematoxylin and eosin
HA haemagluttinin
HEK human embryonic kidney cells
Het heterozygote
HEV high endothelial venule
HHV human herpes vims
HIV human immunodeficiency vims
HRP horseradish peroxidase
HSC haematopoietic stem cell
HSV herpes simplex vims
ICAM-1 intracellular adhesion molecule- 1
IFNy interferon-y
Ig immunoglobulin
IL interleukin
ILN inguinal lymph node
i.v intravenous
IP3 inositol 1,4,5 triphosphate
IRES internal ribosomal entry site
JAK Janus-family tyrosine kinase
kb kilobase pairs
kDa kiloDalton
kg kilogram
KIKO knock in knock out
KO knock out
1 litre
LC Langerhans cell
LEC lymphatic endothelial cell
LN lymph node
LPS lipopoly saccharide
LT lymphotoxin
M molar
MpCD methyl-P-cyclodextrin
M cell microfold cell
MadCAM-1 mucosal addressin cellular adhesion molecule-1
MAPK mitogen activated protein kinase
MEF mouse embryonic fibroblast
MFI mean fluorescence intensity
mg milligram
MHC major histocompatibility complex
min minute(s)
ml millilitre
mM millimolar
MMP matrix metalloproteinase
mRNA messenger RNA
MZ marginal zone
neo neomycin resistance gene
nm nanometre
nM nanomolar
NK natural killer
OD optical density
ORF open reading frame
OVA ovalbumin
PALS periarteriolar lymphoid sheath
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PFA paraformaldehyde
Pg picogram
PGK phosphoglycerine kinase promoter
PH pleckstrin homology
PI3K phosphotidylinositol 3-kinase
PIP2 phosphatidylinositol 4,5-biphosphate
PIP3 phosphatidylinositol 3,4,5-triphosphate
PKA protein kinase A
PKB protein kinase B
PKC protein kinase C
PLC phospholipase C
PLD phospholipase D
pit paucity of lymph node T cells
PMA 12-O-tetradecanoylphorbol-13-acetate
PNAd peripheral node addressin
PP Peyer’s patch
PTEN phosphatase and tensin homologue deleted on chromosome ten
PTX pertussis toxin
RA rheumatoid arthritis
RBC red blood cell
ref gravitational force
RGS regulator of G-protein signaling
RNA ribonucleic acid
rpm revolutions per minute
RPMI Roswell Park Memorial Institute medium
RT room temperature
RT-PCR reverse-transcription PCR
SIP sphingosine 1-phosphate
S1PR1 sphingosine 1-phosphate receptor 1
SCZ subcapsular zone
SDS sodium dodecyl sulphate
sec second(s)
SS Sjogrens syndrome
STAT signal transducer and activator o f transcription
xviii
SV40 simian virus 40
TCA trichloroacetic acid
TCR T cell receptor
Thl T helper cell type 1
Th2 T helper cell type 2
T r e G regulatory T cell
TM transmembrane
TNFa tumour necrosis factor-a
Tween-20 polyoxyethylene-sorbitanmonolaurate
VCAM-1 vascular cellular adhesion molecule- 1
vCKBP viral chemokine binding protein
WT wild-type
w/v weight per unit volume
ABSTRACT
Chemokines comprise a large family of low molecular weight, mainly secreted proteins, 
well known for their role in directing leukocyte traffic, a vital component of immune and 
inflammatory responses. However, chemokines also regulate a broad range of other 
biological functions, including cell survival, growth, and differentiation. All these responses 
are mediated through cognate interactions with chemokine receptors, seven transmembrane 
(T/M) spanning G-protein coupled receptors. Importantly, the role of chemokines and their 
receptors in an enormous range o f pathologies is apparent from a large number of studies in 
the last two decades, and these molecules have become popular targets for the 
pharmaceutical industry.
Despite the explosion in our understanding of chemokine networks, much less is known 
about regulatory mechanisms which must be in place to control and facilitate the biological 
effects of chemokines in vivo. Recent work has suggested the existence of a subset of 
atypical chemokine receptors that sequester their ligands to help remove or transport 
chemokines. This focus of this thesis regards the function of one of these molecules, CCX- 
CKR. This acts as a receptor for CCL 19, CCL21 and CCL25, chemokines involved in 
constitutive and inflammatory trafficking of key leukocytic subsets in lymphoid tissue and 
small intestine. However, CCX-CKR does not appear to directly mediate these migratory 
events and, despite displaying high affinity binding, this receptor does not activate 
downstream signaling pathways typically involved in chemokine receptor function. Instead, 
roles for CCX-CKR in regulating chemokine levels or localisation have been proposed. The 
studies described in this thesis have examined the biochemistry o f CCX-CKR in vitro with 
a view to determining what this receptor is capable of. These studies form a molecular
framework for the interpretation of phenotypes emerging from CCX-CKR null mice 
generated as part of this study.
The results from in vitro assays demonstrate that, in heterologous transfectants, human 
CCX-CKR mediates the internalisation and intracellular degradation of the chemokine 
CCL 19. Importantly, unlike CCR7, CCX-CKR is primed, not desensitised, by previous 
exposure to ligand, allowing continuous CCL 19 sequestration. This endows CCX-CKR 
with an impressive ability to sequester and destroy its ligands in continuous culture and 
therefore modify adjacent CCR7-driven responses. Mechanistically, CCL19 uptake by 
CCX-CKR is dependent on dynamin but, unlike CCR7, not reliant on p-arrestins. Genetic 
inhibition of both clathrin mediated endocytosis and early endosome function had no 
apparent effect upon CCL 19 uptake by CCX-CKR, but inhibited uptake by CCR7. In 
contrast, over-expression of caveolin-1 dramatically inhibited CCX-CKR mediated CCL 19 
uptake while leaving CCR7 function unaffected, implicating caveolae in CCX-CKR 
endocytosis. The significance of these alternative pathways o f receptor internalisation is 
discussed.
In parallel, the in vivo significance of CCX-CKR function was examined by generating 
CCX-CKR knock-out mice. These mice did not display any gross phenotypic 
abnormalities, yet detailed analysis revealed a significant reduction in the cellularity of 
inguinal lymph nodes compared with wild-type mice. In addition, the phenotype of splenic 
macrophages appeared altered in CCX-CKR null mice. Moreover, the topical application of 
irritant or hapten, to these mice, did not cause the subsequent inguinal lymph node 
hypertrophy observed in wild-type couterparts. However, CCX-CKR null mice were 
capable of mounting relatively normal immune responses although proliferative responses 
to antigen appeared to persist longer in the lymph nodes o f null animals.
xxi
Taken together, the results from this study suggest that CCX-CKR contributes to the 
organisation and regulation of the immune system during homeostasis and immune 
response. This may be achieved through the control of chemokine availability such that the 
responses through the receptors CCR7 and CCR9 are modified. Importantly, the work 
described in this thesis represents the first attempt to dissect the function of CCX-CKR and 
provides the foundation for future studies aimed at more precisely defining the function of 
this atypical chemokine receptor.
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CHAPTER ONE 
INTRODUCTION
1.1 The Immune System
Throughout life, we are continually exposed to a diverse spectrum of potentially pathogenic 
microorganisms. In order to survive, a wide variety of protective mechanisms have evolved, 
known collectively as the immune system. When working effectively, our immune system 
can distinguish, at the molecular level, not only self from non-self, but also harmless from 
dangerous. This is achieved through a highly complex system of specific molecular 
recognition events executed mainly by motile cells. Immunology, the study of the immune 
system, is o f great importance to biology and medicine for many reasons. For example, 
induction of immunity through vaccination has largely controlled many previously deadly 
infections, and has led to the near eradication of a major human pathogen: smallpox. 
However, other communicable diseases have not been contained as effectively, especially 
in the third world. The successful control and treatment o f infectious diseases, such as 
HTV/AIDS, malaria, and tuberculosis, remain key goals o f modem medical research. In 
addition, while the immune system has the capacity to protect us from pathogens, it can also 
cause us great harm. Pathological consequences of immunity, such as autoimmune diseases 
and allergies are an increasing cause of death, ill health, and distress in the modem world. 
Similarly, immune rejection of transplanted organs remains a significant obstacle to the 
successful treatment of many patients. An increased knowledge of the molecular workings 
of the immune system is leading to a greater understanding o f these phenomena, and should 
lead to improvements in the treatment of numerous pathologies. Furthermore,
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understanding how to control and harness the power o f the immune system should enable 
us to use it as a more effective tool in the fight against many diseases, including cancer.
Generally, features o f the immune system can be described as being either innate or 
adaptive. These are two distinct, but co-operating, arms o f immunity. Characteristically, 
innate immunity describes those mechanisms which display a limited range o f pathogen 
recognition, and which do not alter upon repeated exposure to the same pathogen. In 
contrast, adaptive immunity is highly specific in nature, and displays ‘memory’: subsequent 
responses to the same stimulus are enhanced. Both innate and adaptive immune responses 
depend largely on leukocytes, the nucleated cells o f the blood. These cells are detailed in 
figure 1.1.1
M onocytes N eutrophils Eosinophils B asophils M ast Cells 
/M acrophages   I
Cytokine Antibody  
Production Production P h a g o c y te s
Inflammatory  
Mediator R e lea seAntigen Presenting  
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Cytotoxic
Figure 1.1.1: Cells of the Immune System: A schematic o f the principal leukocytic cell 
types which comprise the mammalian immune system. The most commonly prescribed 
function o f each o f the cell types is indicated at the bottom o f the figure.
The innate immune system comprises several different types o f defensive mechanism: 
physical and chemical barriers, serum proteins, natural killer (NK) cells and phagocytic
2
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cells. Anatomical barriers, such as the skin and mucous membranes, protect us from 
infection by preventing entry and attachment of pathogenic microbes. The acidic pH of the 
stomach, reflexes such as sneezing and coughing, and the genito-urinary flush, all 
contribute to host defence. Proteins present in blood plasma, such as members of the 
complement system, provide protection against a wide range of foreign pathogens. These 
directly lyse certain types of bacteria, or bind to them allowing more effective recognition 
by other immune mechanisms. NK cells, using innate immune mechanisms, can detect and 
destroy cells infected with viruses. The ingestion of extracellular material such as bacteria, 
a process known as phagocytosis, is another important feature of innate immunity. 
Conserved molecules on the surface of many invading microbes are recognized by 
receptors on the surface of phagocytic leukocytes (eg. neutrophils and macrophages) which 
can then internalise and digest the pathogen.
Tissue damage by wounding, infection with a pathogen, or autoimmune attack, causes the 
induction of a cascade of events known collectively as the inflammatory response. The 
local release of inflammatory mediators causes blood vessel dilation and an increase in 
vascular permeability at the site of damage/infection. Significantly, this is accompanied by 
an influx of phagocytic and cytotoxic cells from the bloodstream to tissue. This generally 
results in clearance and resolution of the infection after which the response subsides and the 
tissue heals, returning to normal. These relatively non-specific mechanisms of innate 
immunity effectively protect us against infection from the vast majority of potential 
pathogens.
Specific immune responses, i.e targeted immune reactions to particular pathogens, are 
termed adaptive immunity. These responses are shaped by previous exposure to pathogens. 
The adaptive immune system can provide effective life-long protective immunity to re-
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infection by a pathogen that has previously been experienced by the host. The essential cells 
for adaptive immunity are a specialized subset of leukocytes termed lymphocytes. 
Lymphocytes are able to specifically recognize pathogens through their expression of 
antigen (Ag) specific receptors, whose diversity and specificity is generated by a complex 
system of genetic recombination and clonal selection. As a result of these phenomena, the 
Ag receptor repertoire o f any one individual should be capable of recognizing any potential 
pathogen. Lymphocytes can be functionally segregated into those which leave the bone 
marrow (BM) and mature in the thymus (T cells), and those which complete their 
maturation in the BM (B cells). Upon exposure to their specific Ag, lymphocytes direct 
and regulate immunity. T cells can be directly cytotoxic and kill cells infected with a 
particular pathogen (CD 8+ T cells) or produce soluble factors such as cytokines (CD4+ T 
cells) which control the activity of other lymphocytes or innate effector cells. In addition, a 
subset of T cells, termed regulatory T cells ( T regs) ,  have specificity for self or harmless 
non-self Ag and produce cytokines that ensure tolerance is maintained to these Ags 
(O'Garra and Vieira, 2004). B cells, when activated, produce specific antibody which can 
neutralize and lead to pathogen clearance. Generally, B cells are reliant upon CD4+ T cell 
help to produce antibody, but can also act as Ag presenting cells (APCs) for T cells, 
stimulating their activation. Upon activation, a certain number of Ag specific lymphocytes 
differentiate into long-lived ‘memory’ cells which are capable of mounting rapid and 
enhanced specific responses to subsequent challenge from the same Ag.
There is significant interaction and cross-talk between the innate and adaptive immune 
systems and indeed the distinction between the two is increasingly blurred. For example, T
I
[
I cells are reliant upon innate phagocytic APCs to display Ag to them and allow them to
i
I become activated. APCs, such as dendritic cells (DCs) or macrophages, non-specifically
i ingest microbes or their products and process antigenic peptides for presentation on major
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histocompatibility complex (MHC) molecules. Depending upon the activation state o f the 
APC and the nature of the Ag presented, T cells can be stimulated in different ways. For 
example, T cells can either become activated to respond to the Ag or become anergic 
(incapable of further activation). Therefore, non-adaptive mechanisms of danger 
recognition by APCs can determine whether tolerance or immunity is acquired to a 
particular Ag. Similarly, the adaptive immune system can influence innate immune cells. 
For instance, T cells produce cytokines which in turn activate macrophages, enabling them 
to more effectively destroy the intracellular pathogens they have phagocytosed; B cells 
produce antibodies which bind specifically to Ag, and these antibodies are then recognized 
either by complement proteins in the serum or receptors on phagocytes, enabling more 
efficient pathogen destruction. Clearly, both innate and acquired immunity are involved in 
the fine tuning and regulation of one another and co-operate to ensure effective responses 
are initiated, maintained and resolved (general textbooks with information about the 
immune system are Abbas and Lichtman, 2005; Goldsby, 2003; Janeway and Travers, 
1997).
1.1.1 The Systemic Organisation of the Immune System
Frequent and co-ordinated interactions between cells of the immune system are essential for 
its proper function. To this end, various organs of the body are specialized to concentrate 
and contain these cells, facilitating these contacts. Generally, the organs of the immune 
system can be classified as either primary or secondary lymphoid organs, depending upon 
their major function in immunity. Primary lymphoid organs are sites of lymphocyte 
maturation and selection, while secondary lymphoid organs are the sites of immune 
response initiation. A description of these organs and the cells which populate them is 
necessary for this introduction.
5
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There are two major primary lymphoid organs in humans and mice. These are the BM and 
the thymus. After birth, the BM is the major site for haematopoeisis and is the location of B 
lymphocyte maturation. Haematopoietic stem cells (HSCs), which are capable of 
differentiation into all the different cell types of the blood, colonise the BM, and grow and 
mature on a mesh work of stromal cells. The stroma provides support for growth and 
differentiation of HSCs by providing essential cell-cell contacts and secreting diffusible 
growth factors. Throughout life, continuous production of haematopoetic cells from the BM 
is maintained. B lymphocyte maturation is also reliant upon interactions with stromal cells 
in the BM. Both membrane-bound and soluble growth factors from the stroma are required 
for the survival, immunoglobulin (Ig) gene-rearrangement, and proliferation o f B cell 
precursors. In addition, self-reactive B cells are either deleted or ‘edited’ following specific 
encounter with Ags expressed by stromal cells within the BM. Mature, non-autoreactive B 
lymphocytes then leave the BM into the circulation (reviewed in Hardy and Hayakawa, 
2001).
T cell precursors emigrate from the BM and complete their maturation in the thymus, an 
encapsulated, bilobed organ situated above the heart. The lobes of the thymus are divided 
into lobules by connective tissue, and each lobule is divided into two compartments, the 
cortex (outer compartment) and the medulla (inner compartment). T-cell precursors enter 
the thymus at the cortico-medullary junction and migrate outwards, through the cortex, 
towards the sub-capsular zone. Following T cell receptor (TCR) gene rearrangements, 
developing thymocytes interact with cortical epithelial cells. Only thymocytes that 
recognize self-MHC molecules on cortical epithilelial cells are positively selected (not 
deleted) and these cells then migrate to the medulla. Here, positively selected thymocytes 
interact with haematopoetic APCs (DCs and macrophages) and are negatively selected 
(deleted) if they recognize self Ags presented via MHC molecules on these cells.
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Thymocytes that survive positive and negative selection leave the thymus, forming the 
peripheral T cell pool (reviewed in von Boehmer et al., 2003).
After their development in the thymus or BM, mature naive lymphocytes circulate through 
the bloodstream, into the secondary lymphoid organs in search o f their specific Ag. 
Although the number of lymphocytes specific for any one Ag may be very few in number, 
and the total number of lymphocytes in the human body ranges from 1010 - 1012, APCs are 
still able to efficiently come into contact with, and activate, lymphocytes specific for the 
Ags they carry. This is due to the exquisite organisation of the secondary lymphoid organs 
and the complex system of cell trafficking that occurs in these tissues. These organs include 
the spleen, lymph nodes (LNs), and gut associated lymphoid tissues (GALT) such as the 
Peyers patches (PPs), tonsils and adenoids. These organs are strategically positioned in 
order to capture Ag from all the organs of the body. The spleen samples Ag from the blood, 
and the PPs sample directly from the intestine. The LNs filter the skin, mucosal surfaces 
and other organs, with Ags delivered by the lymphatic vasculature. Once lymphocytes are 
activated within secondary lymphoid organs, they undergo intense proliferation and 
differentiate into either effector or memory cells with distinct homing capabilities. Effector 
lymphocytes infiltrate sites of inflammation while memory cells recirculate through tissues 
and secondary lymphoid organs, primed for rapid subsequent responses upon repeat 
exposure to their specific Ag. A brief description of the general structure o f the secondary 
lymphoid organs and cellular flow through these tissues will now follow, focussing on LNs, 
PPs and spleen.
LNs are a series of encapsulated structures which are dispersed strategically throughout the 
body and which contain a densely packed network of lymphocytes, macrophages and DCs. 
Structural features of a LN and routes of cellular entry and exit are represented
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schematically in figure 1.1.2. There are two distinct vascular systems which allow entry 
into the LN. First, Ags, APCs and memory lymphocytes can enter through the afferent 
lymphatic vessels which drain tissue fluid, to the LN. Alternatively, circulating 
lymphocytes (and certain other cell types eg. monocytes and NK cells during inflammation) 
can enter LNs from the bloodstream through specialized high endothelial venules (HEVs). 
Once inside LNs, Ag and cells percolate via a conduit system, interacting with cells and 
matrix components of the LN (Gretz et al., 1997; Sixt et al., 2005). Structurally, LNs can be 
segregated into three separate compartments, each supporting distinct microenvironments. 
The outermost layer contains mainly follicular DCs (FDCs) and B cells arranged into 
follicles, which can develop into germinal centres (GCs) during immune responses. 
Beneath this lies the paracortex, sometimes called the T cell area. As the names suggests, 
this area consists mainly o f T cells but also contains interdigitating DCs which present Ag 
to the T cells. The innermost area of the LN is known as the medulla. This area is much 
more sparsely populated than other regions of the LN and contains lymphoid cells, such as 
antibody secreting plasma cells. Cells leave LNs via efferent lymphatics, which empty back 
into the bloodstream via the thoracic duct (reviewed in von Andrian and Mempel, 2003).
APCs continuously drain from the periphery to LN, bringing Ag and information of tissue 
health status. Inflammation in the tissue augments this APC exodus to speed up information 
flow and prepare the LN for initiation of immune responses. To do this, cellular entry to the 
LN is enhanced and egress is slowed down. This causes LN enlargement (independently of 
cell proliferation) and aids the cognate interactions between APCs and T cells required for 
many immune responses. DCs play an important role in causing the induction o f this LN 
hypertrophy. Indeed, recent studies have shown that the more DCs migrate to a LN, the 
more expansion takes place (Martln-Fontecha et al., 2003). This change in LN cellularity is
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also induced by inflammatory cytokines draining from the periphery, such as mast cell 
derived tumour necrosis factor-a (TNFa) (McLachlan et al., 2003).
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Figure 1.1.2: Structure of a Lymph Node. A schematic representation of the major 
structural features o f a LN. The indent shows a close up o f lymphocytes emigrating across a 
high endothelial venule into the LN. Blue cells = lymphocytes, light coloured cells= 
endothelial venules, red circles^ red blood cells. A cell (in green) is shown entering via the 
afferent lymphatic vessel and its route through the lymphatic channels, LN conduits, and 
exit via the efferent lymphatics is depicted with arrows. The main features o f the LN 
(described in the text) are highlighted by solid arrows.
Peyer’s patches are largely similar structures to peripheral LNs but differ in several key 
aspects. Located along the length o f the submucosa o f the small intestine, PPs are 
specialized to sample Ag directly from the gut lumen. Therefore, the entry o f an Ag to the 
PP is quite distinct from that found in the LN, being transported through specialized cells
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called microfold cells (M cells) which effectively form pores in the gut epithelial wall. In 
the layer below the M cells and epithelium, lies the subepithelial dome, an area rich in 
APCs. Beneath this is a layer of lymphoid cells, segregated into T cell areas and B cell 
follicles. Lymphocyte entry into PPs occurs through HEVs which open into either the T cell 
area or, unlike peripheral LNs, open directly into B cell follicles. Cellular exit from PPs is 
distinct from peripheral LNs, with cells leaving through the afferent lymphatics which drain 
from the gut to the mesenteric LNs (the structure and function of PPs is covered in Mowat, 
2003).
The spleen, located in the upper abdominal cavity, is the largest secondary lymphoid organ 
and is specialized both for the disposal of senescent erythrocytes, and for detecting blood 
borne Ags leading to the initiation of systemic immune responses. The organization of the 
spleen is shown schematically in figure 1.1.3. The splenic red pulp is the site of red blood 
cell (RBC) phagocytosis by macrophages. The white pulp surrounds the splenic artery and 
consists of the T cell rich periarteriolar lymphoid sheath (PALS) and the B cell rich 
follicles. The marginal zone (MZ), which is peripheral to the PALS, is populated mainly by 
MZ B cells and macrophages. Macrophages within the MZ are essential for the capture of 
blood-bome Ags (Aichele et al., 2003). In contrast to LNs and PPs, where lymphocytes 
enter through HEVs, leukocyte entry into the spleen comes through terminal arterioles of 
the splenic artery which open into either the MZ or the red pulp. Most blood cells then pass 
through the the red pulp and rejoin the circulation through venous sinuses. However, 
lymphocytes migrate from the red pulp to the white pulp and organize into the T and B cell 
areas described above.
10
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Sheath (PALS)
Figure 1.1.3: Structure of the Spleen: The general structural features of the spleen 
relevant to this discussion are shown in a cross section schematic. Features described in the 
text are highlighted by arrows.
1.1.2 The Multistep Paradigm of Leukocyte Extravasation
From the discussion above, it is clear that central to effective immunity and inflammation 
are mechanisms controlling the temporal and spatial positioning o f leukocytes. From their 
emigration from the BM, circulation through tissues, blood and lymph, tissue infiltration 
during inflammation, and egress during wound healing -  leukocyte homing is an extremely 
important and exquisitely orchestrated process involving a diverse range o f molecular 
mechanisms. A key feature is the ability o f leukocytes to migrate out o f the bloodstream, 
across endothelial barriers and into either peripheral tissues (across inflamed endothelium) 
or secondary lymphoid organs (across HEVs). When the extremely high shear pressure 
encountered by leukocytes within blood vessels is considered, this extravasation cannot be
© Iain Comerford, 2005 CHAPTER ONE IN TRO DU CTION
regarded as anything other than an impressive feat. Quite how leukocytes are able to do this 
is still to be completely resolved. However, a multistep paradigm o f leukocyte extravasation 
has emerged over the past thirty or so years. This is summarized in figure 1.1.4. Normally, 
leukocytes coursing through the circulation will randomly collide with blood vessel walls 
and immediately rebound to be carried on with the flow o f blood. However, low affinity 
interactions mediated by selectins and their ligands causes some leukocytes to adhere to the 
endothelial cells (ECs) o f the vessel wall for a fraction o f a second, causing them to ‘roll’ 
along, sampling the endothelial surface. During this time, and given the appropriate signals 
from the EC, a proportion o f these leukocytes are able to increase the strength o f the 
interaction via activation o f integrins, and firmly adhere to the vessel wall. Further signals 
between adhered leukocytes and the endothelium allow the leukocyte to undergo 
cytoskeletal changes and squeeze through gaps between ECs, out o f the circulation and into 
tissues.
Figure 1.1.4: The Multistep Paradigm of Leukocyte Extravasation. A diagram showing 
the different steps involved in leukocyte extravasation from the circulation into tissues. 
Leukocytes within the bloodstream ‘roll’ on ECs. Cells become activated following a 
specific signaling event allowing firm adhesion. Finally cells can cross the endothelial 
barrier and enter the inflamed tissue. See text for more details. Chemokines depicted as blue 
spheres, receptors are red and purple rods represent bacteria. Figure modified from a 
diagram downloaded from the website o f Chemocentryx Inc.
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Once a leukocyte has left the blood, its correct homing within a tissue is critical to enable 
that leukocyte to exert its function, and ensure appropriate leukocyte compartmentalisation, 
exquisitely demonstrated in tissues like LNs and spleen. Among the molecules known to 
play important roles in these complex migratory events are cell surface adhesion molecules 
such as selectins and integrins, soluble proteins such as leukotrienes, prostaglandins, 
sphingosine-phosphates, and chemotactic factors such as the complement component C5a 
and the formyl peptide fMLP. However, in the field of leukocyte migration, perhaps the 
most important and now best understood molecules are a class of cytokine known as the 
chemokine superfamily. It is these molecules, their function in immunity and inflammation, 
and their regulation which form the basis of this thesis.
1.2 The Chemokines
1.2.1 Historical Perspectives
The importance of directed cell migration in the immune system has long been recognized. 
Indeed, studies as far back as the 1950’s established that leukocyte migration was a 
dynamic process which could be influenced by bacteria or their products (Martin and 
Chaudhuri, 1952). Subsequent investigations characterized lymphocyte trafficking patterns 
(Cannon and Wissler, 1965; Elves, 1970; Gowans, 1959) and demonstrated that subsets of 
lymphocytes could be segregated based upon their differential migration properties (Lance 
and Taub, 1969). However, the molecular mechanisms controlling these processes 
remained largely elusive until relatively recently. The field of chemokine biology has 
emerged within the last 18 years. Although a molecule now recognized as a chemokine, 
Platelet-Factor 4 (PF4), was identified as far back as 1977 (Walz et al., 1977; Wu et al., 
1977), specific chemotactic properties of this molecule have still not been established. It
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was not until 1987 and the discovery of the secreted neutrophil-attracting cytokine 
Interleukin-8 (IL-8) (Walz et al., 1987; Yoshimura et al., 1987) that a true CHEMOtactic 
cytoKINE (Chemokine) had been recognised. This was quickly followed up with the 
discovery of many other similar molecules such as Macrophage Inflammatory Protein i  a  
(M IP-la) (Davatelis et al., 1988; Wolpe et al., 1988), Regulated upon Activation, Normal T 
cell Expressed and Secreted (RANTES) (Schall et al., 1988), Monocyte Chemotattractant 
Protein-1 (MCP-l) (Yoshimura et al., 1989), and Interferon inducible Protein-10 (IP-10) 
(Ohmori and Hamilton, 1990; Vanguri and Farber, 1990). Investigators identified these 
molecules while attempting to characterise proteins secreted by leukocytes upon activation, 
or after the addition of an inflammatory stimulus. Subsequently, through the increased use 
of bioinformatics and mining of expressed sequence tag (EST) databases, many other 
chemokines have now been recognized. Due to their relatively short coding sequences and 
conserved motifs, chemokines can be encompassed by a single EST and are particularly 
easily identified by these methods (Wells and Peitsch, 1997). This allowed the cloning and 
identification of chemokines which are not highly or inducibly expressed, or those which 
are restricted to particular tissues. Consequently, in the last 10 years there has been an 
explosion of the discovery of these molecules. Today, the known chemokine superfamily in 
humans comprises 44 proteins (37 in mice), and the rate of identification of novel 
molecules within this superfamily has slowed significantly. Indeed, the most recent 
chemokine to be identified was CXCL16 in 2000 (Matloubian et al., 2000) and it is now 
thought likely that most, if not all, human and murine chemokines have been discovered.
Shortly after the discovery of IL-8, it was demonstrated that the neutrophil chemotactic 
properties of this molecule could be prevented by pharmacological inhibition o f a class of 
intracellular signaling molecules called G-proteins (Bacon and Camp, 1990). This 
suggested that the secreted chemokine was exerting its biological effects through a cell
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surface G-protein coupled receptor (GPCR). Indeed, it was subsequently shown (Holmes et 
al., 1991; Murphy and Tiffany, 1991) that the IL-8 receptor was a GPCR, which are a large 
family of seven T/M spanning receptors with a wide range of biological functions. The 
cloning and characterization of other chemokine receptors quickly followed (Birkenbach et 
al., 1993; Combadiere et al., 1995; Gao et al., 1993; Nomura et al., 1993; Schweickart et al., 
1994; Yamagami et al., 1994) and these were categorized into four subfamilies based on 
their chemokine ligand specificities. At present, 18 tme human chemokine receptors have 
been described. A more detailed description of chemokine receptors follows in section 1.3.
Combined with the explosion in chemokine identification, the demonstration in 1996 that 
two chemokine receptors, termed CCR5 and CXCR4, were essential co-receptors for the 
entry of human immunodeficiency virus (HIV) into host cells, and that the chemokine 
ligands of these receptors could block viral infection, stimulated great interest in the field of 
chemokine and chemokine receptor biology (reviewed in Simmons et al., 2000). An 
enormous amount of research into these molecules has taken place in the last decade and 
chemokines are now recognized as important regulators in virtually all immune-mediated 
pathologies. Furthermore, chemokines and chemokine receptors are now also known to 
play roles in processes as divergent as central nervous system (CNS) function, embryonic 
development, wound healing, and cancer, and control the biology of many non-leukocytic 
cell types. A detailed summary o f all these functions is beyond the scope of this thesis. 
Instead, I intend to introduce the field of chemokine/chemokine receptor biology, focussing 
on its role in immunity. In particular, the biology of three chemokine receptors called 
CCR7, CXCR5, and CCR9, and their ligands shall be discussed as these have most 
relevance to this study. I also intend to discuss the regulation of chemokine activity and 
introduce the emerging concept o f decoy receptors in this system. I shall go on to describe
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CCX-CKR, a recently cloned receptor that binds to the same chemokines bound by CCR7, 
CXCR5, and CCR9, and whose function is the main subject o f investigation in this thesis.
1.2.2 Nomenclature
As chemokines were rapidly and independently identified, many existed in the literature 
under different names. For example, Epstein-Barr Virus Induced Molecule-1 Ligand 
Chemokine (ELC) is also known as MIP-3J3 and exodus-3 (Kim et al., 1998; Yoshida et al., 
1997; Yoshie et al., 1997). Additional confusion was created by the fact that the genes 
which coded for the chemokine proteins also had unique names. These were designated 
Small secreted Cytokine (SCY), followed by a letter designating which chemokine 
subfamily the protein they coded for belonged to (SCYa, SCYb, SCYc, and SC Yd), and a 
number indicating the chronological order in which the genomic sequence was identified. 
To eliminate any ambiguity, a new systematic nomenclature was introduced in 2000 based 
around the important amino-terminal cysteine motif (described in detail below) and the 
number assigned to the gene which coded the protein (Zlotnik and Yoshie, 2000). Thereby, 
ELC is now known as CC chemokine ligand 19 (CCL19), with CC indicating the 
subfamily, L indicating that it is a ligand, and 19 corresponding to the gene SCYb 19 (the 
19th SCYb gene cloned). From here-on, the new systematic name for each chemokine will 
be used exclusively. The chemokine superfamily with traditional and new systematic 
nomenclature is summarised in table 1.1.
The nomenclature for the 18 chemokine receptors has not had the complications which 
have surrounded the ligands. Ever since it was recognized that chemokine receptors were 
generally restricted to responding to chemokines of a particular subclass (see section 1.2.3), 
they were named with that subfamily prefix, followed by an R for receptor, and a number 
designated chronologically to their discovery. Hence the first CXC chemokine receptor was
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named CXCR1 and so on. It is important to note that to be officially designated as a 
chemokine receptor, and to be included in the systemic nomenclature, a given receptor must 
be demonstrably able to transduce intracellular signals upon chemokine binding (Murphy, 
2002; Murphy et a l, 2000). On this basis, three receptors which display high affinity 
binding but apparently do not couple to downstream signaling pathways have been 
excluded from the nomenclature. These receptors, which are of particular relevance to this 
study, are the Duffy antigen / receptor for chemokines (DARC), D6, and CCX-CKR (and 
are discussed in more detail later). The ligands bound by these molecules are indicated in 
Table 1.1.
1.2.3 Chemokine Structure and Subclassifications
Chemokines share a number of key structural and functional similarities. Although they 
often display only a limited amount of primary amino acid sequence homology, it is the 
primary sequence which defines them as chemokines. This is the because of a conserved 
motif which confers a well-defined secondary structure on these molecules (see figures 
1.2.1 and 1.2.2). Generally ranging between approximately 6-llkD a in size, these mainly 
secreted molecules characteristically display a three stranded anti-parallel (3-pleated sheet 
(the so called ‘Greek Key’ motif) with a C-terminal a-helix laid across (Baldwin et al., 
1991; Chung et al., 1995; Hoover et al., 2000; Lubkowski et al., 1997). This distinctive 
three-dimensional structure of chemokines is the result of disulphide bonds between a 
defining tetra-cysteine motif. The chemokine superfamily can be subdivided by the exact 
configuration of this motif at the amino terminus. The two major subfamilies of chemokines 
are the a  (or CXC) chemokines, and the (3 (or CC) chemokines. The CXC chemokines have 
a single, non-conserved, amino acid between the first two cysteine residues of this motif, 
while in the CC chemokines these residues are directly juxtaposed.
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Table 1.1: The Chemokine Superfamily. Systematic nomenclature for each chemokine is 
given along with common old name or names. CCX-CKR ligands are highlighted in green. 
The human chromosomal location and structural subdivision o f the chemokines is also 
included where relevant. Those chemokines only present in humans or mice are prefixed 
with ‘h ’ or ‘m ’ respectively. Italicized chemokines are generally classified as ‘constitutive’. 
Receptors which the full length unmodified chemokine acts as an agonist are shown, along 
with potential decoy receptor, D6 , DARC or CCX-CKR. Abbreviations: ELR+/-, the 
presence or absence respectively o f Glu-Leu-Arg m otif in CXC chemokines (see text for 
details); T/M, chemokine with transmembrane domain. (Adapted from a table in Comerford 
and Nibbs, 2005).
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There are two other minor chemokine subfamilies which have different variations o f this 
motif. The CX3C chemokines, of which there is only one identified member, CX3CL1, 
have three amino acids between the first two cysteines, while in the C chemokine subfamily 
one o f these residues is lacking. As already eluded to, this structural subdivision is also a 
functional division as members o f a particular subfamily are generally restricted to binding 
only chemokine receptors specific for that subclass o f chemokine (there are some notable 
exceptions to this, o f which more later). However, within each subfamily there is a degree 
of redundancy and promiscuity. Many chemokines are able to bind to multiple different 
receptors o f that subtype and many receptors are able to bind several different chemokines. 
The significance o f this will be discussed in more detail later.
Figure 1.2.1: The Chemokine Subfamiles. The structural subdivisions which segregate 
the 4 chemokine subfamilies are shown. These are described in detail in the text. Cysteine 
residues are marked with a ‘C \  Disulphide bonds which give the ‘chemokine fold’ are 
shown in yellow arrows. Amino and carboxy termini are marked NH2 and COOH 
respectively. Mucin like stalk and T/M domains are also shown where appropriate. 
Proteolytic cleavage site shown in yellow.
Mucin lik e  SUiX
C COOrf
Mucin Like Slalk T/M ; COCM
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Figure 1.2.2: Chemokines: Prim ary, Secondary, and Tertiary Structure. (A) When 
secondary and tertiary structure is examined between 3 chemokines from different 
subfamilies (in red CX3CL3, in blue CCL2, in yellow CXCL8 ) there are clear structural 
similarities. However, a line up o f the primary amino acid sequence (B) shows that there is 
limited homology between chemokines at this level. The defining cysteine residues are 
marked in bold. Conserved residues linked with a (|). Part (A) o f this figure is modified 
from a diagram downloaded from the website o f Chemokine Therapeutics Corp.
CC chemokines, which make up the largest chemokine subfamily, are potent 
chemoattractants for a wide range o f leukocytes including monocytes, DCs, eosinophils, 
basophils, NK cells and lymphocytes. Chemokines o f the CXC class were initially thought 
to exert their functions primarily on neutrophils. However, the discovery o f CXCLs9-16 
showed that some members o f this family have specificity for lymphocytes and other cell
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types also. In the past, the CXC subfamily has been further subdivided based upon the 
presence or absence of a glutamic acid-leucine-arginine (ELR) motif directly preceding the 
first amino terminal cysteine residue. ELR+ CXC chemokines have specificity for the 
receptors CXCR1 and/or CXCR2 (and were thought to exclusively attract neutrophils), 
while ELR- chemokines use other CXC chemokine receptors (and were thought to only 
attract lymphocytes). This subdivision was also thought to divide CXC chemokines into 
those that are angiogenic (promote blood vessel growth, ELR+), and those which are 
angiostatic (inhibit blood vessel growth, ELR-) (Koch et al., 2001; Strieter et al., 1995). 
However, this functional subdivision is less clear now with evidence that ELR+ 
chemokines can also attract cells other than neutrophils (Hess et al., 2004; Ramjeesingh et 
al., 2003; Salcedo et al., 2000; Takata et al., 2004) and that ELR- chemokines can also be 
angiogenic (Kryczek et al., 2005; Salcedo and Oppenheim, 2003). The most recently 
identified CXC chemokine, CXCL16, differs from all the other members o f this subfamily, 
in that it is expressed with a mucin-like stalk and a T/M domain and therefore is primarily 
expressed at the cell surface, rather than being secreted (see figure 1.2.1). The only member 
of the CX3C chemokine family, CXCL1, also displays these T/M features. Both CXCL16 
and CX3CL1 are able to be released as soluble proteins following proteolytic cleavage and 
this has functional relevance for their biology (discussed in more detail in section 1.4.1).
Most chemokines are expressed in one of two characteristic patterns and have been 
subdivided on this basis. Generally, chemokines can be described as being either 
inflammatory (inducible) or constitutive (homeostatic) (see table 1.1). Inducible 
chemokines are expressed following an inflammatory stimulus. Leukocytes, including 
neutrophils, macrophages, immature DCs and lymphocytes, express chemokine receptors 
for inducible chemokines. This allows them to infiltrate damaged tissues in order to 
orchestrate and effect inflammatory and immune responses. Due to their inducible and high
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level expression, these chemokines tended to be among the earliest identified. As such they 
include CXCLsl-11, (perhaps excluding CXCL4), CCLs2-16, XCL’sl-2 and CX3CL1 (see 
table 1.1). In contrast, constitutive chemokines are continuously expressed in the absence of 
danger signals, and control a wide range of homeostatic functions such as cell homing 
during embryonic development, lymphorganogenesis and immune surveillance. They are 
also of fundamental importance in co-ordinating cell movements during immune responses. 
Of particular relevance to this thesis are the constitutive chemokines CCL19, CCL21 and 
CXCL13 which are intimately involved in the homing of cells to, and their 
compartmentalisation within, secondary lymphoid organs. These chemokines facilitate the 
homing of T and B cells, along with DCs, into the appropriate areas o f these organs where 
they undergo interactions essential for lymphocyte activation and immunity, and will be 
discussed in more detail in section 1.5. Other constitutive chemokines are tissue restricted 
and control traffic to those sites. For example, CCL25 (again of relevance to this thesis) is 
expressed in the thymus and by epithelial cells of the small intestine (Campbell and 
Butcher, 2002), while CCL27 directs migration to the skin (Homey et al., 2002). Whilst this 
functional division of chemokines has general use, the difficulty with the 
inducible/constitutive classification of chemokines is that most constitutive chemokines are 
subject to some degree of induction during inflammation, which blurs the distinction 
between these groups (Bonacchi et al., 2003; Christopherson et al., 2003; Columba-Cabezas 
et al., 2003; Nakayama et al., 2001; Serra et al., 2004).
1.2.4 Genetic Organisation and Phylogenic Origin
Similar to other gene families with pivotal roles in the immune system, such as the MHC 
genes, the chemokine gene family has evolved rapidly, probably through a series of 
duplication events followed by divergence. Phylogenic analysis suggests that the 
chemokine CXCL12 is the modem representative o f an ancestral chemokine. Functional
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CXCL12 orthologs are conserved from higher mammals through other vertebrates, such as 
birds and fish (Huising et al., 2004) and to lower vertebrates, such as Xenopus laevis (Braun 
et a l, 2002). It should be noted that this means chemokines must have evolved before the 
development of complex immune systems, probably with the development of the CNS. 
Indeed, chemokines such as CXCL12 (and its receptor CXCR4) are essential for successful 
embryogenesis, with CXCR4 or CXCL12 null mice displaying a wide variety of defects in 
such things as cerebellar and cardiac development, and vascularisation of the 
gastrointestinal tract (Tachibana et al., 1998; Zou et al., 1998). The rapid expansion of 
chemokine genes in higher mammals coincides with the development of more sophisticated 
immune systems. It is likely that the intricate cell homing that is required for the 
development of complex primary and secondary lymphoid microenvironments, and for 
robust immune and inflammatory responses, has driven the selective pressure which has 
forced the dramatic adaptive radiation of mammalian chemokine genes (Huising et al., 
2003). The adaptive nature of the chemokine system means that these genes have evolved 
so recently that functional chemokine orthologs do not always exist even between relatively 
closely related species. For example, there is no mouse ortholog of human CXCL8 and no 
human equivalent of murine CXCL15. It is likely that the human chemokine system is still 
evolving relatively rapidly, as the selective pressure exerted by the HIV pandemic is likely 
to favour the survival of individuals with high copy number o f CCL3-L1 or who have the 
CCR5A32 mutation (Gonzalez et al., 2005; Mummidi et al., 1998).
In humans, the major chemokine clusters are on chromosomes 14 and 17 (the CXC cluster 
and the CC cluster, respectively) and in mice these clusters are located on chromosomes 5 
and 11 (see figure 1.2.3) (Nomiyama et al., 2001). Structurally and functionally related 
chemokine genes tend to be closely linked, reflecting their probable origin from recent (in 
evolutionary terms) genetic duplication events. This is especially true of ‘inducible’
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chemokines, which have the highest tendency to be clustered. Not all chemokines lie within 
these clusters. Indeed, CXCL12 is the only chemokine gene on the human chromosome 10 
(Shirozu et al., 1995) and other smaller minor clusters exist, such as on human chromosome 
9 where CCL 19 and CCL21 reside (Nakano and Gunn, 2001; Yoshida et al., 1998) and 
human chromosome 16 which is home to CCL 17 and CCL22 (Imai et al., 1998). In mice, 
CCL 19 an CCL21 are found on chromosome 4 but have undergone considerable 
duplication events. Significantly, this has generated two forms o f CCL21, termed 
C C L2\ser  and CCL2\leu, expressed in different arms o f the vasculature. Thus, CCL21 leu 
is expressed by lymphatic endothelial cells (LECs), whilst CCL21 ser is produced by HEVs.
The Major CXC chem okine gene cluster in humans and mice
Mouse Chromosome 5
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Figure 1.2.3: Genetic Organisation of Chemokines. The major chemokine gene clusters 
in humans and mice are shown. Filled blue boxes represent chemokine genes while purple 
boxes represent pseudogenes. The protein that is coded by the gene is indicated.
1.2.5 Redundancy and Promiscuity
As has been touched on briefly earlier, a degree o f redundancy and promiscuity exists 
within the chemokine system with some receptors able to bind multiple ligands and some 
chemokines able to bind several different receptors. For example, CCR7 is a receptor for
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both CCL19 and CCL21 while the chemokine CCL5 can bind to CCRI, CCR3, CCR5, D6 
and DARC (see table 1.1). There are many probable reasons for these phenomena. First, 
this provides a level of robustness to the chemokine system. Thus, natural polymorphisms 
in an outbred population which affect the chemokine system can be compensated for by the 
redundancy of the system. Because multiple chemokines can, for example, attract 
macrophages through CCR5, the loss of production of one of these chemokines will not 
necessarily have functional consequences (reviewed in Mantovani, 1999). Second, the 
redundancy of the chemokine system may help prevent pathogen subversion o f the system. 
As shall be discussed in more detail later, as a strategy to manipulate host immune 
responses and favour their survival, many viruses produce chemokine binding proteins, 
chemokine decoy receptors, and receptor antagonists (reviewed in Liston and McColl,
2003). By having multiple chemokines capable o f producing the same or similar functional 
outcomes, our immune systems are often relatively resistant to these forms o f microbial 
subversion. Third, different chemokines are produced in response to different types of 
stimulus. Therefore, to ensure robust responses, a single chemokine receptor may need to 
be able to recognise several different chemokines which are differentially produced. 
Furthermore, different chemokines are produced in different anatomical locations. For 
example, CCL 19 is expressed by stromal cells and DCs within secondary lymphoid organs, 
while the alternative CCR7 ligand, CCL21 is produced by LECs and HEVs. This may be 
important in allowing the step-wise navigation o f cells expressing a single receptor to 
specific anatomical compartments. Moreover, although different chemokines may be able 
to bind to the same receptor, different signals and functional responses may be induced. 
Indeed, recent studies have shown this to be the case. For example the two CCR7 ligands, 
CCL 19 and CCL21, differentially activate signaling pathways (Kohout et al., 2004) and the 
different CCRI ligands also lead to different types of signals from this receptor (Tian et al.,
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2004). In fact, gene knock-out (KO) studies have demonstrated that chemokines which 
bind to the same receptor are not always redundant. The loss o f one ligand is not always 
replaced by another. Examples of this are the CCL2 and the CCL3 KO mice. Although both 
of these chemokines are ligands for receptors which bind several different chemokines, 
mice deficient in either CCL2 or CCL3 still exhibit significant functional defects 
(Chintalacharuvu et al., 2005; Cook, 1996; Huang et al., 2001).
1.3 Chemokine Receptors
1.3.1 Structure of Chemokine Receptors
Chemokines exert their biological functions at nanomolar (nM) concentrations through their 
interactions with cell surface-expressed chemokine receptors that belong to the large family 
of type-V GPCRs. Although chemokine receptors, unlike their ligands, lack a single 
structural signature, the general structure of these receptors is largely conserved. This 
structural homology is evident at the level of primary sequence with chemokine receptors 
displaying between 25 to 80% identity. It should be noted that other non-chemokine 
receptor GPCRs, such as the dopamine or p-adregenic receptors, are also largely similar to 
chemokine receptors at this level. Characteristically, chemokine receptors are about 40kDa 
in size and between 340-370 amino acids in length. They feature seven hydrophobic T/M 
domains, an acidic extracellular amino terminus, an intracellular tail at the carboxy 
terminus, and three intracellular and extracellular loops. The second intracellular loop 
contains the motif DRYLAIVHA, or a variation of it, which is involved in G-protein 
coupling, and the third intracellular loop tends to be short and basic. Each o f the 
extracellular loops contains a cysteine residue, between which form disulphide bridges
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important for maintaining the 3 dimensional structures o f these molecules (see figure 1.3.1) 
(reviewed in Horuk, 1994).
Extracellular
Intracellular
coon
TOP
VIEW
Figure 1.3.1: General Structural Features of a Chemokine Receptor. A schematic 
representation o f a chemokine receptor in the plasma membrane, from two different 
perspectives. TOP: A chemokine receptor showing the seven T/M spanning domains (green 
rectangles), the extra- and intracellular loops and amino (NH2) and carboxy (COOH) 
termini are shown by solid black lines. Extracellular cysteine residues and the disulphide 
bonds between them shown by © and dotted lines, respectively. The conserved DRY m otif 
on the second intracellular loop is shown. INDENT: A top view of a chemokine receptor 
looking down onto a cell. Green elipses represent T/M domains.
1.3.2 Chemokine Receptor Expression
The expression o f chemokine receptors, and hence the diversity o f cells which respond to 
particular chemokines, is highly restricted and tightly regulated. Although it now 
recognized that some chemokine receptors are expressed on a wide range o f cell types, it is 
receptor expression on leukocytes which has been studied in greatest detail. Different 
leukocytic subsets display different chemokine receptor preferences. Importantly, the
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expression of chemokine receptors is also modified in certain cell types upon activation or 
differentiation. This not only allows the immune system to differentially attract functionally 
distinct subsets of cells depending upon the type of receptors which are expressed, but also 
permits cells to modify their responses in concert with functional differentiation requiring 
relocalisation. A brief outline of the chemokine receptor expression profiles o f the various 
leukocytic cell types and the functional significance of this follows.
Generally, innate effector cells express receptors allowing homing to sites o f peripheral 
inflammation. Different types of innate effector cells express a different array of chemokine 
receptors allowing specificity o f attraction depending on the type of response required. 
Neutrophils, for example, express CXCR1 and CXCR2 allowing their infiltration to sites of 
acute inflammation, where production of chemokines such as CXCL8 tends to be an early 
event. Eosinophils express CCR3 which favours their recruitment to sites of Th2 type 
immune responses, such as airway allergy or schistisome granulomas. Macrophages 
express CCR1 and CCR5 which favours their migration to Thl effector sites (reviewed in 
Baggiolini, 1998).
DCs have two distinct functional phases in their life, designated immature and mature. 
Immature DCs express receptors such as CCR1 and CCR5 allowing their localisation in 
peripheral tissues where they can pick up Ag. Upon activation, these cells must present this 
Ag to lymphocytes within LNs and their chemokine receptor expression profile is altered 
accordingly. A loss of CCR1 and CCR5 is therefore accompanied by an acquisition of 
CCR7 expression, facilitating emigration of DCs to the LN via the afferent lymphatics 
(reviewed in Sallusto and Lanzavecchia, 2000).
Similarly, expression of chemokine receptors by lymphocytes is a dynamic process, 
changing as cells develop and differentiate. Naive lymphocytes express chemokine
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receptors such as CCR7 which enable their efficient trafficking to secondary lymphoid 
organs. Upon activation however, the chemokine receptor expression profile of 
lymphocytes is reprogrammed. T cells destined for follicles upregulate CXCR5, and 
activated Thl or Th2 effector cells differentially express CXCR3 or CCR3 and CCR8, 
respectively. This allows the immune system to differentially attract functionally distinct 
subtypes of leukocytes depending upon the type of response required. In other scenarios, 
lymphocytes activated by DCs which picked up Ag the mucosa of the small intestine are 
programmed by these DCs to express CCR9, facilitating lymphocyte migration to the 
intestine. Conversely, lymphocytes activated by skin derived DCs are induced to express 
CCR4 and CCR10, enabling their migration to the skin. These alterations in chemokine 
receptor expression are normally in concert with changes in adhesion molecule expression, 
further assisting in the tissue specific migration of these cells (Moser and Loetscher, 2001; 
Sallusto et al., 2000).
The biological significance of CCR7 and CCR9 and their ligands will be discussed in 
greater depth in section 1.5. However, there first follows a discussion of the biochemical 
properties of chemokine receptors, a key introductory section to set the scene for in vitro 
studies performed in this thesis on CCX-CKR.
1.3.3 The Chemokine/Chemokine Receptor Interaction
The molecular interactions between chemokines and chemokine receptors have been 
studied in detail and reveal many interesting aspects of chemokine biology. Although in 
concentrated solution, or in crystals, chemokines have a tendency to oligomerise (Baldwin 
et al., 1991; Clore et al., 1990), it is clear that chemokines interact with their receptors as 
monomers (Clark-Lewis et al., 1995). Structural studies of various chemokines have 
revealed the critical importance o f the amino terminus for receptor binding and activation.
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For example, the aforementioned amino terminal ELR motif found in a subset o f CXC 
chemokines is essential for their activation o f either CXCR1 or CXCR2 (Baggiolini et al., 
1997). Discrete motifs have been identified which differentially affect receptor binding and 
activation. The extreme amino terminus o f CXCL12 (residues 1 and 2) have been 
demonstrated to be critical for activation (but not binding) o f CXCR4, while another motif, 
designated RFFESH, in the loop region o f CXCL12 has been shown to be crucial for 
receptor binding but not activation (Crump et al., 1997). Collectively, structure-activation 
studies have revealed a two step model for a chemokine agonizing its cognate receptor. 
First, the receptor recognizes the binding site within the loop region o f the chemokine (so 
called ‘docking’). This immobilizes the chemokine and allows its extreme amino terminus 
to interact with and activate the receptor, inducing a conformational change in the receptor 
(so called ‘triggering’) (Crump et al., 1997). This two step model o f receptor activation is 
illustrated in figure 1.3.2. As shall be discussed in section 1.4.3, this has great relevance to 
the regulation o f the chemokine system as some N-terminally modified chemokines retain 
receptor binding, but lose activation capabilities, creating effective receptor antagonists.
1) Approach 2) Docking 3) Triggering
Docking site
Inactive Receptor Occupied Receptor Activated Receptor
Conformational Change
Figure 1.3.2: Chemokine Receptor Ligation. Chemokines interact with chemokine 
receptors with their docking site, shown in (1). Docked chemokines (2) bring their N- 
terminal triggering domain into close proximity with the extracellular helices o f the 
receptor, leading to a conformational change and receptor activation (3).
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1.3.4 Signal Transduction
The molecular events in the responding cell following chemokine/chemokine receptor 
ligation determine the downstream biological effects of this interaction. These responses 
can be highly diverse depending on the specific chemokine/chemokine receptor interaction, 
which cell type is responding to the chemokine, and the context of the signal. Directed 
leukocyte motion, the most commonly associated downstream effect o f chemokine receptor 
signaling, involves many phenomena including cytoskeletal rearrangements, cell 
polarization and changes in integrin affinities. A great deal is known about various 
signaling pathways which are activated downstream of chemokine receptors, however it is 
less well understood how these signals result in effective polarized chemotactic responses. 
A full summary of these diverse pathways is beyond the scope of this thesis, however, I 
shall briefly summarise the most well-characterized signaling pathways downstream of 
chemokine receptors and outline the current thinking on how chemotaxis and integrin 
activation can take place.
Chemokine receptors are known to couple to several well-characterised intracellular 
signaling cascades upon agonist stimulation. All of the best understood of these signals 
originate from the exchange of GDP for GTP between the activated receptor and its 
associated G-proteins (see figure 1.3.3). Chemokine receptors are coupled to heterotrimeric 
G-proteins, and act as a GDP exchange factors (GEF) for these proteins upon receptor 
activation. This leads to dissociation of heterotrimeric complex, with the GTP bound Ga 
subunit splitting from the Gpy subunit, both of which go on to initiate the activation of a 
range of signaling cascades. This response is subsequently terminated by the hydrolysis of 
GTP on the Ga subunit which, now in its GDP bound form, reassociates with the Gpy 
subunit. The rate of this hydrolysis can be enhanced by regulators of G-protein signaling 
(RGS proteins) which provides both a means of negative feedback to this system and
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provides a mechanism for cells to regulate responsiveness to chemokine induced signals 
(Agenes et al., 2005; Moratz et al., 2004; Moratz et al., 2000). The exotoxin o f the bacteria 
Bordetella pertussis, pertussis toxin (PTX), inhibits the interaction of heterotrimeric G 
proteins with receptors by catalysing the ADP-ribosylation o f the G a  subunits, keeping 
them in their GDP bound inactive state (Ladant and Ullmann, 1999). PTX effectively 
inhibits many responses driven through chemokine receptors (Bacon and Camp, 1990; 
Cyster and Goodnow, 1995; Qin et al., 2005).
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Figure 1.3.3: G-Protein Activation. Unoccupied receptors associate with the 
heterotrimeric G-protein complex in which the Ga subunit is bound to GDP. Receptor 
activation following ligand binding causes a conformational change in the receptor which 
allows the receptor to act as a guanine neucleotide exchange factor for the associated G- 
proteins. The now GTP bound G a subunit dissociates from the Gpy subunits. Both o f these 
subunits go on to activate downstream signaling cascades. Following GTP hydrolysis, G- 
protein subunits reassociate, terminating signaling. The rate o f this hydrolysis can be 
enhanced by RGS proteins. (See text for more details).
Various cascades o f downstream second messengers are activated by the G-protein 
subunits. The principal subunit required for chemotactic responses is the Gpy subunit. 
When released from the heterotrimeric complex, Gpy rapidly activates various downstream 
effectors. For example, Gpy activates the phopshoinositide specific phospholipase C (PLC) 
which catalyses the cleavage o f phosphoinositide inositol diphosphate (PIP2) into
32
© Iain Comerford, 2005 CHAPTER ONE INTRODUCTION
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) (see figure 1.3.4). IP3 binds to a 
specific receptor on the endoplasmic reticulum (ER) which subsequently causes 
mobilisation o f intracellular calcium stores causing a transient rise in calcium ion (Ca2 ) 
concentration within the cell. DAG, along with the released Ca2+, activates various isoforms 
of protein kinase C (PKC), a family o f serine/threonine kinases. Activation o f PKC is a 
common event downstream from various membrane receptor induced signals and is not 
unique to chemokine receptors. As shall be discussed in more detail later, signals activated 
downstream of PKC are important for receptor desensitisation and internalisation, and are 
required for responses mediated through chemokine receptors such as integrin activation, 
through activation o f the GTPase RhoA. However, PKC signaling does not seem to be 
particularly important for gradient sensing and directed cell chemotaxis (chemokine 
receptor signalling is reviewed in Thelen, 2001).
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Figure 1.3.4: Signaling Pathways Downstream of Chemokine Recetor Ligation. Some 
o f the major signaling players involved in various pathways activated by chemokine 
receptors and the effects of signaling are shown (see text for more details). Arrows indicate 
‘activated downstream’.
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One o f the major players in directing cell chemotaxis is phosphoinositide 3-kinase-y 
(PI3Ky). The importance o f PI3Ky activation in directing leukocyte chemotaxis has been 
demonstrated in numerous studies with cells lacking this enzyme (Del Prete et al., 2004; 
Reif et al., 2004; Sasaki et al., 2000). However, this seems to depend upon the cell type 
studied and the receptor being activated, with T cells in particular seemingly able to 
utilise PI3Ky independent mechanisms (Cronshaw et al., 2004; Ward, 2004).
Like PLC, activation of PI3Ky is also mediated by the Gpy subunit following its release 
from the heterotrimeric complex. PI3Ky rapidly phosphoylates the membrane lipid 
phosphatidylinositol leading to the formation of the second messenger phosphatidylinositol 
3,4,5-triphosphate (PIP3). Interestingly, this occurs principally at the leading edge of the 
chemotaxing cell. PIP3 provides high affinity docking sites in the cell membrane for 
proteins containing pleckstrin homology (PH) domains. One of the best characterised PH 
domain containing proteins, and one which is recruited to the membrane by PIP3, is the 
sereine/threonine protein kinase B (PKB). Here, PKB is activated by another PH domain 
containg protein, PIP3-dependent protein kinase 1. Activated PKB then phosphorylates 
various downstream effectors of chemokine receptor signaling. Proteins which have been 
shown to be critical for chemotaxis are the Rho family of GTPases, such as RhoA, Rac, and 
cdc42, whose activity is regulated by guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs), which are recruited to the leading edge of the cell via 
PH domains. Therefore, activation of PI3Ky leads to rapid accumulation at the leading edge 
of the cell, activated factors critical for the actin polymerisation and cytoskeletal 
rearrangements required for chemotaxis. In addition, the PDVspecific phosphatase, PTEN, 
is excluded from the leading edge and accumulates at the trailing edge, preventing PTEN 
from dephosphorylating PIP3 which would inhibit the accumulation of positive regulators 
of chemotaxis at the leading edge (reviewed in Procko and McColl, 2005).
34
© Iain Comerford, 2005 CHAPTER ONE INTRODUCTION
Activation of membrane lipids are not the only types o f signals directly transduced through 
chemokine receptors. Protein kinase pathways are also directly activated, though in many 
instances the functional importance of these kinases in mediating chemokine responses 
remains unclear. The Ga subunits, when released form the heterotrimeric complex, can 
activate Src family kinases leading to activation of proteins such as focal adhesion kinase 
(FAK), an important regulator of cytoskeletal adhesion to the extracellular matrix (ECM) 
(Le et al., 2005). Mitogen-activated protein kinase (MAPK) cascades are also activated in 
response to chemokine receptor signaling, although the direct role of G-protein subunits in 
their activation is not clear. In addition, other diverse signaling pathways may also be 
activated by chemokine ligation of receptor. For example, there are reports that chemokine 
receptors oligomerise following ligation and that this can lead to G-protein independent 
activation of j anus-family tyrosine kinases and signal transducers and activators of 
transcription (JAKs and STATs) (Mueller and Strange, 2004; Soldevila et al., 2004; Vila- 
Coro et al., 1999; Zhang et al., 2001) However, this remains a controversial issue, with 
recent studies disputing the importance of this signaling pathway, at least for some 
receptors (Moriguchi et al., 2005).
Despite the many advances in understanding chemokine receptor signaling, the precise 
program of molecular events involved in transducing signals from chemokine receptors 
leading to chemotaxis are not yet fully understood. Moreover, it should be noted that the 
signaling requirements clearly vary depending upon the cell type studied, the activation 
state of that cell, and the chemokine receptor which has been ligated. Most detailed studies 
of the complex signaling required for chemotaxis have used the model organism 
Dictyostelium amoebae, or have studied neutrophils (reviewed in Parent, 2004). However, 
extension of these findings to other cell types such as lymphocytes has revealed that 
homologous mechanisms do not always apply.
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Chemotaxis requires a complex series o f molecular events occurring over minutes or hours 
as the cell finds its home. However, another important outcome of chemokine receptor 
signaling, crucial for leukocyte extravasation, is integrin activation that mediates 
chemokine induced firm adhesion. This needs to be extremely rapid, and gradient sensing is 
unlikely to be of importance. It is increasingly well-understood which pathways are used 
downstream of chemokine receptors to induce conformational changes in integrins (placing 
them in a high affinity state) and causing integrin clustering (figure 1.3.5). Ligation o f 
CCR7 or CXCR4 causes LFA-1 integrin affinity changes independently o f PI3K but 
dependent on the rapid activation of RhoA (Giagulli et al., 2004). Clustering o f integrins is 
however dependent on PI3K (Constantin et al., 2000) and RhoA and PKCS, (Giagulli et al., 
2004). Supporting this model, a recent study showed that RhoA was required for integrin 
activation and firm adhesion to vascular cell adhesion molecule-1 (VCAM-1) using mouse 
thymocytes (Vielkind et al., 2005).
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Figure 1.3.5: Signal Transduction Leading to Rapid Integrin Activation. Induction of 
LFA-1 high-affinity state by chemokines is controlled by the signaling activity o f RhoA. 
Induction o f LFA-1 lateral mobility is controlled by PKC and by further signals generated 
by RhoA. The capability o f PKC to control LFA-1 lateral mobility depends on translocation 
to the plasma membrane, which is controlled by the RhoA, as well as by PKC kinase 
activity. PKC appears to be an effector o f both PI3K and RhoA mediating LFA-1 lateral 
mobility induced by chemokines. (reproduced from Giagulli et al., 2004)
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1.3.5 Desensitisation, Endocytosis, and Recycling of Chemokine 
Receptors
Of particular relevance to this study are the molecular mechanisms which control 
chemokine receptor internalisation, intracellular trafficking, and recycling. Typically, 
GPCRs including chemokine receptors, following agonist ligation, transiently activate the 
various signaling pathways described above and are then subject to desensitisation and 
internalisation. Once internalised, the receptor can become resensitised and recycle back to 
the cell surface, or be targeted to lysosomes where it is degraded (Grady et al., 1997). This 
behaviour is of fundamental importance in determining GPCR signal magnitude and 
duration, and is an essential component of chemokine receptor function. Indeed, as 
discussed in section 1.4.5.2, the manner whereby D6 engages the endocytic machinery has 
proven instrumental in defining the function of this ‘silent’ receptor.
Signaling induced by chemokine receptor ligation leads to the activation of second 
messenger protein kinases (eg. PKB, PKC see above). These kinases, in addition to 
phosphorylating effector proteins enabling chemotaxis etc. also lead to the phosphorylation 
of serine and threonine residues on the C-terminus of chemokine receptors (figure 1.3.6). 
These events are insensitive to PTX and are therefore independent of Gai-protein mediated 
signals. Receptor phosphorylation leads to steric inhibition of G-protein coupling, leading 
to receptor desensitisation. In particular, protein kinases with specific acitivity for GPCRs, 
G-protein coupled receptor kinases (GRKs), are activated by the kinase activity o f second 
messengers (such as PKC), and specifically phosphorylate residues in the C-terminus of 
agonist-occupied GPCRs. This receptor phosphorylation by GRKs provides a binding site 
for multifunctional intracellular adaptor and scaffold proteins called P-arrestins. There are 
various consequences for the receptor once arrestins have bound. First, P-arrestins provide 
further steric blockade to the interaction of the receptor with G-proteins, contributing to
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desensitisation of subsequent signaling through the receptor. Thus, p-arrestins provide a 
negative feedback mechanism regulating GPCR activity. Second, p-arrestins act as adaptor 
proteins linking the receptor complex to the endocytic machinery via interactions with the 
polyhedral lattice-forming molecule clathrin (Goodman et al., 1996), and the p2-adaptin 
subunit o f the key clathrin adaptor protein AP-2 (Laporte et al., 1999). This generally leads 
to internalisation of the receptor complex via clathrin-coated pits (CCPs). Finally, recent 
work has shown that p-arrestins also act as a scaffold which actually transduce certain 
signals, such as MAPK activation (reviewed in Lefkowitz and Shenoy, 2005).
Endocytosis via CCPs is a complex process dependent upon interactions between an array 
of molecules. The extensive effort to understand this process has revealed novel genetic 
approaches to inhibit this pathway. Of particular relevance to this thesis are epidermal 
growth factor receptor substrate 15 (EPS 15), and dynamin. EPS 15 interacts via a C- 
terminal binding domain to AP-2, and has been shown to be important in linking AP-2 to 
the plasma membrane. Interactions between the EPS 15 homology (EH) domains at the N- 
terminus of EPS 15 and various other proteins critically involved in endocytosis, such as 
synaptojanin (Haffner et al., 1997) and epsin (Salcini et al., 1999), link AP-2 and hence 
clathrin to the endocytic machinery. Numerous studies have shown that inhibition o f EPS 15 
function via use of dominant negative inhibitors effectively prevents endocytosis via CCPs 
(Belleudi et al., 2003; Benmerah et al., 1999; Benmerah et al., 1998). The large GTPase 
dynamin is also recruited to endocytosing clathrin-complexes, where it self assembles into 
ring-like supramolecular structures, stimulating its own GTPase activity and ‘pinching’ the 
invaginating pit of clathrin-coated plasma-membrane to form an intracellular vesicle. 
Dynamin is thought to be essential for all forms of receptor-mediated endocytosis 
(reviewed in Sever, 2002).
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Figure 1.3.6: Molecular Control of Endocytosis and Vesicular Traffic. The two best 
understood pathways o f endocytosis, CCPs and caveolae are shown. Selected molecules 
known to play crucial roles in these pathways are shown and the routes o f intracellular 
trafficking and recycling are shown with arrows. GPCR internalisation following ligand 
binding is shown. For more details see the text.
Alternative means o f endocytosis are utilised by some GPCRs. The best understood 
clathrin-independent endocytic compartment are caveolae, a subset o f cholesterol-enriched 
lipid rafts which characteristically contain the dimeric cholesterol-binding membrane 
proteins, the caveolins. These structures are present in many cell types, but are particularly 
abundant in ECs, where they are proposed to play a role in transendothelial transport o f 
various macro-molecules. Caveolins are 21-24kDa proteins which function to stabilise 
caveolae at the plasma membrane (Thomsen et al., 2002). However, signaling resulting in 
tyrosine phosphorylation o f caveolins can result in endocytosis o f caveolae into an 
endosomal compartment termed the caveosome (Pelkmans and Helenius, 2002). Similar to 
clathrin-mediated endocytosis, the activity o f the GTPase dynamin is critically involved in
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the ‘pinching’ of the invaginating caveosome from the plasma membrane (Henley et al., 
1998). Certain GPCRs are known to localise to caveolae, where many diverse signaling 
molecules often cluster, and some have been shown to internalise via these structures, such 
as the p-adregenic and A l adenosine receptors (Escriche et a l, 2003; Gines et al., 2001; 
Rapacciuolo et al., 2003). However, reports of chemokine receptors undergoing caveolar 
endocytosis are patchy. CCR5 has been shown to localise to lipid rafts and this is important 
for ligand binding and receptor activation. However, endocytosis of CCR5 has, like almost 
every other chemokine receptor studied, been shown to be dependent on CCPs (Signoret et 
al., 2005). The only chemokine receptor which so far, to my knowledge, has been shown to 
internalise via caveolae is CCR2 when stimulated with CCL2, at least in ECs from the 
blood-brain barrier and astrocytes (Andjelkovic et al., 2002; Dzenko et al., 2001; Ge and 
Pachter, 2004). However, the possibility, that in this context, CCR2 is mediating chemokine 
transcytosis must be considered. It also of interest to note, especially in the context of the 
potential role in protein transcytosis mediated by caveolae, that DARC has been detected in 
EC structures containing caveolin (more details on the potential role of DARC in 
chemokine trancytosis follow in section 1.4.5.1) (Chaudhuri et al., 1997).
Once internalised, clathrin-coated-vesicles (CCVs) fuse with vesicles of the early 
endosomal compartment. An important regulator of this is the small GTPase, Rab5, a 
member of a large family of RabGTPase Ras-like G-proteins. These proteins act as a 
molecular ‘switch’ cycling between an inactive GDP bound state and active GTP bound 
state. This is regulated by guanine nucleotide exhange factors (GEFs) and GTPase 
activating proteins (GAPs). The different isoforms of the RabGTPases localise to the 
membranes of different intracellular compartments and organelles (reviewed in Tuvim et 
al., 2001). Here, Rab proteins, through their GTPase activity, regulate the transport, fusion, 
and budding of vesicles. Importantly, the function of Rab proteins in intracellular
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trafficking has been determined by using dominant negative or constitutively active forms 
of a given Rab protein, which inhibit endogenous Rab functions or mimic Rab-GTP, 
respectively. These molecules have been employed to great effect in dissecting the 
trafficking tendencies of GPCRs (Seachrist and Ferguson, 2003). Rab5 is found the early 
endosomal compartment and regulates fusion of CCVs to this compartment and subsequent 
behaviour of these early endosomes. Agonist occupied GPCRs which are internalised and 
reach the early endosomes can have two fates. 1) The ligand dissociates from the receptor, 
the receptor is dephosphorylated and recycles back to the cell surface (resensitisation). 2) 
The receptor is targeted to lysosomes for degradation (long-term downregulation). 
RabGTPases also play an impotant role in regulating these processes. Some Rab5+ early 
endosomes fuse with Rab4+ endosomes, and recycle rapidly back to the cell surface. This 
route is employed by some GPCRs following their dephosphorylation (Seachrist et al.,
2000). Alternatively, receptors can recycle back to the plasma membrane via the slower 
Rab 11+ recycling endosomal compartment. The chemokine receptor CXCR2 has been 
shown to employ this route of recycling (Fan et al., 2003). Receptors which are targeted for 
degradation upon long term agonist stimulation traffic there via a Rab7+ compartment 
which fuses to the lysosomes.
The molecular mechanisms which control the fate o f cargo internalised via caveloae are not 
yet well-characterised. However, simian virus 40 (SV40) and cholera toxin, both 
internalised via caveloae can enter the Rab5+ early endosomes, and are directed to the 
Golgi apparatus or ER, respectively (Pelkmans et al., 2004). Similarly, the autocrine 
motility factor receptor is also internalised via caveolae and traffics to the ER (Benlimame 
et al., 1998; Le et al., 2002). Trafficking of cargo endocytosed via caveolae is not yet well- 
understood and is an active area o f current research.
41
© Iain Comerford, 2005 CHAPTER ONE INTRODUCTION
1.4 Post-Translational Control of Chemokines (parts of this section
have previously been published in a modified form (Comerford and Nibbs, 2005)). 
Chemokines and their receptors play critical roles in many aspects of a fully functional 
immune system. Much research has focussed upon chemokine production and receptor 
activation, but comparatively less attention has fallen upon the regulation of chemokines 
after they have been produced. Indeed, such processes may act to limit or modify the 
responsiveness of these systems or control the localisation or presentation of chemokines. It 
is now clear that post-translational control of the chemokine network is of fundamental 
importance in regulating immune cell function. Importantly, as will be discussed later, the 
properties of CCX-CKR, the focus of this thesis, have led to the hypothesis that this 
molecule plays a role in chemokine regulation. Thus, in this next section, I consider 
mechanisms that influence chemokine activity after synthesis and describe emerging 
evidence for the existence o f a subset of chemokine receptors involved in chemokine 
sequestration and/or transport. Within this context, CCX-CKR is introduced.
1.4.1 Chemokine Storage and Release
Excluding the nuclear-targeted form o f murine CCL27 (Gortz et al., 2002), synthesized 
chemokines are transported into the cell’s secretory apparatus. However, this does not 
necessarily lead to immediate chemokine release. In certain scenarios, chemokines can be 
directed to intracellular storage compartments, for rapid release on cell activation. For 
example, CCLs 3 and 5 are stored in the granules of HIV-specific CD8+ T cells, alongside 
the cytolytic enzymes, granzyme and perforin. Upon antigenic stimulation these cells 
degranulate, lysing virus-infected cells, and releasing CCL3 and 5 which can help prevent 
free HIV from infecting neighboring cells (Wagner et al., 1998). Another recent study 
found that CD8+ T cells release pre-stored CCL5 from a novel storage compartment upon 
T cell receptor engagement (Catalfamo et al., 2004). The consequences of this storage and
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release may be diverse - leukocyte attraction, further T cell degranulation, or amplification 
of T cell activation -  and by storing packages of chemokine, the response will be relatively 
instantaneous, bypassing the need for comparatively slow transcriptional changes.
T cells are not alone in storing chemokines. Many chemokines, are stored in platelet a- 
granules and released on platelet activation, allowing rapid participation in thrombus 
formation and possibly angiostasis (through CXCL4), plus leukocyte attraction (by other 
chemokines CCL3, 5, 7, CXCL8) at sites of vascular injury. CCL5 and 11 are found in 
eosinophils and released after degranulation signals are received (Bandeira-Melo et al.,
2002). In addition, at least in vitro, ECs can store many chemokines for rapid release, 
including CCL26 and CXCL8 in Weibel-Palade bodies, and CXCL1 and CCL2 in a 
histamine-responsive compartment (Oynebraten et al., 2004). In fact, it has been proposed 
that CXCL8 storage acts as an EC ‘memory’ o f inflammatory stimulation based on the 
observation that this chemokine was stored during the first stimulation, allowing rapid 
release on the second stimulation (Utgaard et al., 1998; W olff et al., 1998). The 
physiological significance of chemokine storage has yet to be examined in vivo, but it 
seems likely that the secretion of these stores provide for the rapid initiation of chemokine- 
driven responses without the delay required to initiate transcription.
In addition to storage, CXCL16 and CX3CL1, are produced attached to a mucin-like stalk 
and T/M domain. In this form, they act as adhesion molecules, sticking the chemokine- 
expressing cell to cells expressing the appropriate receptor. However, members o f the ‘a 
disintegrin and metalloproteinase’ (ADAM) family of proteases can specifically cleave 
these molecules, releasing the chemokine domain (Gough et al., 2004; Hundhausen et al.,
2003). This not only disrupts chemokine/receptor-mediated cell-cell adhesion, but also 
allows the attraction o f distant cells expressing the appropriate receptor.
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1.4.2 Chemokine Presentation
Once chemokines are secreted, their diffusion is limited by complex interactions with 
extracellular and cell surface constituents. High profile has been given to their binding to 
charged sulphated sugars of the glycosaminoglycan (GAGs) family. The in vivo 
significance of this interaction in chemokine biology has been a matter of much discussion. 
Undoubtedly, interactions with GAGs on ECs provides chemokine presentation to 
peripheral blood cells, preventing soluble chemokines from being washed away by blood 
flow, and allowing for the induction of firm leukocyte adhesion to the vessel wall. 
Interestingly, GAGs are differentially expressed on different types o f ECs and different 
GAGs have varying binding affinities for different chemokines. It is possible that this may 
permit the selective display of certain chemokines, and hence for selective cellular influx 
into particular tissues. Interestingly, in vivo studies exploiting recombinant chemokine 
mutants suggests that oligomeric chemokine binding to GAGs is crucial for biological 
responses (Proudfoot et al., 2003). These mutants retained full in vitro activity, but their 
inability to oligomerise on GAGs was hypothesized to be responsible for their lack o f in 
vivo activity. Beyond the blood vessels, in the interstitial space, it has long been suggested 
that GAG binding is required to maintain haptotactic chemokine gradients along which 
migrating cells traffic. It is indeed likely that chemokines are presented on GAGs to 
migrating cells, and that GAGs act to store, protect, or limit the distribution o f chemokines. 
However, the existence of continuous chemokine gradients in vivo has, to my knowledge, 
received no experimental support and indeed presents significant conceptual problems 
concerning their establishment and maintenance in complex 3-dimensional tissues. Instead, 
perhaps, the idea o f chemokine boundaries proposed by Pelletier and colleagues (Pelletier et 
al., 2000) seems more realistic, where responsive cells polarize once a chemokine/no
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chemokine boundary is encountered on a suitable substratum, and this polarization and 
directed migration occurs in the absence of a continuous gradient.
GAGs also seem to influence the nature of the chemokine/receptor interaction. Soluble 
components of GAGs, such as heparin sulphate, bind chemokines and modulate their 
activity, although in many instances the data is inconsistent. For example, some reports 
present data that heparin-CXCL8 complexes do not have agonistic effects on either CXCR1 
and CXCR2, and that heparin reduces the chemotactic activity of this chemokine on 
neutrophils (Kuschert et al., 1999). However, earlier work suggested that these complexes 
were in fact more active as neutrophil attractants (Webb et al., 1993). Nonetheless, the 
release of soluble GAGs may be a strategy to rapidly modulate local chemokine function 
whilst the ECM is degraded during inflammation. Such control may contribute to the 
resolution of the response, and encourage wound healing and tissue repair.
1.4.3 Proteolytic Control of Chemokines
Including the ADAM-mediated release of membrane-bound chemokines described above, 
many mammalian proteases have specific regulatory effects on the bioactivity of 
chemokines. Some simply degrade chemokines, but others exert more subtle regulation 
either by modification of the chemokine itself, or through the restructuring o f the ECM. 
The dipeptidyl peptidase CD26 and the large matrix metalloproteinase (MMP) family have 
come under most scrutiny and the ways these proteases control and fine tune local in vivo 
chemokine responses are discussed below and summarised in figure 1.4.1.
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Figure 1.4.1: Proteolytic Control of Chemokines: Chemokine regulation by matrix 
metalloproteinases (MMPs) and the dipeptidyl peptidase CD26. (A+B) MMPs can cause 
the degradation, shedding or amino terminal clipping o f select chemokines. (C) CD26 
also clips the amino terminus o f some chemokines. Clipping can result in inactivation or 
potentiation o f chemokine bioactivity, alter receptor specificity, or generate antagonists. 
For further details, refer to the main text.
The MMPs are a family o f zinc-dependent proteinases, expressed as either as membrane- 
anchored or secreted forms, which are critical in ECM degradation and remodelling. These 
proteases play an important role in the tissue degradation required for leukocyte infiltration 
during inflammation, and tumour cell escape during metastasis. The action o f these 
proteases will release GAGs that, as discussed above, can alter chemokine interactions with 
its receptor. In addition, cleavage o f ECM components may allow the release o f deposits of 
chemokine. Compelling work from Li and colleagues (Li et al., 2002) has suggested that 
MMP-7 mediates the shedding o f chemokines associated with the proteoglycan, syndecan- 
1, into alveolar fluid from the surface o f damaged lung epithelial cells. Pro-inflammatory 
CXC chemokines associate with syndecan-1 after their production in response to injury, 
and also help attract neutrophils from the blood vessels. However, these neutrophils will 
only move into the alveolar space if  MMP-7 releases syndecan/chemokine complexes. As
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a consequence, MMP-7 null mice are protected from the neutrophil-mediated lung injury 
seen in wild type (WT) mice in response to bleomycin, with neutrophils accumulating in 
the interstitial space rather than traversing the epithelium. In a similar manner, mice 
lacking MMP-2 showed reduced bronchoalveolar lavage (BAL) chemotactic activity, 
including lower levels of CCL11, in a model of asthma. This was accompanied by reduced 
leukocyte egress across the epithelium with these cells appearing to be retained in the lung 
parenchyma, which in this model, lead to a significantly increased risk of asphyxiation 
(Corry et al., 2002). On the other hand, MMP-9 null mice have exaggerated allergic 
inflammation and higher BAL chemokine levels, suggesting this MMP may regulate 
chemokine destruction (McMillan et al., 2004). Indeed, MMP-9 does degrade several CXC 
chemokines in vitro, but it can also clip the amino terminus of CXCL8 and CXCL12 either 
potentiating or inactivating, respectively, their activity on their known receptors 
(McQuibban et al., 2001; Opdenakker et al., 2001). Interestingly, MMP-9 is released from 
neutrophils after CXCL8 stimulation, enhancing neutrophil infiltration by ECM 
degradation, and through the cleavage o f CXCL8 to make it a more potent CXCR1 agonist. 
Thus, regulation of CXCL8 by MMP-9 may create an amplification loop promoting 
neutrophil chemotaxis and tissue invasion during inflammation.
It is now clear that many MMPs can regulate chemokine bioactivity by taking amino acids 
(typically the first four) off the critical receptor interaction/activation domain in the amino 
terminus. Truncated forms of CCL2, 7, 8, and 13 created by MMP cleavage in vitro lose 
their ability to activate their receptors, CCR2 or 3, but binding is retained (McQuibban et 
al., 2000; McQuibban et al., 2002). Thus, these molecules are transformed into effective 
antagonists, blocking migration mediated by the uncleaved chemokine, both in vitro and in 
vivo. A similar MMP-2-mediated four amino acid truncation of CXCL12 had been viewed 
as being inactivating, as interaction with its receptor CXCR4 is lost (McQuibban et al.,
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2001). However, recent intriguing work has shown that truncated CXCL12, possibly 
generated during HIV-associated dementia, is able to bind to a currently unidentified G- 
protein coupled receptor on neurons, through which it mediates cell death (Zhang et al., 
2003). Proteases again impinge on the biology of CXCL12 during haemopoietic stem cell 
(HSC) mobilization from the BM by granulocyte-colony stimulating factor (G-CSF) 
treatment (Petit et al., 2002). CXCL12/CXCR4 interactions play a crucial role in HSC 
homing and retention in the BM: G-CSF stimulates the release o f elastase from neutrophils 
which degrades CXCL12, releasing HSCs into the blood. Contrary to these general views 
of chemokine inactivation by proteases, has come the recent demonstration that unusual 
‘long’ chemokines CCL6, CCL9 and CCL15 and CCL23 are cleaved by proteases to 
generate extremely potent CCR1 agonists (Berahovich et al., 2005). Together, these 
observations suggest that the specific MMP milieu found in an inflamed site will have a 
profound impact on chemokine bioactivity and subsequent immune cell recruitment.
CD26 is a T/M serine protease which can clip two amino acids from the amino termini of 
proteins carrying a proline or alanine at the second position (Van Damme et al., 1999). 
This includes the chemokines CXCLs 6, 9-12, and CCLs 3L1, 4, 5, 11 and 22 (Guan et al., 
2004; Lambeir et al., 2001; Proost et al., 1998), which can be trimmed to -2 variants in 
vitro, with a further two amino acids removed in some instances. Notably, -2 forms of 
several chemokines are detectable in biological samples. N-terminal truncation of 
chemokines by CD26 results in different functional alterations depending on the 
chemokine, and the receptor interaction studied. For example, CD26-processed CXCL12 is 
inactive on CXCR4, and its HIV entry inhibitory properties are abolished. Similarly, 
CD26-truncated forms of CXCLs 9-11, and CCLs 5, 11 and 22 all have reduced ability to 
attract target cells through their cognate receptors (Lambeir et al., 2001; Proost et al., 2001). 
In addition, whilst truncated CCL5 loses its ability to agonise CCR1 and CCR3, it retains
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CCR5 binding, and hence its HIV-1 suppressive properties (Proost et al., 1998). CD26- 
truncated CCL3L1 bioactivity is also dramatically different from its intact form, losing the 
ability to signal through CCR3, but showing increased activity through CCR1 and 5. This 
converts CCL3L1 into a potent monocyte chemoattractant and HIV entry inhibitor, that 
lacks the ability to attract CCR3+ cells, such as Th2 lymphocytes, eosinophils and 
basophils (Proost et al., 2000). Removal of the first two amino acids from CCL4 has little 
impact on CCR5 binding, but now allows this chemokine to interact with CCR1 and 2 
(Guan et al., 2002). Thus, by regulating chemokine function by subtly clipping the amino 
terminus, CD26 may be able to alter local recruitment of leukocytes.
The in vivo significance of CD26-mediated chemokine trimming has yet to be fully 
explored, and experimental analysis is likely to be confused by the other substrates and 
functions of CD26. Also, target chemokines show dramatic variation in their readiness to 
be clipped by CD26 (Lambeir et al., 2001), with CXCL12 and CCL22 being particularly 
sensitive. It is possible that these molecules are the principal chemokine targets for this 
protease. CD26 is expressed by a variety of cell types, and is present as a soluble form in 
normal plasma. It is also up-regulated by T cells upon activation (Fleischer, 1994), 
maintained on CXCR3+ Thl cells (Ludwig et al., 2002), and is particularly abundant on 
anergic T cells (James et al., 2003). It is tempting to speculate that this gives T cells the 
option of modifying their local chemokine milieu to alter the composition and behaviour of 
their leukocytic neighbours. Alternatively, it may allow T cells to extinguish the signals 
that attracted them in the first place, and it is perhaps no coincidence that CXCL12 and 
CCL22, excellent CD26 substrates, are potent T cell attractants. This may be o f particular 
significance for anergic T cells, where the clipping of T cell chemokines on EC surfaces or 
emanating from an APC could help suppress the attraction of non-anergic, Ag-specific 
cells, and thus prevent their activation (James et al., 2003).
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1.4.4 Microbial Regulation of Chemokines
During millions of years of co-evolution with their hosts, microbes have developed 
numerous adaptations to combat the host immune response (reviewed in Alcami, 2003). 
Many viruses have developed ways of manipulating the chemokine system, presumably to 
promote their own survival. The existence of these strategies not only emphasises the 
importance of the chemokine system in host defense: but also highlights potential 
mechanisms of chemokine regulation that could exist in the mammalian host, or that could 
be exploited therapeutically. This is achieved by viral genes encoding soluble chemokine- 
binding proteins, chemokine receptor antagonists, or receptor homologues with chemokine 
sequestration activity.
Viral chemokine binding proteins (vCKBPs) fall into three groups. vCKBPl, from 
myxoma virus, interacts weakly with chemokines via their GAG binding domains, although 
homologous proteins from related viruses show no chemokine affinity. This may dislodge 
chemokines from their GAGs, disrupting presentation to leukocytes (Lalani et al., 1997). 
vCKBP2, encoded by myxoma and vacinnia viruses, interacts with most CC chemokines 
through their receptor-binding domain, blocking receptor interaction (Alcami et al., 1998). 
Similarly, herpesvirus vCKBP3 blocks host chemokine activity, but has even broader 
specificity binding members from all four chemokine subfamilies, and also disrupting 
chemokine-GAG binding like vCKBPl (Parry et al., 2000). Viruses have also evolved 
soluble proteins to neutralize inflammatory cytokines, a regulatory mechanism mimicked in 
mammals with soluble versions o f cytokine receptors created by protease cleavage or 
alternative splicing (Alcami, 2003). However, despite vCKBPs representing an effective 
mechanism for modulation and tuning of chemokine responses, mammalian homologues 
have not been described. This may be due to the fact that such molecules cannot be readily 
generated by cleavage or alternative splicing of heptahelical chemokine receptors.
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Viruses can also encode chemokine homologues that are able to exhibit two significant 
properties. First, they can mimic the activity of host chemokines, attracting select leukocyte 
subsets through host chemokine receptors, most likely to create an environment conducive 
to viral survival at the site of infection. For example, human herpesvirus-8 (HHV-8) 
encodes vMIPI and III which act as specific CCR8 and CCR4 attractants, respectively 
(Endres et al., 1999; Stine et al., 2000). These receptors are preferentially expressed on Th2 
cells, and the attraction of these cells to sites of virus infection could feasibly create an 
environment low in anti-viral Thl activity. Second, some viral chemokines can act as 
chemokine receptor antagonists. Most notably, vMIPII, again from HHV-8, interferes with 
chemokines from all four subfamilies by binding to their receptors without activating them 
(Kledal et al., 1997). In this case, there are parallels within mammalian chemokine biology, 
as an increasing number of chemokines have been shown to have antagonistic activity. 
This includes MMP-truncated forms described above, but unmodified chemokines also 
show antagonistic activity e.g. CCL18 and CXCLs 9-11 on CCR3, CCL26 on CCR2, and 
CCL11 on CXCR3 (Loetscher et al., 2001; Nibbs et al., 2000; Ogilvie et al., 2003; Ogilvie 
et al., 2004; Xanthou et al., 2003). It is notable that agonists for CCR3 antagonise CXCR3, 
and vice versa. CXCR3 is predominantly found on Thl cells, whilst CCR3 is involved in 
homing in Th2 responses. In this way, there exists the possibility that inflammation can be 
regulated by the balance of positive and negative chemokines present at the inflamed site. 
Indeed, CXCL9 and 10 are produced at sites of lung inflammation during a typical 
eosinophilic Th2 allergic response: experimental neutralization of CXCL9 enhances 
eosinophilia, whilst i.v. administration of low doses of the same chemokine reduces this 
response (Fulkerson et al., 2004).
Viruses can also carry functional homologues of chemokine receptors able to bind host 
chemokines and fulfill a variety o f functions, presumably to the advantage of the vims.
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They can behave like typical host receptors allowing infected cells to migrate in response to 
endogenous host chemokines, perhaps enabling them to seek out new infectible cells 
(Billstrom et al., 1998). Alternatively, as these receptors can often exhibit constitutive, 
ligand-independent signaling, they have the potential to reprogram infected cells. The best 
example of this is the HHV-8 encoded receptor ORF-74 which promotes angiogeneisis, 
oncogenesis, and cellular activation through constitutive signaling resulting in excessive 
activation of various signaling pathways (Bais et al., 1998; Bais et al., 2003). Finally, and of 
most relevance here, is the proposal that viral chemokine receptors may regulate the 
chemokine system by acting as decoy receptors. Even in the absence of ligands, the 
cytomegalovirus (CMV) encoded receptor, US28 undergoes constitutive internalisation 
from the cell surface and recycles through late endocytic vesicles and lysosomes (Bodaghi 
et al., 1998; Fraile-Ramos et al., 2001). Ligands that bind US28 are consequently 
internalised and destroyed, preventing them from activating endogenous host receptors. In 
addition, as US28 resembles a constitutively activated receptor, cross desensitisation of 
other GPCRs (including chemokine receptors) may also be an important aspect of its 
biology. The mechanisms behind these unusual behaviours o f US28 could provide a useful 
paradigm for the function of the putative mammalian chemokine decoy receptors, discussed 
below. The intracellular C-terminus of US28 is constitutively phosphorylated (a 
modification that requires ligand binding in most chemokine receptors), and this enables 
internalisation and recycling o f US28 without stimulation (Mokros et al., 2002; Waldhoer et 
al., 2003). Interestingly for a GPCR, endocytosis, while being clathrin-dependent, does not 
appear to require p-arrestins (Droese et al., 2004; Fraile-Ramos et al., 2003).
1.4.5 Chemokine Decoy and Transport Receptors
Within cytokine biology, particularly in the interleukin-1 and tumour necrosis factor 
families, numerous mechanisms o f interference have evolved to regulate responses
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(reviewed in Mantovani et al., 2001). True decoy receptors are present, defined as cell 
surface ligand-binding proteins with high affinity and specificity, but which are unable to 
induce downstream signaling, or present ligand to a signaling receptor. Soluble receptor 
forms exist, as do specific receptor antagonists. Recently, receptor-like molecules, that 
deplete signaling molecules away from active receptors, have also been described (Brint et 
al., 2004; Mantovani et al., 2004). Together, these molecules serve not only to emphasise 
the importance of tight regulation of these systems, but also represent potential therapeutics 
in a wide variety of pathologies. As discussed above, the nature of host chemokine 
receptors, precludes the production of soluble extracellular forms by simple proteolytic 
cleavage or alternative splicing. However, the existence of three, apparently ‘silent’, 
chemokine receptors in mammals has lead to proposals that they are specialized decoys 
scavenging extracellular chemokines, or alternatively, that they mediate transcellular 
chemokine transport. These proteins, DARC (Chaudhuri et al., 1993; Lee et al., 2003b), D6 
(Nibbs et al., 2001; Nibbs et al., 1997) and CCX-CKR (Gosling et al., 2000; Townson and 
Nibbs, 2002) bind subsets of chemokines, but exhibit unusual properties compared to 
typical leukocytic chemokine receptors. Despite structural homology to other chemokine 
receptors, and showing high affinity interactions with chemokines, these molecules do not 
couple to the major signaling pathways activated by other chemokine receptors upon ligand 
stimulation (described in 1.3.4), and thus do not mediate cell migration. In fact, no 
alternative signals have been described from these receptors, leading to them often being 
referred to as ‘silent’. Furthermore, they exhibit unusual expression patterns and, unlike 
typical chemokine receptors, are difficult to find on peripheral blood leukocytes. Moreover, 
recent exciting data have provided further support that these molecules neutralise or 
transport chemokines. These concepts are discussed below and summarised in figure 1.4.2.
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Figure 1.4.2: Regulation of Chemokine Function by Chemokine Decoy and 
T ransport Receptors. Pro-inflammatory chemokines (1) (represented as red circles) may 
be sequestered by virus-infected cells (2) using receptors like CMV US28. On blood 
vessel ECs, DARC transports pro-inflammatory CC and CXC chemokines (3) from the 
interstitial space to the luminal surface for presentation on GAGs to blood leukocytes. 
DARC may also mediate chemokine degradation on ECs (4). On RBCs, DARC appears 
to buffer serum chemokine levels (5). D6 , found on LECs, internalizes and destroys its 
CC chemokine ligands (6 ). A role for chemokine transport (7) by D 6  is not yet clear. 
CCX-CKR, the third atypical mammalian chemokine receptor, may possibly act as a 
decoy receptor for its ‘constitutive’ CC ligands, CCLs 19, 21 and 25 (represented as green 
circles), from a currently unknown cellular home ( 8 ). See main body o f the text for 
further details.
1.4.5.1 The Duffy Antigen Receptor for Chemokines (DARC)
The Duffy blood group Ag was first described in 1950. The same protein acts as an entry 
receptor on erythrocytes for some malarial parasites (Miller et al., 1975), and interestingly, 
its absence, caused by promoter mutation in Duffy negative individuals, provides 
erythrocyte resistance to malarial infection (Horuk et al., 1993). It later transpired that 
Duffy Ag is a receptor for various pro-inflammatory chemokines o f both CC and CXC 
subclasses (Neote et al., 1993) (Table 1.1), leading to its renaming as DARC, Duffy 
antigen/Receptor for Chemokines. Along with erythrocytes, DARC is also expressed on 
vascular ECs, where it is up-regulated during inflammation (Lee et al., 2003a; Patterson et
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a l, 2002). It is particularly prominent at sites of leukocyte extravasation, including the 
HEVs of LNs and post-capillary venules (Girard et al., 1999; Hadley et al., 1994). 
Importantly, DARC lacks canonical intracellular signaling motifs (Chaudhuri et al., 1993), 
and does not support any detectable ligand-induced signaling or migration (Neote et al., 
1994). Furthermore, as mentioned earlier, DARC is associated with caveolae vesicles in 
ECs, and these structures are commonly associated with transcellular transport o f their 
cargo (Chaudhuri et al., 1997). These features have lead to hypotheses that DARC is 
involved in the transcytosis, or neutralization, of chemokines at EC barriers (Lee et al., 
2003b) and, on erythrocytes, that it may act to regulate plasma chemokine concentrations 
(Darbonne et al., 1991).
In situ binding assays have revealed that radiolabelled chemokines selectively bind to vein 
and venule ECs and that the specificity of this binding matched the ligand specificity for 
DARC (Hub and Rot, 1998). Indeed, unpublished studies using DARC null mice have 
shown that this EC chemokine binding is DARC dependent (see review by Nibbs et al.,
2003). More refined immunoelectron microscopy studies in skin have demonstrated that 
chemokines can be internalized by ECs, transported across the cell, and presented on the 
tips of luminal microvilli, presumably associated with GAGs (Middleton et al., 1997). 
Although GAGs may play a significant permissive role in transcellular chemokine 
transport, DARC has been put forward as the key mediator. In keeping with this, recent in 
vitro data have shown that CXCL8 can be transported across EC monolayers in a DARC- 
dependent fashion (Lee et al., 2003b). Moreover, neutrophil recruitment to tissues, after 
intratracheal CXCL8 administration or bacterial lipopolysaccharide (LPS) injection, is 
diminished in DARC null mice (Lee et al., 2003b; Luo et al., 2000). However, a separate 
report suggested an anti-inflammatory role for DARC, observing increased neutrophil 
infiltration in response to higher doses of LPS in DARC null mice (Dawson et al., 2000).
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One possible explanation for this apparent discrepancy is that at low doses of LPS, DARC- 
mediated chemokine transcytosis is required for optimal neutrophil homing, while 
increasing the amount of LPS induces more chemokine production, dampened through a 
decoy receptor function of DARC. Additional evidence for a decoy function of DARC has 
emerged from studies on mice engineered to over-express DARC in ECs. These mice show 
reduced angiogenic responses to certain CXC chemokines. In this instance, DARC may 
sequester these chemokines, preventing them agonizing EC CXCR2, thus blocking 
angiogenic signals from this receptor (Du et al., 2002). The combined data from these in 
vivo studies are an interesting start, but it is clear that further careful investigations are 
required to dissect the function of DARC on ECs.
What of the role of erythrocyte DARC? A serum chemokine sink, or decoy, function has 
been proposed, but it is now emerging that DARC may also function as a chemokine 
reservoir, maintaining plasma concentrations of certain chemokines. DARC negative 
humans display reduced plasma levels of CCL2 compared with DARC positive individuals 
(Jilma-Stohlawetz et al., 2001) and injected chemokines more rapidly disappear from the 
circulation in DARC null mice (Fukuma et al., 2003). Thus, erythrocyte DARC may act as 
a chemokine buffer, sequestering chemokines present at high levels in the serum, but 
maintaining a homeostatic level as their presence subsides. Because plasma chemokines 
desensitize circulating leukocytes, careful buffering by DARC may control leukocyte 
sensitivity to pro-inflammatory chemokines, limiting under- or over-responsiveness.
1.4.5.2 D6: A Pro-inflammatory Chemokine Scavenger
D6 binds to almost all pro-inflammatory CC chemokines (CCLs 2, 3L1, 4, 5, 7, 8, 11-14, 
and 22, and weakly to CCL17 (Bonecchi et al., 2004; Nibbs et al., 2001; Nibbs et al., 1997) 
but is unable to couple to the major signaling pathways typically activated by chemokine
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receptors, or mediate chemotaxis. This may in part be due to D6 lacking a canonical 
DRYLAIV motif in the second intracellular loop, carrying DKYLEIV instead. 
Interestingly, when this sequence is introduced in place of DRYLAIV in CCR5, signaling is 
blocked, whilst mutation to DRYLAIV in D6 introduces weak signaling capability into D6 
(Nibbs, unpublished). In humans, D6 is abundant on the LECs of the vessels draining the 
skin, the gut, and the lungs (Nibbs et al., 2001). It can also be found on tissue mast cells, 
macrophages, and DCs in some contexts. In addition, D6 is also expressed by trophoblasts 
at the foetal-maternal interface (Nibbs, unpublished). From these observations, it has been 
hypothesised that D6 is involved in the clearance of inflammatory chemokines from these 
sites, by acting as decoy receptor. Indeed, subsequent in vitro biochemical investigations 
revealed several key properties of D6 that appear to make it ideally suited for a role as a 
functional decoy receptor. First, D6 can rapidly internalise its ligands (Bonecchi et al., 
2004; Fra et al., 2003; Weber et al., 2004). How does D6 achieve this in the absence of 
signaling? As detailed in section 1.3.5, chemokine receptors normally require ligand- 
induced signals to induce their endocytotic internalisation. However, D6 undergoes ligand- 
independent constitutive internalisation, rapidly cycling to and from the cell surface through 
the early and recycling endosomal compartments (Weber et al., 2004). One consequence of 
this is that the majority (>95%) of cellular D6 is found inside cells at any one time. Second, 
unlike CCR5, the affinity of D6 for it’s ligands is reduced at the low pH conditions found in 
endosomes, facilitating the dissociation of internalised chemokine from D6, and ensuring 
intracellular retention (Weber et al., 2004). These internalised chemokines are then 
degraded, whilst the receptor recycles. In this way, D6 ligands can hitch their way into 
cells for degradation, without requiring signalling and without desensitising the cell to 
subsequent exposure to D6 ligands. The molecular mechanisms controlling the behaviour 
of D6 in these systems have not yet been fully resolved. However, investigations have
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shown that D6, similar to CMV US28, is constitutively phosphorylated, and that exposure 
to ligand does not increase the extent of phosphorylation (Blackburn et al., 2004). Thus, the 
possibility arises that constitutive phosphorylation facilitates ligand-independent 
endocytosis of D6 in a manner akin to US28. Notably, endocytosis of D6 appears to be via 
CCPs, since genetic inhibition of EPS 15, clathrin, and dynamin all inhibit chemokine 
uptake via this receptor. The role of p-arrestins in D6 endocytosis remain unresolved 
however, with two independent studies coming to conflicting conclusions (Galliera et al., 
2004; Weber etal., 2004).
Despite questions remaining over the precise mechanisms at work, the in vitro data strongly 
suggest that D6 has the biochemical hallmarks o f a chemokine-sequestering decoy receptor. 
Importantly, this has recently received support from the analysis of D6 null mice. These 
animals display an exaggerated inflammatory response to the repeated application of a 
topical phorbol ester irritant, PMA (Jamieson et al., 2005). In this model of cutaneous 
inflammation, local production of TNFa induces production of inflammatory chemokines 
in the skin which drives leukocyte infiltration (see figure 1.4.3). In WT animals, 
inflammation resolves several days after the cessation of PMA painting. However, in D6 
null mice inflammation is dramatically enhanced leading to a pathology which resembles 
human psoriosis. This phenotype was characterised by a hyper-proliferative epidermal 
compartment containing CD3+ T cells and enhanced dermal mast cell numbers. Blocking 
studies clearly demonstrated the importance of TNFa, and T cells in the development of the 
pathology. Moreover, inflammation was associated with higher levels of inflammatory D6 
binding CC chemokines in skin o f the D6 knock-outs. Therefore, it appears that in this 
model D6 acts as a decoy receptor, removing inflammatory CC chemokines from the skin, 
inhibiting further leukocyte infiltration and dampening the inflammatory response.
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Figure 1.4.3: D6 and Cutaneous Inflammation: PMA initiates an acute and self-limiting 
inflammation in WT mice, the initiation o f which is dependent on the generation o f TNF. 
Later, genes encoding many CC chemokines, in addition to the CXC chemokine CXCL2 
(which uniquely recognizes CXCR2), are induced and transcribed, forming a chemotactic 
gradient that attracts CD4 and CD 8  T lymphocytes (T), polymononuclear neutrophils (E) 
and mast cells (M). In D6  null mice, the inflammatory response is intense and prolonged, as 
the chemokine half-life is extended. As a result, the pathological picture resembles human 
psoriasis. D6  is found in the lymphatic endothelium, where it acts as a 'conveyor belt' to 
'mop up' and deliver the chemokines to degradative endosomes. (reproduced from Gerard, 
2005).
This data is strengthened by a recent report demonstrating that D 6  null mice, receiving a 
subcutaneous injection o f complete freunds adjuvant (CFA), develop a more severe 
cutaneous lesion than WT mice. Furthermore, this study also showed that, when compared 
to WT mice, the draining LNs o f D 6  null mice contained higher levels o f inflammatory 
chemokines and had increased cellularity following CFA injection (de la Torre et al., 2005). 
This suggests that D6  restricts the transport o f these chemokines from the tissue to the
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draining LN. The broader role of D6 in the resolution of inflammatory disease is now an 
active area o f investigation. Preliminary experiments indicate that D6 may be important in 
successful pregnancy (at least after cross-strain embryo transfer and presumably due to its 
placental expression) and also acts as a tumour suppressor gene (Nibbs, unpublished 
observations). The in vivo function of D6 in other tissues merits further investigation, and 
the potential therapeutic manipulation of this molecule remains an untested, but important, 
avenue of research.
1.4.6 CCX-CKR, A Chemokine Receptor of Unknown Function
Our emerging understanding of DARC and D6 clearly broadens the potential roles played 
by chemokine receptors. In 2000, a novel human chemokine receptor was identified by 
various groups of investigators. This was originally designated CCR11 based upon apparent 
induction of chemotaxis through this receptor by CCL2, CCL8 and CCL13 (Schweickart et 
al., 2000). However, this was later revised following the demonstration that the high affinity 
ligands for the receptor were, in fact, CCL19, CCL21, CCL25, and (more weakly) human 
CXCL13 (Gosling et al., 2000; Townson and Nibbs, 2002), chemokines that were already 
known to interact with one o f the receptors CCR7, CCR9 or CXCR5 (Figure 1.4.4). 
Importantly, like D6 and DARC, mobilisation of intracellular Ca2+ and cellular chemotaxis 
are not detected following ligation of CCX-CKR with any of its ligands (Gosling et al., 
2000; Townson and Nibbs, 2002). Structurally, CCX-CKR most closely resembles CCR7, 
CCR9 and CCR6. However, the canonical DRYLAIVHA motif in the second intracellular 
loop of CCX-CKR is changed to DRYVAVTKV (in humans) and DRYWAVTKA (in 
mice) (see Appendix 6.4) which may explain the lack o f typical signaling through this 
receptor. However, this has yet to be addressed experimentally. In the absence of signaling, 
the use of CCR nomenclature was inappropriate and the name CCX-CKR has become 
accepted (Chemocentryx chemokine receptor) after the name o f the company that first
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described this molecule. More importantly, these properties place CCX-CKR firmly in a 
group o f ‘atypical’ chemokine receptors, along with D6 and DARC. Perhaps it too plays a 
role in chemokine removal or transport.
Little else is known about this receptor. Receptor expression is detected in a wide range o f 
tissues and cell types by RT-PCR (Dorf et al., 2000; Gosling et al., 2000; Townson and 
Nibbs, 2002), with strongest Northern blot signals from the heart, small intestine, and lung 
(Khoja et al., 2000; Schweickart et al., 2000; Townson and Nibbs, 2002). In humans, two 
copies o f CCX-CKR exist. These encode proteins which differ by one amino acid and their 
expression is differentially regulated (Townson and Nibbs, 2002). However, in both 
humans and mice, the specific cell types expressing CCX-CKR remain unclear.
The presence o f an additional receptor for these chemokines is intriguing bearing in mind 
their key importance in regulating leukocyte migration, lymphorganogenesis, secondary 
lymphoid tissue compartmentalisation, immune responses and tissue specific lymphocyte 
homing (all discussed in detail in the section 1.5). It is clear that our understanding o f CCX- 
CKR is seriously limited and the function o f this receptor is the main focus o f this study. To 
begin to understand this molecule, we first need to understand what its ligands can do.
C C L19 CCL21
--'If*! CXCL13
itffifiSftftjttifmtsffrf
C CR7
CXCR5
CCR9
Figure 1.4.4: CCX-CKR Ligands: The chemokines which bind to CCX-CKR are shown 
alongside the other chemokine receptors which they also bind to. Binding in both humans 
and mice are shown by solid arrows, binding in humans only is shown by a dotted arrow. 
See text for more details.
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1.5 Immunological Function of CCX-CKR Ligands
A complete and detailed summary of the diverse biological functions of all aspects o f the 
chemokine system in immunology is clearly beyond the scope of this introduction. Thus, 
instead, there follows a detailed discussion of key components of the chemokine network of 
direct relevance to CCX-CKR, the ligands for which are constitutive chemokines which 
play a major role in primary and secondary lymphoid microenvironments. These effects 
appear to be exclusively mediated through the receptors CCR7 (for CCL19/21), CCR9 (for 
CCL25), and CXCR5 (for CXCL13). Understanding the biology of these chemokines is 
clearly of paramount importance if  we are to form hypotheses of CCX-CKR function. With 
this in mind, there follows a discussion of the function of these chemokines and their 
receptors in lymphoid organ development, leukocyte traffic, and the induction of immunity, 
focussing on primary and secondary lymphoid organs, and covering tissue-specific 
leukocyte homing. In addition, the role of CXCR4/CXCL12 and the lysophospholipid 
sphingosine 1-phosphate (SIP) and its receptor shall be discussed where appropriate, as 
these are also important factors in understanding the biology of these organs.
1.5.1 Chemokines and Primary Lymphoid Organs
1.5.1.1 The Bone Marrow
In humans and mice, the BM is the site of haematopoeisis and B cell maturation (see 
section 1.1.1). CXCL12/CXCR4 appears to be the principal chemokine/receptor pair 
involved in this B cell development. BM stromal cells produce the chemokine CXCL12, 
which attracts B cell progenitors through their expression of CXCR4. Stromal cells produce 
growth factors and provide cell-cell contacts essential for B cell maturation. In fact, 
CXCL12 itself has been shown to be a growth factor for these cells (D'Apuzzo et al., 1997). 
The essential role of this chemokine/chemokine receptor pairing for B cell development is
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demonstrated by the severe impairment of B cell lymphopoeisis in mice which lack either 
CXCL12 or CXCR4 (Ma et al., 1998; Nagasawa et al., 1996). These mice die perinatally 
with numerous developmental defects and display elevated numbers of B cell precursors in 
the blood and reduced BM numbers (Ma et al., 1999).
The role in BM of CCX-CKR ligands is not particularly well-established, and they are 
likely to play a peripheral role in this organ. A recent study reported that both CXCR5 and 
CCR7 are expressed during B cell ontogeny and it is known that the responsiveness to 
CXCL13 and CCL19/21 changes as maturation progresses (Bowman et al., 2000). Further 
evidence exists suggesting that CCX-CKR ligands may play additional roles in BM. 
Lymphocyte, NK cell, and macrophage precursors have been reported to express CCR7 and 
to be attracted by CCL21 in vitro (Kim et al., 1999; Kim et al., 1998). In addition, BM 
stromal cells have been shown to inducibly express CCL 19 in response to inflammatory 
stimulus (Kim et al., 1998). Therefore, it has been suggested that CCR7 ligands play a role 
in increasing macrophage production in the BM during inflammation, although to my 
knowledge, this has not yet received experimental support. Regarding CCL25 in BM, 
knock-out mice lacking expression of CCR9 have been reported to have fewer BM pre-pro 
B cells (a population of cells responsive to CCL25). However, no differences in the 
resulting mature B cell populations are evident in these mice, making interpretation of this 
observation difficult (Wurbel et al., 2001).
1.5.1.2 The Thymus
As mentioned in section 1.1.1, T cell precursors enter the thymus at the cortico-medullary 
junction as so-called double negative (DN) thymocytes, as they express neither CD4 nor 
CD8. These cells migrate outwards toward the subcapsular zone (SCZ) where the undergo 
proliferation and T-cell receptor (TCR) gene rearrangement. Later, once TCR
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rearrangement has taken place, thymocytes mature into CD4+, CD 8+ double positive (DP) 
cells, as they undergo positive selection in the thymic cortex. Following positive selection, 
DP thymocytes migrate inwards to the medulla where they are negatively selected. 
Thymocytes surviving negative selection leave the thymus as single positive (either CD4+ 
or CD8+) cells which form the mature T cell pool. Thus, T cell maturation occurs in a 
spatially-defined manner and chemokines are now known to provide crucial migratory cues 
controlling thymocyte entry, localisation, and exit from the thymus (Annunziato et al.,
2001). Pivotal CXCR4/CXCL12 interactions have been shown to play an important role in 
the thymus. Initially, this receptor ligand pairing was thought to be of peripheral importance 
in the thymus as CXCR4 deficient mice were observed to be capable of supporting entry of 
thymic precursors into the fetal thymus, and thymi engrafted from CXCR4 deficient 
embryos into T cell deficent mice still support emigration of mature T cells. However, 
CXCL12 has been shown to play a role in maintaining a proliferative thymocyte pool 
(Hemandez-Lopez et al., 2002), and a role for CXCR4 in directing thymic emigration by 
chemofugetaxis has been proposed (Poznansky et al., 2002). Egress of departing 
thymocytes has also been shown to be critically dependent upon interactions between SIP 
and the sphingosine 1-phosphate receptor 1 (S1PR1) (Matloubian et al., 2004).
CCX-CKR ligands CCL19, CCL21 and CCL25 play significant roles in the thymus. These 
chemokines are expressed in the thymus and thymocyte precursors have been shown to 
express CCR7 and CCR9 (Campbell et al., 2003). Their importance has been demonstrated 
by using neutralising antibodies to these chemokines, or genetically-modified mice. This 
includes the pit (paucity o f lymph node T cells) mouse strain, that lacks expression of 
CCL 19 and a LN expressed isoform o f CCL21 (CCL21 ser), though the LEC-specific 
CCL21 leu remains intact. Specifically, the migration of thymic precursors into the fetal 
thymus has been shown to be impaired in the p it mouse and neutralising antibody against
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CCL25 further blocked this (Liu et al., 2005). Although analysis of CCR7 deficient mice 
did not initially reveal any abnormalities in the thymus (Forster et al., 1999), more recent 
investigations have revealed the essential role of this chemokine receptor and its ligands in 
several aspects of thymocyte homing (Figure 1.5.1). Thymocyte migration from the cortico- 
medullary junction to the subcapsular zone has been shown to be dependent upon CCR7 
and its ligands (Misslitz et al., 2004) and migration of positively selected thymocytes 
towards the medulla is also impaired in these mice (Ueno et al., 2004). In addition, 
emigration of mature SP thymocytes from the thymus has also been proposed to be partially 
controlled by CCL19/CCR7 (Ueno et al., 2002). Quite how CCR7 can be involved in 
trafficking cells both inwardly and outwardly in the thymus remains to be resolved, 
although the possibility that the high CCR7 ligand density in the medulla initially exerts a 
chemorepulsive effect on DN thymocytes and then later chemoattracts positively selected 
DP cells is intriguing.
Analysis of CCR9 deficient mice revealed that this receptor is not essential for thymocyte 
development. However, a transient delay in the arrival of DP thymocytes to the thymi of 
these animals was observed (Wurbel et al., 2001). In addition, BM cells from CCR9 null 
mice were less efficient at reconstituting the thymus o f irradiated recipient mice than BM 
from WT littermates. Furthermore the total number of a(3-T cells (which mature in 
thymus) were reduced in CCR9 knock-out mice (Uehara et al., 2002a). CCR9 expression is 
detectable on DP thymocytes but seems to be downregulated following positive selection 
(Uehara et al., 2002b). More recent work has demonstrated that CCR9/CCL25 interactions 
are essential for thymocyte migration from the cortex to the SCZ. However, surprisingly, 
this was not essential for T cell development (Benz et al., 2004). Overall, these data suggest 
that the CCR9/CCL25 axis plays a partially redundant role in directing thymocyte 
migration and development, which overlaps with CXCR4 and CCR7. To fully understand
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the role o f these chemokines and their receptors in the thymus, careful analysis o f double 
deficient mice will be required.
Figure 1.5.1: The Role of CCR7 in Thymocyte Development. Thymocyte migration and 
the role o f CCR7 and its ligands in the adult thymus. The migratory paths taken by 
developing thymocytes and the proposed roles for CCR7 in these migrations is shown. 
The density o f CCR7 ligands, CCL 19 and CCL21, is represented by blue shading, with 
highest levels in the medullary region, and additional sites o f expression in the SCZ and 
scattered cells throughout the cortex, (reproduced from Witt and Robey, 2004)
1.5.2 The Secondary Lymphoid Organs
As discussed in section 1.1.1, secondary lymphoid organs are structures specialized for the 
initiation o f immune responses. Experiments with animals lacking these organs have 
demonstrated their essential role in adaptive immunity (Lakkis et al., 2000; Miyawaki et al., 
1994; Rennert et al., 2001), and a great deal o f evidence now demonstrates a key role for 
the chemokine system in almost all aspects o f their biology. In particular, the chemokines 
CCL 19, CCL21 and CXCL13 are o f central importance, first for secondary lymphoid 
organogenesis during development, and also subsequently for cell homing to, and 
compartmentalisation within, these organs during homeostasis and responses. In addition, 
these chemokines play a role in the ectopic formation o f secondary lymphoid like structures
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seen in some chronically inflamed sites, such as the inflamed synovium in Rheumatoid 
arthritis (RA).
1.5.2.1 Chemokines and the Organogenesis of Secondary Lymphoid 
Organs
The development of the secondary lymphoid organs is a highly complex process, involving 
the appropriate temporal and spatial expression of a variety of molecules. Generally, a 
common developmental pathway is followed by LNs and PPs but entirely different signals 
are required for the development of the spleen. Genetic studies have highlighted the role of 
chemokines in secondary lymphoid organogenesis, with various KO and mutant mice 
strains unable to support the correct development of different LNs and PPs. However, 
because overall splenic development is not impaired in these animals, the subsequent role 
of chemokines in compartmentalisation within secondary lymphoid organs can be studied 
in this organ (see section 1.5.2.4).
In LN and PP development, current paradigms highlight the importance of clustering of so 
called ‘inducer’ cells with stromal ‘organiser’ cells to initiate the development of these 
organs (figure 1.5.2). The inducers are haematopoetic cells which originate from the fetal 
liver and are phenotypically characterised as being IL-7aR+, CD3-, CD4+, CD45+. They 
also express the chemokine receptors CXCR5 (Honda et al., 2001; Mebius et al., 1997) and 
CCR7 (Luther et al., 2003; Ohl et al., 2003) which play an important role in the attraction of 
these cells to the sites of lymphoid organogenesis, and subsequent inducer cell behaviour. 
The ligands for these receptors have been shown to be expressed by mesenchymal cells in 
proximity to the stromal organiser cells (Ohl et al., 2003), where they presumably mediate 
the recruitment of inducers. Once inducers and organisers come together, clustering is 
maintained by interactions between adhesion molecules, such as VCAM-1 on the stromal 
cells and the (31 or (37 integrins on the inducers. CXCR5 triggering activates the (3-integrins,
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encouraging tight adhesion between the cells. This allows members o f the TNF 
superfamily, such as lym photoxin-alp2 (L T a lp 2 ) on the inducers and LTp receptor 
(LTpR) on the stroma, to interact, activating various signaling pathways leading to gene 
transcription. In fact, there is evidence that CXCR5 activation directly upregulates further 
L T a ip 2  expression (Ansel et al., 2000). Prominent amongst newly transcribed proteins 
downstream o f LT(3R signaling are various chemokines. Additional CXCL13 is produced 
by the stromal cells, creating a positive feedback loop attracting in more inducer cells 
(Ansel et al., 2000). CCL 19 and CCL21 are also switched on and contribute to the 
recruitment o f inducer cells through CCR7. CXCL12 is also induced and may contribute to 
inducer responses through CXCR4 activation. Thus, through the concerted action o f 
cytokines and chemokines, the inducer/organiser clusters subsequently grow in size and 
complexity creating the secondary lymphoid anlagen. Notably, inducer cells cannot 
differentiate into lymphocytes but instead develop into FDCs, NK cells or APCs within the 
secondary lymphoid organ (Mebius et al., 1997). Once sufficient clustering has taken place, 
ECs differentiate into HEVs and the chemokine milieu in the structure effectively promotes 
the colonisation o f the organ by attraction o f lymphocytes from the circulation.
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Figure 1.5.2: Organogenesis of Secondary Lymphoid Organs. a )L T alp 2  expressing 
inducer cells bind to stromal organiser cells which express the LTpR via interactions 
between adhesion molecles. Chemokines are produced as a result o f LTpR signaling, b) 
Chemokine production leads to further accumulation o f inducer cells causing clustering and 
setting up a positive feedback loop leading to enhanced L T a lp 2  production and enhanced 
chemokine production, c) Large cell clusters form and blood vessels develop into HEVs. 
See text for more details.(reproduced from Mebius, 2003)
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The relative importance of CXCR5, CCR7 and their respective ligands in secondary 
lymphoid development varies between different secondary lymphoid structures and has 
been revealed by gene KO experiments. For example, mesenteric LNs are still present in 
CXCR5-/- and CXCL13-/- mice despite these mice having severely reduced numbers of 
PPs and almost no development of other peripheral LNs (Ansel et al., 2000). In p it and 
CCR7-/- mice, LN and PP development still takes place (Forster et al., 1999; Nakano et al., 
1997). However, anecdotal evidence suggested that there was occasional absence of some 
LN in these mice (Luther et al., 2003). Indeed, when CXCL13-/- mice were crossed with p it 
mice, they displayed a greater disruption to secondary lymphoid organ development than 
CXCL13-/- mice alone, although mesenteric nodes remained (Luther et al., 2003). The 
possibility that mesenteric LNs are able to develop in these mice under the control o f the 
CCR7 ligand C C Lllleu, the LEC-specific CCL21 isoform, not affected by the pit mutation, 
was ruled out by a subsequent study which observed a similar phenotype in mice double­
deficient for CXCR5 and CCR7 (Luther et al., 2003; Ohl et al., 2003). Together, these 
experiments demonstrate an overlapping role for CCR7 and its ligands with the more 
important CXCR5/CXCL13 interaction for the development of PP and most LNs. 
Mesenteric LN development is an interesting anomaly and it is tempting to speculate that 
the CXCL12/CXCR4 axis represents the dominant chemokine requirement in this organ.
1.5.2.2 Ectopic Secondary Lymphoid Formation
During the course of certain types of chronic inflammation, such as the autoimmune 
diseases RA and Sjogrens syndrome (SS), a common feature in the diseased tissue is the 
formation of structures resembling secondary lymphoid organs (Hjelmstrom, 2001). These 
structures probably potentiate local self-antigen presentation, perpetuating autoimmunity. 
The chemokines CCL 19, CCL21, and CXCL13 have been shown to play differing but 
important roles in the formation o f these structures (Luther et al., 2002). Similarly to
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organogenesis of secondary lymphoid organs during development, the induction of 
L T alp2  signaling leads to chemokine production and infiltration of lymphocytes and DCs. 
The expression of CXCL13 drives the development of lymphoid follicles, while CCL21 
and CCL 19 define the T cell areas. Furthermore, production of these chemokines 
establishes a positive feedback loop which promotes further L T alp2  production, which 
itself promotes further chemokine production. Thus, once initiated, this process promotes 
its self continuation until sufficient cell infiltration and organisation has occurred.
It has been shown using transgenic models that ectopic expression of CCL21 is sufficient to 
drive the formation of secondary lymphoid-like structures in the pancreas (Chen et al.,
2002). However, tissue specific factors are clearly involved as these phenomena were not 
seen after transgenic expression of CCL21 in the skin (Chen et al., 2002). Furthermore, 
CCL21 expression has also been shown to be associated with lymphoid neogenesis in 
human chronic liver disease (Grant et al., 2002), and expression of CXCL13 and CCL21 is 
associated with lymphoid neogenesis in SS (Barone et al., 2005). The precise mechanisms 
by which initiation and regulation o f these processes takes place have not yet been fully 
elucidated, and this remains an important area o f research in the potential treatment of 
autoimmune diseases.
1.5.2.3 Lymphocyte Entry via High Endothelial Venules
Once lymphoid tissues have developed, they recruit lymphocytes, a process that occurs 
continuously throughout life with an estimated 2.5xl010 lymphocytes passing through a LN 
each day. Naive lymphocyte entry to LNs and PPs is dependent upon entry through HEVs 
found in the cortex of LNs and PPs and additionally in PP follicles. Lymphocytes roll along 
on HEVs of LNs via interactions between L-Selectin on lymphocytes and its ligand, 
peripheral node addressin (PNAd), on the endothelium. In PPs, a4(37 integrin expressing
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lymphocytes roll on HEVs which express the mucosal addressin cell adhesion molecule 1 
(MadCAM-1). In both PPs and LNs, these rolling lymphocytes express chemokine 
receptors, principally CCR7, CXCR5 and CXCR4. The ligands for these receptors are 
presented on the luminal surface of the HEV (see figure 1.5.3). The chemokine receptor 
signals induced by ligand activation cause integrin activation, firm adhesion and subsequent 
extravasation into the LN or PP (see sections 1.1.2 and 1.3.4). The relative importance of 
the different chemokine receptor ligands in mediating HEV extravasation into LNs and PPs 
is not yet clear, although it is well-characterized that different cell types have distinct 
chemokine entry requirements. T cells are mainly dependent upon CCR7 and its ligands for 
entry (Stein et al., 2000). The secondary lymphoid organs of pit mice show severe 
reductions in the number of T cells which enter the secondary lymphoid organs, 
demonstrating the crucial role o f HEV presentation o f CCR7 ligands for T cell entry 
(Nakano and Gunn, 2001). The importance of CCR7 in T cell entry across HEVs has also 
been demonstrated by analysis of CCR7-/- mice. These animals have markedly reduced 
number of T cells in LNs and PPs and elevated numbers in peripheral blood (Forster et al., 
1999). It should also be added that CXCL12 and CXCR4 interactions may also be 
important for T cell entry across HEVs. However, although this receptor ligand pairing can 
induce integrin activation of T cells in vitro (Campbell et al., 1998), this is less pronounced 
in vivo (Weninger et al., 2003). However, other genetic factors may be involved, as there 
seems to be strain dependence on the importance of CXCL12/CXCR4, with C57B1/6 mice 
able to support some T cell entry through this interaction, while mice on a DDD/1 
background are less able to do so (Okada et al., 2002; Wamock et al., 2000).
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Figure 1.5.3: The Multi-step Adhesion Cascade for Naive T cell Entry into LN from
the Blood. T cell rolling on HEVs is mediated by binding o f T cell-expressed L-selectin to 
PNAd displayed on HEV. In the second step, CCL21, and perhaps CCL 19, which are 
presented on the HEV surface, bind to CCR7 on rolling T cells. CXCR4/CXCL12 
interactions have also been proposed to play an accessory role. Chemokine binding to their 
respective receptors elicits intracellular G protein-linked signals, which induce a rapid 
confirmational change in LFA-1 on T cells. LFA-1 in its active form then binds to 
endothelial ICAM-1 and/or ICAM-2, which mediates firm arrest o f rolling T cells 
(reproduced from Weninger and von Andrian, 2003).
B cells also use CCR7 to gain entry across HEVs, although they are less reliant upon it than 
T cells. In p it mice, CXCR4/CXCL12 interactions are sufficient to support extravasation o f 
B cells (Okada et al., 2002). In PPs, B cells can directly enter the follicular regions through 
HEVs which traverse them via interactions between CXCR5 on the B cell and CXCL13 
presented on the HEV (Okada et al., 2002). However, the role o f CXCL13/CXCR5 in B 
cell trafficking entry into LNs is a matter o f debate. One study could not detect CXCL13 
expression on HEVs o f peripheral LNs, and saw no reduction in B cell entry to these nodes 
in CXCR5-/- mice (Okada et al., 2002). However, a separate investigation detected 
CXCL13 on approximately 50% o f peripheral LN HEVs, and measured a quantifiable
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reduction in B cell accumulation in peripheral LNs in CXCR13-/- compared with WT 
animals (Ebisuno et al., 2003). The reasons for these discrepancies are not clear and require 
future resolution. The fact that HEVs in peripheral LNs generally do not enter the follicular 
regions, suggests that functional CXCR5 will still be required for B cell accumulation in 
these areas. Some desensitisation of CXCR5 is likely to occur if it is activated during HEV 
passage, which would perhaps limit the ability of B cells to enter the follicles. It seems 
more likely therefore, that in LNs at least, B cell entry is mainly dependent upon CXCR4 
and CCR7.
1.5.2.4 “Remote Control” and Chemokine Transcytosis
To draw cells from blood into LNs requires the presentation of appropriate chemokines on 
HEV surfaces. In mice, mRNA encoding CCL21 and CXCL13 can be expressed by HEVs, 
while CCL 19 mRNA is produced only in the T cell area in non-ECs. However, in humans 
CCL21 is not detectably produced by HEVs, and is instead expressed with CCL 19 by cells 
in the T cell area, including perivascular cells (Carlsen et al., 2005). So how do chemokines 
produced on the wrong side of ECs induce the firm adhesion of blood lymphocytes? One 
attractive hypothesis is that chemokines are actively transported, or transcytosed, across 
ECs for presentation, a process discussed in section 1.4.5.1. Indeed, two studies have 
demonstrated that CCL 19 and CCL21 can be transcytosed across HEVs and thereby 
influence lymphocyte recruitment (Baekkevold et al., 2001; Stein et al., 2000). In fact, 
CCL 19 injected intradermally is able to drain to the LN, cross HEVs, and recruit 
lymphocytes. This intriguing observation suggests that peripheral tissues exert chemokine 
mediated “remote control” over LN cell recruitment. This is not limited to CCL 19. CCL2 is 
able to drain from inflamed sites to HEV surfaces where it recruits monocytes into LNs 
(Palframan et al., 2001). As DARC is expressed on HEVs, it is tempting to speculate that it
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facilitates the transport of chemokines across these cells, and that perhaps D6 aids 
transcytosis across LECs into lymphatics. These ideas await investigation.
1.5.2.5 Chemokines and Lymphocyte Compartmentalisation
Once naive lymphocytes have entered secondary lymphoid organs, they segregate into 
distinct T cell and B cell areas. This is controlled to a large extent by chemokines and is 
largely similar in all secondary lymphoid organs. Differential expression of CXCR5 and 
CCR7 between naive B and T cells generally dictates whether they locate to the follicles or 
to the T cell areas, respectively. Gene KO studies have revealed the relative importance of 
chemokines in the organization o f the T and B cell areas in the spleen and mesenteric LNs 
(secondary lymphoid organs which develop in the absence of these chemokine/receptor 
pairs). Deficiency in CXCR5 results in a reduction in numbers of splenic white pulp B 
cells (Forster et al., 1996) (Figure 1.5.4). In contrast, CCR7-/- and pit mice show reduced T 
cell migration into the PALS (Forster et al., 1996; Forster et al., 1999; Gunn et al., 1999). 
Analysis o f mice deficient in both CXCR5 and CCR7 further reveals the critical role of 
these receptors in the development and organization of splenic architechture. In these 
animals, both the T and B cell areas are sparsely populated and highly disorganised, 
follicles do not develop, and there is no discernible MZ (Figure 1.5.4). Similar phenotypes 
to those seen in CXCR5-/-, CCR7-/- and double CXCR5-/- CCR7-/- are observed in mice 
lacking the ligands o f these chemokine receptors, confirming the importance o f these 
chemokine/receptor pairings in splenic architecture. Importantly, these results suggest that 
the biological effects o f CCL 19, CCL21 and CXCL13 on LN development and lymphocyte 
homing and compartmentalisation are mediated exclusively through CCR7 and CXCR5. 
KO studies have not provided any indication o f additional receptors to mediate the 
biological effects o f these chemokines. This is important when the potential functions of 
CCX-CKR are considered.
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Figure 1.5.4: The Splenic A rchitecture in C X C R 5-/-, C C R 7-/- and C X C R 5-/- 
C C R 7-/- Mice. Sections o f spleen stained with green-labeled anti-B220 and red-labeled 
anti-CD3 to visualize the arrangement o f B-cells and T-cells within the white pulp. In WT 
mice, the T-cell zone is situated around a central arteriole with B-cell-rich areas 
peripheral to these. T-cell areas o f the C X C R 5-/- mice are encircled by a small ring o f B 
cells. In C C R 7-/- mice, few T cells can be detected next to the central arteriole; however, 
B-cell-rich areas are still present. T cells are mainly excluded from the white pulp and can 
be found scattered throughout the red pulp. T-cell-rich and B-cell-rich areas are largely 
disintegrated in mice double deficient for CXCR5 and CCR7. Small clusters o f B cells are 
intermixed with the red pulp. T cells are randomly distributed throughout the red pulp (B, 
B-cell zone; RP, red pulp; T, T-cell zone), (reproduced from Muller et al., 2003).
Although direct experimental evidence is lacking, it is assumed that after CCR7-mediated 
extravasation CCR7 also contributes to the navigation o f T cells to the appropriate areas 
within LNs and PPs. However, for this to be the case, CCR7 would have to not be subject 
to desensitisation following its activation at HEVs. Differences in the behaviour o f CCR7 in 
response to its two ligands CCL 19 and CCL21 may help to explain this. Studies have 
demonstrated that CCL 19 and CCL21 differentially stimulate CCR7 (Bardi et al., 2001; 
Kohout et al., 2004). CCL21 does not induce p-arrestin recruitment and subsequent
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receptor desensitisation and internalisation, while CCL 19 does. This has led to a two-step 
model of receptor activation and trafficking being proposed, whereby CCR7 regulates HEV 
extravasation through interactions with CCL21, but retains its activity allowing subsequent 
migration towards CCL 19 in LN T cell areas.
In addition to follicular B cells, the spleen also contains a population of B cells which reside 
in the MZ (MZ B cells), an area also rich in macrophages (section 1.1.1). Localisation of B 
cells within the MZ depends upon the aLp2 and a 4 p l integrins (Lu and Cyster, 2002), and 
SIP overcoming the follicular attraction of CXCL13 (Cinamon et al., 2004). In addition, it 
has been demonstrated that macrophage localisation in the splenic MZ depends upon 
CCL19 and CCL21 acting through CCR7 on these cells (Ato et al., 2004) and that 
macrophages also control the retention of B cells within the MZ via direct interactions via 
the macrophage scavenger receptor (Karlsson et al., 2003). Therefore, CCL 19 and CCL21, 
perhaps indirectly, may contribute to B cell compartmentalisation within the spleen.
1.5.2.6 Lymphocyte Egress
As discussed above, many of the molecular mechanisms governing cell entry and 
localisation within secondary lymphoid organs are broadly understood. In contrast, the 
molecular requirements for cellular egress from these tissues, either during homeostasis or 
during immune responses, are only now becoming clear. In this regard, SIP and its receptor 
S1P1 have recently gained much prominence. As in cellular egress from the thymus, the 
exit of cells from LNs is dependent upon signaling by the receptor S1P1 (Matloubian et al., 
2004). The immunosuppressant drug FTY720 mimics SIP and causes downregulation of 
S1P1 resulting in cellular retention in secondary lymphoid organs (Mandala et al., 2002). 
Chemokines are also likely to be involved to some extent in egress from secondary 
lymphoid organs. CXCL12 expression in the spleen and LNs is highest in the red pulp and
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medullary cords respectively. Here it is likely that it is involved in attracting CXCR4 
expressing cells, which have downregulated CXCR5 and CCR7, out o f the follicles and T 
cell areas, encouraging their exodus (Ellyard et al., 2005; Hargreaves et al., 2001).
1.5.2.7 Dendritic Cell Trafficking and Antigen Presentation
Most populations o f DCs, similar to other non-lymphocyte leukocytes, do not normally 
express the appropriate chemokine receptors and adhesion molecules to allow direct entry 
into secondary lymphoid organs via blood HEVs. However, DC entry into LNs is a crucial 
aspect of their biology, as lymphocyte activation and hence immunity is largely dependent 
upon cognate interactions between professional APCs and lymphocytes. It is now clear that 
CCR7 and its ligands play crucial roles in steady state and inflammatory DC migration and 
function.
In the absence of infection or inflammatory stimulus, most DCs are tissue resident cells 
found in virtually all anatomical surfaces and compartments (reviewed in Banchereau and 
Steinman, 1998). Here, DCs have an ‘immature’ phenotype and they are very potent at Ag 
uptake and processing. DCs are dynamic cells even in the absence o f inflammatory 
stimulus. DC precursors circulate through the bloodstream and express chemokine 
receptors and adhesion molecules which allow their extravasation into peripheral tissues, 
especially inflamed tissues (Randolph et al., 1998; Sozzani et al., 1995). This is facilitated, 
at least to some extent, by chemokine receptors such as CXCR1, CCR1, CCR2 and CCR5. 
Furthermore, there is a basal rate of DC traffic from tissues to the draining LNs. These 
semi-mature DCs, which have presumably sampled self-Ag in the periphery, have a slow 
rate of traffic to LNs where they present these Ags to T cells, a process postulated to be 
important in the maintenance of self-tolerance (Wilson et al., 2003). In the skin, using 
CCR7 null mice, this steady state traffic has recently been shown to be dependent upon
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transient expression of CCR7 by Langerhans cells (LC), the specialised epidermal DC (Ohl 
et al., 2004). Steady-state trafficking of LCs into afferent lymphatics is not impaired in the 
pit mouse, indicating that expression of C C Lllleu  by LECs, not abrogated in the pit 
mutant, is the likely ligand attracting LCs out of the dermis (Gunn et al., 1999). However, 
DC accumulation in the T cell areas o f LNs of both CCR7 null and p it mice is severely 
reduced when compared with WT mice. These observations indicate that CCR7 and its 
ligands within the LN are required for the precise localisation of migrating DCs under 
steady state conditions (Forster et al., 1999; Gunn et al., 1999; Martln-Fontecha et al., 2003; 
Ohl et al., 2004). Thus, rather like the extravasation across HEVs (section 1.5.2.3) there 
appears to be a two-step process o f DC homing to LN T cell areas, where the differential 
CCR7 internalisation properties o f CCL21 and CCL19 may be significant to maintain 
responsiveness.
Although there is a relatively slow rate of DC migration from peripheral tissues to LNs 
during homeostasis, a dramatic change in DC behaviour and trafficking is evident following 
exposure to an inflammatory stimulus, eg. LPS, dsRNA, and pro-inflammatory cytokines, 
which induce a process referred to as DC maturation. The changes in DC phenotype are 
manifold, including reduction in Ag uptake, expression of MHC-II molecules, and 
upregulation of co-stimulatory molecules. Importantly, these changes are accompanied by 
alterations in DC migratory capacity that are critically dependent upon chemokine receptor 
switching. Chemokine receptors (e.g. CCR1 and CCR5) and adhesion molecules which 
promote retention in inflamed sites are downregulated, and this is concomitant with an 
upregulation of CCR7 and expression o f adhesion molecules for entry to the secondary 
lymphoid organs. CCR7-/- or pit mice, do not accumulate mature DCs in LN T cell areas in 
response to antigenic stimulus though it is notable that in p it mice, DCs accumulate in the
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subcapsular sinuses suggesting LEC C C Lllleu  drives DCs into lymphatic vessels (Forster 
et al., 1999; Gunn et al., 1999; Ohl et al., 2004).
Interestingly, interactions between CCR7 and CCL19/21 are not only crucial for regulating 
DC traffic to and within secondary lymphoid organs, but also impact upon the maturation 
and morphology of DCs. CCL 19 stimulation of mature DCs has been shown to induce the 
rapid formation of dendrites, extensions of the cytoskeleton which may greatly enhance the 
availability of contacts for T cell interaction during Ag presentation. CCL21 stimulation 
had an antagonistic effect on this phenomenom (Yanagawa and Onoe, 2002). This further 
suggests that CCL21 mainly controls DC migration into the secondary lymphoid organ 
(where a motile morphology would be advantageous) and that CCL 19 production by DCs 
acts in an autocrine manner further activating the DC for Ag presentation. Furthermore, 
recent data suggests that both CCL 19 and CCL21 act upon DCs to induce terminal 
maturation of these cells. Mature LN DCs which express high levels o f CCR7 have been 
shown to produce pro-inflammatory cytokines and upregulate MHC-II molecules upon 
stimulation with either CCL 19 or CCL21 (Marsland et al., 2005).
The arrival of mature activated DCs in the LN has further implications for the phenotype of 
the node. In order to facilitate Ag presentation between cognate APCs and T cells, cellular 
exodus from LN is inhibited, and cell entrance enhanced following the arrival o f mature 
DCs. The extent of LN hypertrophy caused by these phenomena has been shown to be 
directly proportional to the number of DCs which reach the LN, and is (at least initially) 
independent of lymphocyte proliferation (Martln-Fontecha et al., 2003). Interestingly, the 
arriving DCs produce CCL19. After transcytosis across HEVs, this chemokine may 
contribute to enhanced lymphocyte recruitment into activated LNs. Alternatively, DC- 
derived CCL 19 may encourage T cells to interact directly with arriving DCs to initiate key
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events of Ag recognition. However, it must be emphasised that studies using the pit mouse 
have shown that this is not essential in facilitating these contacts (Mori et al., 2001). In the 
pit mouse, DC and T cells seem to co-localise in the subcapsular regions o f LNs rather than 
in the T cell areas, but interactions still occur. Instead other chemokines may be important 
in initiating DC/T cell interactions. Indeed, there is some evidence that CCL22 may be 
involved in drawing recently activated T cells towards mature DCs (Tang and Cyster, 
1999). However, CCL 19 may be required for the priming of CD8+ T cells within the LN. A 
recent study, using a truncated form of CCL 19 which acts as a CCR7 receptor antagonist 
blocking CCL 19, but not CCL21 interactions, led to inhibition of CD8+ T cell responses in 
an allogeneic immune response without globally preventing cell migration to the LN 
(Pilkington et al., 2004).
1.5.2.8 Lymphocyte Activation
The activation of naive T cells within secondary lymphoid organs, via interactions with 
APCs expressing antigenic peptides on MHC molecules with appropriate co-stimulatory 
molecules, leads to T cell activation, proliferation and differentiation. Chemokines play 
major roles in influencing and executing these differentiation decisions. First, it is 
becoming increasingly evident that chemokines influence whether CD4+ T cells develop 
with a Thl or a Th2 cytokine secretion profile (reviewed in Luther and Cyster, 2001). 
Indeed, CCR7 ligands are now known to be involved, as recent evidence suggests that 
CCL 19, acting on DCs, can induce IL-12 production and thereby indirectly promote CD4+ 
T cell Thl differentiation (Marsland et al., 2005). In addition, CCL21 has been shown to 
directly induce proliferation and Thl polarisation of naive T cells (Flanagan et al., 2004).
Second, once primed, chemokines direct the subsequent behaviour o f T cells. Most CD4+ T 
cells activated by DCs in the T cell area, transiently increase responsiveness to CXCL13
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(perhaps through upregulation of CXCR5), and migrate to the edge of the follicles where 
they interact with B cells (Ansel et a l, 1999; Garside et al., 1998; Schaerli et al., 2001). 
Likewise, Ag-activated B cells upregulate CCR7 (while keeping expression of CXCR5) 
and migrate to the edge o f the follicles at the boundary of the T cell area (Reif et al., 2002). 
Cognate interactions between T and B cells lead to the formation of GCs, areas of rapid 
proliferation where somatic hypermutation and high affinity antibody maturation take place 
(reviewed in Berek and Ziegner, 1993). GCs can be histologically divided into dark and 
light zones. Dark zones are areas of intense proliferation and are the site of somatic 
mutation of B cell receptors, whereas the light zone is the area where selection of B cells, 
based upon the affinity of their receptors for Ag, takes place. The chemokine receptors 
CXCR4 and CXCR5 differentially direct B cells into the dark and light zones, respectively, 
and the ligands for these receptors are differentially expressed in these zones (Allen et al.,
2004). B cells which survive this selection and express high affinity immunolglobulin can 
differentiate to become tissue homing plasma cells or memory B cells, cells with their own 
distinct homing properties determined by their chemokine receptor repertoire.
1.5.3 Tissue Specific Homing of Antigen Activated Cells
Chemokines are critical mediators of lymphocyte homing to peripheral sites following 
activation. Activated proliferating T cells downregulate CXCR5 (Schaerli et al., 2001) and 
develop down one o f two major developmental pathways. Most become effector T  cells, 
and express chemokine receptors, such as CCR1, CCR2, CCR5, and CXCR3, which 
facilitate homing to sites o f inflammation. Alternatively, some T cells become memory 
cells, primed for their next exposure to the same Ag.
Activated effector Thl lymphocytes express receptors such as CXCR3 and CCR5, while 
Th2 lymhocytes express CCR3 and CCR8. This allows effective recruitment of different T
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cell subsets based upon the chemokine ligands produced in different types of inflammatory 
situations. T cells which home to the skin express CCR10 and CCR4 which facilitate 
homing to epithelial sites which produce CCL27 and CCL 17, respectively (reviewed in 
Kunkel and Butcher, 2002). IgA secreting plasma cells have been also been shown to use 
CCR10 for tissue specific homing. However, these cell migrate primarily towards CCL28 
produced in mucosal tissues (Kunkel et al., 2003). An interesting role for CCR9 and CCL25 
in the specific homing o f cells to the small intestine has emerged in recent years. In addition 
to being expressed in thymus, CCL25 is highly expressed by epithelial cells o f the small 
intestine, especially those most closely associated with vessels expressing the mucosal 
addressin cell adhesion molecule, MAdCAM-1 (Kunkel et al., 2000). Here, CCL25 is 
displayed on the endothelium (perhaps following transcytosis) and attracts CCR9+ cells 
(which also express the a4(37 integrin) out of the circulation, into the gut mucosa during 
both inflammation and homeostasis (Hosoe et al., 2004; Marsal et al., 2002). The 
importance o f this is highlighted by the fact that the majority of T cells in the small intestine 
are CCR9+ (Kunkel et al., 2000). Interestingly, DCs which pick up Ag in the gut mucosa 
can specifically program the T cells which they prime in regional LN to migrate to the 
small intestine. This is achieved by the DC inducing the expression of CCR9 (and the 04^7 
integrin) on the T cell (Johansson-Lindbom et al., 2003). CCR9/CCL25 is also involved in 
the homing of precursor cells to cryptopatches (sites of extrathymic T cell matuaration) 
(Wurbel et al., 2001), and also in the homing of IgA secreting plasma cells to the small 
intestinal epithelium (Bowman et al., 2002).
CCR7 expression on mature T lymphocytes helps define a population o f memory T cells 
based upon their migratory capacity. Long-lived Ag experienced T cells can be segregated 
into central memory or effector memory T cells (Sallusto et al., 1999). Central memory 
cells express CCR7 and L-selectin, enabling their recirculation through the secondary
82
© Iain Comerford, 2005 CHAPTER ONE INTRODUCTION
lymphoid organs. Effector memory cells on the other hand do not express CCR7 and 
instead home to inflamed peripheral tissues via expression of receptors such as CXCR3. 
However, it has been suggested that upon activation, effector memory cells can regain 
CCR7 expression and subsequently traffic to secondary lymphoid organs (Ebert et al.,
2005).
1.5.4 Immune Responses in Null Mice
It is clear from the above discussion that CXCR5 and CCR7 are o f fundamental importance 
in controlling lymphocyte and DC localisation. Thus, it would be anticipated that the 
absence of these molecules would impact upon immune responses. Indeed, mice lacking 
expression of CCR7 display no contact or delayed-type hypersensitivity (DTH), processes 
dependent upon T cell activation. In addition, these animals have delayed development of 
antibody responses compared with WT animals (Forster et al., 1999). Furthermore, immune 
responses leading to the rejection of allografts is also partially impaired in these mice 
(Beckmann et al., 2004). CD8+ T cell responses against viral infections still develop, but 
priming is less efficient and the response is delayed (Junt et al., 2004). These defects in 
CCR7 null mice are more severe than those seen in p it mice, where some CCL21 
expression is maintained, pit mice exhibit delayed, but enhanced, T cell responses to 
subcutaneous Ag and are capable o f contact sensitisation immune responses (Mori et al., 
2001). This surprising result suggests that, although DC migration is impaired to some 
degree in these mice, lymphatic CCL21 still allows their migration to the LN. Furthermore 
DC-T cell interactions may not be regulated in the same way when they occur outside the T 
cell area, leading to the exaggerated response seen in these animals. Alternatively, this 
phenomenon could reflect a failure of CCR7+ T r e g s  to become activated, which may be 
necessary for response resolution.
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CXCR5 null mice are still capable of GC formation in the spleen, although these are 
severely disrupted (Voigt et al., 2000). Other studies have shown that although follicular 
migration is dependent upon CXCR5 and CXCL13, GC formation once it is initiated in the 
T cell zone is independent of CXCL13 (Ansel et al., 2000). However, it is perhaps 
surprising that major defects in the induction of immune responses have not been reported 
in mice lacking CXCR5 or CXCL13.
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1.6 Aims of Study
The chemokine ligands for CCX-CKR are of central importance in controlling 
lymphocyte and DC localisation and thereby regulating immune responses. However, 
the functions o f these chemokines appear to be mediated by CCR7 and CCR9, and from 
the outset of the project, it was completely unknown how CCX-CKR influenced or 
mediated the biology o f  these chemokines. In the absence o f ligand-induced signals 
from CCX-CKR, chemokine decoy and transport functions had been proposed, but no 
evidence existed to support these hypotheses. Thus, to examine these ideas, a two­
pronged approach was planned. First, investigations designed to characterise the 
biochemical properties in heterologous transfectants were undertaken. Initial focus lay 
on determining whether CCX-CKR could mediate ligand internalisation, and if  so, to 
define the fate o f the internalised ligand and the molecular mechanisms underpinning 
this internalisation. It was hoped that these experiments would provide the molecular 
basis for ideas about in vivo functions which could be tested. However, the in vivo 
characterisation of this ‘silent’ chemokine receptor was in its infancy at the outset of 
this study. Nothing was known o f the cell types expressing CCX-CKR in vivo, reliable 
anti-mouse CCX-CKR antibodies were not available, and CCX-CKR null mice had not 
been described. Therefore, to simultaneously define expression profiles and assess 
indispensable in vivo function, ‘knock-in knock-out’ (KIKO) mice were planned, 
replacing the CCX-CKR gene with a readily detectable reporter surrogate. Combined, it 
was anticipated that these studies would provide new insight into the function o f this 
unusual chemokine receptor, and expand understanding o f chemokine networks in vivo.
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CHAPTER TWO  
MATERIALS AND METHODS
2.1 Materials
2.1.1 Antibodies and Secondary Detection Reagents
ANTIBODY/REAGENT SPECIES CONJUGATE SUPPLIER
Ant -FLAG M1 mouse n/a S igm a
Ant -human CCR7 mouse n/a R+D Systems
Ant -KLH (isotype control) rat FITC BD Pharm ingen
Ant -mouse B220 rat FITC BD Pharmingen
Ant -mouse C D 11c ham ster PE BD Pharm ingen
Ant -mouse CD19 rat PE BD Pharmingen
Ant -m ouse CD3 rat PE BD Pharm ingen
Ant -mouse CD4 rat PE BD Pharmingen
Ant -m ouse CD8c* rat FITC BD Pharm ingen
Ant -mouse F4/80 rat PE Serotec
Ant -m ouse l-A /l-E rat FITC BD Pharm ingen
Ant -mouse IgG sheep PE Sigma
Ant -m ouse IgG goat HRP Am ersham  B iosciences
Ant -mouse IgG goat Peroxidase Sigma
Ant -rat p-arrestin  I mouse n/a BD B iosciences
Ant -rat dynamin I mouse n/a BD Biosciences
Ant -TNP (isotype control) ham ster PE BD Pharm ingen
ExtrAvidin n/a cy3 Sigma
Streptavid in n/a PE M olecular Probes
2.1.2 Bacteriology
It e m /R ea g en t Sup p l i er
90m m  bactrio log ica l petri d ishes B ibby S terilin  Ltd
Ampicillan Sigma Chemicals
Escherichia Coli D H 5a com pe ten t cells Inv itrogen
Falcon 2059 polypropelene tubes Becton Dickinson Labware
K anam ycin S igm a  C hem ica ls
LB (Luria Bertani) liquid Medium Beatson Institute Central Services
SOC m edium Inv itrogen
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2.1.3 Cell Culture 
Cell lines:
Human embryonic kidney cells (HEK-293) 
Mouse embryonic fibroblasts (MEF)
129/1 W4 mouse embryonic stem cells
129/1 RW4 mouse embryonic stem cells
Item/Reagent Supplier
10ml plastic pipettes Becton Dickinson Labware
1 ml plastic pipetes Becton Dickinson Labware
2.5% Trypsin Invitrogen
200mM L-Glutamine Invitrogen
25ml plastic pipettes Becton Dickinson Labware
2ml plastic pipettes Becton Dickinson Labware
50ml plastic pipettes Becton Dickinson Labware
5ml plastic pipettes Becton Dickinson Labware
6 well tissue culture plates Nunc
90mm tissue culture dishes Becton Dickinson Labware
Cryotubes Nunc
Dulbeccos Modified Eagle Medium (DMEM) Invitrogen
Effectene Transfection Reagent QIAGEN
Foetal Bovine Serum Perbio
FuGene Transfection Reagent Roche
Fungizone Invitrogen
Geneticin (G418) Invitrogen
Penicillan/Streptomycin Invitrogen
Puromycin AutoGen Bioclear
RPMI 1640 Invitrogen
Sterile 1xTE Ambion
Sterile distilled water Beatson Institute Central Services
Sterile phoshate buffered saline + EDTA (PE) Beatson Institute Central Services
Sterile phosphate buffered saline (PBS) Beatson Institute Central Services
Sterile plastic bijoux and universal containers Bibby Sterilin Ltd
T25. T75, T175 cm2 tissue culture flasks Nunc
Fibronectin Sigma
HEPES 1M Solution Invitrogen
Concanavalin A W orthington
96 well tissue culture plates Corning
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2.1.4 Chemicals
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Chemical Supplier
10M Ammonium Acetate Solution Sigma
12-0 -te tradecanoy lphorbo l-13 -ace ta te Sigm a
Acetic Acid Fisons Scientific Equipment
A cetone Fisons S cientific  Equipm ent
Agarose (electrophoresis grade) Sigma
Bovine Serum A lbum in Sigm a
Bromophenol Blue Sigma
Butan-2-ol F isons Scientific  Equipm ent
CellLytic-M Mammalian cell lysis buffer Sigma
Choloroform Fisons S c ientific  Equipm ent
Dimethyl sulfoxide Fisons Scientific Equipment
Di-N itro Fluro B enzene (DNFB) Sigm a
Dithiothretiol Promega
EGTA Fisons S c ientific  Equipm ent
Ethanol James Burrough Ltd
Ethidium  Brom ide Sigm a
Ethylene diamine tetra acetate disodium salt Fisons Scientific Equipment
G lycerol Beatson Institu te Centra l S erv ices
Hydrochloric Acid Fisons Scientific Equipment
M ethanol F isons S cientific  E quipm ent
Mouse Serum Sigma
O valbum in (from ch icken egg) S igm a
Paraformaldehyde Sigma
Phenol S igm a
Propan-2-ol Fisons Scientific Equipment
Propidium  Iodide Sigm a
Sodium Acetate Fisons Scientific Equipment
Sodium  Azide Sigm a
Sodium Chloride Fisons Scientific Equipment
Sodium  C itrate F isons Scien tific  Equipm ent
Sodium dodecyl sulphate Fisons Scientific Equipment
Sodium  Hydroxide BDH, UK
The RNA storage solution Arnbion
Tris-base F isons Sc ien tific  Equipm ent
TRIZOL Reagent Invitrogen
Tween-20 Sigm a
Urea Sigma
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2.1.5 Chemokines
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Chemokine Labelled with Supplier
hCCL19 Biotin Albachem
hCCL19 [125l] Amersham Biosciences
hCCL19 n/a Peprotech
hCCL21 n/a Peprotech
hCCL25 n/a Peprotech
2.1.6 Enzymes and Kits
Reagent Supplier
L1x Pre-Aliquoted ReddyMix PCR Master Mix in Thermo-Tubes ABgene
Alkaline Phosphatase Kramel Biotech
BamH1 Roche
Chemiluminescent WestPico Kit Pierce Chemical
CT-GFP-TOPO'*'TA Expression Kit Invitrogen
DNAase free RNAaseA QIAGEN
DNA-free™ kit Ambion
ECoR1 Roche
ECoRV Invitrogen
Hind III Invitrogen
Mouse IL-13 Antibody Beads for Luminex™ Biosource
Notl Invitrogen
pCR2.1 TOPO TA Cloning Kit Invitrogen
Proteinase K Roche
QIAprep Plasmid Maxi Kit QIAGEN
QIAprep Spin Miniprep Kit QIAGEN
QIAquick Gel Extraction Kit QIAGEN
QIAquick PCR Purification Kit QIAGEN
Rapid DNA Liqation Kit Roche
Ready-To-Go™ DNA Labelling Beads Amersham Biosciences
Six Plex Mouse TH1/Th2 Antibody Bead Kit for LuminexIM Biosource
Sst1 Invitrogen
Superscript™ First-Strand Synthesis System for RT-PCR Invitrogen
Xbal Invitrogen
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2.1.7 Miscellaneous
Reagent Supplier
[■'H]-thymidine West of Scotland Nucleotide Dispensary
[y32P]dCTP Amersham Biosciences
0.2ml Microcentrifuge Tubes Eppendorf
0.5ml Microcentrifuge Tubes Eppendorf
1.5ml Microcentrifuge Tubes Eppendorf
15ml centifucje tubes Becton Dickinson
24 well chemotaxis plate (5uM pore) Corning
50ml centrifuge tubes Becton Dickinson
Complete Freunds Adjuvant Sigma
Decon 75 Decon Laboratories
DEPC treated water Ambion
Gilson Pipette Tips (10,200.1000j.il) Fisher Scientific Ltd
Glass coverslips Fisher Scientific Ltd
Glass fibre filter mats Wallac Oy
Glass slides Fisher Scientific Ltd
Haemocytometer Fisher Scientific Ltd
Hybond-N+ Amersham Biosciences
Hyperladder I DNA ladder Bioline Ltd
Hyperladder IV DNA ladder Bioline Ltd
Marvel (dried skimmed milk) Premier Beverages
Multimark protein molecular weight markers Invitrogen
Polypropylene FACS tubes Becton Dickinson
Sterile 0.2uM acrodisc filters Gelman Sciences Ltd
Ultrahybe Ambion
Vectasheild with DAPI Vector Labs
Whatman 3mm filter paper Whatman International Ltd
X-Ray Film Kodak
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2.1.8 Oligonucleotides
With the exceptions o f the M13 forward, M13 reverse, and T7 oligonucleotides (all 
supplied by Invitrogen), all primers were supplied by the Beatson Institute Technology 
Services (BITS) and synthesised by the methods outlined in section 2.2.1.1.
2.1.8.1 Tagged Expression Construct Oligos
Oligo Name Oligonucleotide Sequence 5' to 3'
H3FLAGhCCR7 A GA iItA GAAGC TTCC AACATGGACTA CAAOGAC CvAC GAC GACAAGGACCTGGGG AAA C C AA TGAAAAG
H3HAhCCR7 AGAGlAGAAGCTTCCAACATGTACCCCTACGACGTGCCCGACTACGCCGGGCCGGGGGACCTGGGGAAACCAATGAAAAG
H3HAhCCX AGAGAGAAGCTTCCAACATGTACCCCTACGACGTGCCCGACTACGCCGCTTTGGGAACAGAACCAGTCAACAGATTATT
hCCR7-B-GFP GAG AGA GGA TCC GTA TGG GGA GAA GGT GGT GGT G
hCCR7-Not1 GAG AGA GCG GCC GCC TAT GGG GAG AAG GTG GTG GTG
hCCX-B-GFP CTC TCT GAA GCT TGA AAT GCT AAA AGT ACT GGT TGG CT
hCCX-B-GFP(2) GGT AAA TGC TAA AAG TAC TGG TGG G
2.1.8.2 Sequencing Oligos
Oliyo Nam© O ligonucleotide S eq u en ce  5 to 3'
GFPD1 GT G CT G CTT CAT GTG GT C G
GFPD2 GGC GGA TCT TGA AGT TCA CC
GFPD3 CTC AGG AGA GCA CAC ACT TGC
GFPU1 GCT GAC CCT GAA GTT CAT CTG
GFPU2 GCA TCG ACT TCA AGG AGG AC
GFPU3 CCG ACA ACC ACT ACC TGA GC
hCCR7D1 GTG GGC ATC TGG ATA C A GCC
hCCR7D2 GGA CGT GCG GAA CTT TAA AG
hCCR7D3 GTC A7C ATC CGC ACC CTG C
hCCR7C4 CGA TCT CTT CAA GCT CTT CAA G
hCCR7UI CAG CTT GCT GAT GAG AAG GAC
hCCR7U2 TGA GAG AGC ATC GCA TCG C
hCCR7U3 GGT AGG TAT CGGTCA TGG TC
hCCR7U4 GAG AAG GTG GTG GTG GTC TC
hCCXDI AGC ATC ATT CAT ATG TAT CCA AGC
hCCXD2 TTA AAT GCT AAA AGT ACT GGT TGG C
hCCXD3 CTT GAC AAT GTT ATA AGG CAG TTG
hCCXD4 GGG TAT GCT CAG CAA GAT GG
hCCXDS CCA TGA ACT GCA TTA ACA GCC
hCCXUt ATG GCT TTG GAA CAG AAC CAG
hCCXU2 CAA TTC CAT GGT AGT GGC AAT
hCCXU3 GGA AAA CCA TGC TTG ATC ATC
hCCXU4 CTA CTT TAT CAC AGC AAG GAC ACT C
hCCXUS TAC TCC CTG ATC ACC AGC TGC
M13 forward GTA AAA CGA CGG CCA G
M13 reverse CAG GAA ACA GCT ATG AC
T7 TAA TAC GAC TCA CTA TAG GG
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2.1.8.3 Genotyping Oligos
Oliyo Nam© O ligonucleotide S eq u en ce  5' to 3'
3 IRES COO TAC ATG CAT GCT CGA CG
CommonScneer CCC CTT CCA CGT TCT GTC TCT G
Crel ATT TGC CTG CAT TAC CGG TC
Cre2 ATC AAC GTT TTC TTT TCG G
CreT ester TTT GGC AAA GAA TTC ACT CCT C
mCCXCKRwt GCT CAT CAA GAT GCC CAA CA
mCCXoomS TGC TGG TGA GCT CTG GGT TC
mCCXwtS AAT CGC CAC AAC TAC GGA GTT C
target, neo CCG TGA TAT TGC TGA AGA GC
2.1.8.4 Screening Oligos
Oligo Nam© O ligonucleotide S eq u en ce  5' to 3'
mCCXout TTG CTG TGC CTT GAT AGT CAC
mCCXoutB AAA AAC AGA GCT CAG ACC TGT G
mCCXoutC GTT GTT TCT GCA GTT GCT GTG
neoA CCG TTA CTA GTG GAT CCT GGA G
neoB CT A AAG CCA CAG TGT GGA ACA G
neoC CAC GCT TGT GCT CTG GAA A
2.1.8.5 cDNA Amplification Oligos
Oligo Nam© O ligonucleotide S eq u en ce  5' to 3'
5’IRES CAC GAT GAT AAG CTT GCC AC
(J-ActinD TAC TCC TGC TTG CTG ATC CAC
P-ActinU TCC ATC ATG AAG TGT GAC GT
GFPD1 GTG CTG CTT CAT GTG GTC G
mCCXD TGC TCT CTG TGA GTT GGA TGG
mCCXU GCC ATC TTG CTG AGC ATA CC
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2.1.9 Plasmids
Plasmid Name Description Source
p-arrestin (V53D) Encodes a dominant negative(J-arrestin-1 S.Ferguson. London. Canada
Caveolin-1-GFP Encodes a C terminal GFP tagged caveolin-1 A.Helenius. Zurich. Switzerland
CCX-CKR lacZ KIKO Targeting construct replacing mCCX-CKR gene with lacZ Dr Nibbs
D6 lacZ KIKO Targeting construct replacing mD6 gene with lacZ Dr Nibbs
dynamin (K44A) Encodes a dominant negativalynamim 1 S.Ferguson. London. Canada
EPS15 (Dill) GFP Encodes a GFP tagged EPS15 mutant (see fig 3.1.28) A.Benmerah, Paris, France
EPS15 <DIIIa 2) GFP Encodes a GFP tagged EPS15 mutant (see fig 3.1.28) A.Benmerah, Paris. France
EPS15 (EA95/295) GFP Encodes a GFP tagged EPS15 mutant (see fig 3.1.28) A.Benmerah, Paris, France
GFP-Caveolin-1 Encodes a dominant negative N terminal GFP tagged caveolin-1 A.Helenius. Zurich. Switzerland
GFPneolox Encodes Farnesylated GFP with PGKneo cassette Dr Nibbs
mCCX-CKR genomic clone Plasmid with mCCX-CKR ORF+ genomic flanking sequences Dr Nibbs
PCDNA3.1 Empty expression vector Invitrogen
pcDNA3,1.hCCR7 Encodes human CCR7 Dr Nibbs
pcDNA3.1 .h-CCX-CKR Encodes human CCX-CKR Dr Nibbs
peGFPN2 Plasmid encoding EGFP Clontech
peGFPN3 Plasmid encoding EGFP Clontech
Rab11 (S25N) GFP Encodes a dominant negative GFP tagged Rab11 S.Ferguson, London. Canada
Rab4 (N121I) GFP Encodes a dominant negative GFP tagged Rab4 S.Ferguson, London. Canada
Rab5 (S34N) GFP Encodes a dominant negative GFP tagged Rab5 S.Ferguson. London. Canada
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2.2 Methods
2.2.1 Molecular Biology
2.2.1.1 Oligonucleotide Synthesis
Oligonucleotides were synthesized by the BITS using an Applied Biosystems Model381A 
DNA synthesiser using Cruachem reagents and following the manufacturer’s instructions. 
Oligos were synthesised without trityl group protection, obtained as pellet, and resuspended 
in 600pi sterile distilled water. The optical absorbance at 260nm and 280nm was measured 
using a Beckman DU 650 spectrophotometer and used to determine the oligonucleotide 
concentration. DNA purity was estimated from the OD26o/OD28o-
2.2.1.2 Nucleic Acid Preparation
2.2.1.2.1 Genomic DNA Extraction with Phenol
Confluent T75 flasks of mouse ES cell clones were harvested by brief trypsinisation (see 
2.2.2.1) and pelleted by brief centrifugation (5min, 700 ref) in 50ml falcon tubes. Cells 
were then resuspended in 10ml of extraction buffer (lOmM TrisCl pH8, 0.1M EDTA, 
0.5%SDS, 20pg/ml DNAase-free RNAaseA), and the mixture incubated at 37°C for lh 
with shaking. A final concentration of 0.1 mg/ml ProteinaseK was then added, and the 
samples icubated at 55°C for 3h with occasional swirling. 10ml of phenol was then added to 
each tube, which were then centrifuged briefly (5min, 700 ref). The top layer was then 
carefully removed from each sample and placed in a fresh tube, to which another 10ml of 
phenol was added. Samples were centrifuged briefly and again the top layer carefully 
removed and placed in a fresh tube. 0.2 volumes of 10M ammonium acetate solution and 2 
volumes of ethanol (EtOH) were added to each sample. The solution was thoroughly mixed
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and incubated at -20°C to allow DNA precipitation. The DNA precipitate was then 
‘hooked’ out using a clean pipette tip and placed in a 1.5ml microfiige tube. Pellets were 
washed twice in 1ml of chilled 70% EtOH and air dried for 10-15min. DNA pellets were 
then resuspended in an appropriate volume of sterile lxTE (lOmM TrisHCl, ImM EDTA). 
The optical absorbance at 260nm and 280nm was measured using a Beckman DU 650 
spectrophotometer and used to determine the concentration, which was then adjusted to 
1 mg/ml.
2.2.1.2.2 Genomic DNA Extraction on 96 Well Plates
The growth medium from 96 well plates with confluent wells of mouse ES cell clones was 
removed by blotting onto paper towels. Wells were then washed in 200pl of PBS before 
50pl of lysis buffer (lOmM Tris.HCl, pH 7.5, lOmM EDTA, lOmM NaCl, lmg/ml 
proteinase K, 0.5% SDS) was added to each well. The plate was then sealed with plate 
sealing tape and incubated at 55°C overnight. The next day, 200pi freshly prepared, ice 
cold, precipitation buffer (75mM NaCl in EtOH) was added to each well, mixed slowly, 
and the plate incubated at room temperature for lh. Liquid in the wells was then blotted 
onto paper towels and the wells washed three times in cold 70% EtOH. The plates were 
then air dried for 10-15min and the precipitated DNA resuspended in 35pi of lxTE.
2.2.1.2.3 Preparation of Genomic DNA from Tailtips for Genotyping
Tailtips were removed from weaned mice and incubated in 1.5ml screwcap tubes at 55°C 
overnight in lOOpl lysis buffer (lOOmM Tris.HCl pH8.5, 5mM EDTA, 0.2% SDS, 200mM 
NaCl, 0.1 mg/ml Proteinase K). Tubes were then heated to 96°C on a heating block for 5min 
before 500pl of dcttLO was added. Tubes were then spun in a microfiige at 13,000 ref for 
5min and then stored at 4°C.
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2.2.1.2.4 Preparation of Genomic DNA from Tailtips for Southern Blots
Tailtips were removed from weaned mice and incubated in 1.5ml screwcap tubes at 55°C 
overnight in lOOpl lysis buffer (lOOmM Tris.HCl pH8.5, 5mM EDTA, 0.2% SDS, 200mM 
NaCl, 0.1 mg/ml ProteinaseK). Tubes were then spun at 13,000 ref for lOmin in a microfiige 
and the supernatant collected into a fresh tube to which o f 1ml of propan-2-ol was added to 
allow DNA precipitation. The precipitate was ‘hooked’ out using a clean pipette tip and 
placed in a fresh tube. The DNA was washed twice in cold 70% EtOH, air dried for 10- 
15min, and resuspended in 400pl of sterile lxTE.
2.2.1.2.5 Plasmid DNA Preparation (Minipreps/Maxipreps)
Single bacterial colonies were picked and incubated with shaking at 37°C overnight in 5ml 
of LB-medium containing 50pg/ml ampicillin or 50pg/ml kanamycin. 1.5ml of the 
overnight culture was pelleted by centrifugation (lOmin, 13,000 ref). DNA was purified 
using the QIAprep Spin Miniprep Kit according to the manufacturer’s instructions. DNA 
from larger volumes of overnight cultures (100-200ml) was purified using the QIAGEN 
Maxi kit following manufacturer’s instructions.
2.2.1.2.6 Plasmid DNA Precipitations
To concentrate or sterilise plasmid DNA, precipitation was employed. Briefly, 50|ug of 
plasmid DNA was incubated with 0.1 volume of 3M sodium acetate (pH5.5) and 2 volumes 
o f EtOH on dry ice for 15min. Samples were then spun at 13,000 ref for lOmin and the 
pellet washed twice in ice cold 70% EtOH. Plasmid pellets were then air-dried (in laminar 
flow hood if to be used for sterile applications) and resuspended in lxTE to give 1 mg/ml.
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2.2.1.2.7 RNA extraction with Trizol
Mouse tissues were dissected out, rinsed in PBS, snap frozen in liquid nitrogen, and stored 
at -70°C. ~50mg of tissue was ground up whilst frozen using a mortar and pestle under 
liquid nitrogen. Ground up tissue was then collected in a sterile RNAase free microfuge 
tube and homogensised in 1ml of Trizol™ by pipetting vigorously up and down. RNA was 
then extracted according to the Trizol™ manufacturer’s instructions. In brief, samples were 
incubated at room temperature for 5 min, spun at 12,000 ref for lOmin at 4°C and the top 
layer collected and placed in a fresh tube. 0.2ml of chloroform was added to samples which 
were then shaken vigorously for 15 sec and incubated at room temperature for 2min. 
Samples were then spun in a chilled microfuge for 15 min at 12,OOOrcf before the upper 
layer carefully removed and placed in a fresh tube. 0.5ml of propan-2-ol was added to each 
sample which were then incubated at room temperature for lOmin to allow nucleic acid 
precipitation. Samples were then centrifuged at 8,OOOrcf for lOmin at 4°C. RNA pellets 
were washed in 75% EtOH, air dried, and resuspended in The RNA Storage Solution. The 
optical absorbance at 260nm and 280nm was measured using a Beckman DU 650 
spectrophotometer and used to determine the RNA concentration. Purity was estimated 
from the OD260/OD280 •
RNA samples were DNAase treated using the DNA-yree™ kit according to the 
manufacturer’s instructions. In brief, 10pg of each RNA sample was diluted in lxDNAasel 
buffer containing ljul of DNAasel with the total volume made up to 50pl with 
diethylpyrocarbonate (DEPC) treated water. Samples were mixed, and incubated at 37°C 
for 30min. 5pi of DNAase Inactivation Reagent was then added and samples mixed 
thoroughly during incubation at room temperature for 2min. Samples were centrifuged at 
10,OOOrcf for 1.5 min and the supernatant, containing the DNAase treated RNA, placed in a 
fresh tube.
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2.2.1.2.8 cDNA Synthesis from RNA
cDNA was reverse transcribed from DNAase-treated RNA using the Superscript™ First- 
Strand Synthesis System for RT-PCR according to manufacturer’s instructions. Briefly, 
5pg of each RNA sample was mixed with lOpg/ml 01igo(dT)i2-i8, 200nM dNTP mix, and 
the volume made up to lOpl with DEPC treated water. Samples were incubated at 65°C for 
5 min and then placed on ice for -lrn in . To each sample, 9pi of a mixture containing the 
following components (final concentrations) was added: lxRT-buffer, 5mM MgC^, 10nM 
DTT, and lp l of RNaseOUT™ Recombinant RNase Inhibitor. Samples were incubated at 
42°C for 2min and then lp l (50units) of Superscript™ II Reverse Transcriptase was 
added to each sample (except -R T  controls). Reactions were incubated at 42°C for 50min 
before being terminated by incubation at 70°C for 15 min. Samples were collected by 
centrifugation and 1 pi of RNAaseH added to each one. These were incubated at 37°C for 
20min, and then stored at -20°C until used for PCR amplification.
2.2.1.3 Polymerase Chain Reaction (PCR)
PCR for all applications was performed using Reddymix™ PCR Master Mix tubes 
according to manufacturer’s instructions. Briefly, 2pi of an oligonucleotide primer mixture 
(forward and reverse primers) was added to each tube such that each primer was at a final 
molarity of 0.2pM. Where the concentration of DNA template was known, 50-100ng of 
template was added to appropriate tubes and the final volume made up to 50pl with ddH20. 
When the template concentration was not known (such as when screening DNA from ES 
cell clones or cDNA amplification), 3pl of DNA was added to the appropriate tubes. Tubes 
were then incubated in a thermocycler.
Thermocycler programs used varied depending upon the application, and were as follows:
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LONG SCREENING:- 94°C 2mins, (94°C lOsec, 58°C lmin, 68°C 3min30sec) x35, 68°C 
lOmins, 4°C until end;
GENOTYPING:- 94°C 2mins, (94°C 30sec, 55°C lOsec, 68°C lmin) x35 68°C lOmins, 
4°C until end;
TAGGED EXPRESSION CONSTRUCT:- 94°C 2mins, (94°C 30sec, 55°C lm, 68°C 
2min) x35 68°C lOmins, 4°C until end;
cDNA AMPLIFICATION:- 94°C 2mins, (94°C 30sec, 55°C 30sec, 68°C lmin) x35 68°C 
lOmins, 4°C until end.
PCR products were then analysed by agarose gel electrophoresis. Where appropriate, PCR 
products were purified using the technique described in 2.2.1.6
2.2.1.4 Agarose Gel Electrophoresis
Unless otherwise stated 1% agarose gels were used for all applications. Electrophoresis 
grade agarose was dissolved in lxTAE (40mM Tris-acetate, ImM EDTA) by heating. A 
final concentration of 0.5 fig/ml ethidium bromide was added to cooled gels before pouring. 
The gel was then poured into horizontal gel cast apparatus and allowed to set at room 
temperature.
Unless using Reddy mix PCR tubes with loading buffer already included, DNA loading 
buffer (6x solution: 30% glycerol and bromophenol blue to colour) was added and samples 
were added to appropriate wells alongside DNA ladder markers. Unless otherwise stated, 
gels were run at 100V in lxTAE buffer until bands clearly separated. DNA was visualised 
on a transilluminator and photographed.
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2.2.1.5 Restriction Enzyme Digests
DNA was digested in a volume of 20-50pl using enzymes and the appropriate reaction 
buffers according to manufacturer’s instmctions. Between 5 and 10 units o f restriction 
enzyme/pg of DNA was used. Generally, reactions were carried out for l-2h at 37°C. 
However, for complete digestion of genomic DNA for Southern blotting, the reaction was 
for 4h before an extra 10% volume was added containing fresh lx  enzyme. The reaction 
was then incubated at 37°C for a further 16h. Digested plasmids which were to be used in 
ligation reactions (see 2.2.1.7) were treated with 1 unit of Alkaline Phosphatase and further 
incubated for 30min at 37°C to prevent re-ligation.
2.2.1.6 Gel Purification of DNA Fragments
DNA bands were excised from a gel using a scalpel and purified using a QIAGEN 
QIAquick Gel Extraction Kit according to the manufacturer’s instmctions. The DNA was 
eluted from the columns in 30-50pl of either lxTE or distilled water and the yield 
determined both by spectrophotometry, and running a 5 pi aliquot on an agarose gel 
alongside a DNA hyperladder of known fragment concentration.
2.2.1.7 DNA Ligation
Ligations were carried out using the Rapid DNA ligation kit according to manufacturer’s 
instmctions. Briefly, the amount of vector and insert used in these reactions was calculated 
using the following formula:
(50ng of vector x kb size of insert / kb size of vector) x (ratio insert:vector) = ng of insert
Generally, the ratio of insert to vector used was 4:1 and 1/10th of the above reaction was 
used to transform E.Coli DH5a competent cells (2.2.1.8 )
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2.2.1.8 Transformation of DH5a Competent Bacterial Cells
A 50pl aliquot o f DH5a competent cells was thawed on ice in a chilled 15ml 
polypropylene tube (Falcon 2059). lp l of plasmid DNA was added to each tube and left to 
incubate for 30min on ice. Cells were then incubated at 42°C for ~45 sec and then returned 
to ice for 2min before 400pl of warmed SOC medium (2% bactotryptone, 0.55% yeast 
extract, lOmM NaCl, 2.5mM KC1, lOmM MgCb, lOmM MgSC>4, 20 mM glucose) was 
added. Cells were then incubated at 37°C for lh  with vigorous shaking. Either 40 or 200pl 
o f the reaction was then plated on L-agar plates containing 50pg/ml amplicillan or (when 
appropriate) 50pg/ml kanamycin. Plates were then inverted and incubated at 37°C for 16h 
to allow colony growth.
2.2.1.9 Cloning of DNA Fragments into TOPO® Plasmids
PCR amplification products which had been agarose gel electrophoresed and gel purified 
were cloned into pCR® 2.1-TOPO® (or in one case pcDNA3.1/CT-GFP-TOPO® see
2.2.1.12.3) according to manufacturer’s instructions. Briefly, 4pl of purified PCR product, 
1 pi of salt solution, and 1 pi of linearised TOPO® vector were mixed together and incubated 
at room temperature for 5 min. The reaction mixture was then stored on ice until used for 
transformation.
For each transformation reaction, 2 pi of the TOPO® cloning reaction were transferred into a 
vial of One Shot® Chemically competent E.coli, and gently mixed. This was then incubated 
on ice for 5 min and subsequently heat-shocked for 30sec at 42°C. Tubes were then 
transferred to ice and 250pl of room temperature SOC medium added to each. Reactions 
were then incubated in a shaker (200rpm) for lh  at 37°C and then 50pl of each
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transformation were spread on an agar plate containing 50pg/ml of ampicillin. Plates were 
inverted and incubated overnight at 37°C. Colonies were isolated the following day.
2.2.1.10 Southern blotting
Completely digested DNA samples were separated by electrophoresis on a 0.8% agarose 
gel containing 0.5pg/ml ethidium bromide for 6h at 80V. Gels were then visualised on a 
UV transilluminator and photographed alongside a transluscent ruler as a reference. The gel 
was then trimmed and, when deemed necessary for transfer of ffagments>10kb, placed in 
0.2M HC1 for 5-10min. This was followed by a brief rinse in distilled water and 
equilibration in alkali transfer buffer (0.4M NaOH, 1M NaCl) for lOmin. The DNA was 
transferred from the gel to a Hybond N+ nylon membrane by alkali transfer Southern 
blotting overnight, detailed in figure 2.1.1. The next day, the apparatus was dismantled and 
the HybondN+ membrane containing the DNA fragments was briefly rinsed in 
neutralisation buffer (3M NaCl, 0.5M TrisHCl).
G la s s  Plate
W h atm an n  Filter
"Alkali Transfer Buffer
Figure 2.2.1: A Southern Blot by Cappilary T ransfer. A glass dish is half filled with 
alkali transfer buffer and soaked 3mm filter paper is place upon a glass plate with both ends 
of the filter paper submerged in the buffer. The gel is placed upside down on the filter paper 
and a Hybond N+ nylon membrane (soaked in transfer buffer) carefully placed on top the 
gel (taking care to remove any bubbles). Three pieces o f filter paper are placed on top of 
this with 3-4inches of paper towels above this. A glass plate with several weights is placed 
on the top. Parafilm is used to prevent short-circuiting by covering any spaces on the lower 
piece of filter paper not covered by the gel.
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Preparation of DNA for Probes: The probes used for analysis of Southern blots were 
generated by restriction digestion of plasmid DNA with restriction enzymes (see figure 
3.2.2 for details of where probes are located). Fragments were separated by agarose gel 
eletrophoresis and bands of the indicated sizes were excised and gel purified. DNA was 
then resuspended at 25pg/ml. CCX-CKR 5' probe: Plasmid containing mCCX-CKR 
genomic clone was digested with EcoRl and Hindlll and the ~500bp fragment purified. 
CCX-CKR 3' probe: Plasmid containing mCCX-CKR genomic clone was digested with 
EcoRl and Hindlll and the ~1.6kbp fragment purified. lacL  probe: The CCX-CKR lacZ 
KIKO plasmid was digested with Xbal and BamHl and the ~3kb fragment purified. Neo 
probe: The CCX-CKR lacZ KIKO plasmid was digested with Xbal and EcoRl and the 
~ lkb fragment purified. GFP probe: The pEGFPN2 plasmid was digested with EcoRl and 
Notl and the ~800bp fragment purified.
Labelling of Probes: DNA fragments for probing Southern blots were labelled using 
Ready-To-Go™ DNA Labelling Beads according to manufacturer’s instructions. In brief, 
labelling beads were resuspended in 20pl of lxTE and incubated on ice. 25ng o f DNA 
fragment was added to a total volume of 25pi of lxTE in a separate screwcap tubes and this 
was boiled for 3min, and then incubated on ice. The two mixtures were then combined and 
5pl of [y32P]dCTP added. Reactions were mixed and then incubated at 37°C for 30min.
Unincorporated label was removed by running the samples through NICK™ columns 
according to manufacturer’s instructions. Briefly, columns were equilibrated by running 
through lxTE. The labelled probe samples were then added and an extra 350pl o f lxTE 
added to the column which was allowed to empty. Probes were then eluted in 500pl of 
lxTE. The probe was then counted in a liquid scintillation counter, boiled for 3min, and 
added to hybridisation reactions at 2 x l0 6 cpm/ml.
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Hybridisation of Blots: Membranes containing blotted DNA fragments were rinsed briefly 
in 2xSSC (0.3M NaCl, 30mM Na Citrate) and rolled up in hybridisation bottles, taking care 
to remove any air bubbles. Blots were then prehybridised using Ultrahyb™ according to 
manufacturer’s instructions. In brief, the Ultrahyb was pre-warmed to 6 8 °C and 10ml added 
to each bottle. The bottles were then incubated in a rotating hybridisation oven at 42°C for 
30min. Labelled, denatured, DNA probes were then added as outlined above. The 
hybridisation reaction continued at 42°C overnight.
Washes and Probe Detection: Following hybridisation, the membranes were removed 
from the bottles and washed twice with gentle shaking for 5 min at 42°C in low stringency 
wash buffer (2xSSC, 0.1% SDS). This was followed by two washes with gentle shaking for 
15 min at 42°C in high stringency wash buffer (O.lxSSC, 0.1%SDS). Washed membranes 
were then exposed to X-ray film, which was then developed.
2.2.1.11 DNA Sequencing
All DNA sequencing was performed by members of the BITS using an Applied Biosystems 
373A automated sequencer. Briefly, PCR amplification of the region to be sequenced was 
carried out with primers complimentary to domains upstream and downstream of the region 
o f interest. PCR reactions contained 0.5pg plasmid DNA, 3.2pmoles of primer and 4pi of 
Big Dye Terminator Reaction premix in a final volume of lOpl (made up with distlilled 
water).
The oligonucleotides used for sequencing the various different fragments of DNA in this 
study were: i) For GFP portion of CCX-CKR GFP KIKO plasmid: GFPU1, GFPU2, 
GFPU3, GFPD1, GFPD2, GFPD3. ii) For hCCR7 constructs: hCCR7Ul, hCCR7U2, 
hCCR7U3, hCCR7U4, hCCR7Dl, hCCR7D2, hCCR7D3, hCCR7D4. iii) For hCCX- 
CKR constructs: hCCXUl, hCCXU2, hCCXU3, hCCXU4, hCCXU5, hCCXDl,
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hCCXD2, hCCXD3, hCCXD4, hCCXD5. iv) For fragments cloned into TOPO® 2.1: The 
M l3 forward and M13 reverse oligos were also additionally used for sequencing PCR 
products v) For inserts cloned into pcDNA3.1: The T7 primer was additionally used.
2.2.1.12 Plasmid Construction
2.2.1.12.1 FLAG-tagged hCCR7
hCCR7 was amplified by PCR using the pcDNA3.1.hCCR7 plasmid as template and 
priming using the oligonucleotides ‘H3FLAGhCCR7’ and ‘hCCR7-7Vo/T using the 
‘Tagged Expression Construct’ thermocycler conditions (detailed in section 2.2.1.3). A 
- lk b  fragment was resolved by agarose gel electrophoresis, gel purified, and cloned into 
Topo®  2.1. This plasmid was then verified by DNA sequencing and digested with Hindlll 
and Noil. The lkb fragment was again resolved and purified from an agarose gel, then 
cloned into pcDNA3.1 which had been cut with the same restriction enzymes. This plasmid 
was verified by DNA sequencing to check that the N-terminal FLAG epitope 
(DYKDDDDK) had been correctly inserted between the first two amino acids of hCCR7.
2.2.1.12.2 HA-tagged hCCR7-GFP
hCCR7 was amplified by PCR using the pcDNA3.1.hCCR7 plasmid as template and 
priming using the oligonucleotides ‘H3HAhCCR7’ and ‘hCCR7-B-GFP’ using the ‘Tagged 
Expression Construct’ thermocycler conditions (detailed in section 2.2.1.3). A - lk b  
fragment was resolved by agarose gel electrophoresis, gel purified, and cloned into TOPO 
2.1. This plasmid was then verified by DNA sequencing and digested with Hindlll and 
BamHl. The lkb fragment was again resolved and purified from an agarose gel, then cloned 
into pEGFPN3 which had been cut with the same restriction enzymes. This plasmid was 
verified by DNA sequencing to check for the haemagglutinin (HA) N-terminal epitope tag 
(YPYDVPDYA) and an in-frame hCCR7-GFP fusion.
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2.2.1.12.3 HA-tagged hCCX-CKR-GFP
Strategy A: hCCX-CKR was amplified by PCR using the pcDNA3.1.hCCX-CKR plasmid 
as template and priming using the oligonucleotides ‘H3HAhCCX’ and ‘hCCX-B-GFP’ 
using the ‘Tagged Expression Construct’ thermocycler conditions (detailed in section
2.2.1.3). A —1.1 kb fragment was resolved by agarose gel electrophoresis, gel purified, and 
cloned into TOPO® 2.1. This plasmid was then verified by DNA sequencing and digested 
with Hindlll and BamHl. The 1.1 kb fragment was again resolved and purified from an 
agarose gel, then cloned into pEGFPN3 which had been cut with the same restriction 
enzymes. This plasmid was verified by DNA sequencing to check for the haemagglutinin 
(HA) N-terminal epitope tag and an in-frame hCCX-CKR-GFP fusion.
Strategy B: hCCX-CKR was amplified by PCR using the pcDNA3.1.hCCX-CKR plasmid 
as template and priming using the oligonucleotides ‘H3HAhCCX’ and ‘hCCX-B-GFP(2)’ 
using the ‘Tagged Expression Construct’ thermocycler conditions (detailed in section
2.2.1.3). A —1.1 kb fragment was resolved by agarose gel electrophoresis, gel purified, and 
cloned into pcDNA3.1/CT-GFP-TOPO®. This plasmid was then verified by DNA 
sequencing.
2.2.1.12.4 CCX-CKR-GFP-KIKO
The CCX-CKR lacZ KIKO plasmid was digested with BamHl and the large (~15kb) 
fragment purified following agarose gel electrophoresis. A plasmid containing famesylated 
GFP cloned upstream of the PGKneo cassette (called GFPneolox) was also digested with 
BamHl and a ~5kb fragment purified from this reaction following agarose gel 
electrophoresis. These two DNA fragments were then ligated together, clones produced in 
bacteria, and plasmid orientation checked by restriction digestion. The resulting CCX-CKR 
GFP KIKO plasmid was further verified by sequencing of the GFP portion of the construct.
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2.2.1.13 SDS-PAGE and Western Blotting
Cell lysates from lxlO6 cells were prepared in CellLytic-M Mammalian Cell Lysis Buffer 
according to manufacturer’s instructions. An equal volume of HU buffer (8  M urea, 5% 
SDS, 200 mM Tris-HCl, pH 8 , 0.1 mM EDTA, 100 mM dithiothreitol (DTT), 0.5% 
bromphenol blue) was added. Samples were incubated at room temperature for lOmin, 
subjected to SDS-PAGE alongside Multimark protein markes, electrophoretically 
transferred onto polyvinylidene difluoride membrane, and blocked overnight in 10% 
milk/PBS. Blots were incubated with the appropriate primary antibody, washed in 
PBS/0.1% Tween, visualized with a a-mouse IgG horseradish peroxidase-coupled 
secondary antibody, developed using a WestPico kit according to manufacturer’s 
instructions, and exposed to X-ray film.
Samples from radioligand degradation experiments (2.2.4.2) were boiled for lOmin, 
centrifuged (13,000rcf, 3min), and 25pl electrophoresed on a 4-12%  Bis-Tris gradient 
acrylamide gel in lx  MES buffer. An aliquot of 125I-hCCL19 stock, containing an 
equivalent number of cpm to that found in 25 pi of the most radioactive test sample, was 
prepared in lxLB (50mM Tris-HCl, pH6.5, 2% SDS, lOmM DTT, 10% glycerol, 0.1% 
bromphenol blue) and loaded on the gel. Samples were run adjacent to MultiMark protein 
markers. After electrophoresis, gels were dried onto filter paper and exposed to X-ray 
film.
2.2.2 Cell Culture
All cell culture work was performed using strict aseptic techniques inside a Medical Air 
Technology Ltd Class II Microbiological Safety Cabinet laminar flow hood. Cells were 
incubated at 37°C in a dry atmosphere containing 5% (w/v) CO2. Human embryonic 
kidney (HEK)293 cells were grown in an appropriate volume of 293 medium (Dulbecco’s
107
© Iain Comerford, 2005 CHAPTER TWO MATERIALS AND METHODS
minimal essential medium (DMEM), 10% fetal calf serum, 4mM L-glutamine, and 
100pg/ml streptomycin, and lOOU/ml penicillin) in either T25, T75 or T 175 tissue culture 
flasks. Cell culture of mouse embryonic fibroblasts (MEFs) was performed by Dr Milasta 
in the Department of Biochemistry at the University of Glasgow. Culture o f mouse 
embryonic stem cells was performed by members of the Beatson Institute Transgenics 
Unit.
2.2.2.1 Harvesting Cells
Medium was removed from cells by aspiration. Cells were then rinsed briefly in sterile PBS 
and then incubated with 5ml warmed 1 x trypsin solution (0.25% trypsin in PE) for ~5min. 
Cells were then harvested from surface of plate by pipetting up and down and placed in 
sterile universal container containing 5ml 293 medium. Cells were then collected by 
centrifugation and resuspended in 293 medium for counting, re-seeding, and experiments.
2.2.2.2 Freezing Cells
Harvested cells were resuspended at 2xl06 cells/ml in 293 medium containing 10% DMSO 
and 1ml volumes were aliquoted into cryotubes. Cryotubes were then either placed into a 
‘Mr Frosty’ (filled with 250ml propan-2-ol) or placed in a plastic beaker padded with cotton 
wool. The ‘Mr Frosty’ or the beaker was then incubated at -70°C for 12-16h before 
cryotubes were removed and stored in liquid nitrogen tanks for long-term storage.
2.2.2.3 Defrosting Cells
Cryotubes containing frozen cells were removed from liquid nitrogen storage and thawed in 
warm (~37°C) water for several min. Cells were removed from cryotubes and diluted with 
20ml 293 medium, collected by centrifugation, resuspended in 10ml 293 medium
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(containing 0.8mg/ml G418 or 2pg/ml puromycin where appropriate) and seeded into T25 
flasks.
2.2.2.4 Cell counts
400pi aliquots of harvested cells were diluted to a total of 20ml in PBS and the sample 
counted using a Casy® Technology Cell Counter. The approximate cell concentration was 
calculated. Alternatively, cells were counted in a haemocytometer. —lOpil of single cell 
suspensions were transferred to one side of a haemocytometer and the number of cells in 
one comer square counted under the light microscope. Cells which appeared non-viable 
were excluded. At least 100 cells were counted (using extra squares if  necessary). The cell 
concentration was calculated using the following formula:
Cells/ml= (average cell count per square) x 104
2.2.2.5 Transfection of HEK293 Cells
2.2.2.5.1 Transient Transfections
2xl0 5 cells in a volume of 2ml in 293 medium were plated into the wells of a six-well tissue 
culture dish and cultured for 48h (37°C, 5% CO2). Effectene was used for transfection 
according to manufacturer’s instructions and using supplier’s buffers. Except where 
indicated lpg  of plasmid DNA was mixed with lOOpl of EC buffer, 3.2pl of Enhancer 
added, left for 5 min at room temperature, 10pl of Effectene added, and the sample mixed 
and incubated for a further 5-10min at room temperature. Then, 600pl of 293 medium was 
added, and the whole mix was added dropwise to one well of cells bathed in 2 ml of warm 
293 medium. Mock transfectants, omitting DNA, were done as a control. Cells were 
incubated (37°C, 5%CC>2) overnight and harvested the next day.
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2.2.2.5.2 Stable Transfections
lxlO 6 cells were seeded onto a 90mm tissue culture dish in 10ml of 293 medium and 
incubated (37°C, 5 %C0 2 ) for 48h. Transfections were performed using the FuGENE 6 
Reagent according to manufacturer’s instructions. In brief, either 3 or 5pg of sterile plasmid 
DNA was added to 18 pi of fuGENE 6 and the volume made up to 300pi with serum free 
DMEM in a small sterile bijou tube. This complex was incubated at room temperature for 
15-20min and then added dropwise onto the cells. Samples with no DNA added were 
included as mock transfected controls. Cells were incubated (37°C, 5 %C0 2 ) overnight, 
then harvested and plated out with selection medium containing 0 .8mg/ml geneticin 
(G418). Culture continued for several weeks until stable G418 resistant colonies came 
through.
2.2.3 Analysis of Cell Fluorescence
2.2.3.1 Confocal Microscopy 
Preparation of Slides
Two 13mm diameter glass coverslips were put into each well of a 6  well tissue culture 
plate. 3ml of sterile fibronectin (lpg/m l in PBS) was added to each well and the plate 
incubated at 37°C in the dark for one h. The fibronectin was then aspirated off and wells 
washed twice with PBS. lxlO 5 cells in 3ml of 293 medium were then added into the wells 
and then grown for 48h. Following experimental procedures, cells were washed gently in 
PBS and then incubated with 4% paraformaldehyde (PFA) for 15 min at room 
temperature. Cells were again rinsed with PBS and the coverslips carefully removed from 
the wells, air-dried, and mounted on glass slides in Vectashield containing 4,6-diamidino- 
2-phenylindole (DAPI). Coverslips were sealed using nail vamish, dried in the dark, and 
stored at 4°C until analysed.
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Image Capture
Images were captured using a Leica SP-2 confocal microscope configured with Leica 
software, with a 40x oil immersion objective and digital zoom. Fluorochromes were 
excited sequentially where appropriate with lasers at 488nm (GFP) or 543nm (Cy3), or a 
UV laser (DAPI), images superimposed using Leica software, and assembled using 
Thumbs-Plus software. Serial z-sectioning was used where necessary to confirm 
intracellular fluorescence localisation.
2.2.3.2 Flow Cytometry
a) HEK-293 Cells
Cells from experiments were collected in 5ml polypropylene FACS tubes, resuspended in 
400pl of ice cold FACS buffer (2% FCS, 0.1% sodium azide in PBS). Data acquisition was 
performed using a Becton Dickinson FACSscan running CellQuest™ software. Cells were 
gated using forward and side scatter (see figure 2.2.2A). When only one colour was being 
detected, negative control cells were used to adjust the cytometer settings so that >95% of 
cells fell between 10° and 101 on the FL2-H (for phycoerythrin) or the FL1-H (for GFP) 
channels (see figure 2.2.2B). For two colour analysis, negative control and single stained 
cells were used to adjust the settings and cytometer compensation (see figure 2.2.3). Test 
samples were analysed with at least 10,000 gated events counted per sample. Data collected 
was analysed using either CellQuest™ or WinMDI software.
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Forward Scatter
M1(>95%)
FL-2H
Figure 2.2.2: Setting up the Flow Cytometer for Single Colour Analysis. (A) Events 
which fall within the 4R1’ gated region (coloured red) are considered viable cells and only 
these are subsequently analysed. (B) The cytometer is set up so that >95% o f viable 
negative control cells fall within ‘M l ’ (have a fluorescence intensity between 10° and 10] 
units).
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Figure 2.2.3: Setting up the Flow Cytometer for 2 Colour Analysis. Settings are 
adjusted so that unstained negative control cells (black-top left) fall within the bottom left 
quartile. GFP transfected cells (green-top right) are used to set the compensation so that 
these mostly fall under the line in the lower section o f the plot. GFP-ve, PE stained cells 
(red-lower left) are used to set compensation so that these fall on left hand side o f the 
vertical line. Cells both transfected with GFP and stained with PE (blue-lower right) can 
then be analysed.
b) Mouse Leukocytes
Immunostained mouse leukocytes were analysed by flow cytometry using a Becton 
Dickinson FACSCalibur immunocytometry system. The leukocyte fraction o f cells from 
suspensions o f mouse spleen and LNs were gated based upon forward and side scatter (see 
figure 2.2.4A). Prior to analysis, a drop o f propidium iodide was added to each sample. 
Dead cells were then excluded from analysis by gating on those which did not take up
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propidium iodide, measured on the FL3-H channel (see figure 2.2.4B). Samples which had 
been stained with isotype-control fluorochrome labelled antibodies were used to adjust 
settings and cytometer compensation (see figure 2.2.4C). Once the cytometer had been set 
up, test-samples were analysed.
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Figure 2.2.4: FACS Analysis of Mouse Leukocytes. (A) Leukocytes are gated upon based 
their forward and side side scatter. Those cells within ‘R l ’ (labelled in red) are 
subsequently analysed. (B) Dead cells are excluded by propidium iodide staining. Cells 
within ‘R2’ (labelled in green) are subsequently analysed. (C) Cytometer settings and 
compensation are set using cells double stained with isotype control antibodies (black), 
cells stained with PE-conjugated antibodies and FITC conjugated isotype controls (red), 
and cells stained with PE-conjugated isotype controls and FITC conjugated antibodies 
(green). Cells stained with two labelled antibodies can then be analysed (blue).
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2.2.4 In Vitro Assays
2.2.4.1 Radioligand Internalisation Assays
0 .5 -lx l0 6 harvested cells were incubated at 4°C for lh  in 50jul o f binding buffer (BB) 
(293 medium plus 20mM HEPES, pH7.4) containing 2nM 125I-CCL19. Cells were 
pelleted by centrifugation and washed in ice-cold phosphate-buffered saline (PBS). Cell- 
associated radioactivity was determined using a Beckman Gamma 5500B counter. After 
PBS washing, cells were resuspended in 200pl o f BB, and shifted to 37°C for up to 2- 
30min. Cells were then pelleted, the BB removed, and the cells washed with either PBS 
or acid wash (generally 0.2M acetic acid, 0.5 M NaCl unless indicated in the text), both 
ice-cold, for 5 min. Cell-associated radioactivity was determined using a Gamma 5500B 
counter. Ligand internalisation was calculated by the ratio of radioactivity in acid-stripped 
versus PBS-washed cell pellets.
2.2.4.2 Radioligand Degradation Assays 
Preloaded Cells
lxlO 6 harvested cells were loaded at 4°C with 2nM 125I-CCL19 in BB for lh, washed 
with ice-cold PBS, resuspended in lOOpl of BB, and incubated at 37°C for up to 2h 
(where indicated this incubation was in the presence o f 50mM NH4CI and/or 200nM 
hCCL19). For each time point, triplicate samples were centrifuged, the supernatant taken, 
and the cell pellet washed in 200pl o f BB, which was subsequently combined with the 
first lOOpl of supernatant. Cell pellets were resuspended in lOOpl o f PBS, and 50pl was 
counted in a Beckman Gamma 5500B counter. To the remainder, 50pl of 2x LB (lOOmM 
Tris-HCl, pH6.5, 4% SDS, 20mM DTT, 20% glycerol, 0.2% bromphenol blue) was added 
in readiness for SDS-PAGE (see 2.2.1.13). 150pl o f the supernatant was subjected to 
precipitation in 12.5% trichloroacetic acid (TCA). Radioactivity in the TCA pellet and 
non-TCA precipitable material was determined in a Beckman Gamma 5500B counter.
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The percentage of retrieved radioactivity in cells, TCA pellet, and non-TCA precipitable 
fraction was then calculated. To the remaining 150(il o f supernatant, an equivalent 
volume of 2xLB was added for SDS-PAGE analysis.
Degradation in Continuous Culture
7.5x106 cells were seeded into 75cm2 tissue culture flasks and cultured for 2 days. The 
growth medium was then replaced with 5ml of BB containing lOnM CCL19, plus 0.1 nM 
125I-CCL19 as a tracer. Cells were then incubated at 37°C. At various times, 200pl aliquots 
of medium were removed and subjected to TCA precipitation. TCA pellets and non-TCA 
precipitable fractions were prepared and counted in a Beckman Gamma 5500B counter. 
50jil aliquots were also taken and an equivalent volume os 2xLB was added for SDS-PAGE 
analysis.
2.2.4.3 Radioligand Uptake Assay
Cells in culture were incubated +/-10nM chemokine for lh, washed, harvested, and
1 125resuspended in ice-cold BB at 10 cells/ml. 40pl aliquots were taken, lOpl o f 2nM I- 
hCCL19 in BB added, the cells incubated at 37°C for lOmin, retrieved by centrifugation, 
and then washed with ice-cold PBS. Cell-associated radioactivity was determined using a 
Beckman Gamma 5500B counter.
2.2.4.4 Radioligand Binding Assay
Harvested cells were used in equilibrium radioligand binding assays. These were 
performed at room temperature in 293 medium containing 0.5% sodium azide and 20 mM
6 125Hepes (pH 7.4), using 10 cells per point (each point performed in triplicate), InM I- 
hCCL19, and +/- 200nM unlabeled CCL19. After 90min, cells were washed with ice-cold 
PBS and bound 125I-CCL19 was detected in a Beckman Gamma 5500B counter.
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2.2.4.5 Radioligand Dissociation Assay
Harvested cells (5xl05) were incubated at 4°C with 2nM 125I-hCCL19 in BB for at least 
lh , centrifuged, and washed with regular agitation for 5 min in 1.5ml ice-cold BB 
adjusted to pH5-7. Control cells were washed with ice-cold PBS. Cells were retrieved by 
centrifugation and counted in a Beckman Gamma 5500B counter. Further acid washing 
(0.2M acetic acid, 0.5M NaCl) was used on some samples to confirm surface localization 
o f radioligand.
2.2.4.6 Chemotaxis assay
CCL19 was added to cultured cells, incubated at 37°C for 16h, and supernatants collected. 
Splenocytes were isolated from a female FVB mouse, passed through nitex membrane to 
form a single cell suspension, centrifuged, and resuspended at 5xl06 cells/ml. 400pl of 
supernatants from cultured cells were then put in the lower chamber o f a Transwell 
chemotaxis plate (6.5mm diameter filter, 5pm pores) and lOOpl o f splenocyte suspension 
added to the upper chambers. Wells with no chemokine, or 200nM of fresh hCCL19, in 
the lower chambers were included. The plate was then incubated at 37°C for 4h. The 
number of cells successfully migrated to the lower chamber of each well were then 
counted using a haemocytometer.
2.2.4.7 Biotinylated Chemokine Uptake Assays 
By Confocal Microscopy
Bio-CCL19 (250ng), was mixed with 5pl of ExtrAvidin-Cy3, in a final volume o f  lOpl 
(made up with PBS), and incubated at room temperature for 45-60min to generate 
BioCCL19/Cy3 complexes. Control samples lacked Bio-CCL19 (i.e. ExtrAvidin-Cy3 
alone). Cells (HEK293 or transfected derivatives, or MEFs) were grown on fibronectin- 
treated coverslips, and the premixes added where appropriate. After incubation for up to
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lh , cells were washed with PBS, fixed in 4% PFA/PBS, washed again in PBS, mounted 
on glass slides in Vectashield mountant containing DAPI, and sealed with nail varnish 
(see 2.2.3.1).
By Flow Cytometry
Bio-CCL19 (250ng), was mixed with 3jig of Streptavidin-PE (S-PE), in a final volume of 
lOpl (made up with PBS), and incubated at room temperature for 45-60min to generate 
BioCCL 19/PE complexes. Control samples lacked Bio-CCL19 (i.e. S-PE alone). Harvested 
cells (~5xl05), pre-treated with or without chemokines, were resuspended in 190pl of BB, 
the lOpl premixed Bio-CCL19/PE complexes or S-PE alone was added, and the cells were 
incubated at 37°C with regular mixing for the indicated length of time. To end uptake, 1ml 
o f ice-cold FACS buffer was added, and the cells retrieved by centrifugation, resuspended 
in 400jnl of FACS buffer, and analysed by flow cytometry (see 2.2.3.2). Parental HEK293 
cells, treated with Bio-CCL19/PE or S-PE alone, were used as negative controls. To assess 
BioCCL 19/PE uptake into GFP-expressing transfected cells, untransfected parental 
HEK293, mock transfected HEK-hCCX-CKR cells, and GFP+ HEK-hCCX-CKR cells, 
treated with Bio-CCL 19/PE or S-PE alone, were used as controls to set appropriate 
parameters on the FACScan (see figure 2.2.3).
2.2.4.8 Antibody Staining for Surface CCX-CKR or CCR7
lxlO 6 harvested cells per sample were washed with FACS buffer and resuspended in 
lOOpl of ice-cold FACS buffer. After primary antibody (anti-FLAG M l for CCX-CKR, 
and anti-hCCR7 for CCR7) addition, samples were incubated on ice for 30-45 min, 1ml 
o f ice-cold FACS buffer added, and the samples centrifuged. Cells were resuspended in 
lOOpl of ice cold FACS buffer containing PE-coupled anti-mouse IgG secondary 
antibody and placed on ice for 30-45 min. After washing with cold FACS buffer, cells
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were resuspended in 400pl of FACS buffer and analysed by flow cytometry using a 
Becton Dickinson FACScan flow cytometer (see 2.2.3.2). Untransfected cells were used 
alongside test samples as negative controls.
2.2.5 Gene Targeting
Transgenic mice were generated (using the constructs described in section 3.2.1) in 
collaboration with the Beatson Institue Transgenic Unit (BITU). Screening of DNA from 
ES cell clones was achieved using techniques outlined above and is detailed in section 3.2. 
All ES cell culture, electroporations, blastocyst injections, and microinjections were earned 
out by members of the BITU following standard protocols.
2.2.6 In Vivo Analysis
2.2.6.1 Maintenance of Mice
Mice were housed in pathogen free conditions within the animal facility at the Beatson 
Institute and fed food and water ad libitum. All procedures performed on mice were in 
accordance with United Kingdom Home Office guidelines, and under appropriate personal 
and project licences.
2.2.6.2 Genotyping of Mice
Weaned mice were tail-tipped and DNA extracted from these tails (see 2.2.1.2.3). Genotype 
was determined by PCR. The PCR conditions are shown in section (‘Genotyping’ in 
2.2.1.3) using the following primers for the different genotyping PCRs used in this study, i) 
CCX-CKR KO/W T 5': mCCXwt5, mCCXcom5, 3IRES ii) CCX-CKR KO/W T 3’:
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mCCXCKRwt, cretester, commonscreen iii) Cre Recombinase: Crel, Cre2 iv) CCX- 
CK R neo recombination: mCCXCKRwt, commonscreen, target.neo
2.2.6.3 Sacrifice of Mice
Mice were killed by an approved schedule one technique. This was either i) in a rising 
concentration of CO2 or ii) severing of the spinal cord.
2.2.6.4 Dissection of Mice
Killed mice were dissected using standard procedures. The carcass and dissection 
instruments were rinsed in 70% EtOH prior to dissection. Organs were surgically removed 
then rinsed in PBS. Peripheral blood was taken by cardiac puncture. Blood samples were 
immediately microfuged and frozen for serum analysis by ELISA.
2.2.6.5 Weighing Inguinal Lymph Nodes
Inguinal LNs (ILNs) were trimmed under a dissection microscope to remove any attached 
connective tissue or fat, dried briefly on a paper towel, and carefully weighed on a 
microbalance.
2.2.6.6 Harvesting of Leukocytes
ILNs or spleens were homogenised by rubbing through Nitex mesh in RPMI-1640 
medium; the resulting cell suspensions were washed twice by centrifugation at 400rcf for 5 
min and then resuspended in either FACS buffer or complete RPMI depending upon the 
downstream analysis.
2.2.6.7 Immunostaining of Mouse Leukocytes for Flow Cytometry
After cell counting (see 2.2.2.4), single cell suspensions of mouse leukocytes were 
resuspended ( lx l0 6 cells/ml) in cold FACS buffer, and 500pi aliquots taken into
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polypropylene FACS tubes. Samples were then incubated with flurochrome-labelled 
antibodies against cell surface markers or flurochrome-labelled isotype control antibodies, 
and incubated in the dark at 4°C for 45-60min. Tubes were then filled with cold FACS 
buffer, spun, and the cells resuspended in -400pi cold FACS buffer. Samples were then 
analysed by flow cytometry (see 2.2.3.2).
2.2.6.8 Histology of Mouse Tissue
Tissue for histological analysis was fixed in neutral buffered formalin and passed to Colin 
Nixon at University of Glasgow Vetinary School for paraffin embedding, sectioning, and 
staining of sections with Haematoxylin and Eosin (H+E).
2.2.6.9 Cutaneous PMA Paint
Female mice between 6 and 12 weeks o f age were used in all experiments. Mice were 
shaved, and 2 days later cutaneous inflammation was induced by the application of PMA, 
as a 50pM solution in acetone, to the shaved dorsal skin (this was performed by animal 
technicians in the Beatson animal facility). Each animal received 150jnl of this solution, 
which is equivalent to 7.6 nmol per mouse per application. This was done on three 
consecutive days. Mice were then sacrificed either 3, 5, or 7 days hence. The back skin was 
removed from killed mice for histological analysis (see 2.2.5.7) and ILNs carefully 
dissected out.
2.2.6.10 Subcutaneous Immunisation with OVA/CFA
Female mice between 6  and 12 weeks of age were used. 200pl of an emulsion containing 
lOOpg of ovalbumin (OVA) in complete Freund’s adjuvant (CFA) was injected 
subcutaneously into each flank (this was performed by trained animal technicians in the
121
© Iain Comerford, 2005 CHAPTER TWO MATERIALS AND METHODS
Beatson animal facility to ensure consistent injection). Unimmunised mice were included as 
controls. On day 3 after immunisation, a group of mice were sacrificed to assess ILN 
phenotpyes. 10 days after immunisation, mice were bled from from the tailvein and the 
serum collected by centrifugation. The remainder of the mice were sacrificed either on day 
17 or day 24 following immunisation. Blood was collected by cardiac puncture and ILNs 
harvested for analysis of cellular immune responses.
2.2.6.11 Measuring OVA-Speciflc Total Serum IgG Antibody by ELISA
96 well ELISA plates were coated overnight at 4°C with 120pi of a lOpg/ml solution of 
OVA in 0.1 M carbonate buffer. Plates were then washed three times in wash buffer (0.05% 
Tween20 in PBS) before blocking non-specific binding sites with 200pl/well o f blocking 
buffer (10%FCS in PBS) for lh  at room temperature. Serum samples were diluted 1/400 in 
blocking buffer and lOOpl o f diluted sample added to appropriate wells. Plates were then 
incubated at room temperature for ~2-3h before washing the wells three times in wash 
buffer. lOOpl of primary antibody (anti-mouse IgG conjugated to peroxidase) was added to 
each well and the plate incubated for 3h at room temperature. Following three further 
washes, 1 2 0pl of phosphatase substrate (1 mg/ml in 10% diethanolamine) was added and 
the plates were read at 405nm using an automatic microplate reader.
2.2.6.12 Measuring Antigen Specific Cell Proliferation
Single cell suspensions from mouse ILNs (see 22.6.6) taken 17 or 24 days after 
subcutaneous immunization were counted and resuspended at lxlO 6 cells/ml in complete 
RPMI (RPMI 1640, 10% FCS, 4mM L-Glutamine, lOOU/ml Penicillin, 100jig/ml 
Streptomycin, and 50pg/ml Fungizone) or complete RPMI supplemented with 1 mg/ml 
OVA, or 5pg/ml Concanavalin A (ConA). Samples were culture in triplicate wells in a
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volume of 200jul at 37°C in 5% CO2 for 48h before a lOOjal supernatant sample collected 
and frozen for subsequent analysis of cytokine production (see 2.2.5.9). lOOpl of fresh 
complete RPMI (supplemented where appropriate with 1 mg/ml OVA or 5pg/ml ConA) 
was added to cultures and the cells incubated for a further 64h at 37°C 5% CO2. Cell 
proliferation was assessed by the addition of 1 pCi/well [3H]-thymidine for the last 18h of 
culture. DNA-bound radioactivity was harvested onto glass-fiber filter mats, and thymidine 
incorporation was measured on a Wallac Oy 1205 Betaplate scintillation counter.
2.2.6.13 Measuring Antigen Specific Cytokine Production
Aliquots of supernatants removed from cultures after 48h (see 2.2.5.8) were analysed using 
a Mouse Thl/Th2 Six-Plex Antibody Bead Kit according to the manufacturer’s 
instructions. In addition, Mouse IL-13 Antibody Beads were also included. Briefly, 25jnl of 
the bead mixture was addded to the wells of a pre-wetted (in ‘wash buffer’) 96 well plate 
and then a further 200pl of ‘wash buffer’ added to each well. This was followed by 50pi of 
‘incubation buffer’ to each well and lOOpl of standards was added to approriate wells. 
Then, 50pl o f assay dilutent and 50pl of supernatant sample was added to each well, the 
plate covered in foil and incubated at room temperature with shaking for 2h. The plate was 
then washed and lOOpl of biotinylated detector antibody added to each well. The plate was 
the incubated at room temperature for lh  with shaking in the dark. Following washing, 
lOOpl of streptavidin-PE was added and the plate wrapped in foil and incubated at room 
temperature with shaking for 30min. The plate was then washed three times and the beads 
resuspended in lOOpl of ‘wash buffer’. The plate was then analysed in a Luminex 100™ 
instument, and the concentration of each cytokine in each sample determined from standard 
curves generated from curve fitting software. The lower detection limits (in pg/ml) o f this
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assay for each cytokine were as follows: - IL-2=11.08; IL-4=15.67; IL-5=7.96; IL-10=4.01; 
IL-12=4.47; IL-13=29.65; IFNy=7.41.
2.2.6.14 Induction of Contact Sensitivity with the Hapten DNFB
Male mice aged between 12-16 weeks were used in this experiment. The back skin was 
shaved and 20pi of 0.5% DNFB in acetone/olive oil (4:1 ratio) applied to the shaved area 
on two consecutive days. 24h later, ILNs were removed from some mice, for analysis. 7 
days later, with the remainder o f the mice, ear thickness was measured using electronic 
callipers and then left ears were painted with lOpl 0.2% DNFB in acetone/olive oil, and 
right ears painted with lOpl acetone/olive oil alone. Ear thickness was then measured 24h 
and 48h later, and after 48h, the ears were removed for sectioning and H+E staining 
(2 .2 .6 .8).
2.2.7 Statistical Analysis
All statistical analyses were made using GraphPad Prism software (GraphPad Software). 
Comparisons between data sets were made with Student's /-test. Results with p values <0.05 
were considered to be statistically significant.
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CHAPTER THREE 
RESULTS
3.1 Biochemical Analysis of human CCX-CKR and CCR7
3.1.1 Constructs and Cell Lines
At the outset o f this project it was planned to investigate the biochemistry of CCX-CKR, 
using in vitro transfected cell systems. As the only commercially-available radiolabelled 
CCX-CKR ligand was CCL19, it was decided to focus mainly upon this chemokine’s 
interactions with CCX-CKR. In comparison, the other CCL19 receptor, CCR7 was to be 
used, a receptor which couples to intracellular signaling cascades and mediates chemotaxis 
following ligation. Before this project commenced, detailed biochemical studies of 
CCR7/CCL19 interactions had not, to my knowledge, been done. Thus, to compare the 
biochemistry of these two receptors, it was planned to generate various cell HEK293 lines 
expressing either human CCX-CKR or human CCR7, both with an N-terminal epitope tag 
and/or C-terminal GFP to allow receptor detection using antibodies and fluorescent 
visualisation. A HEK293 cell line expressing human CCX-CKR with an N-terminal FLAG 
epitope (DYKDDDD) was already available (described in Gosling et al., 2000). These cells 
are referred to hereafter as HEK-hCCX-CKR cells. Unlike untransfected counterparts, these 
cells showed displaceable binding to 125I-CCL19 and surface receptor could be detected 
using the anti-FLAG M l antibody (Figure 3.1.1 and Gosling et al., 2000). Other cell lines 
generated are outlined below. A schematic of all tagged chemokine receptors planned for 
this study (and the plasmids generated to express them) can be found in figure 3.1.2.
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Figure 3.1.1: 125I-CCL19 Binding and CCX-CKR Surface Expression by HEK-hCCX- 
CKR Cells. Top panel shows displaceable binding o f l2>I-CCL19 by HEK-hCCX-CKR but 
not untransfected HEK293 cells. Inclusion o f 200nM unlabelled CCL19 compeies for 
binding o f radioligand at 4°C on receptor transfectants only. Each sample was performed in 
triplicate and error bars shown are +/- the standard deviation. Statistical analysis was 
performed using a Student’s t-test. Repeat experiments gave similar results (n=2). Lower 
panel shows detection FLAG epitope at 4°C on HEK-hCCX-CKR and untransfected 
HEK293 cells. Using the anti-FLAG M 1 antibody and secondary detection with anti-mouse 
IgG -PE, surface expression can be detected on HEK-hCCX-CKR cells. Data shown is 
representative o f that collected in 6  independent experiments.
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Figure 3.1.2: Plasmids and Tagged Receptors used in Study: Schematic representation 
o f constructs on left hand side with resulting proteins being expressed on right hand side. 
Expression o f the CCX-CKR-GFP protein was not detected (see text for details), illustrated 
by the red-cross.
3.1.1.1 FLAG tagged CCR7
A PCR-based strategy (see 2.2.1.12) was used to insert DNA encoding the FLAG epitope 
between nucleotides encoding the first 2 amino acids of hCCR7 to enable subsequent 
protein detection with the same antibody used to detect hCCX-CKR. This was then cloned
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into pcDNA3.1 and verfied by DNA sequencing before the construct was stably transfected 
into HEK293 cells, a cell line which does not express any detectable endogenous 
chemokine receptors and has been shown to be capable of high levels of chemokine 
receptor surface expression following transfection with similar constructs (Blackburn et al., 
2004; Weber et ah, 2004). These cells are referred to hereafter as HEK-hCCR7 cells. As 
can be seen in figure 3.1.3, HEK-hCCR7 cells bound 125I-CCL19 and this could be 
competed by excess unlabelled CCL19. Notably, uncompeted binding was consistently 
significantly higher (2-3x) than that observed for HEK-hCCX-CKR cells. However, surface 
CCR7 could only be detected with the anti-CCR7 antibody and not with the anti-FLAG 
antibody. This could be due to the fact that the anti-FLAG antibody is not of high enough 
affinity to detect the receptor at the cell surface (although it is of high enough affinity to 
detect FLAG-hCCX-CKR), or alternatively the FLAG epitope may be in some way 
unavailable to the antibody in the context of hCCR7.
3.1.1.2 GFP Fusion HA Tagged Receptors
Constructs encoding hCCX-CKR and hCCR7 with a C terminal GFP fusion were generated 
(2.2.1.12) and stably transfected into HEK293 cells by selection in G418. Untagged GFP 
was used as a control. The presence of GFP+ cells was assessed by fluorescence 
microscopy or flow cytometry. With hCCR7-GFP, stably transfected GFP+ cells were 
evident, with CCR7 causing the GFP to localise predominantly to the cell surface (data not 
shown). However, despite using two distinct GFP fusion vectors (see 2.2.1.12.3) and 
successfully generating G418 resistant cell lines, GFP+ cells were never seen after 
transfection with plasmids encoding CCX-CKR-GFP fusion proteins. There could be 
several explanations for this. First, the structure of CCX-CKR may interfere with the 
fluorescence of GFP when the two proteins are fused in this way. Second, this fusion 
protein may be highly toxic to cells which express it, preventing positive cells from being
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identified. Whatever the reason for this difficulty, this inability to produce fluorescently 
tagged CCX-CKR unfortunately prevented future experiments where visualisation or 
quantification o f this receptor was desirable. Thus, all subsequent experiments used HEK- 
hCCX-CKR and HEKhCCR7 cells, unless otherwise stated.
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Figure 3.1.3: 125I-CCL19 Binding and Surface CCR7 expression by HEK-hCCR7 
Cells. Top panel: Displaceable radioligand binding detected on HEK-hCCR7 cells. Each 
sample was performed in triplicate and error bars shown are +/- the standard deviation. 
Statistical analysis was performed using a Student’s t-test. Repeat experiments gave similar 
results (n=2). Middle panel: Histogram of flow cytometric analysis showing surface FLAG- 
CCR7 not detectable on HEK-hCCR7 cells using anti-FLAG M l antibody. Lower panel: 
Histogram of flow cytometric analysis o f surface CCR7 detection using an anti-CCR7 
antibody and anti-mouse IgG-PE secondary. Data shown is representative o f that collected 
in 6  independent experiments.
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3.1.2 Internalisation and Degradation of CCL19 by its Receptors
Both CCR7 and CCX-CKR bind CCL19, and other chemokines. In the case of CCR7, this 
results in the transduction of signals that orchestrate the chemotactic migration o f the 
receptor-expressing cell. This does not occur after CCL19 binding to CCX-CKR. CCR7 
activation by CCL19 also generates signals that lead to CCR7 desensitisation, and 
internalisation of CCL19/CCR7 complexes. Studies on one of the other atypical chemokine 
receptors, D6 , ongoing in the lab at the start of the project, and reported recently (Weber et 
al., 2004), were revealing that this molecule was able to internalise and retain its chemokine 
ligands, which were then subsequently targeted for degradation. D6 , like CCX-CKR, 
appears to be silent after chemokine binding, and rather than using ligand-driven signals to 
bring about receptor internalisation instead achieves chemokine sequestration through 
constitutive receptor trafficking to and from the cell surface. This internalisation is not 
desensitised by chemokine exposure. These biochemical properties provided support for the 
D6  ‘decoy’ hypothesis further validated by more recent studies on D6  null mice (de la 
Torre et al., 2005; Jamieson et al., 2005). Thus, the question arose as to whether CCX-CKR 
also exhibited biochemical properties consistent with a role as a chemokine-sequestering 
decoy or transport receptor. To address this, experiments were initiated to first investigate 
whether CCX-CKR could internalise CCL19, and if  so determine the fate of this 
internalised ligand. Throughout, for comparative purposes, the typical CCL19 receptor 
CCR7 was studied.
3.1.2.1 CCL19 Internalisation
3.1.2.1.1 Optimisation of Radioligand Internalisation Assay
To investigate CCL19 internalisation by receptor transfectants, experiments were initiated 
to assess whether receptor associated 125I-CCL19 could, after incubation at 37°C, become 
resistant to washing with acidic salt solutions (2.2.4.1). Such approaches provide an
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indication o f internalisation and have been used previously in work investigating D 6  and
other chemokine receptors (Fra et al., 2003; Weber et al., 2004). In order to do this, it was
first necessary to demonstrate that the chemokine remaining at the cell surface could be
effectively stripped off by specific acid wash solutions. Therefore different strength acid 
washes were tested for their ability to remove 125I-CCL19 bound to HEK-hCCX-CKR cells 
at 4°C. As shown in figure 3.1.4, acid wash C most effectively removed I-CCL19
reducing the total numbers o f cell-associated counts to levels seen with untransfected
HEK293 cells. Similar results were obtained with HEK-hCCR7 cells (data not shown).
Thus, acid wash C was used in all subsequent experiments.
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Figure 3.1.4: Optimisation of Acid Wash. Harvested HEK-hCCX-CKR or untransfected 
HEK293 cells were loaded at 4°C with 12>I-CCL19 and then washed in either PBS, Wash 
A: 50nM Glycine /0.1M NaCl pH3, Wash B: 0.15M NaCl / 0.005M acetic acid or Wash C: 
0.5M NaCl / 0.2M acetic acid. Cell pellets were then counted. The amount o f radioactivity 
stripped by the wash from the cell surface was then assessed by comparison to PBS washed 
cells. Each sample was performed in triplicate and error bars shown are +/- the standard 
deviation. Statistical analysis was performed using a Student’s t-test. Acid wash C 
effectively strips specifically bound radioligand from HEK-hCCX-CKR cells (p<0.01). A 
repeat experiment gave similar results (n=2 ).
3.1.2.1.2 CCX-CKR and CCR7 Internalise Bound l25I-CCL19
Next, HEK-hCCR7 and HEK-hCCX-CKR cells, loaded with l25I-CCL19, were incubated at
37°C prior to acid washing. As expected, acid washing then failed to remove much of the
HEK-hCCX-CKR
E HEK
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radioactivity from HEK-hCCR7 cells, consistent with ligand internalisation, and indicating 
that the acid wash conditions used do not disrupt cell integrity to release internalised 
material (Figure 3.1.5). The majority o f radioactivity associated with HEK-hCCX-CKR 
cells also became acid resistant after shift to 37°C. These data suggest that both CCR7 and 
CCX-CKR internalise 125I-CCL19 at 37°C. Next, more detailed analysis o f the kinetics o f 
this internalisation was undertaken by shortening the 37°C incubation time (Figure 3.1.6). 
Again, both cell lines internalise >95% of surface 125I-CCL19 within 15min o f shifting to 
37°C. However, differences in the precise kinetics o f this internalisation were observed, 
with HEK-hCCX-CKR cells having internalised -90%  of surface l2T-CCL19 after 2min, 
while HEK-hCCR7 cells had internalised only -40% .
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o c
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Figure 3.1.5: Internalisation of ,25I-CCL19 by HEK-hCCX-CKR and HEK-hCCR7.
Cells were loaded with 12 I-CCL19 at 4°C, then incubated either at 4°C or 37°C for 15 min. 
Cells were then washed in either PBS or Acid wash C and the number o f counts associated 
with cell pellets then assessed. Incubation at 37°C causes the cell associated radioactivity to 
become resistant to acid washing (p<0.01 for both cell lines). Each sample was performed 
in triplicate and error bars shown are +/- the standard deviation. Repeat experiments gave 
similar results (n=6 ).
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Figure 3.1.6: Kinetics of ,25I-CCL19 Internalisation by HEK-hCCX-CKR and HEK- 
hCCR7. Cells were loaded with l25I-CCL19 at 4°C, then incubated either at 4°C for the 
duration o f the assay, or 37°C for 2-30min, then back to 4°C. Cells were then washed in 
either PBS or Acid wash C and the number o f counts associated with cell pellets then 
assessed. The percentage internalisation at each time-point was determined by the ratio o f 
acid resistant- to acid-sensitive radioactivity associated with the cell pellet. Each sample 
was performed in triplicate and data shown is representative o f 5 independent 
experiments.
3.1.2.1.3 Internalisation of Biotinylated CCL19/ Streptavidin-Cy3
To further examine CCL19 internalisation by CCX-CKR and CCR7, assays using 
biotinylated CCL19 (BioCCL19) were developed. This reagent contains a single 
biotinylated lysine residue at the C-terminus o f CCL19, and retains full biological activity. 
Complexes o f BioCCL19 associated with fluorescent streptavidin can be created by 
incubation o f the two at room temperature (see 2 .2 .4.7), and these complexes can be fed to 
cells. This allows fluorescent detection o f BioCCL19 and is an assay that has proved to be 
o f considerable utility in quantifying CCL19 uptake, as will be outlined later. However, 
here it has been used simply to demonstrate CCL19 uptake by cells. Careful optical 
dissection o f cells using confocal microscopy revealed that BioCCL19 complexed with 
streptavidin-Cy3 (BioCCL19/Cy3) rapidly accumulated (within 5min o f incubation at 
37°C) in endosomal-like structures o f HEK-hCCX-CKR cells and HEK-hCCR7 cells, but
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did not enter untransfected HEK293 cells (Figure 3.1.7). In addition, receptor transfectants 
treated with streptavidin-Cy3 alone, failed to accumulate fluorescence (not shown).
HEK-hCCX-CKR HEK-hCCR7 HEK
Figure 3.1.7: Internalisation of BioCCL19/Cy3 by HEK-hCCX-CKR and HEK- 
hCCR7. Cells adhered to fibronectin coverslips were incubated with complexes o f 
BioCCL19/Cy3 at 37°C for 15min. Cells were then washed and fixed, and the coverslips 
mounted with Vectashield with DAPI (blue) for nuclear visualisation. Cells were then 
analysed by confocal microscopy. Extensive BioCCL19/Cy3 uptake could be seen in most 
cells from HEK-hCCX-CKR and HEK-hCCR7 slides (left hand panels) but not in 
untransfected HEK293 cells (right hand panel). Careful optical sections o f cells were made 
to confirm intracellular localisation o f red fluorescence. Images shown are representative of 
those observed in many fields o f view.
3.1.2.2 Fate of Internalised CCL19
The data above clearly demonstrate that both CCR7 and CCX-CKR internalise CCL19. As 
discussed in the introduction, the chemokine receptor D 6  is able to more readily retain and 
degrade its internalised cargo than the conventional chemokine receptor CCR5 (Weber et 
al., 2004), a property that may conceivably aid its in vivo decoy function (Jamieson et al., 
2005). Thus, experiments were initiated to compare the fate o f labelled CCL19 internalised 
through CCX-CKR or CCR7.
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3.1.2.2.1 Degradation of Preloaded 125I-CCL19 by CCX-CKR and 
CCR7
Cells were loaded with I25I-CCL19 at 4°C, washed, resuspended in medium, and incubated 
at 37°C for 15-120min (2.2.4.2). Cell pellets and supernatant fractions were then collected 
and the supernatants precipitated in TCA, an approach used previously to distinguish 
degraded from intact protein (Fra et al., 2003; Weber et a l, 2004). The amount o f radiolabel 
associated with different fractions of the cell was then determined. It should be noted 
however that TCA-precipitable fractions do not necessarily consist entirely of intact 
protein, as some partially degraded polypeptides may still precipitate under these 
conditions. Thus, to further examine CCL19 integrity, supernatants and cell lysates were 
examined by SDS-PAGE (2.2.1.13). Importantly, preliminary experiments had shown that 
untransfected HEK293 cells had minimal amounts o f radioligand associated with them 
following 4°C loading, with the majority of counts associated with the TCA precipitable 
fraction of the supernatant (data not shown).
With HEK-hCCX-CKR cells, radiolabel was predominantly associated with the cells at 
early time-points, but over time began to appear in the TCA-soluble (degraded) fraction of 
the supernatant (Figure 3.1.8A). Indeed, after 2h at 37°C, -90%  of the recovered counts 
from HEK-hCCX-CKR fractions can be found in this fraction, indicating that the 
radioactivity is being expelled from the cells in a TCA-soluble, and presumably degraded 
form. No counts above background levels could be detected in the TCA-precipitable 
fraction, suggesting that CCL19 internalised by CCX-CKR is not subsequently released in 
an intact form. In contrast, radiolabel internalised by HEK-hCCR7 cells remains 
predominantly associated with the cell pellet throughout the time-course studied. A 
reduction in counts from these cell pellets was observed, but this was not as rapid as that 
seen for HEK-hCCX-CKR cells, with >50% of total recovered counts remaining in the cell
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pellet after 120mins. Furthermore, at 120mins, a small but significant percentage (10-15%) 
of the radiolabel released from these cells was in the TCA-precipitable supernatant fraction, 
suggesting that a proportion o f the ligand internalised through CCR7 is released intact.
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Figure 3.1.8: Degradation of ‘^ I-CCL19 by HEK-hCCX-CKR and HEK-hCCR7 
Cells. Cells were loaded at 4°C with 125I-CCL19 and then shifted to 37°C for 15 min to 
allow internalisation. Cells were then washed, resuspended, and incubated at 37°C for 15- 
120min. Cell pellets were harvested and supernatants subjected to TCA precipitation. The 
proportion o f counts associated with each fraction is illustrated in (A). Each sample was 
performed in triplicate and counts in each fraction associated with untransfected HEK293 
cells subtracted from those in transfected cells. Repeat experiments gave similar results. 
Cell lysates and supernatants from the experiment were analysed by SDS-PAGE (B). Blue 
lines indicate top o f gel. I25I-CCL19 runs at approximately 8 kDa. A high mobility smear 
band becomes apparent in some samples, indicative o f chemokine degradation.
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Cell lysates and supernatants were then analysed by SDS-PAGE (see 2.2.1.13). As can be 
seen in figure 3.1.8B, 125I associated with the cells is mainly found in a band which runs 
coincident with 125I-CCL19, indicating that it has undergone little, if any, modification. As 
expected, the relative amount of cell-associated radioactivity reduced over time, more 
rapidly in HEK-hCCX-CKR than HEK-hCCR7 cells. The disappearance of intact 125I- 
CCL19 from HEK-hCCX-CKR cell lysates coincides with the emergence of radioactivity 
which does not enter the gel properly, running as a diffuse upper smear, perhaps indicating
125a degradation product. When supernatants were analysed, barely detectable intact I- 
CCL19 emerges from HEK-hCCX-CKR cells. The diffuse upper smear seen in the cell 
pellets begins to accumulate over time in the supernatants also. In HEK-hCCR7 cells, this 
putative degradation product also becomes evident over time in the supernatants but an 
increase in the intact 125I-CCL19 also occurs at late timepoints, in concurrence with data in 
figure 3.1.8A. Together, these data indicate that CCL19, internalised via CCX-CKR, is 
more readily retained in cells, and degraded.
3.1.2.2.2 Dissociation of CCL19 from CCX-CKR and CCR7
Studies with D6  had revealed that affinity for its ligand, CCL3-L1, decreased as pH was 
lowered from pH7 (Weber et al., 2004). This was in contrast to CCR5 which showed 
increased affinity for CCL3-L1 at these mildly acidic pHs. This was hypothesized to 
explain the tendency for ligand internalised by D6  to be retained in cells, while CCL3-L1 
internalised by CCR5 could recycle intact out of the cell, still associated with receptor 
(Weber et al., 2004). Therefore, the more pronounced ligand degradation and retention 
observed in HEK-hCCX-CKR cells, compared to HEK-hCCR7 cells, could be explained by 
differing abilities of these two receptors to hold on to CCL19 at the low pHs encountered in 
endosomes. To test this, radioligand dissociation assays were performed at low pHs (see 
2.2.4.5). As can be seen in figure 3.1.9, 125I-CCL19 bound to hCCR7 was relatively
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resistant to alterations in the pH, with no significant differences at pH7 and pH6 compared 
with PBS washed cells. A significant reduction in binding was observed at pH5, but -80%  
o f the 125I-CCL19 still remained bound to CCR7. In contrast, ligand bound to hCCX-CKR 
was much more susceptible to displacement by increasing acidity. Washing at pH7 
displaced -25%  o f bound 12>I-CCL19 while cells washed at pH6 and pH5 showed a 70- 
80% reduction in bound ligand. These data clearly demonstrate a difference in the 
sensitivity o f CCL19 binding to low pH between these two receptors. This presents a 
model, similar to that proposed for D6 and CCR5 (Weber et al., 2004), that in acidifying 
endosomes CCX-CKR rapidly releases its cargo into the cell while CCR7 is less-inclined to 
do so, leading to the observed differences in ligand fate after internalisation via these 
receptors.
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Figure 3.1.9: Effect of Alterations in pH on l25I-CCL19 Binding to CCX-CKR and 
CCR7. Harvested cells were loaded with radioligand at 4°C for 1 h then washed for 5 min in 
either PBS or medium with the pH adusted between pH7-pH5. Cell pellets were then 
counted to assess to percentage o f radioligand remaining bound to the cells, relative to those 
washed in PBS alone. Each sample was performed in triplicate and error bars represent +/- 
the standard deviation. Statistical analysis was performed using a Student’s t-test. pH 
adjusted washes reduced the binding o f radioligand to HEK-hCCX-CKR cells compared 
with PBS washed cells (p<0.01). Repeat experiments gave similar results (n=3).
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3.1.2.2.3 Effect of Cold Competitor and Endosomal Neutralisation
One prediction of this model is that neutralisation of vesicle acidification, by NH4CI for 
example, should i) prevent lysosome-mediated ligand destruction, and ii) dismpt 
intracellular ligand retention, thus permitting enhanced intact chemokine re-emergence. 
Indeed, this is what is observed after D6 -mediated internalisation of CCL3-L1 (Weber et 
al., 2004). Thus, experiments identical to those above were performed, except 50mM 
NH4CI was included in the medium (2.2.4.2). In addition, to ensure that all re-emerging 
radioligand was effectively displaced from the cell surface, unlabelled competitor CCL19 
(present in large excess) was added during the degradation phase of the assay. This will 
limit re-intemalisation of radioligand by competing for the re-emerging receptor. Thus, 
once HEK-hCCX-CKR and HEK-hCCR7 cells had been pre-loaded with 125I-CCL19, 
200nM unlabelled CCL19 and/or 50mM NH4CI was added and the fate of the 125I-CCL19 
gauged in comparison to samples free o f these additives. The data from these experiments 
is shown in figure 3.1.10. First, it is o f note that NH4CI inhibited the accumulation over 
time of counts in the TCA-soluble supernatant fraction from HEK-hCCX-CKR cells, 
indicating that chemokine degradation is being inhibited by endosomal neutralisation. 
However, surprisingly, the inclusion of unlabelled CCL19 alone to HEK-hCCX-CKR cells,
1
loaded with internalised I-CCL19, caused a significant increase in the proportion of 
TCA-precipitable counts in the supernatant from these cells. Analysis of supernatants by 
SDS-PAGE confirmed that the extra counts released into the supernatant were 
electrophoretically indistinguishable from unmodified I-CCL19 (data not shown). Thus, 
after 30min at 37°C, -30%  of the counts were outside the cell in apparently non-degraded 
form. This proportion did not increase as the assay progressed, indicating that release of 
intact CCL19 only occurred early on, rather than continuously, after the addition of excess 
unlabelled extracellular ligand. These data suggest that a proportion of CCL19 internalised
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by CCX-CKR recycles back to the cell surface in the first 30min following internalisation. 
When both unlabelled CCL19 and NH4 C1 were present during the assay, the release o f TCA 
soluble radioactivity from HEK-hCCX-CKR cells was prevented as expected, and whilst 
TCA preciptable counts were released into the supernatant the NH 4 CI did not increase the 
amount o f radioactivity in this fraction.
With HEK-hCCR7 cells, as seen in previous experiments, intact 12"I-CCL19 was released 
in the absence o f unlabelled extracellular competitor. When excess unlabelled CCL19 was 
included, release o f intact chemokine by HEK-hCCR7 cells was marginally increased. The 
extra release o f intact l2 I-CCL19 caused by unlabelled competitor from HEK-hCCR7 cells 
did not inhibit the relatively small fraction o f chemokine which was degraded by these 
cells. NH 4 CI reduced the release o f degraded material by HEK-hCCR7 cells though the 
addition o f unlabelled competitor CCL19 did not noticeably change the distribution of 
radiolabel.
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Figure 3.1.10: Effect of Cold Competitor and Endosomal Neutralisation. This figure is 
continued overleaf. Refer to the legend on next page for details.
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Figure 3.1.10: Effect of Cold Competitor and Endosomal Neutralisation. Cells were 
harvested and loaded with 12 I-CCL19 at 4°C and then incubated at 37°C for 15 min to 
allow internalisation. Cells were then washed and resuspended in medium alone or medium 
which contained either 200nM CCL19 (+CC), 50mM NH 4 CI (+N), or both (+CC+N). 
Cells were then incubated at 37°C for up to 90min. Supernatants were then subjected to 
TCA precipitation and the radioactivity associated with cells and supernatant fractions 
counted. The proportion o f recovered counts residing in each fraction is from HEK-hCCX- 
CKR and HEK-hCCR7 cell illustrated in the graphs on the previous and current page, 
respectively. Each sample was performed in triplicate and is shown as the mean +/- the 
standard deviation. Repeat experiments gave similar results.
Taken together, these data suggest the following regarding the comparative biochemistry o f 
CCX-CKR and CCR7:
i) 125I-CCL19 internalised by CCX-CKR is degraded and this degradation is 
dependent upon endosomal acidification (inhibited by NH 4 CI).
ii) A proportion of P5I-CCL19 internalised by CCR7 is also degraded (via a NH4 CI
sensitive pathway).
141
© Iain Comerford, 2005 CHAPTER THREE RESULTS
iii) A proportion (-30%) of 125I-CCL19 internalised by CCX-CKR is not targeted 
immediately for degradation and recycles to the cell surface where its release 
from cells requires the presence of unlabelled competitor. A significant fraction 
of CCR7-intemalised CCL19 is released intact from the cell, mainly 
independently of the presence of unlabelled extracellular competitor, and this 
can be increased by neutralising endosomal acidification.
These data are confusing and clearly influenced by the trafficking properties o f the 
receptors and their affinity for CCL19. Nonetheless, what they do demonstrate is that 
although there are clear differences between the behaviour of CCR7 and CCX-CKR, these 
differences are not huge. Internalisation via CCX-CKR appears to favour CCL19 
degradation compared with that mediated by CCR7, but ligand internalised by either 
receptor can be degraded or released intact. These data do not demonstrate a specific 
specialisation of CCX-CKR for ligand sequestration.
3.1.2.2.4 CCL19 Degradation in Continuous Culture
Data thus far indicate that both receptors (CCR7 and CCX-CKR) internalise ligand, and 
although there are some differences in the fate of the internalised CCL19, both mediate at 
least some CCL19 removal and destruction. However, all the above experiments were 
short-term, and following a single round of ligand internalisation. It is known that 
desensitisation and receptor degradation limit repeated stimulation o f typical chemokine 
receptors. Thus, to examine the long-term impact of CCL19 sequestration by CCR7 and 
CCX-CKR, a more physiological bulk culture degradation assay was developed. For each 
cell line, 7.5xl06 cells were incubated in 6ml of binding buffer containing lOnM unlabelled 
CCL19. A trace amount of 125I-CCL19 (0.1 nM) was included to allow subsequent tracking 
of chemokine fate. The cells were incubated for several days at 37°C, with supernatants
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being periodically sampled and subjected to TCA-precipitation to assess chemokine 
degradation (see 2.2.4.2). Surprisingly, despite the ability o f both receptors to bind, 
internalise, and degrade CCL19 in the short term assays described above, there were 
dramatic differences in the behaviour o f HEK-hCCX-CKR and HEK-hCCR7 cells in this 
assay (Figure 3.1.11). After 12h, the majority (>60%) of counts from the culture 
supernatants o f HEK-hCCX-CKR cells lie in the TCA-soluble (degraded) fraction, while 
those from HEK-hCCR7 cells precipitate with TCA (intact). By 24h, HEK-hCCX-CKR 
cells had degraded -85%  o f the chemokine, while HEK-hCCR7 cells were no more 
effective at destroying intact chemokine than untransfected HEK293. When the number o f 
degraded CCL19 molecules is considered in this assay, the differences between HEK-CCX- 
CKR and HEK-hCCR7 cells seems even more dramatic. Indeed, after 48h o f culture, in 
excess o f 2x10 1' more CCL19 molecules have been degraded by HEK-hCCX-CKR cells 
(figure 3.1.11). In fact, it can be calculated that over 48h, HEK-hCCX-CKR cells degrade 
-10'^ molecules o f C C L19 per cell per hour.
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Figure 3.1.11: Degradation of CCL19 by HEK-hCCX-CKR Cells in Continuous 
Culture. Cells were cultured for 48h, before 6ml o f fresh medium was added containing 
lOnM CCL 19, o f which 0.1 nM was radiolabelled. Supernatants were sampled over the next 
48h and subjected to TCA precipitation. CCL 19 degradation was assessed by the proportion 
o f counts in the TCA soluble and TCA precipitate fractions. Samples were performed in 
triplicate. Error bars are +/- the standard deviation and repeat experiments gave similar 
results (n=2). Statistical analysis was performed by a Student’s t-test and p<0.001 at all 
timepoints measured after 12 hours between HEK-hCCX-CKR and other cell lines. The 
-num ber o f degraded CCL 19 molecules was calculated (# o f CCL 19 molecules added to 
each flask was —3x10 13).
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To further analyse extracellular chemokine during these experiments, samples o f 
supernatant were analysed by SDS-PAGE. As figure 3.1.12 clearly shows, 125I-CCL19 
incubated with untransfected or HEK-hCCR7 cells remains predominantly intact 
throughout the course o f the experiment. A slight reduction in the amount o f extracellular
125“ I-CCL19 is observed in supernatants from HEK-hCCR7 cells when compared with 
untransfected cells. In contrast, intact chemokine becomes markedly less evident in HEK- 
hCCX-CKR supernatants as the experiment progresses. The disappearance o f this band 
from these supernatants occurs concurrently with the appearance o f a diffuse smear running
125at high molecular weight, similar to that seen in previous experiments, indicative o f a I- 
CCL19 degradation product.
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Figure 3.1.12: SDS-PAGE Analysis of Supernatants from Continuous Culture with 
CCL19. 50pl o f supernatants from the experiment shown in figure 3.1.11 were analysed by 
SDS-PAGE. The gel was dried onto filter paper and exposed to X-ray film. A band of 
approximately 8kDa is visible, showing intact l25CCL19. High mobility smear bands are 
visible in supernatants from HEK-hCCX-CKR cells which have been cultured for more 
than 4h.
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Finally, to exclude the possibility that HEK-hCCX-CKR cells release a soluble CCL 19 
degrading factor (possibly in response to CCL 19), rather than breaking down the 
chemokine within the cells, supernatants were prepared from HEK-hCCX-CKR cells which 
had been incubated with or without lOnM unlabelled CCL 19 for 9h (referred to as ‘primed’ 
or ‘untreated’, respectively). These supernatants were then assessed for their ability to 
degrade 12 I-CCL19. It was anticipated that only 5nM CCL 19 would remain in the ‘primed’ 
supernatant, as the 9h timepoint selected is the time at which -50%  o f CCL 19 is degraded 
in similar cultures (Figure 3.1.11). Thus, to ensure a comparable amount o f CCL 19 in the 
‘untreated’ supernatant it was first supplemented with 5nM unlabelled CCL 19. Then 0.1 nM 
]2fr-CCL19 was added to both supernatants, which were then incubated at 37°C for 0- 
120min. Supernatant samples were then subjected to TCA-precipitation. Figure 3.1.13 
shows that there is no difference between the supernatants from ‘primed’ and ‘untreated’
125cells. The supernatants themselves do not have any significant degradative effects o f " I- 
CCL19, with most radioactivity remaining in the TCA-preciptable fraction.
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Figure 3.1.13: Activity of HEK-hCCX-CKR Supernatants on ,25I-CCL19
Degradation. Supernatants from HEK-hCCX-CKR cells which had been primed in culture 
with lOnM CCL 19 for 9h or left untreated were tested for their ability to degrade 0.1 nM 
12 I-CCL19 by incubation with chemokine at 37°C for 0-120min followed by TCA 
precipitation. Supernatants from untreated cells were supplemented with 5nM unlabelled 
CCL 19, as this is the estimated concentration o f unlabelled CCL 19 remaining in primed 
supernatants. Samples were done in triplicate and error bars are +/- the standard deviation.
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3.1.2.2.5 Inhibition of Spienocyte Chemotactic Responses
To further assess whether the CCL 19 degradation observed in the bulk culture experiments 
was functionally neutralizing this chemokine, chemotaxis assays were performed using 
supernatants harvested from receptor bearing cells. 10 or 200nM CCL 19 was added to 
flasks o f untransfected HEK293 or HEK-hCCX-CKR cells and incubated for 16h at 37°C. 
These supernatants were then collected and used in chemotaxis assays (see 2.2.4.6) using 
freshly-isolated mouse splenocytes, a population o f cells that migrate readily to CCL 19 
(Pilkington et al., 2004). As can be seen in figure 3.1.14, prior incubation for 16h o f 200nM 
CCL 19 with cells which expressed CCX-CKR significantly reduced the chemotactic 
potential o f this chemokine for mouse splenocytes when compared with chemokine 
similarly exposed to untransfected cells. These data indicate that expression of CCX-CKR 
in an environment high in CCL 19 can cause the destruction o f this chemokine, reducing its 
potential to chemoattract cells responsive to CCR7 ligands.
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Figure 3.1.14: Inhibition of Spienocyte Chemotaxis by Pre-incubation of CCL19 with 
CCX-CKR. 10 or 200nM CCL 19 was added to 2ml o f medium containing either 2x10^ 
HEK293 or HEK-hCCX-CKR cells which had been growing in culture for 48h and 
incubated overnight. 16h later, freshly isolated mouse splenocytes were used in transwell 
chemotaxis assays with either medium alone, medium with 200nM CCL 19 or cell cultures 
supernatants in the lower chamber. The plate was incubated at 37°C for 6h and the number 
o f migrated cells in the lower chambers counted in a haemocytometer. Each sample was 
performed in triplicate and the error bars represent +/- the standard deviation o f the mean. 
Statistical analysis was performed using a Student’s t-test.
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Summary of CCL19 Internalisation and Degradation Studies
1 . CCX-CKR and CCR7 internalise CCL19.
2 . CCL 19 internalised by CCX-CKR is removed from the cell in a degraded form. 
However, some CCL 19 traffics via the cell surface prior to its degradation.
3. CCL 19 internalised by CCR7 is removed less rapidly and in both degraded and 
unmodified forms.
4. CCL 19 binding to CCX-CKR is more sensitive to acidic pH than CCL 19 binding to 
CCR7.
5. Endosomal neutralisation with NH4CI inhibits degradation o f CCL19 internalised 
by CCX-CKR.
6 . A proportion of CCL 19 internalised by CCX-CKR or CCR7 recycles back to the 
cell surface.
7. Significantly, in continuous culture, CCX-CKR mediates the effective degradation 
of large quantities of extracellular CCL 19, while CCR7 does not.
8 . CCX-CKR-mediated degradation of CCL19 can modify CCR7-mediated spienocyte 
responses.
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3.1.3 Receptor Behaviour after Chemokine Exposure
The observed differences in CCL 19 degradation between CCX-CKR and CCR7 in the 
continuous culture assays were something o f a surprise. Although in preloaded radioligand 
degradation assays more extensive CCL 19 degradation had been measured using HEK- 
hCCX-CKR cells rather than HEK-hCCR7 cells, this was not so pronounced that the very 
large differences observed between these cell lines in continuous culture could be expected. 
Hypothetically, this could be explained by CCR7 desensitisation following exposure to 
CCL 19, leading to a reduction in its ability to continue to internalise and degrade this 
chemokine. CCX-CKR on the other hand, if it is biochemically suited to its’ proposed role 
as a decoy receptor, may not be subject to ligand driven desensitisation. To test this, we 
studied the ability of these two cell lines to mediate CCL 19 uptake following ligand pre­
stimulation, i.e. does experiencing CCL 19 alter receptor behaviour?
3.1.3.1 Biotinylated CCL19 Uptake by Flow Cytometry
In order to characterise CCL 19 uptake, a convenient flow cytometric assay was developed, 
using BioCCL19. This reagent had been used earlier in the project to assess uptake, where 
the BioCCL19 had been coupled to streptavidin-Cy3 (section 3.1.2.1.3). To adapt this for 
flow cytometry, a more suitable streptavidin linked fluorophore, phycoerythrin (PE), was 
used as the marker. As shown in figure 3.1.15, both HEK-CCX-CKR and HEK-hCCR7 
(but not untransfected HEK293 cells) become similarly fluorescent when incubated for 
lOmin at 37°C with BioCCL 19/PE complexes. All cell lines when incubated with 
streptavidin-PE alone accumulated minimal fluorescence (not shown). Therefore, uptake of 
fluoresence in this assay is dependent upon the presence of both BioCCL19 and a CCL19 
receptor.
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Figure 3.1.15: Uptake of BioCCL19/PE is Dependent on the Expression of a CCL19 
Receptor. Harvested cells were incubated with BioCCL 19/PE for lOmin at 37°C. Cells 
were then washed and analysed by flow cytometry. The plot on the left hand side shows a 
representative histogram overlay showing accumulation o f fluorescence by HEK-hCCR7 
and HEK-hCCX-CKR but not untransfected HEK293 cells. This is quantified in the bar 
graph on the right hand side. Each sample was performed in triplicate with error bars 
showing +/- the standard deviation. Repeat experiments gave similar results.
From the continuous culture CCL 19 degradation data (figure 3.1.11), it may be expected 
that HEK-hCCX-CKR cells would continue to accumulate BioCCL 19/PE, the longer they 
were incubated with this complex. To test this, cells were incubated with BioCCL 19/PE for 
2 min to lh. HEK-hCCX-CKR continued to accumulate fluorescence during the course of 
this experiment (see figure 3.1.16). HEK-hCCR7 cells behaved quite differently however. 
The internalisation o f fluorescence by these cells mainly took place within the first few 
minutes and did not increase to any great extent with longer incubation times. These data 
show that CCX-CKR continues to internalise CCL 19 while CCR7 becomes desensitised, 
thus providing an explanation for the ability o f HEK-hCCX-CKR cells to degrade such 
significant quantities o f CCL 19 in continuous culture.
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Figure 3.1.16: Continued Chemokine Accumulation by HEK-hCCX-CKR Cells.
Harvested cells were incubated at 37°C for 2-60min with BioCCL 19/PE then washed and 
analysed by flow cytometry. The MFI o f untransfected HEK293 cells was subtracted from 
the MFI o f receptor transfectants at each timepoint. The top right histogram overlay shows 
representative plots o f HEK-hCCX-CKR cells and the lower right hand histogram shows 
the same for HEK-hCCR7 cells. The bar graph on the left shows the MFI (minus 
background uptake from untransfected cells. Each sample was performed in triplicate and 
eror bars represent +/- the standard deviation. Repeat experiments gave similar results.
Importantly, in this assay, the extent o f fluorescence is indicative o f the amount o f CCL 19 
that has been internalised during the incubation time, rather than the amount o f CCL 19 
present at the end o f the incubation. Thus, HEK-hCCX-CKR cells retain their fluorescence 
following uptake o f BioCCL 19/PE, for at least 3h at 37°C. Previous experiments had shown 
that practically all internalised CCL 19 had been degraded over this time frame (Figure
3.1.8). This can be explained by the fact that although chemokine internalised by CCX- 
CKR is degraded, the PE remains. Therefore, this assay allows quantification o f the total
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amount o f chemokine taken up by individual cells over time without having to 
pharmacologically interfere with intracellular degradation (Figure 3.1.17).
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Figure 3.1.17: BioCCL19/PE Uptake Assay Measures Total Chemokine
Accumulation. Harvested cells were incubated with BioCCL 19 for lh at 37°C. Cells were 
then washed and either incubated on ice or at 37°C for 3h. Cells were then analysed by flow 
cytometry. The histogram above shows a representative plot from 2 independent 
experiments.
Next, to further assess CCX-CKR and CCR7 desensitisation, transfected cells were 
stimulated in culture for lh with lOnM CCL 19 or CCL21. Harvested cells were thoroughly 
washed then used in BioCCL 19/PE uptake assays. From these data it emerged that the 
hypothesis that CCX-CKR may be resistant to desensitisation (and therefore more able to 
degrade CCL 19 in continuous culture) does not go far enough. In fact, it appeared that 
CCX-CKR, rather than being subject to ligand induced desensitisation, was actually being 
primed to more efficiently accumulate CCL 19 following ligand exposure. As shown in 
figure 3.1.18, HEK-hCCX-CKR cells were primed by both CCL 19 and CCL21 stimulation 
such that they were able to accumulate more BioCCL 19/PE than untreated cells over the 
same time-frame. Furthermore, and as expected, pre-exposure o f HEK-hCCR7 cells to
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ligand reduced their capacity to subsequently take up BioCCL 19/PE. These data also show 
that CCL19 was a more efficient ligand at desensitising CCR7 for subsequent 
BioCCL 19/PE uptake than CCL21. This is consistent with published data which 
demonstrated that CCR7 is internalised and desensitised more effectively by CCL19 than 
by CCL21 (Kohout et al., 2004).
Figure 3.1.18: Priming and Desensitisation of HEK-hCCX-CKR and HEK-hCCR7 
Cells. Cells in culture were treated with either lOnM CCL19, lOnM CCL21 for lh or left 
untreated. The cells were then washed, harvested, and incubated with BioCCL 19/PE for 
15min at 37°C. Cells were then washed and analysed by flow cytometry. The top left 
histogram shows a representative overlay o f the results obtained for HEK-hCCR7 cells, and 
the top right histogram shows the same for HEK-hCCX-CKR cells. Each sample was 
included in triplicate and the results shown in the lower bar graph are the MFI +/- the 
standard deviation. Statistical analysis was performed using a Student’s t-test (* indicates 
p<0.001 compared with untreated cells; A indicates p<0.05 compared with untreated cells). 
Repeat experiments gave very similar results (n=4).
Next, the dose-response kinetics o f CCX-CKR priming by all three o f its ligands was 
studied in more detail. HEK-hCCX-CKR cells were primed in culture with 0.1 nM to 
lOOnM of CCL19, CCL21, or CCL25 for 1-16h. Cells were then washed, harvested and fed
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BioCCL 19/PE at 37°C for lh. As can be seen in figure 3.1.19, all o f the ligands effectively 
and similarly primed subsequent BioCCL 19/PE uptake through CCX-CKR. Maximal 
priming was obsevered from the longest incubations (16h) with the maximum amount o f 
chemokine (lOOnM). For practical purposes however, lOnM chemokine prestimulations for 
2h induces an effective level o f receptor priming and therefore, these conditions were used 
in all subsequent investigations o f receptor priming. It is notable from these data that the 
lOnM concentration induces a priming effect that goes up, then down over time, whilst the 
higher (lOOnM) concentration does not. These data suggest that the continued presence of 
CCL19 may help maintain the priming effect, but as the chemokine gets degraded, this 
effect is reduced.
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Figure 3.1.19: Dose and Time Dependent Priming of CCX-CKR by CCL19, CCL21 
and CCL25. Cells in culture were treated with O.InM-lOOnM o f CCL19, CCL21, CCL25 
for 1-16h or left untreated. Cells were then washed, harvested and incubated with 
BioCCL 19/PE for lh. Cell were analysed by flow cytometry. The graphs above plot the 
relative MFI o f each sample compared with HEK-hCCK-CKR cells which were not primed 
with chemokine. Repeat experiments gave similar results (n=2).
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Next, the effect o f prior chemokine exposure on the rate o f BioCCL 19/PE uptake by HEK- 
hCCX-CKR cells was examined. Cells were incubated with lOnM CCL19 or CCL21 in 
culture for 2h then harvested and used in BioCCL 19/PE uptake assays for 2-60min. The 
results clearly show that prior exposure to either CCL19 or CCL21 causes not only an 
increase in uptake o f BioCCL 19/PE by HEK-hCCX-CKR cells, but also causes an increase 
in the rate o f accumulation o f this complex, indicated by the slope o f the graph (Figure 
3.1.20). Indeed, the rate more than doubles from -2 .4  fluorescent units/min in untreated 
cells to ~5 units/min in chemokine-primed cells.
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Figure 3.1.20: Chemokine Priming of CCX-CKR Increases the Rate of BioCCL19/PE 
Uptake. Cell were treated in culture for 2h with either lOnM CCL19, lOnM CCL21 or left 
untreated. Cells were then washed, harvested, and incubated at 37°C for 2-60min with 
BioCCL 19/PE. Analysis o f cells by flow cytometry followed. The graph above shows the 
MFI o f each sample over the length o f time of the incubation at 37°C. The rate o f uptake is 
calculated as the slope o f the line between 30 and 60mins. Dotted lines show the 
triangulation used to calculate the number o f fluorescent units taken up by the cells per min 
Each sample was included in triplicate and error bars are +/- the standard deviation. Repeat 
experiments gave similar results (n=2).
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3.1.3.1 Radiolabelled CCL19 Uptake
Next, to confirm that these phenomena were not limited to the BioCCL 19/PE assay, I- 
CCL19 uptake was assessed (see 2.2.4.3). Prior to harvesting cells, lOnM of CCL19 or 
CCL21 was added to cells in culture for 0.5-12h. Cells were then incubated with 2nM 125I- 
CCL19 for lOmin at 37°C. This short incubation time was chosen as it should allow cell 
lines to accumulate radiolabelled chemokine but significant quantities should not be 
degraded and released from the cells. As can be seen in figure 3.1.21, preincubation of 
HEK-hCCX-CKR cells with either CCL19 or CCL21 led to a ~2-fold increase in the ability
p r
of this receptor to subsequently mediate the accumulation o f I-CCL19. This effect was 
observed with chemokine pre-incubation times as short as 30min and was maintained at the 
longest chemokine incubation of 12h. In contrast, the amount of 125I-CCL19 uptake 
mediated by HEK-hCCR7 cells was reduced by preincubation with its ligands. This effect 
was not evident until these cells had been incubated for lh  in CCL19 and was not observed 
with CCL21 incubations until the chemokine had been present for 12h. These data were 
consistent with the hypothesis that CCX-CKR becomes primed, while CCR7 becomes 
desensitised, following agonist stimulation, and confirm the BioCCL 19/PE uptake data. 
Together, these results demonstrate fundamentally different behaviour of CCX-CKR and 
CCR7 following ligand exposure, and provide a rational explanation for the remarkably 
different propensities of these two receptors to degrade CCL19 in continuous culture.
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Figure 3.1.21: Radioligand Uptake by CCX-CKR and CCR7 Following Chemokine 
Stimulation. Cells were treated in culture for 1-12h with either lOnM CCL19, lOnM 
CCL21 or left untreated. Cells were then harvested and incubated with 2nM 12 I-CCL19 for 
30min. Cells were then washed and the amount o f radioactivity associated with the cell 
pellet quantified. The relative number o f counts compared to untreated cells was then 
plotted for each sample at each length o f treatment. Each sample was included in triplicate 
and error bars represent +/- the standard deviation. Repeat experiments gave similar results 
(n=2 ).
3.1.3.2 Surface Receptor Levels following Ligand Exposure
Most chemokine receptors are internalised and sequestered from the cell surface following 
exposure to ligand. Conversely, the increased amount o f ligand uptake by HEK-hCCX- 
CKR cells following priming could be explained by the maintenance or increase in the 
amount o f cell surface receptor after ligand exposure. To examine this, surface CCX-CKR 
levels were assessed exploiting the N-terminal FLAG epitope engineered into CCX-CKR. 
HEK-hCCX-CKR cells were given hCCL19 (1-lOOnM) for 5-60min at 37°C, before 
harvesting, washing, and detection o f surface receptor using an anti-FLAG antibody (see
2.2.4.8). Although detection o f surface CCX-CKR using this antibody was variable, and 
typically relatively poor, carefully controlled experiments revealed that surface CCX-CKR
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levels surprisingly go down in a dose-dependent manner after incubation with CCL19 
(Figure 3.1.22). All three CCX-CKR ligands were tested for their ability to induce this 
response and were all found to cause loss o f surface receptor expression (figure 3.1.23). 
CCR7 surface receptor levels in HEK-hCCR7 cells were also assessed using an anti- 
hCCR7 antibody (as discussed in section 3.1.1, the FLAG tag was not detectable on these 
cells). Similar to CCX-CKR, the amount o f CCR7 at the cell surface goes down following 
incubation with CCL19. However, unlike CCX-CKR, but in agreement with a previous 
report (Bardi et al., 2001), CCL21 does not cause internalisation o f CCR7 (Figure 3.1.24).
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Figure 3.1.22: CCL19 causes CCX-CKR Internalisation in a Dose Dependent M anner.
Cell were treated in culture for 5-120min with 1-lOOnM CCL19 or left untreated. Cells 
were then cooled to 4°C before washing and harvesting. Harvested cells were incubated 
with anti-FLAG M l antibody at 4°C which was then detected using anti-mouse IgG 
coupled to PE. Cells were then washed and analysed by flow cytometry. The relative 
amount o f fluorescence o f each sample, compared with untreated cells, is plotted. Each 
point shows the mean of a triplicate repeat and error bars are +/- the standard deviation. 
Repeat experiments showed similar trends (n=5).
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Figure 3.1.23: CCL21 and CCL25 Induce Similar CCX-CKR Internalisation as 
CCL19. Cells were harvested and then incubated at 37°C for 5-60min with lOOnM o f 
CCL19, CCL21, CCL25, or left untreated for the same length o f time at 37°C. After 
washing, surface receptor assessments were made by staining with the anti-FLAG M l 
antibody at 4°C followed by the anti-mouse IgG-PE antibody and analysed by flow 
cytometry. The relative amount o f surface receptor compared to untreated cells (not 
incubated at 37°C) is plotted above. Each sample was included in triplicate and error bars 
represent +/- the standard deviation. A repeat experiment gave similar results (n=2).
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Figure 3.1.24: Internalisation of CCR7 Following Ligand Stimulation. HEK-hCCR7 
cells were treated in culture for lh  with lOnM CCL19, lOnM CCL21 or left untreated. Cells 
were then washed, harvested, and surface CCR7 detected at 4°C using the anti-hCCR7 
antibody followed by anti-mouse IgG-PE. Assessment o f surface levels o f CCR7 following 
chemokine treatment was made by flow cytometric analysis. The relative MFI of 
chemokine-treated cells was compared to that o f untreated HEK-hCCR7 cells. Each sample 
was included in triplicate. Error bars represent +/- the standard deviation and statistical 
analysis was performed using a Student’s t-test (p<0.001). Repeat experiments gave similar 
results (n=2).
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From these experiments, it can be reasoned that i) the ligand-driven desensitisation of 
CCR7 can be explained, at least in part, through receptor internalisation, and ii) the greater 
degree o f desensitisation induced by CCL19 is due to it more effectively causing CCR7 
internalisation than CCL21. However, it is not the case that the ‘priming’ of CCX-CKR for 
CCL19 uptake is achieved through maintenance or increases in the levels o f surface 
receptor. Instead, although less CCX-CKR is at the cell surface following ligand exposure, 
the behaviour of the receptor must have changed in a way that enables more rapid ligand 
internalisation (this is discussed further in chapter four). Detailed subsequent analysis of 
this was limited by the difficulties encountered with reliable antibody detection of CCX- 
CKR and the failure to successfully generate a CCX-CKR-GFP fusion protein, approaches 
that could help test this hypothesis. Finally, it is worthy of note that CCX-CKR appears to 
be behaving in a manner similar to typical signaling chemokine receptors, in that ligand- 
driven alterations in surface receptor levels are occurring. This in itself is likely to be 
controlled by ligand-induced receptor-derived signals, providing tentative evidence that 
CCX-CKR may not be a ‘silent’ receptor, and may couple to as yet uncharacterised 
signaling pathways.
Summary
1. HEK-hCCX-CKR cells continue to accumulate CCL19 after chemokine exposure, 
while HEK-hCCR7 cells are less able to do this. Thus, CCX-CKR appears to avoid 
desensitisation.
2. Exposure to CCL19, CCL21 and CCL25 ‘primes’ CCX-CKR to more efficiently 
sequester CCL19.
3. Subsequent CCL19 accumulation through CCR7 is desensitised by prior exposure 
of the receptor to CCL19, and to a lesser extent, CCL21.
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4. Ligand ‘priming’ of CCX-CKR increases the rate at which CCL19 is internalised by 
this receptor.
5. Priming of CCX-CKR cannot be explained by an increase in the amount of cell 
surface receptor following ligand exposure, as like CCR7, CCX-CKR surface 
receptor levels decrease following CCL19 stimulation.
These data suggest that CCX-CKR exhibits properties consistent with a ‘decoy’ receptor. 
The remainder of this thesis attempts to explain the molecular basis underpinning this 
behaviour, and explores the importance of CCX-CKR in vivo by generating and analysing 
CCX-CKR null mice.
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3.1.4 Molecular Mechanisms of CCL19 Uptake
The data from the preceding sections clearly demonstrated that in the same cellular 
background, CCX-CKR behaves very differently to the related CCL19 receptor, CCR7. 
Dissecting the molecular mechanisms responsible for these differences is of considerable 
interest in understanding the biochemistry of these receptors. Thus, a comparative 
investigation of the molecular mechanisms of CCX-CKR and CCR7 internalisation was 
carried out aimed at determining how these receptors engage the endocytic machinery of 
the cell. The BioCCL 19/PE uptake assay described in the previous section was particularly 
amenable to these investigations, as it allowed quantifiable assessment of levels of total 
chemokine uptake by live cells on a cell-to-cell basis. By exploiting this assay, and treating 
cells with well-characterised pharmacological or genetic inhibitors of various pathways of 
receptor internalisation or recycling, their importance in CCX-CKR- and CCR7-mediated 
CCL19 internalisation was revealed.
3.1.4.1 Dynamin
The first molecule to be examined was dynamin, a large GTPase essential for most types of 
receptor-mediated endocytosis (but not pinocytosis), and which functions by ‘pinching’ 
vesicles from the plasma membrane (see section 1.3.5). To assess the impact o f dynamin 
inhibition on CCL19 uptake, increasing quantities o f a plasmid encoding a well- 
characterised dominant-negative version of this protein (dynamin K44A) were transiently 
transfected into HEK-hCCX-CKR cells. In parallel cultures, to give an indication of 
transfection efficiency, the same quantities of a plasmid encoding GFP were transfected 
into cells and the percentage of GFP+ cells assessed by flow cytometry, comparing GFP 
with mock-transfected cells. 24h after transfection, cells were harvested and assessed for 
their ability to accumulate BioCCL 19/PE. In addition, cell lysates were made from 
transfected cells and dynamin expression visualised by Western blotting using a dynamin-
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specific antibody. The data from these experiments are shown in figure 3.1.25. Increasing 
the quantity o f o f transfected pEGFP-N2 plasmid led to a stepwise increase in GFP+ cells. 
Concurrently, increasing the quantity o f transfected dynamin K44A plasmid caused a 
stepwise increase in dynamin protein expression and a concurrent inhibition o f the ability o f 
HEK-hCCX-CKR cells to accumulate BioCCL 19/PE. These data are consistent with the 
hypothesis that BioCCL 19/PE is internalised by CCX-CKR via receptor-mediated 
endocytosis with dynamin playing an important role.
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Figure 3.1.25: Effect of Dynamin (K44A) on BioCCL19/PE Uptake by CCX-CKR. (A)
Dynamin (K44A) has a single amino acid substitution in the GTPase domain (1-900 are 
amino acid from N to C terminus; PH=Pleckstrin homology domain). HEK-hCCX-CKR 
cells transiently transfected with l-3pg o f dynamin (K44A), or l-3pg o f pEGFPN2, or 
mock-transfected were harvested 24h later. pEGFP-N2 transfectants were analysed by flow 
cytometry to estimate transfection efficiency relative to mock transfectants. (B) 
Transfection efficiency for each amount o f plasmid is indicated above the graph. Dynamin 
(K44A) transfectants and mock transfectants were used in BioCCL 19/PE uptake assays. 
The MFI relative of dynamin (K44A) transfectants to mock transfectants is plotted in the 
bar graph (p<0.05 between mocks and all transfected cells). Sample were included in 
triplicate, error bars are +/- the standard deviation and repeat experiments gave similar 
results (n=2). (C) Increasing expression o f the dynamin (K44A) with DNA quantity 
confirmed by cell lysates detecting dynamin by Western blotting, shown below the graph. 
Equal loading o f these blots was ensured by careful lysis o f lxlO 6 cells in each case. (D) 
Representative histogram overlay showing maximal inhibition o f uptake by dynamin 
(K44A).
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3 .1 .4 .2  (3-arrestins
Next, the potential role o f p-arrestins in CCL19 uptake by CCX-CKR was explored. As 
discussed in section 1.3.5, p-arrestins are important in bringing about internalisation o f a 
variety o f GPCRs, including chemokine receptors. Two approaches were taken to 
investigate this. First, in a similar set o f experiments to those carried out for dynamin, a 
well-characterised dominant-negative mutant o f (3-arrestin-l (V53D) was transiently 
transfected into HEK-hCCX-CKR cells. Protein expression and transfection efficiency 
were determined by Western blotting and pEGFP-N2 transfection respectively, as described 
above for dynamin. As can be seen in figure 3.1.26, and in contrast to dynamin, increasing 
the expression o f p-arrestin (V53D) in HEK-hCCX-CKR cells had no significant inhibitory 
effect upon BioCCL 19/PE uptake, even when >50% of the cells were likely to have been 
transfected, and when robust protein expression could be confirmed by Western blotting. 
These data suggested that CCX-CKR internalisation o f BioCCL 19/PE was via a p-arrestin- 
independent route.
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Figure 3.1.26: Effect of p-arrestin-1 (V53D) on BioCCL19/PE Uptake by CCX-CKR.
Legend Overleaf.
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Figure 3.1.26: Effect of p-arrestin-1 (V53D) on BioCCL19/PE Uptake by CCX-CKR 
(from previous page). (A) p-Arrestin-1 (V53D) has a single amino acid substitution at 
position 53 (Depicted schematically: 1-420 are amino acid number from N to C terminus). 
HEK-hCCX-CKR cells were transiently transfected with l-3jLig of P-arrestin-1 (V53D), or 
l-3pg of pEGFPN2, or mock transfected. 24h later cells were harvested. pEGFP-N2 
transfectants were analysed by flow cytometry to estimate transfection efficiency relative to 
mock transfectants. (B) The estimated transfection efficiency for each amount of plasmid 
used is indicated above the graph, p-arrestin-1 (V53D) transfectants and mock transfected 
cells were incubated with BioCCL 19/PE for lh  and analysed by flow cytometry. The 
relative MFI o f p-Arrestin-1 (V53D) transfectants compared to mock transfectants is 
plotted in the bar graph. Each sample was included in triplicate, error bars are +/- the 
standard deviation and repeat experiments gave similar results (n=3). (C) Increasing 
expression of the p-arrestin-1 (V53D) was confirmed by making cell lysates and detecting 
p-arrestin-1 by Western blotting, shown below the graph. Equal loading of these blots was 
ensured by careful lysis o f exactly lx l 06 cells in each case. (D) A representative histogram 
overlay showing uptake of BioCCL 19/PE uptake by cells maximally expressing p-arrestin- 
1 (V53D) is shown.
To more definitely address the role of p-arrestins, the ability of CCX-CKR and CCR7 to 
mediate CCL19 uptake into p-arrestin null and WT mouse embryonic fibroblasts (MEFs) 
was assessed. Ideally, constructs encoding GFP tagged receptors were to be used. However, 
as described in section 3.1.1.2, CCX-CKR GFP fusion proteins could not be generated. 
Thus, whilst CCR7-GFP was used, non-GFP tagged expression plasmids were used to 
express CCX-CKR, making careful comparisons with mock transfectants. Thus, MEFs 
were grown on fibronectin-coated coverslips and transiently transfected with either hCCX- 
CKR or hCCR7-GFP, or mock-transfected (Dr. Milasta in the laboratory of Prof G. 
Milligan in the Department of Biochemistry at the Univerisity of Glasgow carried out all 
MEF cell culture and performed these transfections). 24h after transfection, cells were 
washed and incubated with BioCCL19/Cy3 complexes at 37°C for 30min. Confocal 
microscopy was then used to assess ligand uptake and CCR7-GFP distribution (2.2.4.7 and 
2.2.3.1). A number of observations were made. First, in MEFs which had been transfected 
with hCCR7-GFP there were clear differences observed between the p-arrestin WTs and 
nulls. In p-arrestin WT MEFs, those cells which expressed CCR7-GFP could clearly be
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seen to have internalised BioCCL 19/Cy3 with punctate intracellular red fluorescence, some 
o f which appeared to co-localise with CCR7-GFP. BioCCL 19/Cy3 uptake was specific to 
cells in which GFP could be visualised. The majority o f the CCR7-GFP was located 
cytoplasmically in WT MEFs following BioCCL 19/Cy3 incubation. In contrast, in p- 
arrestin null MEFs CCR7-GFP expressing cells did not contain any visible internalised 
BioCCL 19/Cy3 and most o f the CCR7-GFP remained at the cell surface after ligand 
application. This result, in agreement with previous studies (Kohout et al., 2004), strongly 
suggests that internalisation o f CCR7 caused by CCL19 is dependent upon p-arrestins.
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Figure 3.1.27: Uptake of BioCCL19/Cy3 by MEFs (-/- or +/+ for P-arrestins). WT and
p-arrestin null MEFs were grown on fibronectin coated coverslips and transfected with 
either hCCR7-GFP, or FLAG-hCCX-CKR (see figure 3.1.1) plasmids or left mock 
transfected. 24h later cells were washed and BioCCL 19/Cy3 added in fresh medium. Cells 
were then incubated in the dark at 37°C for 30min before being washed, fixed, and mounted 
on slides with Vectashield with DAPI. Slides were then analysed by confocal microscopy. 
Careful optical sections were taken to confirm intracellular location o f BioCCL 19/Cy3 
(red). Cell nucleus appears blue in above pictures. Images shown are representative o f cells 
observed in many fields. Repeat experiments gave similar results (n=2).
[3-A rrestin  + /+  p -A rrestin
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The second, and more significant, observation was that, in contrast to CCR7, no clear 
differences could be observed between p-arrestin WT and null MEFs which had been 
transfected with hCCX-CKR. Internalised punctate BioCCL 19/Cy3 could be visualised in 
both P-arrestin WT and null cells, and careful optical dissection confirmed intracellular 
localisation. Mock-transfected cells did not display any uptake, indicating a dependence 
upon hCCX-CKR transfection. As a whole, these data, strongly suggest that CCX-CKR is 
capable of mediating CCL19 uptake independently o f p-arrestins. As CCX-CKR is unlike 
all other described chemokine receptors in that it is ‘primed’ not desensitised by ligand, the 
fact that it is able to operate in a p-arrestin independent manner may be an important aspect 
o f its biology.
3.1.4.3 EPS15
Many cell surface proteins are internalised via CCPs which invaginate from the plasma 
membrane forming intracellular vesicles. For many, but not all GPCRs, this is co-ordinated 
by P-arrestins that link activated receptors to the machinery of clathrin-mediated 
endocytosis. Therefore, to investigate the role o f clathrin-mediated endocytosis in 
BioCCL 19/PE uptake by CCX-CKR and CCR7, the potential involvement o f the molecule 
EPS 15 was examined. EPS 15 has been demonstrated to play a critical role in the 
internalisation of several receptors by docking the AP-2 complex to the plasma membrane 
and CCPs (see section 1.3.5). Three well-characterised plasmids encoding forms of EPS 15 
were used in this study. These were two dominant negative forms of EPS 15: EA95/295 and 
Dili, and a non-inhibitory form, DIIIA2. All were produced fused to GFP (see figure 
3.1.28) and have been successfully used in parallel studies with D6 to demonstrate the 
involvement of the clathrin pathway in receptor internalisation in a similar experimental 
system (Weber et al., 2004). The advantage of using GFP-tagged proteins is that they allow
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a direct correlation between the levels o f expression o f the GFP-tagged protein and the 
amount o f inhibition caused, allowing a quantifiable assessment o f the effects o f these 
plasmids on populations o f transiently transfected cells.
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Figure 3.1.28: M utants of EPS15. Three GFP tagged mutant o f EPS15 which were used 
in this study. The three main domains o f WT EPS 15 (DI-DIII) are shown. Numbers 
represent the amino acid number from N-C terminus o f the WT protein. The EPS 15 
homology domains (EH) are shown. The second and third o f these is missing in the 
EA95/295 mutant. The D ili mutant contains only the AP-2 binding D ili domain fused to 
GFP. The DIIIA2 mutant contains only a GFP fused D ili domain with the AP-2 binding 
region removed.
Thus, HEK-hCCX-CKR and HEK-hCCR7 cells were transiently transfected with either one 
o f these constructs or pEGFPN2, and 24h later fed BioCCL 19/PE, and analysed by flow 
cytometry. Mock-transfected cells, and cells which had only been incubated with 
streptavidin-PE alone, were used as controls to set gates and compensation on the flow 
cytometer. As the amount o f GFP-tagged protein in individual cells can be quantified on a 
cell-to-cell basis alongside the total amount o f internalised BioCCL 19/PE, the extent o f 
uptake in cells expressing high levels o f the GFP-tagged protein can be directly compared.
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A comparison between cells expressing similar amounts of the GFP-tagged EPS 15 mutants 
or GFP alone can then be made. As shown in figure 3.1.29 (page 169), both o f the 
inhibitory EPS 15 mutants, when expressed at high levels in HEK-hCCR7 cells caused 
significant inhibition of BioCCL 19/PE uptake by these cells when compared with cells 
expressing high levels of GFP (p<0.01). HEK-hCCR7 cells with high expression o f the 
non-inhibitory EPS 15 mutant (DIIIA2) were indistinguishable from cells expressing high 
levels of GFP in terms of BioCCL 19/PE uptake (see figure 3.1.29). In contrast, expression 
of these inhibitors of clathrin-mediated endocytosis has no significant effect on the ability 
HEK-hCCX-CKR cells to internalise BioCCL 19/PE, even at high levels of expression. 
Taken together, these data provide evidence that hCCR7 internalisation is dependent, at 
least to some extent, on the formation of CCPs, whilst hCCX-CKR employs alternative 
routes of internalisation, not inhibited by dominant-negative forms of EPS 15.
3.1.4.4 Rab GTPases
Next, the potential role of several RabGTPases in receptor-mediated endocytosis of CCL19 
was studied. As discussed in the introduction, the Rab family of GTPases have important 
functions in regulating the intracellular trafficking and fusion of various endosomal 
compartments. To this end, we hypothesised that Rab5, a marker of the early endosomal 
compartment, may play an important role in the accumulation of BioCCL 19/PE through 
hCCX-CKR and hCCR7, in a similar way as it does with CCL3 uptake by D6 (Weber et al., 
2004). Furthermore, Rab4 and Rabl 1, which are involved in the function of the rapid and 
slow recycling endosomal compartments respectively, were also considered to possibly 
play a role in the continued intracellular accumulation of BioCCL 19/PE through CCX- 
CKR. To this end, plasmids encoding dominant-negative GFP-tagged versions of each of 
these RabGTPases were obtained, and used in very similar assays to those described above 
using the EPS 15 mutants.
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Figure 3.1.29: Effect of Genetic Inhibition of EPS 15 on BioCCL19/PE Uptake. Cells 
were transfected with lpg  o f each o f one of the GFP tagged EPS 15 mutants (figure 3.1.28) 
or pEGFPN2. 24h later, cells were harvested and incubated with BioCCL 19/PE for lh  at 
37°C. Cells were then washed and analysed by flow cytometry. The mean fluorescence 
intensity on the FL-2 channel was assessed for those cells which expressed high levels o f 
GFP (red gates on density plots). Representative density plots for HEK-hCCX-CKR cells 
transfected with these plasmids are shown above with those for HEK-hCCR7 cells below. 
The MFI o f gated cells is plotted below (* indicates p<0.05 compared to pEGFP controls). 
Each sample was included in triplicate and error bars are +/- the standard deviation. Repeat 
experiments gave similar results (n=2).
Analysis o f BioCCL 19/PE uptake in HEK-hCCR7 cells which express high levels of 
Rab5(S34N)GFP shows that expression o f this protein significantly reduces the amount of 
internalisation through this receptor when compared with cells expressing similar levels of 
GFP (Figure 3.1.30). This is consistent with the hypothesis that CCR7 internalises through
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CCPs which then fuse with Rab5 positive early endosomes. In contrast, HEK-hCCX-CKR 
cells which abundantly express Rab5(S34N)GFP are indistinguishable from ‘high’ GFP 
expressers in terms o f BioCCL19/PE uptake (Figure 3.1.30). As with the EPS15 data, this 
suggests that alternative routes o f internalisation are being employed by this receptor. High 
levels o f dominant-negative Rab4(N121I) had no significant effect upon chemokine uptake 
by HEK-hCCR7 or HEK-CCX-CKR cells, while moderate inhibition o f chemokine uptake 
was measured when Rabl 1(S25N) was abundant in HEK-CCX-CKR cells but not HEK- 
hCCR7 cells. This suggests that Rab 11 may play a role in the accumulation of 
BioCCL 19/PE by CCX-CKR through its role in the recycling endosomal compartment.
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Figure 3.1.30: Effect of Genetic Inhibition of RabGTPases on BioCCL19/PE Uptake.
Plots for HEK-hCCR7 cells shown. Legend and HEK-hCCX-CKR plots follow overleaf.
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Figure 3.1.30: Effect of Genetic Inhibition of RabGTPases on BioCCL19/PE Uptake.
Cells in culture were transfected with 1 pg o f each of one o f the GFP tagged RabGTPase 
mutants (described in text) or pEGFPN2. 24h later, cells were harvested and incubated with 
BioCCL 19/PE for lh at 37°C. Cells were then washed and analysed by flow cytometry. The 
mean fluorescence intensity on the FL-2 channel was assessed for those cells which 
expressed high levels o f GFP (red gates on density plots). Representative density plots for 
HEK-hCCX-CKR cells transfected with these plasmids are shown here and for HEK- 
hCCR7 on the previous page. The MFI o f gated cells is plotted below. Each sample was 
included in triplicate and error bars are +/- the standard deviation (* indicates p<0.05 
compared to GFP controls). Repeat experiments gave similar results (n=3).
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3.1.4.5 Caveolae and Lipid Rafts
The data above suggested that CCL19 uptake by CCX-CKR, in contrast to CCR7, was 
independent of p-arrestins, that interference with the formation of CCPs by genetic 
inhibition of EPS 15 did not alter chemokine internalisation, and that uptake was not 
inhibited by blocking Rab5 function. Therefore, the involvement of alternative mechanisms 
of internalisation employed by CCX-CKR was investigated. The best-characterised 
clathrin-independent endocytic compartment is caveolae, a subset of cholesterol-rich 
plasma membrane-derived vesicles and invaginations which contain the membrane protein 
caveolin. The first approach taken to examine the possibility that these domains may be 
important in BioCCL 19/PE internalisation was to use the cholesterol-depleting agent 
Methyl-p-Cyclodextrin (MepCD), which is commonly used to prevent the formation of 
lipid raft structures. As previous work (Subtil et al., 1999) had demonstrated that 
cholesterol-depletion can affect clathrin-mediated endocytosis, MepCD treatment was at a 
concentration and duration previously shown not to disrupt transferrin uptake in HEK293 
cells (V. Morrow and R.Nibbs, unpublished), a process dependent upon CCP formation. 
Figure 3.1.31 shows that pre-treatment of either HEK-hCCX-CKR or HEK-hCCR7 with 
MepCD effectively inhibits subsequent BioCCL 19/PE uptake into these cells. While these 
data indicate that while both of these receptors require membrane cholesterol for optimal 
BioCCL 19/PE uptake, this does not necessarily show that internalisation is via caveolae. 
Indeed, many receptors have a dependence on membrane cholesterol for proper function 
but do not endocytose via caveolae. Studies with CCR5 have recently shown that lipid rafts 
and cholesterol play a role in receptor activation and subsequent internalisation (which is 
via CCPs) (Signoret et al., 2005). The data here would suggest that CCR7 is like CCR5 in 
this regard.
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Figure 3.1.31: Effect of Cholesterol Depletion on BioCCL19/PE Uptake. Cells were 
harvested and treated for 30min at 37°C with 5mM MepCD or left untreated for the same 
length o f time. Cells were then washed and incubated with BioCCL 19/PE for lh  and 
analysed by flow cytometry. Representative histogram overlays showing treated and 
untreated cells are shown above. The relative MFI o f treated cells compared to untreated 
cells is shown below. Each sample was included in triplicate and error bars are +/- the 
standard deviation. Repeat experiments gave similar results (n=2).
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To follow up this observation, cells were transiently transfected with a plasmid encoding 
either caveolin-1 with a C-terminal GFP tag (Cav-GFP: which behaves as the WT protein) 
or caveolin-1 with an N-terminal GFP tag (GFP-Cav: reported to act as a dominant- 
negative) (Pelkmans et al., 2001). Again, as in previous experiments, cells were harvested 
and assessed for their ability to accumulate BioCCL 19/PE by flow cytometry. Although 
moderate to low expression of these proteins had minimal effect on uptake by HEK-hCCX- 
CKR cells, more abundant expression led to significant inhibition of BioCCL 19/PE uptake 
(Figure 3.1.32). This was particularly evident for the Cav-GFP protein, in which high 
expressers were barely able to internalise any BioCCL 19/PE. Because uptake in the HEK- 
hCCR7 cells is not significantly affected by high expression o f these proteins (fig 3.1.33), 
the possibility that the inhibition is due to non-specific defects in cell viability, can be ruled 
out. Further supporting this contention, transfection of these plasmids had no impact on D6 
mediated uptake of CCL3, or CCR5 internalisation (Nibbs, unpublished observation and 
Signoret et al., 2005).
Alongside the assessment of BioCCL 19/PE uptake in these cells, levels of surface CCX- 
CKR were examined by staining with an anti-FLAG antibody at 4°C, with subsequent 
detection with a PE-conjugated anti-mouse IgG secondary antibody (2.2.4.8). When GFP+ 
cells were gated and analysed from these transfections, those transfected with Cav-GFP 
could be detected to have more than double the amount of receptor on their surface when 
compared with those which express GFP alone, and a more modest but significant increase 
was measured from cells expressing GFP-Cav (Figure 3.1.33).
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Figure 3.1.32: Effect of Genetic Inhibition and Overexpression of Caveolin-1 on 
BioCCL19/PE Uptake. Cells in culture were transfected with ljag o f each o f one o f the 
GFP tagged versions o f caveolin-1 (depicted at top o f figure) or pEGFPN2. 24h later, cells 
were harvested and incubated with BioCCL 19/PE for lh at 37°C. Cells were then washed 
and analysed by flow cytometry. The mean fluorescence intensity on the FL-2 channel was 
assessed for those cells which expressed high levels o f GFP (red gates on density plots). 
Representative density plots for HEK-hCCX-CKR cells transfected with these plasmids are 
shown above with those for HEK-hCCR7 cells below. The MFI o f gated cells is plotted 
below. Each sample was included in triplicate and error bars are +/- the standard deviation. 
Repeat experiments gave similar results (n=3).
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Figure 3.1.33: Effect of Over-expression of Caveolin-1 on CCX-CKR Surface 
Receptor Levels. Cells in culture were transfected with lpg  o f each o f one o f the GFP 
tagged versions o f Caveolin-1 (depicted at top o f figure 3.1.33) or pEGFPN2. 24h later, 
cells were harvested and stained with anti-FLAG M l followed by anti mouse IgG-PE at 
4°C to assess surface receptor levels. Cells were then analysed by flow cytometry. Cells 
which expressed GFP were gated upon and the MFI on FL-2 o f these cells compared 
between pEGFPN2 transfectants and cell transfected with GFP-tagged Caveolin-1. The 
relative MFI o f these cells compared to pEGFPN2 transfectants is shown above. Samples 
were performed in triplicate and error bars are +/- the standard deviation. Statistical analysis 
was performed using a Student’s t-test.
The fact that overexpression o f a protein with the same activity as endogenous caveolin 
(Cav-GFP) and a dominant negative inhibitor o f caveolin (GFP-Cav) both have similar 
inhibitory effects on BioCCL 19/PE uptake by HEK-hCCX-CKR cells is not necessarily 
contradictory. Caveolins reportedly function to stabilise caveolae at the cell surface, 
preventing their internalisation (Thomsen et al., 2002). Thus, if CCX-CKR internalises 
predominatly via caveolae, their stabilisation would limit CCL19 uptake and would concur 
with the increase in surface receptor measured. On the other hand, internalisation of 
caveolae can be induced by extracellular factors and this requires signals dependent upon
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caveolin (Nabi and Le, 2003). A dominant-negative caveolin-1 would by its 
overexpression, reduce activation of endogenous caveolin-1 and thereby limit stimulated 
caveolae internalisation.
Summary
1. CCL19 uptake by CCX-CKR is by receptor mediated endocytosis, dependent upon 
dynamin.
2. Unlike CCR7, CCL19 uptake by CCX-CKR does not require p-arrestins.
3. Genetic inhibition of endocytosis of CCPs inhibits CCL19 uptake by CCR7 but not 
CCX-CKR.
4. Inhibition of the early endosomal small GTPase Rab5 inhibits CCL19 uptake by 
CCR7 but not CCX-CKR.
5. Pharmacological depletion of membrane cholesterol inhibits CCL19 uptake by both 
CCX-CKR and CCR7, indicating that lipid rafts are likely to play a role in the 
biology of these receptors.
6 . Overexpression of caveolin-1 strongly inhibits CCL19 uptake by CCX-CKR but not 
by CCR7. Expression o f a dominant negative inhibitor o f caveolin-1 also inhibits 
CCX-CKR driven CCL19 uptake. Overexpression of caveolin-1 leads to an increase 
in the levels of surface CCX-CKR.
Together, the data presented in this section demonstrate that CCX-CKR and CCR7 employ 
different routes of endocytosis. This may have important consequences for understanding 
the remarkably different behaviours these receptors have following exposure to ligand.
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These issues, along with a more in-depth discussion of the possible implications of the data 
in this section are further debated in section 4.1. In parallel with the biochemical analyses 
described above, from the outset it was intended to study the in vivo significance of CCX- 
CKR through the generation and analysis of gene targeted mice. The remainder of this 
thesis focuses on this work.
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3.2 Generation of Chemokine Receptor Knock-out mice
3.2.1 Strategy
The data presented in the previous sections show that clear differences in biochemical 
properties exist between CCX-CKR and a typical signaling chemokine receptor like 
CCR7. From this, it may be hypothesised that CCX-CKR plays a role in regulating the 
availability and/or the distribution of the chemokines CCL19, CCL21, and CCL25 in 
vivo. However, analysis o f protein function by overexpression in heterologous 
transfectants is limited by the fact that conclusions can only be extended to encompass 
the experimental system used. A more robust approach to determining the essential 
functions of a particular gene is via the analysis o f gene targeted animals in in vivo 
models. Therefore, mice were generated with a targeted ablation of CCX-CKR to enable 
an investigation o f the indispensable function o f CCX-CKR in vivo. As information 
regarding the different cell types which expressed CCX-CKR was not available, 
targeting constructs were designed to result in the insertion of a reporter gene in place 
o f CCX-CKR under the control o f endogenous CCX-CKR regulatory elements (a so 
called knock-in knock-out (KIKO) approach). There were several important 
considerations to take into account when deciding to generate KIKO mice. First o f all, 
this is a more complicated process than the creation o f a simple gene KO mouse. As 
reporter expression analysis is intended, the promoter from the selection cassette must 
be removed (in this case by Cre recombinase mediated deletion) to minimise 
interference with reporter expression. This adds extra steps to the process o f generating 
the mice. However, there are many advantages to the KIKO approach. In the absence of 
suitable antibodies, these mice should provide a means o f convenient analysis o f CCX- 
CKR expression at the level o f individual cells, and help provide a cellular basis for 
CCX-CKR null phenotypes that emerge.
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Both to ensure that analysis of gene expression and studies of essential gene function were 
robust, two alternative reporter genes were employed, GFP and lacZ. There were two main 
reasons for this. First, the observed expression of a single reporter gene could be confirmed 
by the other, providing stronger evidence that the reporter expression accurately reflects 
that o f the gene of interest. Second, methods of detection o f GFP and lacZ are quite distinct, 
with lacZ detection more convenient on tissue sections and GFP easily detected in live cells 
by flow cytometry. Thus, the two different reporters would allow simple, convenient 
analysis of expression in a broad range of assays.
Alongside this process, it was intended to generate analogous mice for the chemokine 
receptor D6 . Although D6  KO mice had already been generated elsewhere (in a 
collaboration between Prof. Graham and Dr. Nibbs at the Beatson Institute, and Dr. Cook 
and Dr. Lira at Schering Plough) (Jamieson et al., 2005), detailed information regarding the 
in vivo expression of D6 in the mouse was not available. Therefore, to enable analysis of 
D6  expression in the absence of a reliable anti-mouse D6  antibody, and to allow us to have 
D6  null mice to use in experiments of our choosing (without enforced Materiel Transfer 
Agreement restrictions), KIKO mice with a reporter gene under the control of the 
endogenous D6  promoter were also planned. From the outset, the CCX-CKR null mouse 
generation and analysis was to be the prinicipal focus of the work for this thesis. Indeed, as 
time progressed the D6 project was transferred to post-doctoral colleagues.
This was a very ambitious project but, as described below, the availability o f appropriate 
targeting constructs at the outset of the project, coupled to the expert assistance provided by 
the BITU, ensured success. All four planned KIKO strains were generated and phenotypes 
emerging in the CCX-CKR null mice are described in section 3.3.
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3.2.2 Construction of CCX-CKR Targeting Vectors
A construct for targeting CCX-CKR containing the lacZ  reporter had already been 
generated by Dr. Nibbs before this study commenced, using a genomic clone o f the 
mouse CCX-CKR gene isolated and mapped in the lab (Townson and Nibbs, 2002). 
This construct is shown graphically in figure 3.2.1, and contains the following 
important features. Arms at either end o f the construct are homologous to the genomic 
sequence flanking either side o f the coding exon o f CCX-CKR. Instead o f the CCX- 
CKR open reading frame, a reporter cassette was inserted between these homology 
arms. W ithin this cassette, the lacZ  gene was flanked upstream by an intra-ribosomal 
entry site (IRES) and downstream by a polyA tail. It was hoped that the IRES would 
ensure robust translation o f the reporter transcripts. 3' o f  the polyA tail was a neomycin 
cassette, with the strong phosphoglycerine kinase (PGK) promoter driving expression o f 
the neomycin resistance gene (neo), to allow selection for construct integration in ES 
cells. This portion o f  the construct was flanked by loxP sites to allow post-selection 
splicing o f this region with Cre Recombinase, as open chromatin caused by the PGK 
promoter could influence the reporter gene expression.
5’ homology ami IRES I S PolyA | PGK neo 3' homology arm
1
Lox site
1
Lox site
5* homology ami IRES GFPiE) PolyA PGK neo 3' homology arm
Lox site  Lox site
Figure 3.2.1: Targeting constructs for CCX-CKR containing lacZ  or GFP. These 
constructs contained at each end a region homologous to the genomic sequence either side 
o f CCX-CKR to allow targeted integration events. 5 ’ o f the reporter is an intra-ribosomal 
entry site (IRES). Downstream of the reporter is a poladenylation (PolyA) sequence to 
allow mRNA from the reporter to be translated efficiently. Then, flanked by loxP sites, is 
the sequence PGK which promotes the expression o f the neomycin gene which confers 
resistance to G418, used for the purposes o f ES cell selection.
181
© Iain Comerford, 2005 CHAPTER THREE RESULTS
A GFP reporter construct was generated from this plasmid by removing the lacZ coding 
sequence by restriction digestion and ligation o f sequences encoding famesylated GFP. 
Famesylated GFP was used, as this should be expressed at the cell surface allowing 
convenient visualisation o f positive cells. The resulting plasmid was verified by restriction 
mapping, and the coding sequence o f GFP confirmed by sequencing. Both the lacZ and 
GFP KIKO plasmids were then linearised by restriction digestion, ready for transfection 
into murine embryonic stem (ES) cells. These transfections were performed by members of 
the BITU and while this was being done, a PCR screen for homologous recombination was 
developed. These plasmids are shown schematically in figure 3.2.1 and to scale with the 
CCX-CKR genomic clone in 3.2.2.
(i >
F  II
F II
J___ I
e  11 F-
rTTTTTl I I
II F
1 2  3 LJ L
F B
3 ' p ro b e
i f ™ " " T  B
(i i )
j u t .  p r o b e
X  F E X  B
I I  II
P h ts m id
B a c k b o n e
F  II
5 '  l l o i n o l o < / \
(r> II F
I » 1 2 | * | I I
loxP loxP
G F P  p ro b e
F  B F F \  B
I I
B
Pimm ■<« 
I J .k U v . iu 5* I l o i i inlo"V
—r-r
IUI ' C kJ    ..
*,M  loxP loxP
Figure 3.2.2: Restriction Maps of the Mouse CCX-CKR Genomic Clone and 
Targeting Constructs. (A) The mCCX-CKR genomic clone. Yellow hatched boxes=CCX- 
CKR exons, blue curved arrow=start codon. Portion o f the genomic clone highlighted in the 
green dotted box is refered to again in figure 3.2.3. Fragments used as probes in subsequent 
Southern blots are shown in red. Positions of screening oligos are shown by blue arrows (i) 
and (ii). (B) CCX-CKR lacZ KIKO construct. Green line below shows position o f various 
portions o f the construct. Dotted lines show limits of areas o f homology to genomic clone. 
(C) The CCX-CKR GFP KIKO construct. Grey line below shows position o f various 
portions o f the construct. Probes shown in diagram are restriction fragments between 
indicated sites. E=EcoR\, H=Hindlll, B=BamHl, X=Xbal, N=Notl. (*) indicates that site 
removed in targeting constructs, lkb Scale bar shown above.
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3.2.3 Targeting of CCX-CKR
To enable screening for targeted integrations, a PCR-based screen was designed and 
optimised. To help with this, a positive control plasmid was created by ligation of a 
fragment of the CCX-CKR genomic clone which lay downstream of the 3' homology arm 
present in the targeting construct into a vector containing PGKneo and the 3' homology arm 
(Figure 3.2.3). This plasmid was then diluted in murine genomic DNA such that it was 
present at the ratio 1 copy of plasmid: 1 copy of the genome. Then, to assess the sensitivity 
of the PCR, serial dilutions were made in water or genomic DNA. Various primer pairs 
were then assessed for their ability to detect this plasmid. These primers were designed 
from two specific regions. The 5' primers were from inside the neo cassette, whilst 3' 
primers were from the genomic DNA sequences just outside the 3' homology arm of the 
targeting construct, but within the region inserted into the positive control plasmid (Figure 
3.2.3). This will allow for specific detection of insertion of exogenous DNA (the neo 
cassette) into the CCX-CKR locus. The predicted product size was ~3kb. One pair of 
primers (‘mCCXout’ and ‘neoA’) consistently gave sensitive detection of the positive 
control plasmid and this pair was selected to screen for a targeted integration event in DNA 
extracted from transfected mouse ES cells surviving selection in G418. Each clone was 
triplicate plated into 96-well plates by BITU members; two plates were cryopreserved and 
the other passed on for DNA extraction and screening. The lower panel of figure 3.2.3 
shows a representative gel image of a small number of clones, including one positive.
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A pprui 3kb
1 p <;k IU‘0 3 ifc.oH.ioc. Genomic Fragment (see figure 3.2.2)
Lox site Lox site
A=1 co py  plasmid : 1 copy  m o u s e  g e n o m e  
(3 2pg : 1pg)
B= A diluted \ \  in H20
C= A diluted 1/16 in H20
D= A diluted 1/64 in H20
E= A diluted 1/256 in H20
F= A diluted 1/4 in g en o m ic  DNA
G= A diluted 1/16 in g enom ic  DNA
H= A diluted 1/64 in g en o m ic  DNA
3k It
Figure 3.2.3: PCR Screen for Targeted Integration of CCX-CKR KIKO Constucts.
Top: Schematic diagram o f plasmid used as positive control for PCR identifying targeted 
intergrations. Green dotted fragment is the same fragment in green box in figure 3.3.2. 
Various primer pairs used to optimise assay indicated by arrows. Below: Primer pair 
identified as suitablely sensitive by amplification o f 3kb band in lane ‘FT, shown as ‘neo’ 
and ‘genomic’ primer. This primer pair then used to screen many transfected ES cell clones 
(bottom panel). Clone 1F3 identified on this gel.
The positive clones identified were then expanded in culture and high quality genomic 
DNA prepared for Southern blotting, to confirm that a homologous recombination event 
had taken place, and that the only a single integration o f the construct into the genome had 
occurred. To this end, DNA was completely digested with either EcoRl or BamHl then 
subjected to Southern blotting (as detailed in 2.2.1.10). Four different fragments from 
within and outwith the targeting constructs were then used to probe these blots. The 
position o f the probes used is shown in figure 3.2.2. Representative Southern blots o f all 
probes used for screening ES cell clones transfected with CCX-CKR-GFP-KJKO and 
CCX-CKR-/tfcZ-KIKO are shown in figure 3.2.4. Moreover, by using four distinct probes 
from within and outwith the targeting construct, the integrity o f the integrated construct
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could be validated at the level restriction DNA fragment sizes on a Southern blot. The use 
o f this careful approach to screening the clones was vindicated as one clone, apparently 
containing a well-integrated targeted construct when analysed with three probes, revealed a 
shorter than predicted band with the fourth (not shown). The reason for this was unclear, 
but the exclusion o f this clone from further study ensured that this anomaly did not interfere 
with subsequent work.
3' Probe 5' Probe
ECoR1
7kb 
4 kb
T WT
5
G
ECoR1
T WT
la
ECoR1
T WT
-
BamH1
T WT
ECoR1
T WT
-
BamH1
T WTn»
FP Probe
BamH1
neo Probe of GFP clone
ECoR1 BamH1
T WT T WT T WT
»
-
«
cZ Probe
BamH1
neo Probe of lacZ clone
ECoR1 BamH1
T WT T WT T WT
Figure 3.2.4: Southern Blot Analysis of Targeted CCX-CKR KIKO ES Cell Clones.
Representative Southerns showing the observed bands from targeted (T) and parental/ wild 
type (WT) ES cell clones when probed with the various probes shown in figure 3.2.1. Band 
sizes are indicated at side. Blots from the GFP probe and upper neo blot are from clones 
with a transfected with CCX-CKR GFP KIKO, while those from the lacZ probe and lower 
neo probe are from clones transfected with CCX-CKR lacZ KIKO. 5' and 3' probes gave 
the same bands for both these constructs. Refer to figure 3.2.2 for restriction maps and 
probe locations.
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3.2.4 In Vitro Cre-Mediated Excision of Neomycin Resistance Cassette
Following identification of ES clones with a single targeted integration of the CCX-CKR- 
lacZ-YJKO  or CCX-CKR-GFP-KIKO constructs, two approaches were taken to generate 
mice. As Cre recombination was required for the splicing out of the neomycin cassette, it 
was our intention to transfect ES cells with Cre Recombinase, and screen these clones by 
PCR and Southern blotting for successful splicing. However, conscious o f potential 
difficulties in getting over-manipulated ES cells to contribute to the germline o f chimeric 
animals, it was decided that we should use some of these ES cells for generation of 
transgenic animals which could then subsequently be crossed with animals expressing Cre 
Recombinase in the germline (ZP3-Cre) to drive neomycin cassette excision.
Therefore, ES cells clones containing targeted CCX-CKR-focZ-KIKO integrations were 
transiently transfected with Cre Recombinase (performed by Dr. Forrow (BITU)), 
individual clones isolated, and DNA extracted. A PCR screen for Cre recombination was 
designed, and clones were assessed using this procedure (Figure 3.2.5). Clones positive for 
recombination were then further screened by Southern blotting to confirm that the correct 
recombination event had occurred (Figure 3.2.5). This led to the identification o f ES clones 
in which the neomycin cassette had been successfully deleted in vitro which could then be 
used in blastocyst injections. On the other hand, ES cell clones transfected with CCX-CKR- 
GFP-KIKO which were identified by PCR and Southern blotting were used directly for 
blastocyst injection.
Table 3.1 and table 3.2 summarise the CCX-CKR-focZ-KIKO clones which were identified 
by PCR screening and Southern blotting both before and after transient Cre-mediated 
neomycin cassette excision. These tables also indicate the clones that were used for 
blastocyst injections. Table 3.3 summarises the ES cell clones trasfected with CCX-CKR-
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GFP-KIKO which were identified by PCR screening and Southern blotting and which 
clones that were used for blastocyst injections.
325bp 
PCR product
polyA 3' Homology
loxP loxP
630bp 
PCR product
polyA 3' Hom ology
5 'Probe 
BamH1 
R U
>10kB
3kb
lacZ Probe 
BamH1 
R U
4.5kb 
— ►
6kb
Figure 3.2.5: PCR and Southern Blot Screen for in vitro Cre Recombination. A PCR
was designed to differentiate between clones which had recombined to splice out the 
PGKneo portion o f the construct. Primers used were ‘m CCX CK Rw f, ‘commonscreen’ and 
‘target.neo’ and PCR conditions were ‘genotyping’ (2.2.6.2). Positive clones identified by 
amplification o f the indicated 630bp product were then screened by Southern blotting. The 
5' probe was used to confirm that the CCX-CKR allele remained targeted and the lacZ 
probe used to show the splicing o f PGKneo. R=recombined, U=unrecombined. Fragment 
sizes are indicated. Refer to figure 3.2.2 for restriction map and probe locations.
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P C R  + v e  C l o n e s S o u t h e r n  B lot + v e U s e d  for  in v itro  R e c o m b in a t io n
1A5 Y es No
1C 10 No No
IC11 No N o
2A 9 No No
2D  11 Y es No
2E 9 Y es No
W les
3B 4 Y es N o
4C 5 Y es N o
4D 7 Y es No
Y e s
Table 3.1: CCX-CKR lacZ KIKO ES Cell Clones Identified by PCR and Southern 
Blotting. All ES cell clones identified as positive for a targeted integration o f CCX-CKR 
lacZ KIKO (11 clones out o f 384 screened) are listed along with the results obtained from 
Southern blots carried out subsequently on these. Two clones (highlighted in blue) were 
used for in vitro Cre Recombination.
PCR +ve C lo n es Southern Blot +ve C lone Injected Germ line T ran sm iss ion
1A4 (2H4) No No n/a
1C2 (2H4) Yes No n/a
1C4 (2H4) Yes No n/a
1D1 (2H4) Yes No n/a
2A1 (2H4) No No n/a
Yes Yes
2D1 (2H4) Yes No n/a
3Q M 2H 4) Yes No n/a
1B6 (4G8) No No n/a
2B2 (4G8) No No n/a
2B3 (4G8) Yes No n/a
2B5 (4G8) Yes No n/a
2C2 (4G8) No No n/a
3A2 (4G8) Yes No n/a
3B3 (4G8) Yes No n/a
3C3 (4G8) Yes No n/a
Table 3.2: In Vitro Recombined CCX-CKR lacZ, KIKO ES Cell Clones. All clones o f 
Cre Recombinase transfected ES cell clones from indicated targeted ES cell clones which 
were PCR +ve for recombination. Result o f  subsequent Southern blot analysis, whether this 
clone was used for blastocyst injections, and whether the clones gave germline transmission 
(highlighted in blue) is also indicated.
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PCR +ve Clone Southern Blot +ve Clone Injected Germline Transmission
1F3 No No n/a
2A2 Yes No na
2F12 No No n/a
3C3 No No n/a
3C7 Yes Yes No
3E3 Yes No n/a
4G4 Yes No n/a
5G6 Yes No n/a
5G10 Yes No n/a
6D12 No No n/a
7D6 Yes Yes No
7E6 No No n/a
7E12 Yes No n/a
A5 (W4) Yes Yes Yes
G7 (W 4) Yes No n/a
C11 (W4) Yes No n/a
Table 3.3: CCX-CKR-GFP KIKO ES Cell Clones Identified by PCR and Southern 
Blotting. All ES cell clones identified as positive for a targeted integration o f CCX-CKR 
GFP KIKO by PCR (16 clones out o f 768 screened) are listed along with the results 
obtained from Southern blots carried out subsequently on these. Clones which were then 
subsequently used in blastocyst injections are indicated and the clone which gave germline 
transmission highlighted in green.
3.2.5 Blastocyst Injections, Chimeras, and Test Breeds
Blastocyst injections and implantations were all performed by the BITU according to 
standard protocols. Chimeric offspring produced were then crossed with C57/B16 mice in 
test breeds to investigate whether transgenic ES cells were contributing to the germline o f 
these mice. C57/B16 mice were used as the coat colour o f this strain differs from, and is 
recessive to, the agouti coat colour o f mice derived from 129/W4 ES cells. The presence of 
mice with agouti fur was therefore indicative o f germline transmission. As shown in table 
3.2 and table 3.3, all except two of the injected clones gave successful germline 
transmission.
Tailtip DNA was prepared from the offspring o f chimeric mice and a triple-primer 
genotyping PCR (2.2.6.2) designed to determine which mice carried the CCX-CKR null 
allele (Figure 3.2.6). These triple-primer sets had one common primer from within either
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the 3' or 5' homology arms o f the targeting construct. The two other primers were specific 
either to the CCX-CKR open reading frame (ORF) or to the reporter cassette. Amplification 
products o f the common primer and the two other primers were o f different sizes. The 
advantage o f screening at both ends o f the construct were that not only did this allow 
verification o f genotyping results, but also that if one band were to amplify preferentially 
this could be resolved by examining the result from the opposite end. Following 
optimisation o f this PCR, all subsequent genotyping was carried out by members o f the 
BITS.
5*
WILD TYPE 
ALLELE
610bp
420bp
6 1 0 b p 325bp
420bp 630bp
REPORTER CASSETTE
5 ’ P C R 3 ’ P C R
pb
TARGETED
ALLELE
630bp
325bp
Figure 3.2.6: Genotyping of Pups at CCX-CKR Locus. A schematic o f the targeted and 
WT alleles is shown with approximate positions o f oligonucleotides used to screen. Primers 
common to both WT and targeted alleles are in blue. Primers hybridising only to the WT 
allele are coloured cyan and primers specific for the targeted allele are in purple. Those 
oligos used to screen the 5' end o f the alleles are dotted. The -size  o f fragments are 
indicated by dotted lines. The gel images show tailtip DNA from a mouse o f each genotype 
at this locus screened by these two PCRs.
3.2.6 In Vivo Cre-Mediated Excision of Neomycin Resistance Gene
Chimeras heterozygous for CCX-CKR which were from non-/>7 vitro recombined ES cells 
transfected with CCX-CKR-GFP-KIKO were then bred with ZP3-Cre transgenic FVB 
mice, and tailtip DNA prepared from the offspring. These pups were then genotyped by
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PCR for the presence o f the ZP3-Cre transgene and the CCX-CKR KIKO allele. ZP3-Cre is 
only expreesed in the oocyte, so for recombination to take place, another mating was 
necessary. Therefore, female mice carrying both the ZP3-Cre and the CCX-CKR KIKO 
transgenes were then mated with WT FVB mice. FVB mice were used here as this was the 
strain carrying the ZP3-Cre, so this led to the derivation o f FVB mice carrying the null 
allele. The offspring from these matings were then screened for the absence o f the ZP3-Cre 
gene and presence o f the CCX-CKR KIKO allele. The recombination o f the CCX-CKR 
null locus was then confirmed by Southern blot analysis o f tailtip DNA (representative 
blots shown in figure 3.2.7).
5 'Probe 
BamH1
R U
>10kb
3kb
GFP Probe 
BamH1
R U
1 kb
2.5kb
Figure 3.2.7: Southern Blots of CCX-CKR GFP KIKO neo Recombination After 
ZP3/Cre Cross. Pups from ZP3/Cre crosses were screened for PGKneo recombination by 
Southern blotting. The 5' probe was used to confirm that the CCX-CKR allele remained 
targeted and the GFP probe used to show the splicing o f PGKneo. R=recombined, 
U=unrecombined. Fragment sizes are indicated. Refer to figure 3.2.2 for restriction map 
and probe locations.
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Mice carrying successfully recombined CCX-CKR-GFP KIKO alleles were then
backcrosscd onto an FVB background until F5. These gave rise to the colony o f mice
known hereafter as CCX-CKRGFP-FVB. DNA extracted from the tailtip o f the founder of 
this colony was extensively analysed by Southern blotting, to ensure that the targeted
integration o f the recombined allele was correct (figure 3.2.8).
5 ' P ro b e  3 ' P rob e  GFP P rob e
E B E B E B
>1 Okb
*  7 kb
— >.
4kb 5kb
— ► «—
4 3kb
1.5kb
mm
« •
Figure 3.2.8: Screening of Genomic DNA from CCX-CKR GFP KIKO Founder 
Mouse. Tailtip DNA from the CCX-CKR GFP KIKO mouse which gave germline 
transmission o f the targeted allele was screened by Southern blotting to ensure that the 
genetic structure o f the locus was correct. E=EcoRl digested tailtip DNA, B=BamH\ 
digested tailtip DNA. Fragment sizes are indicated. Refer to figure 3.2.2 for restriction map 
and probe locations.
3.2.7 Other CCX-CKR KIKO Strains
Chimeric mice derived from ES cells which had been recombined in vitro were also used to 
in test breeds as described above. However, chimeras which gave germline transmission o f 
the manipulated ES cells and which carried the CCX-CKR lacZ KIKO allele were bred 
with 129/S6 females to give pure 129/S6 offspring. Although this allowed rapid derivation 
o f a pure strain o f mice carrying the null allele, 129/S6 mice have proved to be a poor
192
© Iain Comerford, 2005 CHA PTER THREE RESULTS
mating strain which led to difficulties in maintaining this colony. Therefore, chimeras 
which were capable o f germline transmission o f the targeted allele were also bred on to a 
C57/B16 background, currently at F7 (June 2005). This approach has led to the generation 
o f CCX-CKR null mice on three different genetic backgrounds. In the future, this will 
enable detailed analysis o f CCX-CKR function in different disease models where strain 
specificity plays a significant role. The overall strategy for the generation o f these mice is 
summarised in figure 3.2.9.
Screen for 
recombination 
By PCR and Southerns
Transient C r e  
transfection to 
splice out PGK-neo
Targeting vector
transfect
Murine ES Cells
Selection in G418
Identify clones with single 
targeted integrations by 
PCR and Southern blotting
Inject identified 
ES cell clone into 
3 and a half day old 
blastocyst
Chimeric litter
Breed chimeras with 
ZP3 Cre expressing 
mice to splice out 
PGK-neo
Implant blastocysts 
Into the uterus o f a 
pseudopregnant 
female
Breed mice onto 
Pure background
Set up test breed to look 
For germline transmission 
Of manipulated ES cells
Figure 3.2.9: Overall Strategy for Generation of CCX-CKR KIKO Mice. A schematic 
diagram showing the basic overall strategy for the generation o f CCX-CKR KIKO mice, as 
detailed in the text.
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3.2.8 Targeting of D6
Alongside the generation of CCX-CKR KIKO mice, analogous mice at the D6  locus were 
also generated. This project involved contributions from several different people. As 
described above for CCX-CKR, a D6  lacZ KIKO construct was previously generated by Dr 
Nibbs. A D6 -GFP KIKO construct was created by modification o f the D6-lacZ KIKO 
plasmid (in a similar way to that described for CCX-CKR constructs in section 3.2.2). 
These were transfected into 129 W4 ES cells (by members of the BITU) and colonies 
surviving selection picked. I then prepared DNA from G418 resistant ES cell clones and 
these were screened by a PCR optimised by Dr. Nibbs. DNA from clones PCR positive for 
targeted integration o f the construct was then digested for Southern blot analysis. These 
blots were then extensively probed with various probes from within and outside the 
contruct to confirm that only a single correctly targeted recombination event had occurred 
(not shown).
ES cell clones identified in this way were then used for in vitro Cre recombination (as ES 
cells manipulated in this way had already been shown to be transmissible through the 
germline from previous experiments targeting CCX-CKR). At this point screening and 
subsequent analysis o f D6 null mice was passed on to Dr. Morrow, to allow this project to 
focus more clearly upon CCX-CKR. D6  null mice, carrying an inserted GFP or lacZ 
reporter, were successfully generated by these techniques.
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3.3 Analysis of CCX-CKR Knock-out mice
3.3.1 Fertilty and Viability
Fertility analysis, assessed by genotyping pups bom from crosses set up between 
heterozygote males and heterozygote females, revealed that the absence o f CCX-CKR does 
not lead to any disadvantage in the survival o f these pups, with close to the expected 
genotyping frequencies observed (Figure 3.3.1). CCK-CKR null mice are viable and show 
no gross phenotypic abnormalities. Size, weight and appearance o f CCX-CKR null mice, 
were normal.
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Figure 3.3.1: Effect of CCX-CKR Ablation on Mouse Fertility. The results o f all 
genotyping performed on the offspring produced by male and female mice both 
heterozygote at the CCX-CKR locus. A total o f 418 mice were screened. Expected numbers 
represent the numbers o f mice expected o f genotype given the normal ratio o f 2:1:1 (Het: 
WT: KO).
3.3.2 Histological Analysis
To further analyse these mice, the major organs from KO and WT littermates were 
removed, fixed, sectioned, and stained with H+E. Examination o f these sections revealed no
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■  E x p e c t e d
W T Het KO
CCX-CKR Genotype
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gross differences between KO and WT mice (not shown). In these, and all subsequent 
experiments, animals were closely age and sex matched.
3.3.3 Secondary Lymphoid Organs
As discussed in detail in the introduction, two of the CCX-CKR ligands, CCL19 and 
CCL21 are intimately involved in cell homing to secondary lymphoid organs. Thus, a 
detailed analysis of these structures in CCX-CKR KO mice compared to WT counterparts 
was initiated. Because the ILNs drain the skin, and planned models of inflammation that 
were routinely used in the laboratory involved the topical route of delivery, analysis of LNs 
focused primarily upon these structures. Analysis of the spleen was also undertaken. This 
work was all performed on age and sex-matched mice from the CCX-CKR-GFP FVB F5 
background. The principal focus o f these studies was to assess the overall structure, size, 
and cellular composition of these organs, and then examine responses in ILN to 
inflammation, and immune challenge using cutaneous inflammatory models. This work was 
initiated late in the tenure of this studentship and while it has revealed a number of 
intriguing observations, these require further in-depth investigation.
3.3.3.1 The Spleen
No abnormalities were apparent from initial analyses of spleens. H+E sections from CCX- 
CKR null mice revealed no gross phenotypic abnormailites with apparently normal red and 
white pulp development and T and B cell areas (not shown). Both the weight and number o f 
recovered cells from WT and CCX-CKR null spleens were not significantly different (not 
shown).
More detailed analysis of the proportions o f different cell populations in the spleen was also 
performed. Leukocytes were harvested from the spleen (see 2.2.6.6), and stained with a 
variety of fluorochrome-labelled antibodies against well-characterised surface markers of
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various leukocyte populations (see 22.6.1). Antibodies against the following markers were 
chosen: CD3 (pan T cell marker), B220 (B cell specific CD45 isoform), CD4 (mainly found 
on helper T cells), CD8 (mainly found on cytotoxic T cells), I-A/I-E (a murine class II 
MHC haplotype), CD 19 (a B cell-specific co-receptor), C D l l c  (an adhesion molecule 
commonly found on DCs) and F4/80 (a glycoprotein normally found on macrophages). 
Fluorochrome-labelled isotype control antibodies were used to set cytometer settings and 
single-stained cells were used to adjust cytometer compensation (see 2.2.3.2). Analysis 
using these antibodies allowed the characterisation o f the main leukocytic subsets 
commonly found in secondary lymphoid organs.
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Figure 3.3.2: Analysis of Leukocyte Populations in Spleens of CCX-CKR +/+ and -/-. 
P art 1. Splenocytes were analysed by flow cytometry using well-characterised 
fluorochrome-labelled antibodies against leukocyte surface proteins. Isotype control 
antibodies were used to set cytometer settings and compensation (see section 2.2.3.2). 
Representative contour plots showing WT and KO cell populations are shown. Cells falling 
within the red gates were quantified (analysis in part 2 o f figure over page).
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Figure 3.3.2: Analysis of Leukocyte Populations in Spleens of CCX-CKR +/+ and -/-. 
P art 2. Representative contour plots showing WT and KO cell populations are shown. 
Cells falling within the red gates were quantified. At least 5 mice in each group were 
analysed and error bars are +/- the standard deviation. Statistical analysis was performed 
using a Student’s t-test. Repeat experiments gave very similar results (n=3).
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As can be seen in figure 3.3.2, the proportions of all cell types examined in the spleens of 
CCX-CKR KO animals was largely similar to the WT animals. There were no significant 
differences in the relative proportions of T cells (CD4+ or CD8+), B cells (determined both 
by B220+ or CD19+/classII MHC+), macrophages (F4/80+) or DCs (CD llc+). However, 
close analysis revealed subtle differences in splenic macrophages. CCX-CKR KO animals 
expressed higher levels of MHC classll (I-A/I-E staining) on F4/80+ cells than WT mice. 
On average F4/80+ cells from CCX-CKR KO mice were more positive for class II MHC 
and fewer F4/80 cells were in the I-A/I-E low population than those isolated from WT FVB 
mice (figure 3.3.2). Recent work has shown that splenic macrophages express CCR7 and 
require this receptor for appropriate localisation in the spleen (Ato et ah, 2004). In addition 
it has been shown that that stimulation o f APCs with CCL19 or CCL21 can induce their 
activation, including up-regulation of class II MHC (Marsland et al., 2005). Therefore the 
possibility that the lack of CCX-CKR is leading to excessive available CCR7 ligands, 
which in turn causes hyper-activation of splenic macrophages, is worthy o f further 
investigation and is discussed in at greater length in the section 4.3. It should be noted 
however, that no significant increase in class II MHC levels was measurable between CCX- 
CKR null and WT C D llc+  DCs, indicating that this phenomenon is not universal for 
splenic APCs.
3.3.3.2 Inguinal Lymph Nodes
Similar analysis to that conducted on the spleen was initiated with ILNs. Analysis of H+E 
stained sections o f ILNs revealed no gross abnormalities between CCX-CKR KO and WT 
animals (Figure 3.3.3). ILNs from CCX-CKR null animals retained major structural 
features such as the cortex, medulla, T cell areas and B cell follicles. However, in contrast 
to the spleen, ILNs from CCX-CKR KO mice were consistently smaller and weighed 
significantly less than those from WT counterparts (figure 3.3.4). Moreover, further
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analysis o f ILNs revealed that the total number o f recovered cells from KO ILNs was 
consistently less than the number recovered from WT ILNs (figure 3.3.4). The reasons for 
this could be manifold and are discussed in detail in section 4.3.
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Figure 3.3.3: Analysis of H+E Sections of ILNs from CCX-CKR +/+ and -/-. ILNs were 
removed from age and sex matched CCX-CKR KO and WT mice and were fixed in 
formalin, paraffin embedded and sectioned. Sections were then stained H+E. Slides were 
then visualized by light microscopy and images obtained using the Axvision digital camera. 
The three main areas o f the LN are highlighted with arrows. Representative images of 6 
sections o f ILNs of each genotype are shown. The black scale bars indicate 200pm.
The question o f whether this difference in cellularity of CCX-CKR KO ILNs could be 
explained by the absence or reduction o f a particular cell population from these LNs was 
addressed next. ILN cells were stained with a variety o f antibodies against well- 
characterised markers o f various leukocyte populations (2.2.6.7), in a similar manner to that 
described above for the spleen. The differences in ILN cellular composition observed 
between CCX-CKR KO and WT ILNs were subtle, but intriguing. No gross differences in 
the proportions T or B cells (assessed by CD3, CD4, CD8, B220, CD 19, and class II MHC 
staining) were apparent between KO and WT ILNs (Figure 3.3.5). However, when a
population o f CD4-, CD8low cells were compared between CCX-CKR KO and WT ILNs,
Medulla Follic le
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there was a significant reduction in the proportion o f these cells in KO ILNs. Further 
investigation is merited to identify the precise phenotype and function o f this population, to 
understand the biological significance o f this observation and the impact on CCX-CKR null 
mice.
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Figure 3.3.4: Weight and Cell Number from ILNs of CCX-CKR +/+ and -/-. ILNs were 
removed from age and sex matched CCX-CKR KO and WT mice and trimmed under the 
dissection microscope. They were then carefully weighed on a microbalance. The weight in 
milligrams of ILNs from KO and WT mice is shown in (A). Cells were isolated from 
pooled ILNs (2 from each animal) by mashing through nitex membrane. Recovered cells 
were counted in a haemocytometer. The number o f cells recovered from pooled ILNs from 
each animal is shown in (B). Statistical analysis was performed using a Student’s t-test.
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Technical difficulties were encountered when attempting to quantify the composition o f 
APCs in ILNs. Recovered ILN cells did not stain with either CD1 lc or F4/80 antibodies 
(for DCs and macrophages respectively) any more than isotype control antibodies. This is 
most likely due to the method o f cell separation used. In future, collagenase treatment 
should be employed to recover and assess these cell types.
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Figure 3.3.5: Analysis of Leukocytes in ILNs from CCX-CKR +/+ and -/-. Contour 
plots from FACS analysis shown. The rest o f the figure and legend are shown overleaf.
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Figure 3.3.5: Analysis of Leukocytes in ILNs from CCX-CKR +/+ and -/-.
Representative contour plots showing WT and KO cell populations are shown on the 
previous page. Cells falling within the coloured gates were quantified. At least 5 mice in 
each group were analysed and error bars are +/- the standard deviation o f the mean. 
Statistical analysis was performed using a Student’s t-test (differences are not significant in 
upper graph and p<0.05 in lower graph). Repeat experiments gave similar results (n=3).
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Summary
1. CCX-CKR ablation has no apparent consequences for mouse fertility, health, or 
viability.
2. CCX-CKR null mice develop normally, with no obvious abnormalities in size, 
weight, appearance or major organ development.
3. CCX-CKR is not required for the development of secondary lymphoid organs. 
Spleen, mesenteric and peripheral LNs, and Peyers patches are all found in null 
mice. Gross architecture of these structures appears to be normal.
4. Analysis of the leukocytes which populate the spleens of CCX-CKR null mice 
reveals that similar frequencies of T cells, B cells, DCs, and macrophages are found 
in both WT and KO animals.
5. F4/80+ cells from the spleens of CCX-CKR KO animals are more strongly positive 
for class IIM HC, indicating that splenic macrophages may be more mature in these 
animals.
6 . ILNs from CCX-CKR null mice are significantly smaller than those found in their 
WT counterparts, explained by the fact that fewer cells are contained within these 
LNs in KO animals.
7. There are no differences in T cell / B cell ratios or CD4hlgh / CD8hlgh ratios in cells 
recovered from ILNs from CCX-CKR KO and WT mice. However, in ILNs of 
CCX-CKR null mice a CD4-, CD8 low population of cells is significantly reduced 
compared to WT counterparts.
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3.3.4 Inguinal Lymph Node and Skin Responses to Topical Application 
of Phorbol Ester Irritant
To further examine the regulation of ILN cellularity in CCX-CKR null mice, a model of 
inflammation known to induce Langerhans cell (LC) migration and subsequent ILN 
hypertrophy was utilised. Specifically, the topical application of the phorbol ester 12-0- 
tetradecanoylphorbol-13-acetate (PMA) was employed (Jamieson et al., 2005; Ragg et al., 
1994). The proposed mechanism of ILN hypertrophy in this model is that the cutaneous 
application of PMA causes the induction o f inflammation, cytokine production and LC 
maturation. Mature LCs upregulate CCR7, and migrate to the ILN where they promote 
lymphocyte recruitment and induce lymphocyte proliferation, causing subsequent ILN 
expansion. In addition, inflammatory cytokine and chemokine production caused by PMA 
application inhibits lymphocyte egress from the ILNs, which may also contribute to the ILN 
hypertrophy. To provide further rationale for doing these experiments with CCX-CKR null 
mice, information regarding CCX-CKR expression in the skin was collected. Available 
cDNA from the skins of WT mice (Jamieson et al., 2005) was analysed by RT-PCR for 
expression of CCX-CKR, using p-actin as a control. Both CCX-CKR and (3-actin 
transcripts were detectable from all skin samples. The possibility that genomic DNA may 
have contaminated this assay was excluded by the inclusion of control samples treated 
identically, with the exception that reverse transcriptase was not included in reactions 
(Figure 3.3.6). More detailed investigations revealed that this expression is maintained after 
PMA painting, though it may decrease at later timepoints (data not shown). This result 
provided the rationale to compare not only ILNs of CCX-CKR KO and WT mice, but also 
to compare the phenotype of the skin itself. The painting procedure followed was one 
which had recently been used extensively in parallel experiments with D6  null mice, 
involving 3 consecutive PMA (or vehicle control) paints on the back skin on 3 consecutive 
days (2.2.6.10). On day 3, 5 and 7 following the third application o f PMA, animals were
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sacrificed and the back skin removed for histological analysis. ILNs were also removed and 
weighed to assess expansion relative to those from mice painted with vehicle only.
+RT -RT
CCX-CKR 
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Figure 3.3.6: Expression of CCX-CKR in Normal Mouse Skin. RNA from skins o f WT 
mice was prepared, DNAase treated and reverse transcribed into cDNA (+/-reverse 
transcriptase enzyme). cDNA was then amplified using PCR cycle ‘cDNA amplification’ 
(2.2.1.3) with primers specific for either CCX-CKR or p-Actin (mCCXU/mCCXD and P- 
actinU/p-actinD respectively) and the resulting products run on a 1.5% agarose gel with 
ethidium bromide.
Examination o f the skin H+E sections revealed that, at a gross level, the cutaneous 
inflammation in CCX-CKR KO and WT mice was broadly similar. Evidence of 
inflammation (epidermal thickening and leukocyte infiltration) was apparent by day 3 in 
both the WT and K O ’s, and remained at day 5. By day 7 post third PMA application, 
inflammation in the back skin from both KO and WT had begun to resolve (Figure 3.3.7). 
Analysis o f ILN weights from these mice revealed that on day 3 and day 5 the ILNs from 
CCX-CKR KO mice were significantly smaller than WT counterparts (Figure 3.3.8). On 
day 7, there was no significant difference in ILN weight between KO and WT. However,
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this can in part be explained by the fact that WT ILNs have reduced in size between day 5 
and day 7.
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Figure 3.3.7: Histolgical Analysis of Mouse Skin Following 3xPMA Paint. The back 
skin from age and sex matched CCX-CKR KO and WT mice which had been either shaved 
then painted with PMA for three consecutive days (or shaved only) was removed on day 3, 
day 5, and day 7 after the third PMA application. Skins were formalin fixed, paraffin 
embedded and sectioned. Sections were then stained with H+E, analysed by light 
microscopy and photographs taken using an Axiom digital camera. Images shown are 
representative o f many fields o f view from sections from 6 mice in each group.
O )
E
U )
12.5-1 p=0.0002
r  i
10.0- ▲
7.5- ▲▲
5.0-
2 . 5 -
• •
a a a
o.o-l
p=0.0003 N/S
i  r
£
▲
KO d3 WT d3 KO d5 WT d5 KO d7 WT d7
Days after 3xPMA Paint 
and CCX-CKR G enotype
Figure 3.3.8: Analysis of Inguinal Lymph Node Weight Following 3xPMA Paint. Age
and sex matched CCX-CKR KO and WT mice were shaved then painted with PMA on 
three consecutive days. On day 3, day 5, and day 7 after the third PMA application, ILNs 
were removed, trimmed, and weighed on a microbalance. Statistical analysis was 
performed using a Student’s t-test (N/S= not significant).
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Next, to assess whether this difference in weight between KO and WT ILNs is due to the 
presence o f fewer cells in CCX-CKR KO ILNs, cell counts were performed from ILNs 
which were harvested from mice on day 3 after triple PMA application. ILNs from CCX- 
CKR KO mice had significantly fewer cells than their WT counterparts (Figure 3.3.9).
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Figure 3.3.9: Analysis of Cellularity of ILNs 3 Days After 3xPMA Paint. Age and sex
matched CCX-CKR KO and WT mice were shaved then painted with PMA on three 
consecutive days. On day 3 after the third PMA application, ILNs from each animal were 
removed, pooled, and mashed through nitex membrane to give a single cell suspension. 
Recovered cells were then counted in a haemocytometer. Statitical analysis was performed 
using a Student’s t-test.
Next, to investigate whether a particular cell population was absent from CCX-CKR KO 
ILNs on day 3 after PMA painting, immunostaining and flow cytometric analysis was 
carried out as previously. The relative proportions o f all major cells types analysed were 
largely similar between KO and WT animals (figure 3.3.10). However, similarly to that 
found in unchallenged mice, the small population o f CD4-, CD8low cells was significantly 
reduced in KO compared with WT mice.
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Figure 3.3.10: Analysis of Leukocytes in ILNs 3 Days After 3xPMA Paint.
Representative contour plots showing WT and KO cell populations are shown for CD4 vs 
CD8 staining. Cells falling within the coloured gates were quantified. At least 5 mice in 
each group were analysed and error bars are +/- the standard deviation. Statistical analysis 
was performed using a Student’s t-test (p<0.001 in lower graph). Repeat experiments gave 
very similar results (n=2). Analysis o f plots for other staining gave the results shown in the 
bar graph at the top o f figure (not significant).
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Summary
1. CCX-CKR is constitutively expressed in mouse skin.
2. Topical application of PMA causes epidermal thickening and apparent 
cutaneous inflammation similarly in both CCX-CKR KO and WT mice.
3. Inflammation in the skins of both WT and CCX-CKR null mice appears to 
resolve with similar kinetics.
4. ILNs of WT mice become significantly enlarged by day 3 and day 5 following 
PMA application. This ILN enlargement is not apparent in CCX-CKR null 
mice.
5. Three days after PMA application has ceased, significantly fewer cells are found 
in ILNs of CCX-CKR null mice compared with WT mice.
6 . All cell populations examined in the ILNs of PMA painted mice were similarly 
represented in CCX-CKR KO and WT mice. However CD4-, CD8 low cells were 
significantly reduced in proportion in KO animals, results similar to those 
observed in untreated animals.
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3.4.5 Primary Immune Responses to Subcutaneous Antigen
The hypotrophic ILNs which had been observed both in resting and PMA-treated CCX- 
CKR null mice led next to an investigation into whether CCX-CKR KO FVB mice were 
capable of mounting normal immune responses in ILNs. To answer this, a model of 
immunity was used whereby OVA emulsified in CFA is injected subcutaneously (see 
2.2.6.10). As previous experiments had shown a phenotype in the ILNs, the injections were 
into each flank of the mice to encourage drainage of Ag to this site. All injections were 
performed with the expert assistance of experienced animal technician Tom Hamilton of the 
Beatson animal facility to ensure consistency between injections. On day 3 after 
immunisation, some animals were sacrificed and cells from the ILNs counted and analysed 
by flow cytometry. Both KO and WT mice showed significant enlargement o f ILNs at this 
timepoint but unlike the PMA model, there was no significant difference between the 
weight or total cellularity of ILNs from KO versus WT (Figure 3.3.11). Immunostaining 
revealed no differences in the proportion of any cell type within these ILNs (figure 3.3.12). 
Interestingly, no differences were apparent between KO and WT mice when the proportions 
o f CD4-, CD8 ,ow cells were analysed at this time (not shown).
Next immune response parameters were measured, examining the generation of OVA- 
specific IgG and T cells. On day 10, mice were bled from the tail-vein to assess the levels 
o f OVA-speciflc IgG antibody in the serum. Mice were then sacrificed on either day 17 or 
day 24. Peripheral blood was removed by cardiac puncture and the serum separated for 
analysis of anti-OVA IgG antibody titres (see 2.2.6.11). ILNs were also removed, the 
number of recovered cells counted, and these cells then cultured with medium alone (to 
assess background proliferation), with OVA (to assess Ag-specific proliferation), or with 
Concanavalin-A (ConA) (to assess non-specific proliferative capability). Supernatants were 
taken from these cultures after 48h for analysis of cytokine production. After 96h, cells
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were pulsed with tritiated thymidine to assess levels o f cell proliferation (2.2.6.12). The 
results from these experiments are shown in figures 3.1.13 to 3.1.19.
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Figure 3.3.11: Analysis of ILN Weight and Cellularity 3 Days After OVA/CFA. ILNs 
were removed from age and sex matched CCX-CKR KO and WT mice on day 3 following 
subcutaneous OVA/CFA immunisiation . These were then and trimmed under the 
dissection microscope. They were then carefully weighed on a microbalance. The weight in 
milligrams o f ILNs from KO and WT mice is shown in (A). Cells were isolated from 
pooled ILNs (2 from each animal) by mashing through nitex membrane. Recovered cells 
were counted in a haemocytometer. The number o f cells recovered from pooled ILNs from 
each animal is shown in (B). Statistical analysis was performed using a Student’s t-test. 
(N/S= not significant)
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First o f all, it is o f note that throughout the course o f the experiment, WT ILNs consistently 
had more cells in them than CCX-CKR KO ILNs, although the differences were not 
significant, except in unimmunised control animals (Figure 3.1.13). Second, levels o f anti- 
OVA serum IgG antibody were not measurably different between KOs and WTs at any 
timepoint (Figure 3.3.14), indicating that humoral immune responses in CCX-CKR 
deficient animals are still intact. ILN cells from both CCX-CKR KO and WT ILNs were 
capable o f proliferation in vitro when cultured with OVA (Figure 3.1.15), indicating that 
cellular immunity has also been induced. At day 17, ILN cells from both KO and WT were 
highly proliferative in vitro to OVA, indicating that many OVA-specific lymphocytes were 
present. Interestingly however, cells taken from KO ILNs 24 days post-immunisation were 
still capable o f proliferation to OVA while cells from WT animals were not. At this 
timepoint, responses to medium alone or ConA were not significantly different between KO 
and WT (Figure 3.3.15).
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Figure 3.3.12: Analysis of Leukocytes in ILNs on Day 3 After OVA/CFA. Graph shows 
the proportions o f cells positive for the markers shown from ILNs taken from mice 3 days 
after OVA/CFA immunization. Refer to figure 3.3.5 for details o f gates used for 
quantification o f staining. 6 mice were included in each group and error bars are +/- the 
standard deviation.
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Figure 3.3.13: Cellularity of ILNs Following OVA/CFA Immunisation. On the
indicated day following OVA/CFA immunisation, mice were sacrificed and ILNs removed. 
ILNs from each animal were pooled and single cell suspension prepared from these. These 
were then counted in a haemocytometer. 6 mice were in each group at each timpoint. Error 
bars are +/- the standard deviation.
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Figure 3.3.14: Analysis of OVA-Speciflc IgG in Mouse Serum After OVA/CFA. 50pl 
o f serum taken from animals over timecourse o f assay was analysed by ELISA for anti- 
OVA IgG. 6 mice were in each group and zero represents unimmunised controls. In the 
absence o f standards, actual concentrations cannot be calculated but relative optical 
densities can be compared. The error bars are +/- the standard deviation.
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Figure 3.3.15: Analysis of OVA-Specific Proliferation in ILN Cell Culture. ILN cells 
were isolated on the days indicated following OVA/CFA immunisation. These were then 
cultured for 96h in either medium alone (MED), with Ovalbumin (OVA) or with 
Concanavilin A (ConA). 3H-thymidine was then added and the cells cultured for an 
additional 24h. Cells were then harvested and the level o f proliferation assessed by H 
Thymidine incorporation. A: unimmunised mice B: mice 17 days after immunisation. C: 
mice 24 days after immunisation. 6 mice included / group. Error bars are +/- the standard 
deviation. Statistically significant differences are indicated.
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Supernatants taken from ILN cell cultures were then analysed for the presence of various 
cytokines. As the FVB mouse is relatively poorly-characterised compared with other strains 
of mice in this type of model, the assessment o f multiple cytokines was desirable. To this 
end, the Luminex™ Six plex Thl/Th2 ELISA kit was utilised (see 2.2.6.13). This was 
performed with the assistance of Dr. Gracie (Glasgow Royal Infirmary) and attempted to 
measure the levels of the following cytokines. These were IL-2, IL-4, IL-5, IL-10, IL-12, 
IL-13 and IFNy. No significant levels of any cytokine were detected in supernatants from 
cells cultured in medium alone, or cells from unimmunised mice which had been cultured 
in OVA (Figure 3.3.16 and data not shown). However, cells taken from both KO and WT 
immunised mice on day 17 had detectable levels of the Th2 cytokines IL-5, IL-10, and IL- 
13, and low levels of the Thl cytokine IFN-y when cultured with OVA (Figure 3.3.16), 
although no significant differences in the levels of these could be quantified between KO 
and WT. IL-2, IL-4 and IL-12 could not be detected in any o f the supernatants (not shown). 
Intrestingly, by day 24, significantly greater levels of IL-5 and IL-13, but not IL-10 or IFN- 
y, could be detected in supernatants from CCX-CKR KO compared to WT cells when 
cultured in OVA. Supernatants from cells from WT ILNs on day 24 contained very low 
levels all cytokines tested. The data from day 24 are consistent with the prolonged presence 
of OVA-responsive T cells in CCX-CKR null ILN revealed by the proliferation assays 
(Figure 3.3.15). With the exception of IL-4, all cytokines were detectably produced by cells 
cultured in the presence of ConA (Figure 3.3.16 and data not shown). The FVB mouse is 
particularly prone to Th2 type immune responses (Choi et al., 2003; Christe et al., 1999; 
Whitehead et al., 2003), and this was reflected the cytokines secreted by cells from these 
mice in response to OVA and ConA, although the inability to detect IL-4 was something of 
a surprise.
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Figure 3.3.16: Analysis of Cytokine Levels in Supernatants from ILN Cell Culture.
Results from Luminex ELISA for IL-5, IL-10, IL-13 and IFN-y from supernatants taken 
from ILN cells cultured for 48h in either medium alone (green fill), OVA (purple fill), or 
ConA (orange fill). Concentrations were calculated from standard curves generated using 
known quantities o f each cytokine (see 2.2.6.13). Supernatants from cells from ILNs o f at 
least 4 mice in each group were analysed. Statistical anlysis was performed using a 
Student’s t-test and error bars are +/- standard deviation.
Summary
1. Subcutaneous injection o f OVA/CFA caused significant ILN hypertrophy post­
immunisation in both CCX-CKR KO and WT animals. No proportional differences 
were apparent between KO and WTs in any cell types examined in the ILNs.
2. Serum levels o f anti-OVA IgG were indistinguishable between CCX-CKR KO and 
WT mice at all time points measured post-immunisation.
3. ILN cells taken from KO and WT mice on day 17 after OVA/CFA immunisation 
were, in response to OVA, similarly capable o f in vitro proliferation and produced 
similar levels o f IL-5, IL-10, IL-13 and IFN-y.
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4. By day 24 after immunisation, WT ILN cells no longer proliferated or produced 
cytokines in response to OVA. However, OVA-responsive cells persisted in KO 
ILNs, proliferating and produced detectable levels of IL-5 and IL-13 after OVA 
stimulation.
A tentative conclusion from these data is that the absence of CCX-CKR encourages the 
persistence of Ag-specific T cells in ILNs after challenge. The interpretation and limitations 
of these results is discussed in greater depth in section 4.3.
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3.5.6 Contact Hypersensitivity Responses to the Hapten DNFB
From the previous experiment, it is clear that whilst the absence of CCX-CKR may 
influence the precise kinetics of an immune response, it is dispensable for the induction of 
Ab and responsive T cells after subcutaneous injection of soluble Ag. However, it is notable 
that the LN phenotype apparent in the PMA model was not observed after subcutaneous 
OVA/CFA immunisation. Thus, this model does not directly examine the impact o f LN 
hypotrophy on immune responses. This clear difference between the PMA and OVA/CFA 
challenges may be related to the anatomical site challenged in these models. PMA will 
principally stimulate the epidermis and lead to LC migration to the ILN. Subcutaneous 
OVA/CFA challenge, on the other hand, will not be so dependent on these cells. Thus, to 
test whether responses to Ag delivered via the epidermis are defective in CCX-CKR null 
mice, a model of immunity using the hapten di-Nitro-Fluoro-Benzene (DNFB) was 
employed. In this model, the topically-applied hapten covalently couples to proteins in the 
skin, these haptenated proteins are ingested and processed by LCs, which then migrate to 
the draining LN where they prime hapten-specific T cells (Engeman et al., 2000; Streilein 
and Bergstresser, 1981). It was hoped that, in this way, it would be possible to examine the 
impact of ILN hypotrophy on immune responses.
DNFB was applied topically to the back skin of mice on two consecutive days (see 
2.2.6.14). 24h later, ILNs were removed from some mice, weighed, and the cell number 
counted. 7 days later, with the remainder of the mice, ear thickness was measured and then 
the left ear was challenged with DNFB and vehicle alone was applied to the right. Ear 
swelling was then measured 24 and 48h later, and after 48h, the ears were removed for 
sectioning and H+E staining.
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Similarly to the PMA painting, ILNs from CCX-CKR KO mice were significantly smaller 
than WT ILNs 24h after two applications of DNFB on the back skin (figure 3.3.17). This 
was quantified both in terms of ILN weight and the number of cells recovered. These data 
suggest that topical delivery of Ag is less effective at inducing ILN hypertrophy in CCX- 
CKR KO animals than subcutaneous delivery.
ILN Weights 24h after DNFB Skin Paint
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Figure 3.3.17: Analysis of ILN Weight and Cellularity on Day 3 After DNFB Paint.
ILNs were removed from age and sex matched CCX-CKR KO and WT mice 24h after 
DNFB painting for 2 consecutive days on the back skin. ILNs were trimmed under the 
dissection microscope and carefully weighed on a microbalance. The weight in milligrams 
o f ILNs from KO and WT mice is shown in (A). Cells were isolated from pooled ILNs (2 
from each animal) by mashing through nitex membrane. Recovered cells were counted in a 
haemocytometer. The number of cells recovered from pooled ILNs from each animal is 
shown in (B). Statistical analysis was performed using a Student’s t-test.
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The left ears of mice painted with DNFB were measurably thicker than the right ears by 
24h after ear challenge (Figure 3.3.18) in both CCX-CKR KO and WT animals. By 48h 
after ear challenge, the difference in ear thickness between left and right was more 
pronounced. Despite the clear differences in ILN cellularity after DNFB painting, no 
differences were apparent in either the extent or timing o f the left ear swelling between KO 
and WT animals (Figure 3.3.18). Histological analysis o f ears 48h after DNFB challenged 
showed a robust inflammation in both KO and WT animals with epidermal thickening and 
leukocyte infiltration. No clear differences in the nature or extent of this response were 
observed (Figure 3.3.19).
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Figure 3.3.18: Measurements of Ear Thickness in Mice Following DNFB Challenge.
Ear thickness of mice before (A) and 24h (B) and 48h (C) after challenge with DNFB on 
the left ear and vehicle control on the right ear. (D) Shows the difference in thickness 
between left and right ears 48h after challenge. Thickness was measured using electronic 
callipers. Statistical analysis was performed using a Student’s-t test.
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Together these data suggest that, in this model, although less pronounced ILN hypertrophy 
is induced by DNFB painting on the back skin in CCX-CKR KO than WT animals, CCX- 
CKR is not required for the induction o f cutaneous immunity. Although an examination o f 
factors such as Ag dose and timing may reveal more subtle phenotypes in this model, CCX- 
CKR appears to be dispensable for the generation o f immune responses. Discussion o f this 
point, along with other issues arising from the results described in this section and 
suggested future experiments, can be found in section 4.3. Although not completely 
resolved, the studies o f the CCX-CKR null mice generated in this thesis are clearly 
revealing exciting phenotypic consequences o f CCX-CKR deletion which will aid our 
understanding o f the indispensable role played by this receptor in vivo.
LEFT RIGHT
Figure 3.3.19: Analysis of H+E Sections of Ears Either Painted or Unpainted with 
DNFB. Left and right ears from from mice which had been challenged with DNFB on the 
left ear and vehicle control on the right ear were removed 48h after challenge. These were 
formalin fixed, paraffin embedded and sectioned. Sections were then stained with H+E and 
analysed by light microscopy. Images were captured using the Axiom digital camera. Scale 
bar=200pm.
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3.4 Reporter Expression in CCX-CKR KIKO Animals
Alongside the phenotypic analysis of the CCX-CKR null mice, parallel investigations to 
reveal the domains of expression of the inserted reporter genes were planned to help 
identify CCX-CKR-expressing cells, and provide a cellular basis for emerging phenotypes. 
Therefore, various approaches were taken to examine expression of GFP and lacL in 
targeted mice. First, the transcription of reporter gene was assessed by RT-PCR to ensure 
that this mirrored the observed pattern of CCX-CKR transcription. As the first CCX-CKR 
KIKO mice available were CCX-CKR-GFP, RT-PCR looking for GFP expression and 
CCX-CKR expression from a range of tissues from these mice was performed. RNA was 
extracted from various CCX-CKR-GFP heterozygote (het) and WT mouse tissues RT-PCR 
used to detect GFP, CCX-CKR, and (3-actin (see 2.2.1.7 and 2.2.1.3). To ensure that the 
GFP signal was specific to the introduced reporter, the 5' oligo was designed to hybridise 
within the IRES. The oligonucleotides used to amplfy these products were as follows: i) for 
GFP: 5'IRES and GFPD1 ii) for CCX-CKR: mCCXU, mCCXD iii) P-actinU, p-actinD. 
Strong PCR signals for both CCX-CKR and GFP were detected in all tissues tested from 
het mice. This CCX-CKR expression pattern was detected similarly in WT mice, which had 
no GFP expression with only weak background bands of the incorrect size observed (Figure 
3.4.1).
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Figure 3.4.1: Analysis of CCX-CKR and GFP Expression in +/+ and +/- CCX-CKR 
GFP KIKO Mice. cDNA was prepared from various tissues o f WT and CCX-CKR GFP 
KIKO heterozygote mice (+/-RT). This was then amplified by PCR with primers specific 
for CCX-CKR and GFP. Products were run on a 1.5% gel stained with ethidium bromide.
This result encouraged attempts to directly visualise GFP in these heterozygote animals.
Several approaches were taken to do this. First, cells from peripheral blood, spleen and
ILNs were isolated and analysed by flow cytometry. By gating on different fractions o f
cells based upon their size and granularity, it was hoped that populations o f cells could be
identified that were GFP, and by inference CCX-CKR, positive. However, no green cells
were detected from any o f these tissues by this method. There are many possible
explanations for this. For example, the CCX-CKR promoter may not be particularly active
in blood cells, the amount o f GFP expressed in these cells may be below the levels o f
detection o f this assay, or the GFP transcript may not be efficiently translated.
Next, to try to visualise GFP reporter expression by a different method, tissue sections from 
a range o f organs from CCX-CKR-GFP mice were prepared, and analysed by confocal 
microscopy. As previous reports had indicated that sites o f high endogenous CCX-CKR 
expression were the heart and gut, these organs were examined in the most detail. 
Unfortunately, fluorescent emissions corresponding to that o f GFP could not be specifically 
detected from het mice on any o f the sections analysed, and a large amount o f background 
auto-fluorescence may have prevented detection o f low level GFP expression.
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When CCX-CKR-lacZ mice became available, staining of embryos and sections of various 
tissues using standard X-gal staining techniques was carried out. This was done both by 
staining sections directly and staining pieces of tissue which were then sectioned. Analysis 
of the stained embryos revealed no blue staining specific to mice which had the reporter. 
Likewise staining of adult tissue sections did not reveal any blue staining which could not 
also be observed in WT animals.
Without appropriate positive controls, detection of the GFP and lacZ reporters by methods 
which were available to me was likely to prove difficult. Careful optimisation of reporter 
detection was therefore deemed likely, and with limited time remaining for my project, I 
was unable to pursue this any further. However, in the future these mice may be an 
extremely valuable tool for continued studies of the expression, regulation, and function of 
CCX-CKR.
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CHAPTER FOUR 
DISCUSSION
4.1 Comparative Biochemistry of CCX-CKR and CCR7
CCX-CKR has been previously classified as a ‘silent’ receptor for the chemokines CCL19, 
CCL21 and CCL25. Similar to D6 and DARC, chemokine decoy and transport functions 
have been hypothesised for this receptor. Therefore, investigations were undertaken to 
study the biochemistry of this receptor to answer the following important questions. Can 
CCX-CKR internalise chemokines? If so, what is the fate of internalised chemokine? Can 
functional consequences of CCX-CKR activity be measured? And what are the molecular 
mechanisms controlling the biochemical behaviour of CCX-CKR? Throughout these 
investigations, the biochemistry of CCX-CKR was compared to that of CCR7. Both are 
receptors for CCL19 and CCL21, but CCR7 is the only known signaling receptor for these 
chemokines, and all the biological functions currently assigned to CCL19 and CCL21 can 
be explained by interactions with CCR7. Therefore, it seemed possible that despite sharing 
high affinity binding for CCL19 and CCL21, these receptors mediate completely different 
outcomes following ligation. The data presented clearly show that CCX-CKR exhibits 
biochemical properties distinct from CCR7, and provide evidence that support its proposed 
role as a decoy receptor. However, as shall be discussed, the results do not exclude 
transport functions or alternative signaling roles for CCX-CKR. Indeed, it is important to 
remember that all three of these possibilities are not mutually exclusive.
The first simple question addressed in this thesis was whether CCX-CKR and CCR7 could 
internalise CCL19. Using radiolabelled or biotinylated CCL19, the results clearly 
demonstrate that both receptors, when expressed in HEK-293 cells, induce the rapid
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internalisation of this chemokine at 37°C. Thus, similar to D6  (Bonecchi et al., 2004; Fra et 
al., 2003; Weber et al., 2004), CCX-CKR is able to internalise chemokine in the apparent 
absence of typical ligand-induced signaling. Moreover, although previous studies had 
shown that CCR7 can be internalised following exposure to CCL19 (Bardi et al., 2001; 
Breitfeld et al., 2000), chemokine internalisation via CCR7, although likely, had not been 
previously demonstrated. Notably, differences in the precise kinetics o f CCL19 
internalisation were observed between the two receptors, with CCX-CKR able to internalise 
CCL19 more rapidly, hinting that different mechanisms of internalisation were being 
employed by the two receptors.
Next, the fate of internalised radiolabelled CCL19 was studied in pulse-chase experiments. 
CCL19, internalised via CCX-CKR, was more rapidly degraded than that internalised via 
CCR7. Furthermore, internalised CCL19 was released intact from CCR7 transfectants, but 
not cells expressing CCX-CKR. A potential explanation for this was provided by the 
demonstration that CCL19 rapidly dissociates from CCX-CKR at the acidic pHs found in 
endosomes, while CCR7 retains ligand binding at these pHs. Together, this data suggested 
that, as previously shown for D6  and CCR5 (Weber et al., 2004), CCX-CKR would release 
its internalised cargo in acidic endosomes, while CCR7-associated chemokine would be 
less inclined to do so. However, surprisingly, CCL19 internalised by CCX-CKR could re- 
emerge intact when competitor was added following internalisation. Thus, prior to being 
targeted for degradation, a proportion of CCL19 internalised by CCX-CKR remains 
associated with a compartment which recycles back to the cell surface. In the absence of 
extracellular CCL19, this is presumably re-intemalised and degraded. The significance of 
this observation is not clear.
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The differences between CCX-CKR and CCR7 when tracking pulsed, internalised 
radioligand were fairly subtle and did not indicate any particular specialisation of CCX- 
CKR for chemokine sequestration. However, when chemokine degradation was measured 
in continuous culture fundamental differences were observed. Specifically, CCX-CKR 
mediated the rapid degradation o f large quantities of CCL19 (~105 molecules/cell/h) while 
CCR7 simply did not. These results are unlikely to be due to differences in the levels of 
receptors on HEK-hCCR7 and HEK-hCCX-CKR cells as HEK-hCCR7 cells consistently 
bound 2-3x more CCL19 than HEK-CCX-CKR cells in radioligand binding assays at 4°C. 
Although differences in affinity rather than receptor number could account for this 
(Scatchard analysis of CCX-CKR was precluded by the low levels of radioligand binding), 
it is nonetheless clear that the cell lines used in this study do not express dramatically 
different numbers of cell surface receptors.
As a result o f this impressive ability to degrade CCL19, CCX-CKR could modify an 
environment high in chemokines such that chemotactic responses through CCR7 were 
partially abolished. This is exactly the functional outcome which one would predict if  a 
decoy receptor hypothesis were correct and it is tempting to speculate that in vivo, CCX- 
CKR sequesters and destroys its ligands to modify responses exerted through CCR7 and 
CCR9. Indeed, similar in vitro observations have been made with D6 , which abolishes 
CCR4-driven chemotaxis towards CCL22 (Bonecchi et al., 2004), and subsequent analysis 
o f D6  null mice demonstrate that this receptor limits pro-inflammatory chemokines in vivo 
(Jamieson et al., 2005), and thereby limits cutaneous inflammation.
So why is CCX-CKR able to mediate such significant chemokine sequestration? 
Interestingly, the answer to this appears to lie in its inability to undergo desensitisation 
following exposure to ligand. Although both CCR7 and CCX-CKR are able to degrade the
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CCL19 they internalise, CCR7 becomes much less able to internalise CCL19 after it has 
been exposed to this chemokine. This may be explained by reduced surface CCR7 
following CCL19 treatment, but is also likely to be influenced by the inability o f remaining 
surface receptor to undergo ligand-driven internalisation. These results are in agreement 
with previous data showing desensitisation and internalisation o f CCR7 in response to 
CCL19 (Bardi et al., 2001; Kohout et al., 2004). Again, consistent with these published 
studies, exposure o f  CCR7 to CCL21 did not induce surface receptor downregulation, or 
desensitise the receptor to subsequently internalise CCL19. This is likely to be due to CCR7 
coupling to distinct signaling pathways depending upon whether it is ligated with CCL19 or 
CCL21 (Kohout et al., 2004).
Contrary to CCR7, it is apparent that CCX-CKR is not only resistant to desensitisation 
when exposed to its ligands, but that its ability to internalise chemokine is actually 
enhanced: a so-called ‘priming’ effect. Perhaps counterintuitively, surface receptor levels o f  
CCX-CKR, as detected by the anti-FLAG antibody, are reduced following exposure to its 
ligands. Ligand-induced surface receptor downregulation is most commonly associated 
with receptor desensitisation. However, in the case o f CCX-CKR, cells with low levels o f  
surface receptor are able to internalise chemokine more rapidly than those with higher 
levels. How is this achieved? The rapidity o f CCX-CKR trafficking may provide an answer. 
Antibody detection o f  surface receptor levels provides only a ‘snapshot’ o f the amount o f 
receptor on the cell surface at any one time. Thus, it is feasible that after initial CCL19 
exposure, CCX-CKR is trafficking more rapidly to and from the cell surface to achieve 
increase CCL19 uptake. This would mean that although less CCX-CKR is on the surface o f 
the cells at a given moment, over time more CCX-CKR will have been to the cell surface 
and thus, the potential exists to internalise more chemokines. The problems encountered 
with the generation o f  GFP-tagged CCX-CKR and the fact that the FLAG epitope was not
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readily detectable in many assays, unfortunately precluded investigations o f  receptor 
localisation and trafficking. Thus, alternative means o f detecting CCX-CKR need to be 
sought in future, such as the development o f reliable antibodies or the use o f alternative 
epitope or fluorescent tags, before this hypothesis can be tested. In addition to changes in 
receptor trafficking kinetics, as discussed below increased ligand affinity may contribute to 
enhanced CCL19 uptake by CCX-CKR after CCL19 exposure, and this also needs to be 
examined in more depth in the future.
Several other key questions arise from these data. First, what are the molecular mechanisms 
underpinning CCX-CKR ‘priming’ for enhanced CCL19 uptake? Second, how is the 
apparent ligand-driven reduction in surface receptor achieved? It is very likely that both o f  
these phenomena require ligand-driven signaling, suggesting that CCX-CKR is not as 
‘silent’ as initially thought. Some investigation into the nature o f these signals was initiated 
during the course o f this thesis, although this work requires future resolution. As CCX- 
CKR resembles a GPCR, preliminary investigations into the involvement o f G-protein 
signaling were undertaken. Intriguingly, priming o f CCX-CKR by CCL21 (but not by 
CCL19 or CCL25) was inhibited by pre-treatment o f CCX-CKR transfectants with the Gai 
inhibitor, pertussis toxin (PTX) (data not shown). Although this result needs to be 
confirmed, it suggests that CCL21 uses Gai-dependent signaling to induce priming o f  CCX- 
CKR, while CCL19 and CCL25 do not. The use o f other pharmocological and genetic 
inhibitors should also be employed to dissect out the essential signaling components o f  
CCX-CKR ‘priming’. For example, PI3K involvement could be examined using 
wortmannin and the small molecule inhibitor LY294002, the role o f PKC could be 
investigated with the inhibitor RO-32-0432, and PKB inhibitors could be employed as well. 
Dominant-negative versions o f signaling molecules could also be introduced to assess the 
relative contributions o f  specific signalling pathways. Indeed, in several o f the assays
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exploiting dominant negative inhibitors o f the endocytic machinery, their effect on CCX- 
CKR ‘priming’ was also assessed. However, inhibitors o f dynamin, (3-arrestins, 
RabGTPases or EPS 15 did not attenuate the ligand-driven enhancement o f  CCX-CKR 
function (not shown).
Alongside the use o f inhibitors, mutagenesis o f CCX-CKR could be employed to identify 
key residues or domains essential for its behaviour. To this end, plasmids encoding CCX- 
CKR C-terminal truncation mutants, and mutants with neutralised DRY motifs were 
successfully generated towards the end o f this study. However, due to time constraints, 
stable cell lines expressing these proteins were not generated. Nonetheless, in transient 
assays, CCX-CKR DRY mutants were able to internalise BioCCL 19/PE, but had reduced 
ligand-driven priming responses (data not shown). Again, this suggests that G-protein 
coupling may be important in the priming response. Another key question must be whether 
CCX-CKR becomes phosphorylated following ligation, or whether, like D6 and US28 it is 
constitutively phosphorylated, presumably to allow continuous trafficking to and from the 
cell surface (Blackburn et al., 2004; Casarosa et al., 2001). Phospholabelling, followed by 
immunoprecipitation o f CCX-CKR would address this issue.
As well as being differentially ‘primed’ or desensitised, CCX-CKR and CCR7 employ 
different routes o f endocytosis described graphically in figure 4.1.1. Indeed, this may 
contribute to their profoundly different responses following ligand exposure. The molecules 
shown to be involved in CCR7 internalisation are typical o f  those known to be involved in 
the endocytosis o f other chemokine receptors (Signoret et al., 2005; Yang et al., 1999), and 
GPCRs in general (Gaborik et al., 2001; Zhang et al., 1997). It was demonstrated in a 
recently published study that p-arrestins are recruited to CCR7 following ligation with 
CCL19 (Kohout et al., 2004). My work confirms and extends this by demonstrating that p-
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arrestins are critically involved in CCL19-driven CCR7 internalisation. As outlined in 
section 1.3.5, p-arrestins bound to a GPCR normally act as adaptors, linking 
phosphorylated receptor complexes to AP-2 and clathrin for internalisation via CCPs. 
Indeed, genetic inhibition o f CCP formation, using EPS 15 inhibitors, prevented CCL19 
uptake through CCR7. As EPS 15 is an essential component o f the clathrin endocytic 
machinery (Benmerah et al., 1999; Carbone et al., 1997), this indicates that CCR7 
internalisation is likely to be dependent, at least to some extent, on the formation o f  CCPs. 
The reason why inhibition was not more marked in these assays could be that CCR7 is also 
able to internalise via clathrin-independent mechanisms, or simply that the EPS 15 dominant 
negative mutants do not completely block clathrin-mediated endocytosis. Interestingly, 
chemokine uptake by CCR7 was also inhibited by depletion o f membrane cholesterol using 
MpCD. This indicates that cholesterol rich lipid rafts are likely to play some role in CCR7 
internalisation. In this respect, CCR7 may be behaving in a similar fashion to CCR5 which 
also requires membrane cholesterol for optimal ligand binding, but the internalisation o f  
which takes place via CCPs (Nguyen and Taub, 2002; Signoret et al., 2005). Once 
internalised, it is likely that CCVs containing CCR7 fuse with the early endosomal 
compartment, a process dependent upon the small GTPase Rab5. Inhibition o f  Rab5 
function significantly reduced the amount o f chemokine uptake through CCR7. Therefore, 
from all these investigations, it seems likely that CCR7 employs a ‘typical’ route o f  
chemokine driven endocytosis and trafficking (Figure 4.1.1). CCX-CKR, on the other hand, 
appears to use a completely distinct route o f  internalisation.
In contrast to CCR7, chemokine uptake was not prevented when CCX-CKR was 
transfected into p-arrestin null cells and overexpression o f  a dominant negative inhibitor o f  
p-arrestins had no effect on chemokine uptake by CCX-CKR. This strongly suggests that 
CCX-CKR internalisation is not dependent on p-arrestins and may explain the ability o f the
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receptor to avoid ligand-driven desensitisation. The viral chemokine receptor US28 has also 
been reported to internalise independently o f p-arrestins (Fraile-Ramos et al., 2003), and the 
role o f p-arrestins in D6 internalisation has yet to be resolved (Galliera et al., 2004; Weber 
et al., 2004). However, both o f these receptors undergo constitutive internalisation via 
CCPs (Fraile-Ramos et al., 2001; Fraile-Ramos et al., 2003; Weber et al., 2004). It was o f  
some surprise therefore that inhibition o f clathrin-mediated endocytosis, using the dominant 
negative inhibitors o f EPS 15, had no effect on chemokine uptake by CCX-CKR. Instead, 
my data strongly suggest that CCX-CKR endocytosis is dependent upon caveolae. 
Impressive inhibition o f CCX-CKR-mediated chemokine uptake was observed using both 
the dominant-negative inhibitor o f caveolin-1 and WT caveolin-1, and this occurred with 
concomitant increases in the level o f surface CCX-CKR. These effects were specific to 
CCX-CKR, as the caveolin plasmids used left internalisation via CCR7 and D6 untouched.
There are several puzzling aspects to the results obtained with the caveolin-1 plasmids, 
although reasonable explanations can be provided. The fact that both dominant-negative 
inhibitor and WT versions o f caveolin-1 inhibit internalisation may at first seem 
counterintuitive. However, caveolin-1 can stabilise caveolae at the cell surface (Minshall et 
al., 2000; Nabi and Le, 2003; Nichols, 2003) with the endocytosis o f these domains being 
regulated by signals dependent upon caveolin-1 (Pelkmans et al., 2001). Therefore, in my 
experiments, it can be envisaged that caveolae are being stabilised at the plasma membrane 
by the overexpression o f the WT caveolin-1, whilst expression o f  the dominant-negative 
inhibitor is preventing the transduction o f signals (presumably originating from CCX-CKR) 
through caveolin, thereby preventing caveolar endocytosis. The fact that surface CCX-CKR 
levels are increased in cells over-expressing caveolin-1 proteins may be further evidence 
that receptor internalisation is being blocked by these proteins. It is notable that cells with 
high levels o f surface receptor have less potential to internalise ligand, while ‘primed’
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HEK-hCCX-CKR cells (which have lower surface receptor levels than untreated cells) 
show increased CCL19 uptake. It is also o f note that overexpression o f WT caveolin-1 
causes greater inhibition o f uptake than dominant-negative caveolin-1, and also causes 
more significant increases to the level o f receptor at the cell surface. Again, these data 
indicate that it may be the rate o f trafficking o f CCX-CKR that determines uptake, rather 
than absolute surface levels at a given time.
CCP!
dynamrn \
Lysosome
Figure 4.1.1: Proposed Model of CCL19 Uptake by CCX-CKR and CCR7. A
schematic showing potential routes o f endocytosis employed by CCX-CKR and CCR7. (1) 
CCX-CKR is outside o f cholesterol rich membrane domains but localise to these regions 
after CCL19 stimulation (2). (3) CCL19 driven signals from CCX-CKR through caveolin-1 
drive endocytosis o f caveolae, dependent on dynamin (4). Chemokine internalised is then 
released intracellularly and degraded (5) while CCX-CKR recycles (6) back to cholesterol 
rich plasma membrane domains where it can rapidly undergo caveolin regulated 
endocytosis. CCR7 (A) may constitutively localise to cholesterol rich domains which are 
important for ligand binding and receptor activation (B). Phosphorylation o f CCR7 recruits 
P-arrestins (C) which links the receptor complex to CCPs which endocytose dependent on 
dynamin and EPS 15 (D). CCVs fuse with Rab5+ early endosomes and the receptor and 
CCL19 either recycle back to the cell surface (F) or are targeted for degradation (G). Key: 
Green receptor=CCX-CKR, blue receptor=CCR7, blue plasma membrane=outside lipid 
rafts, purple plasma membrane=lipid raft, dark green circles=CCL 19.
These observations present the following working model for CCX-CKR internalisation,
summarised in figure 4.1.1. Initially localised outside caveolae, CCX-CKR is envisaged to
require relocalisation to caveolae for internalisation. This could be ligand-driven. Once in
caveolae, CCX-CKR may transduce signals causing caveolar endocytosis and subsequent
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rapid trafficking o f CCX-CKR to and from the cell surface. The presence o f cholesterol in 
membrane microdomains has been shown to alter the ligand affinities o f several GPCRs 
(Gimpl et al., 1997), including the chemokine receptor CCR5 (Nguyen and Taub, 2002). 
Therefore, it is possible that CCX-CKR in caveolae has an increased affinity for ligand. 
This could contribute to the ‘priming’ phenomenon observed, with relocalisation o f CCX- 
CKR, induced by prior exposure to ligand, into this high affinity, internalising state 
resulting in more effective subsequent uptake.
Clearly this hypothesis requires testing. To begin to do this, one would first want to 
examine whether there is a change in receptor affinity following ligand exposure. 
Preliminary data suggest that this is indeed the case (not shown), but careful Scatchard 
analysis should be able to confirm this. Next, if  such an affinity change is dependent on 
localisation to cholesterol-rich domains, it should be inhibitable with cholesterol-depleting 
agents, such as MpCD. Alternatively, the addition o f free cholesterol may be able to mimic 
this change to enhance ligand binding affinity. If relocalisation into caveolae following 
receptor activation does occur, this can also be tested. First, it would be expected that CCX- 
CKR would be found outside o f Triton-X-100 insoluble membrane fractions (indicative o f  
lipid raft localisation) before ligand addition, and within these fractions after exposure to 
chemokine. Ligand-induced co-localisation o f CCX-CKR and caveolin-1 GFP could be 
analysed. With the aid o f a reliable antibody to CCX-CKR (or an epitope tag), localisation 
o f the receptor to caveolae could be assessed by electron microscopy. Furthermore, 
fluorescence resonance energy transfer technology could potentially be used to show 
interactions between CCX-CKR and caveolin. Alternatively, BioCCL19/Cy3 complexes 
could be exploited to examine its localisation with caveolin-GFP during internalisation, an 
association which one might anticipate would be enhanced following priming. Finally, it 
would be predicted that in cells with non-endocytosing caveolae, such as those highly
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overexpressing the WT protein, ligand-induced priming would not occur. This is readily 
testable with existing technology.
If CCX-CKR does localise to caveolae, how does it get there? Other GPCRs found in these 
domains use one o f several mechanisms, including cholesterol binding, fatty acylation, or 
protein-protein interactions (Chini and Parenti, 2004). Indeed, it has been shown that CCR5 
localises to plasma membrane lipid rafts via palmitylation o f cysteine residues in its C- 
terminus, and that this is responsible for the slow rate o f endocytosis o f this receptor 
(Venkatesan et al., 2003). Notably the C-terminus o f CCX-CKR is completely lacking in 
cysteine residues. Interestingly however, CCX-CKR exhibits a putative caveolin binding 
site ((|>XX<J>XXXX(j) or <J)XXXX<t)X<|> where <J)=Tyr, Phe, or Trp and X=any amino acid) 
towards the end o f the final transmembrane region going into the C-terminus. These 
sequences are present in all proteins that have been shown to directly interact with 
caveolins (Couet et al., 1997). This is conserved in CCX-CKR homologs between humans, 
chimpanzees, mice, cows, and even Xenopus laevis (Figure 4.1.2). Whether this sequence 
mediates interactions with caveolins remains to be determined. Caveolin binding motifs are 
not particularly unusual sequences, and do not necessarily result in interaction with 
caveolins. Indeed, other closely-related chemokine receptors to CCX-CKR, such as CCR9, 
also display this motif. Nonetheless, mutagenesis o f  this motif and subsequent analysis o f  
receptor behaviour and association with caveolin would be worthy experiments to consider 
for the future.
To my knowledge, CCX-CKR is the first chemokine receptor to show such tight regulation 
by caveolins over internalisation. As outlined in section 1.3.5, ECs are rich in caveolae, and 
these structures are commonly thought to mediate transcytosis o f nutrients and 
macromolecules across these barriers. This is o f obvious interest when the in vivo function
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o f CCX-CKR is considered. Although, the data presented here suggest that CCX-CKR may 
be specialised to mediate the continuous sequestration and degradation o f chemokines, a 
chemokine transport function cannot be ruled out. In fact, some CCL19 internalised by 
CCX-CKR is able to recycle intact back to the cell surface. Therefore, the possibility exists 
that CCX-CKR may mediate the transport (and perhaps even presentation) o f at least some 
o f  its chemokine cargo. It would be o f interest to determine if  this occurs in a directional 
manner, and in a more significant cell type, such as ECs. With this in mind, defining the 
cell types expressing CCX-CKR in vivo arises as a key future objective.
There is clearly much to be learned about endocytosis via caveolae. The molecular 
mechanisms controlling this process and regulating the fate o f caveosome cargo have not 
yet been fully elucidated. Therefore, the full implications o f CCX-CKR regulation by 
caveolin and caveolae cannot yet be fully understood. Moreover, while the results discussed 
in this section demonstrate clear differences between CCX-CKR and CCR7 in the 
experimental systems used, care must be taken when drawing conclusions from over­
expression o f proteins in cell lines. Ideally, experiments should be performed using cells 
which endogenously express these receptors. Thus, whilst in vitro experimentation on 
transfected cell lines provides clues to receptor functions in their endogenous settings, more 
robust evidence ideally from in vivo studies must be forthcoming before protein functions 
can be reliably assigned. The generation and analysis o f animals lacking CCX-CKR are 
clearly an important step towards achieving this aim.
4.2 The In Vivo Expression of CCX-CKR
The CCX-CKR null mice successfully generated in this study provide an invaluable tool for 
characterising the essential functions o f this receptor. Several intriguing observations have
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already been made in experiments with these mice and the implications o f  these shall be 
discussed in more detail in section 4.3. However, to understand the functions o f CCX-CKR 
in the mouse, it is o f key importance to generate information regarding the cell types which 
express this receptor, and understand how this expression is regulated. In this regard, the 
reporter genes inserted in place o f the CCX-CKR open-reading frame should be o f use in 
providing these valuable insights. Precedents for the successful use o f this approach for 
studying chemokine receptor expression and function have been set by the CX3CR1, 
CCR6, and CCR9 GFP KIKO mice (Benz et al., 2004; Jung et al., 2000; Kucharzik et al., 
2002; Niess et al., 2005).
Although preliminary investigations o f reporter expression were disappointing and did not 
result in the detection o f GFP or lacZ gene products, the suitability o f this approach for 
identifying CCX-CKR-expressing cells should not yet be rejected. It may be that cells 
positive for the reporters were present in these animals, but were so rare, or expressed the 
reporters at such low levels, that detection was not possible. Although neither GFP 
fluorescence nor lacZ activity were consistently observed, this could not be properly 
interpreted without using reliable positive controls. A priority for the future is the 
optimisation o f staining and detection procedures using animals which express these 
reporters in a known pattern, and then applying these techniques to tissues from CCX-CKR 
KIKO mice. If it is the case that the reporters are not being expressed at high enough levels 
to be directly detected, the use o f antibodies to these reporters in immunohistochemical 
approaches may help amplify signals.
However, it is possible that despite transcripts for the reporter genes being readily 
detectable, these transcripts are not being successfully translated into protein. Given the 
importance o f  determining the cell types which express CCX-CKR, it may be necessary to
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consider alternative means o f  CCX-CKR detection. There are various ways this could be 
achieved. In situ hybridisation could be used to detect cells expressing CCX-CKR 
transcripts. The development o f a reliable antibody against mouse CCX-CKR would 
represent an important advance enabling detection o f the receptor on tissue sections by 
immunohistochemistry. Finally, to detect functional expression o f CCX-CKR at the level o f  
single cells, in situ radioligand binding assays, similar to those used to characterise DARC 
and D6 expression (Hub and Rot, 1998; Nibbs et al., 2001), could be performed. In all 
approaches, the comparison o f CCX-CKR KO and WT tissue sections will prove to be very 
useful to validate results.
Once the expression profile o f CCX-CKR has been confirmed, various key experiments can 
be performed. For example, if  the reporter genes can be shown to work, the cells positive 
for the reporter can be purified and used in in vitro assays similar to those performed here 
using transfected HEK293 cells. This will provide a more physiological cell background to 
study CCX-CKR function and can be used to confirm the validity o f the findings presented 
here. In addition, KO vs WT cells can be purified and used in in vitro assays to define the 
indispensible functions o f CCX-CKR in various cell types. The nature o f experiments 
performed would clearly depend upon the types o f  cell, and circumstances under which 
CCX-CKR was expressed. The development o f technologies to help answer the questions 
above, are eagerly anticipated.
4.3 The In Vivo Function of CCX-CKR
The investigations o f CCX-CKR null mice initiated in this study have not yet been 
completed in sufficient detail to precisely determine the indispensable functions o f CCX- 
CKR in the mouse. Clearly, information regarding the cells and circumstances under which
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CCX-CKR is expressed will inform and direct analysis o f these mice in the future. 
However, some basic characterisation o f CCX-CKR null mice has been performed and this 
has revealed several extremely interesting phenotypes worthy o f discussion.
Perhaps unsurprisingly, CCX-CKR null mice are viable, develop normally, and are fertile. 
So far, among chemokine receptors, only the CXCR4 null mouse has displayed defects 
which lead to failure o f embryogenesis (Tachibana et al., 1998; Zou et al., 1998). It is only 
upon more detailed investigation, often in disease models, that defects in other chemokine 
receptor null mice have become apparent (Power, 2003). The biochemical analysis 
(discussed above) prompted consideration that, in vivo, CCX-CKR may play a regulatory 
role in the biology o f CCR7 and CCR9 through controlling availability o f their agonist 
ligands CCL19, CCL21, and CCL25. Based on this, it is in the thymus, secondary lymphoid 
organs, and small-intestinal immune system where one may expect to see an effect o f  
dysregulation o f these chemokines. This study has focussed primarily on the secondary 
lymphoid organs, examining their cellularity at steady state, and their response during 
inflammatory and immune challenge. The main observations made were as follows. First, 
ILNs in CCX-CKR null mice were significantly smaller than those from WT mice, and 
contained fewer cells. Normal proportions o f T and B cells were present in CCX-CKR null 
ILNs, though there was a subtle change in a small population o f CD4-,CD8low cells. 
Specifically, these were significantly reduced in ILNs from animals lacking CCX-CKR. 
Second, in the spleen, normal proportions o f cells were observed, but F4/80+ cells 
expressed higher levels o f MHC classll. Third, in response to the topical application o f  
PMA, draining ILNs o f CCX-CKR null mice did not undergo the same degree o f LN 
hypertrophy, although the inflammatory response in the skin appeared similar. A similar 
phenotype in the ILN was apparent when mice were sensitised topically with DNFB, 
however subsequent DTH responses in the ear were intact. Fourth, subcutaneous
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immunisation with OVA/CFA revealed that CCX-CKR null mice apparently develop 
normal antibody responses, and ILNs expanded in a fashion similar to WT during the 
response. However, the cellular immune response within the ILN appeared to be prolonged.
4.2.1 Steady State Analysis
The first phenomenon to consider is the reduction in resting ILN cellularity. In some 
respects, this has similarities to phenotypes reported in CCR7 null and p it  mice (Forster et 
al., 1999); (Nakano et al., 1997), which display reduced numbers o f cells in LNs. However, 
in both o f these strains, it is T cells which are specifically lacking. In contrast, only a small 
population o f CD4-,CD8low cells appears to be specifically lacking in CCX-CKR nulls, with 
the cellular reduction reflecting a general deficit o f T and B cells within ILNs. The exact 
phenotype o f the CD4-,CD8low cells is clearly worthy o f  further investigation. It is possible 
that they represent a population o f DCs. So-called ‘lymphoid’ DCs express CD8, and are 
present in resting mouse LNs (Salomon et al., 1998). They preferentially stimulate a Thl 
type cytokine profile in CD4+ T cells (Maldonado-Lopez et al., 1999) and have also been 
implicated in the resolution and regulation o f CD4 and CD8 T cell responses (Kronin et al., 
2001; Kronin et al., 1996; Suss and Shortman, 1996). Intriguingly, these cells are likely to 
represent a mobile population o f DCs and have been shown to be responsive to both CCL19 
and CCL21 (but not CCL25) in vitro (Colvin et al., 2004). Alternatively, these cells could 
be CD8low T cells, a poorly-characterised sub-population o f T cells, shown to originate from 
CD8 T cells following activation in the presence o f IL-4 (Kienzle et al., 2005). These cells 
are only weakly cytolytic, but still capable o f cytokine production (Kienzle et al., 2004). 
Further immunophenotyping is merited to properly characterise this cell population. For 
example, analysis o f whether these cells express CD3 or CD 11c and MHC classll should 
give an indication o f the phenotype o f these cells. Once this has been clarified, investigation
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is important to determine the reasons for the lack o f this population and the functional 
impact o f  this defect in CCX-CKR null mice.
When the decoy receptor hypothesis for CCX-CKR is considered, a reduced total cellularity 
in the LNs perhaps seems counter-intuitive. Excess CCL19 and CCL21, caused by a lack o f  
post-translational regulation o f their availability (normally exerted by CCX-CKR), may be 
expected to lead to increased levels o f these chemokines within LNs and hence a greater 
influx o f CCR7+ cells. However, there are several reasons why this may not be the case. 
First, it is possible that CCX-CKR expressed in the peripheral tissues, helps prevent CCR7+ 
cells entering these sites by sequestering CCL21 produced by lymphatic ECs. The loss o f  
this regulation in the knock-out may therefore cause lymphocytes to aberrantly traffic to 
peripheral tissues, rather than secondary lymphoid organs, leading to the observed reduction 
in total ILN cellularity. Second, CCX-CKR may be normally expressed on CCR7+ cells 
themselves, as a mechanism to regulate the responsiveness o f CCR7. The absence o f  CCX- 
CKR could then conceivably lead to excessive activation o f CCR7, leading to its 
desensitisation, and preventing entry into LNs. Third, while the presumption is that more 
chemokines equals more chemotaxis, this may not be the case. As mentioned in the 
introduction, in the thymus CCR7+ DN thymocytes migrate outwards away from the 
medulla, an area dense in CCR7 ligands. A chemorepulsive effect has been suggested to 
drive this (Witt and Robey, 2004). Indeed, chemorepulsion has been proposed to occur 
elsewhere in the chemokine system, such as when high levels o f CXCL12 are encountered 
by CXCR4+ cells in some circumstances (Poznansky et al., 2002; Poznansky et al., 2000). 
Therefore it should be considered that if  CCX-CKR normally regulates CCL19 and CCL21 
levels in secondary lymphoid organs, then overabundance o f these proteins may start to 
exert a chemorepulsive effect on CCR7+ cells, inhibiting their entry into the LNs.
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The above discussion is conjecture, and whilst the biochemical data presented in this thesis 
support a decoy function for CCX-CKR, there are, as yet, no robust in vivo data to suggest 
that CCX-CKR does indeed play such a role. Therefore, alternative hypotheses o f CCX- 
CKR function should be considered. Prominent amongst these is the chemokine transport 
hypothesis. If CCX-CKR is involved in endothelial transcytosis and/or presentation o f its 
ligands, its absence may lead to reduced levels o f  CCL19 or CCL21 available for CCR7+ 
cells on HEVs or lymphatic vessels. This in turn could result in the observed reduction in 
the number o f cells in ILNs. One problem with this hypothesis however, is that one might 
expect that the phenotype o f  ILNs would be more similar to that reported in CCR7-/- or p it  
mice, and show a T cell-specific deficiency. As B cells are still able to enter LNs in these 
mice, through CXCR4/CXCL12 and possibly CXCR5/CXCL13 interactions, a similar 
scenario would be imagined to occur in mice deficient in EC presentation o f CCR7 ligands.
The modified phenotype o f  macrophages in the spleens o f CCX-CKR mice is also 
intriguing and requires further investigation. An increase in MHC class IIh,gh macrophages, 
with a concomitant reduction in MHC classIIlow populations, may indicate that 
macrophages in CCX-CKR-/- spleens are o f a more activated phenotype. Again, this could 
be explained by dysregulation o f the protein levels o f CCL19 and CCL21 in the spleens o f  
these animals. A recent report showed that CCL19 and CCL21 can act as terminal 
differentiation factors for APCs, inducing their maturation including the upregulation o f  
MHC classll (Marsland et al., 2005). Although this phenotype was not apparent in CD1 lc+  
DCs from CCX-CKR null spleens, it is nonetheless conceivable that CCR7 ligation 
contributes to macrophage activation. Alternatively, as F4/80 expression is highest in red 
pulp macrophages and largely absent from MZ macrophages (Taylor et al., 2005), and as 
CCL19 and CCL21 are normally restricted to the PALS o f the spleen, it is possible that 
deficiency in CCX-CKR is allowing access o f these chemokines into the red pulp where it
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is causing this observed upregulation o f MHC classll on resident macrophages. Further 
immunophenotyping o f the macrophage populations in the spleens o f these animals is 
clearly required. Furthermore, as CCL19 and CCL21 have recently been shown to be 
necessary for the localisation o f macrophages within the splenic MZ (Ato et al., 2004), 
immunohistochemistry should be performed to study the localisation o f these cells in the 
spleen.
Thus, in summary, there is much still to be done to fully characterise the steady-state 
phenotypes emerging in the secondary lymphoid organs o f CCX-CKR-/- mice. Principally, 
detailed histological analysis is required to examine the localisation o f different cell types 
within these organs. Although H+E sections o f spleen and LNs were examined and 
revealed no obvious abnormalities, thorough immunohistochemistry examining the location 
o f all the various leukocyte populations is required. Furthermore, detailed analysis o f PPs, 
tonsils, adenoids and other LNs should be undertaken. O f course, a key aim in future work 
is to determine how CCX-CKR is acting at the molecular level such that its loss causes 
these defects. Are the decoy or transport hypotheses justified, or does CCX-CKR control 
some other aspect o f the biology o f its chemokine ligands? In this regard, it will be very 
interesting to examine the protein levels o f  the various chemokine ligands o f  CCX-CKR in 
these organs. If CCX-CKR. exerts a decoy function, then levels o f CCL19, CCL21 and 
CCL25 might be elevated. This should be fairly straightforward to examine by making 
lysates from the tissue o f interest and examining chemokine levels by ELISA. Analysis o f  
CCX-CKR ligand localisation may also be possible via immunohistochemistry. Finally, as 
discussed above, determining which cell types express CCX-CKR will clearly aid in the 
interpretation o f these homeostatic defects in CCX-CKR null mice. It is imperative that 
attempts are made to examine if  the chemokine sequestration properties observed in 
transfected cells, also apply to CCX-CKR in vivo.
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4.2.2 Function of CCX-CKR in Immunity and Inflammation
Topical application o f PMA or DNFB fails to induce ILN hypertrophy in CCX-CKR null 
mice. Although ILNs from CCX-CKR null animals are smaller than their WT counterparts 
prior to challenge, the relative increase in ILN weight and cellularity is much greater in WT 
than in KO animals. This phenomenon could be caused by a number o f aberrations in KO 
mice. First, DCs from the skin may not be migrating as efficiently to ILNs. Published work 
has shown that DC migration from the periphery to LNs is sufficient to cause LN 
hypertrophy and the extent o f this is proportional to the number o f DCs which reach the 
node. In this instance, hypertrophy was observed before the induction o f  cell proliferation 
within the LN, and was maximal at around 3-5 days after the injection o f DCs (Martln- 
Fontecha et al., 2003). There are various ways in which aberrant DC migration could be 
occuring in CCX-CKR-/- animals. CCR7 plays a clear role in controlling LC migration 
from the epidermis into the lymphatic vessels and then into LNs (Forster et al., 1999; Ohl et 
al., 2004). CCX-CKR may play a role at any number o f  stages along this migration 
pathway. For example, LC responsiveness to CCR7 ligands may be regulated by CCX- 
CKR expression on the LCs themselves. Alternatively, CCX-CKR may be involved in the 
presentation o f CCL21 on skin lymphatic vessels or control the positioning or retention o f  
LCs upon arrival at LNs.
Defects in LC migration are not the only possible explanation. CCX-CKR may be required 
for the retention o f lymphocytes within ILNs, perhaps by regulating peripheral levels o f  
CCL21 and CCL19. Alternatively, cells within the ILN may not be as proliferative in CCX- 
CKR -/- mice, or LC maturation may be affected preventing appropriate lymphocyte 
expansion within the LN. Clearly, many o f these ideas are testable experimentally. For 
example, to assess LC migration, various well-established approaches could be taken. The 
topical application o f FITC, followed by analysis o f  green cells arriving in the draining LN
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should answer whether there is a general defect in LC migration from the skin. 
Furthermore, epidermal sheets could be prepared and LCs enumerated, both with and 
without the prior application o f a topical irritant. This would allow assessment o f whether 
there is a steady state defect in LCs and whether these cells are able to begin their exodus 
from the epidermis in CCX-CKR-/- mice.
Despite these alterations in draining LN expansion in response to the epicutaneous Ag 
delivery, immune responses in CCX-CKR-/- mice still develop in response to DNFB 
challenge. Indeed, no differences in the DTH response in terms o f ear thickness were 
observed. This does not necessarily contradict hypotheses which predict abberant LC 
migration in these mice. Although development o f normal contact hypersensitivity 
responses to topically applied Ag requires LC migration (Del Prete et al., 2004; Streilein et 
al., 1980; Toews et al., 1980), the high Ag dose used in the experiments here may mask an 
effect on subsequent responses. Perhaps at lower doses o f DNFB, partial aberrations in LC 
function present in CCX-CKR-/- mice, may result in the emergence o f defects in the 
subsequent induction o f contact hypersensitivity responses.
The immune response to the subcutaneously delivered OVA/CFA also revealed several 
interesting observations, not least the fact that the cellularity o f draining LNs o f CCX-CKR 
KO and WT animals was indistinguishable following administration o f Ag by this route. 
This suggests that the route o f Ag delivery is important and, as lymphatic drainage probably 
accounts for the main route o f delivery in this model, may provide supporting evidence that 
the defect in the cutaneous applied models is indeed due to aberrant LC migration. 
Although relatively normal primary immune response were measured to OVA, the cellular 
response appears to last longer in CCX-CKR KO animals. This may represent a delay in the 
kinetics o f the immune response. More detailed timecourse analysis o f the cellular immune
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response is merited to investigate this. Interestingly, p it  mice have been shown to mount 
delayed, yet enhanced immune responses in a similar model (Mori et al., 2001). It remains 
to be seen if  the CCX-CKR-/- mouse is behaving in a similar way. Alternatively, there may 
be a failure o f regulation o f  T cell responses. Indeed, CD8+ DCs have been shown to 
contribute to T cell regulation (Kronin et al., 2001; Kronin et al., 1996; Suss and Shortman, 
1996), and as it is possible that there is a steady state defect in this population in CCX-CKR 
null mice, this is certainly worthy o f  further investigation. A third possibility is that T cells 
may be primed more efficiently in CCX-CKR null mice. Again, if  CCL19 and CCL21 
levels are enhanced in the LN then one may predict that APCs will be more activated and 
potentially able to induce more robust T cell responses. Finally, defects in T cell apoptosis 
or LN egress could also potentially explain the prolongation o f Ag-specific proliferation 
and cytokine production.
Immunological studies in CCX-CKR null mice should be extended. The experiments 
described here should be repeated, perhaps with variations in Ag dosage or routes o f  
delivery, and more detailed analysis o f the kinetics o f the responses undertaken. 
Furthermore, analysis o f  immune responses could be taken further to examine the 
production o f various different Ig isotypes, the production o f other cytokines, and to assess 
the phenotype o f DCs, macrophages, and lymphocytes in KO and WT LN. As with future 
studies o f the steady-state defects in these mice, detailed analysis o f  cell localisation during 
immune responses should also be studied by immunohistochemistry. It will also be o f 
interest to do these experiments with mice on a better-characterised genetic background, 
such as C57B1/6 or BALB/c, to investigate whether the phenotypes observed in FVB mice 
are observed in other strains. In addition, models o f  immunopathology should be examined 
in these mice, such as experimental autoimmune encephalomyelitis, collagen induced 
arthritis, or allograft rejection. In particular, inflammation and immunity in the small
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intestine, such as salmonella infection or colitis, will be o f interest to study, as the other 
CCX-CKR ligand (CCL25) is o f importance in homing to this site. Finally, as discussed 
above, considerable efforts need to be expended to determine, at the molecular level, 
exactly how CCX-CKR deletion influences the chemokine network to see if  models 
describing CCX-CKR as a chemokine transport or decoy receptor are truly justified.
4.4 Overall Conclusions and Future Perspectives
This study has begun to unravel the biochemistry o f CCX-CKR in vitro, and generated the 
tools which have provided the first insights into the in vivo function o f this receptor. In 
HEK293 cells, CCX-CKR utilises mechanisms o f endocytosis distinct from those typically 
engaged by chemokine receptors, to ensure that it is capable o f the continued internalisation 
o f CCL19. By continually sequestering and degrading CCL19, CCX-CKR is capable o f  
modifying chemotactic responses to this chemokine in vitro. These biochemical properties 
make CCX-CKR ideally suited to its proposed in vivo role as a decoy receptor for CCL19, 
21 and 25, chemokines which play a major role in the primary and secondary lymphoid 
microenvironments. Consistent with this, analysis o f CCX-CKR null mice demonstrated 
that this receptor plays a role in regulating the cellularity and phenotype o f cells in the 
secondary lymphoid organs at steady-state and during cutaneous inflammation. CCX-CKR 
null mice are capable o f mounting humoral and cellular primary immune responses, but the 
kinetics or regulation o f the cellular response appear to be altered. More thorough analysis 
o f CCX-CKR null mice should provide the insights required to determine its in vivo 
function. In addition, the reporter mice generated in this study should provide a valuable 
means o f determining the in vivo expression o f CCX-CKR, which will provide vital clues 
as to the function o f this intriguing receptor.
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Our understanding o f the function o f CCX-CKR is still at a very early stage. However, if  as 
has been hypothesised, CCX-CKR does indeed act as decoy or transport receptor for its 
chemokine ligands then not only will studies o f this receptor give us a deeper knowledge o f  
in vivo chemokine networks, but there are also potential therapeutic applications to be 
considered. CCX-CKR ligands play important roles in the induction o f immunity, and 
represent potential targets for the pharmaceutical industry in the treatment o f autoimmune 
disease, allograft rejection, allergy, infectious disease, and cancer. That CCX-CKR may be 
able to regulate these chemokines means that by controlling its expression with 
pharmaceuticals or gene therapy, we may be able to use this receptor to therapeutically 
modify immune responses in human disease.
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CHAPTER SIX 
APPENDICES
6.1 The Genetic Code
TTT-Phe TCT-Ser TAT-Tyr TGT-Cys
TTC-Phe TCC-Ser TAC-Tyr TGC-Cys
TTA-Leu TCA-Ser TAA-STOP TGA-STOP
TTG-Leu TCG-Ser TAG-STOP TGG-Trp
CTT-Leu CCT-Pro CAT-His CGT-Arg
CTC-Leu CCC-Pro CAC-His CGC-Arg
CTA-Leu CCA-Pro CAA-Gln CGA-Arg
CTG-Leu CCG-Pro CAG-Gln CGG-Arg
ATT-Ile ACT-Thr AAT-Asn AGT-Ser
ATC-Ile ACC-Thr AAC-Asn AGC-Ser
ATA-Ile ACA-Thr AAA-Lys AGA-Arg
ATG-Met ACG-Thr AAG-Lys AGG-Arg
GTT-Val GCT-Ala GAT-Asp GGT-Gly
GTC-Val GCC-Ala GAC-Asp GGC-Gly
GTA-Val GCA-Ala GAA-Glu GGA-Gly
GTG-Val GCG-Ala GAG-Glu GGG-Gly
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6.2 The Amino Acids
APPENDICES
A m i n o  A c i d 3  L e t t e r  C o d e 1  L e t t e r  C o d e M W  ( D a ) P r o p e r t i e s
A l a n i n e A l a
A r  n
A 8 9
■i ~7 A
H y d r o p h o b i c
Arginine______
A s p a r a g i n e
lArg
A s n N
I /4
1 3 2
H y a r c f f r l i i c
H y d r o p h i l i c
A s p a r t i c  A c i d Asp D 1 3 3 H y d r o p h i l i c
C y s t e i n e C y s C 1 2 1 H y d r o p h i l i c
G l u t a m i n e G i n Q 1 4 6 H y d r o p h i l i c
G l u t a m i c  A c i d G l u E 1 4 7 H y d r o p h i l i c
G l y c i n e G l y G 7 5 H y d r o p h i l i c
H i s B f e i B I i p H  5 5 H y d r o p h i l i c
I s o l e u c i n e l i e I 1 3 1 H y d r o p h o b i c
L e u c i n e L e u L 1 3 1 H y d r o p h o b i c
L y s f h e H I B v s K 146 H y d r o p t i f i c
M e t h i o n i n e M e t M 1 4 9 H y d r o p h o b i c
P h e n y l a l a n i n e P h e F 1 6 5 H y d r o p h o b i c
P r o l i n e P r o P 1 1 5 H y d r o p h o b i c
S e r i n e S e r S 1 0 5 H y d r o p h i l i c
T h r e o n i n e T h r T 1 1 9 H y d r o p h i l i c
T r y p t o p h a n T r p W 2 0 4 H y d r o p h o b i c
T y r o s i n e T y r Y 1 8 1 H y d r o p h o b i c
V a l i n e V a l V 1 1 7 H y d r o p h o b i c
Acidic amino acids are shown in red, basic amino acids are shown in purple. Uncharged 
hydrophobic amino acids are in green and residues with non-charged polar side chains are 
highlighted in grey.
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6.3 The Greek Alphabet
APPENDICES
A a Alpha
B P Beta
r Gamma
A 5 Delta
E £ Epsilon
Z r Zeta
H n Eta
O e Theta
I \ lota
K K Kappa
A I Lambda
M r1 Mu■fcT
V Nu'A Xi
0 0 Omicron
n 7T Pi
p P Rho
V a Sigma
T x Tau
Y u Upsilon
<? Phi
X X Chi
'P Psi
o e Omega
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6.4 Primary Sequence Line-up of CCX-CKR Across Species
chimp
cow
mouse
xeno
t e t r a
1 70
 n a le q n  q s td y y y e en  em ngtydysq y e l i c ik e d v  r e f a k v f lp v  f l t i v f v i g l  a g n sm w a iy
"~~--maleqn q s td y y y e en  em ngtydysq y e l ic i ic e d v  r e f a k v f lp v  f l t i a f v i g l  a g n sm w a iy
- ~ ~ -n aveyn  q std y y y eer . em ndthdysq y e v ic ik e e v  r k fa k v f lp a  f f t i a f i i g l  a g n s c w a iy
 m a le ln  q sa ey y y een  em nythdysq y e v ic ik e e v  r q fa k v f lp a  f f t v a f v c g l  a g n s w v a iy
m e e k in t t ir  a c ten y d e y g  d t . . t f d y g n  y e e lc e k k e v  r q f a q i f lp a  f y a v a f v ig v  a g n s lw a iy
— — jndas e e q g y y y le n  . i s f t f s y e d  y p t lc e k e e v  r s f a a l f l p v  m y a v c lv v g l a g n c v w a v y
7 1  1 4 0
human a y y k k q rtk t d v y i ln la v a  d l l l l f t l p f  wavnavhgwv ig k im c k ita  a l y t l n f v s g  m q f la c is id
chimp a y y k k q rtk t d v y i ln la v a  d l l l l f t l p f  wavnavhgwv Ig k ir a c k its  a ly t l r . f v s g  m q f la c is id
cow a y y k k rr tk t  d v y i ln la v a  d l f l l f t l p f  wavnavhgwv Ig k im ck v ts  a ly t v n f v s g  m q f la c is t d
mouse a y y k k q rtk t d v y i ln la v a  d l l l l i t l p f  wavnavfagwi lg k n n c k v ts  a ly t v n f v s g  m q f la c is id
xeno syykkm kskt d v y i ln la v a  d l l l l f t l p f  watdaavgwq f g i f m c k it s  a l y t i n f s s g  m q f la c is id
t e r r a  a y lk r lr tm t  d v fm th la v a  d l l l l i t l p f  waadaaqgwe Ig ta tck ravs s n y t v n f t c c  ram llacisvd
1 4 1  2 1 0
r y v a v t l c p s  q s g v g    . .k p c w i i  c fcv w m a a il I s ip q l v f y t  v .  . . ndnarc i p i f p r y l g t
chimp r y v a v tk v p s  q s g v g  k p cw ii c fcv w m a a il I s i p q l v f y t  v .  . .ndn arc i p i f p r y l g t
cow r y c a v tk a p s  q s g v g  kpcw vi c fc v w v a a i l  I s i p q l v f y t  v . . .n h k a r c  v p i f p y h lg t
mouse r y w a itk a p s  q s g a g  r p c w ii cccvw m aail I s i p q l v f y t  v . . . nqnarc t p i f p h h lg t
xeno r y f a v tk a p s  a q p v g  tar.grvi c lfv w s ts m l I s i p d l y f s t  vkehnnkhac lpvypkdkvk
t e r r a  r r l a l a a a r g  e .g r g r l l q r  v ftkk hcw kv c fa v w a la fg  I g l p d l v l s e  v r w lsr .r sv c  lw y p p sm v g
human sm kaliqm le i c i g f w p f l im g v c y f i ta rtlm lcr.p. . . n ik is r p lk v l l t w i v f  i v tq lp y n iv k f
chimp sm kaiiqm le i c i g f w p f  1 im g v c y f ita r tln k m p . . . n ik is r p lk v I f t w i v f  i v t q lp y n iv k f
cow sm k a s iq ile i c i g f r i p f 1 irta v cy f i t a k t l ik m p . . . n ik k s q t1kv I f  t w i v f  iv t q lp y n iv k f
mouse s lk a s iq m le i g i g f w p f l img\rc y a s  ta raliJcr.p . . . r.i kks r t  Ir v 11a v w v  f  i  v cq lp y n v v k f
xeno q t t v l i q i l e i v f c f l l p f 1 vmvf cyasma k i v l k t t . . . n ik r s r s lk v __a w g v f iV t q lp y n v ik f
t e t r a ggkaglemme v l l g f l l p l l v m if syw rvg q a lk g lp v e s r sr k w r a lr v l l t w a v f w t  q lp y n w k v
2 °  i 3 50
human c r a i d i i y s l itscn r .sk rm d i a i q v t e s i a lfh 3 c lr .p i ly v fm g a sfk r.yvrr.kvakky g sw r r q r . qs
chimp c r a i d i i y s l it3cnm.skrm d i a i q i t e s i a lfr .3 c lr .p i l y v f m gasfk nyvmkvakky g sw r r q r .q s
cow c q a i d i i y s l itdcdm skra. d v a i q i t e s i a lfh s c lr .p v ly v fm g ts fk nyim kvakky g sw rrq r .q n
mouse c q a i d a i y l l itsc d n sk r m d v a iq v t e s i a l f h s c l n p i ly v fm g a sfk nyim kvakky g sw rrq r .q n
xeno w r a id i iy a l i t s c s m s r t i d im iq v t e s l a lfh .cc lr .p v l y a f n g t t f  k c y is k ia k r c g s l r r q r ih s
t e t r a y r a v d s v y t l v th c a s s k a l d r a a q v te s l a lc h c c ln p v ly a f  v g t s f  k qhm vklakqf gqk rrkrrpn
3 5 1 375
human v e .......... e fp fd s e g p te p t 3 t  f  3 i
chimp v e .......... e fp f d s e g p t e t t s t f s i
cow v e .......... e ip f e s e d a t e p t s t f a i
mouse v e .......... e ip fd s e g p te p t 33 f  t i
xeno t e .......... e f s m hsenhveet 3 3 f  3 i
t e t r a paeeggmems fn sh d a sq e t ntf3V
The amino acid sequence from amino to carboxy terminus of CCX-CKR in humans, 
chimpanzees, cows, mice, Xenopus laevis (xeno) and zebrafish (tetra). The modified DRY 
motif is highlighted in green and the potential caveolin binding site highlighted in red.
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